SPIROCYCLE INTEGRIN INHIBITORS

Abstract: This invention relates to novel heterocycles, including (S)-2-phenylsulfonylamino-3-[[[8-(2-pyridinylaminomethyl)-]-1-oxa-2-azaspiro-[4,5]-dec-2-en-3-yl]carbonylamino]propionic acid, which are useful as antagonists of the alpha v beta 3 integrin and related cell surface adhesive protein receptors, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion, the treatment of angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.

Description: TITLE Spirocycle Integrin Inhibitors FIELD OF THE INVENTION This invention relates to novel heterocycles which are useful as antagonists of the αvβ3 integrin and related cell surface adhesive protein receptors, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion, the treatment of angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis. BACKGROUND OF THE INVENTION Angiogenesis or neovascularization is critical for normal physiological processes such as embryonic development and wound repair (Folkman and Shing, J. Biol. Chem. 1992, 267:10931-10934: D'Amore and Thompson, Ann. Rev. Physiol. 1987, !_:453-464) . However, angiogenesis also occurs pathologically, for example, in ocular neovascularization (leading to diabetic retinopathy, neovascular glaucoma, retinal vein occlusion and blindness) , in rheumatoid arthritis and in solid tumors (Folkman and Shing, J. Biol. Chem., 1992, 2£2:10931-10934; Blood and Zetter, Biochim. Biophys. Acta., 1990, ϋ__2:118-128). Tumor dissemination, or metastasis, involves several distinct and complementary components, including the penetration and transversion of tumor cells through basement membranes and the establishment of self- sustaining tumor foci in diverse organ systems. To this end, the development and proliferation of new blood vessels, or angiogenesis, is critical to tumor survival. Without neovascularization, tumor cells lack the nourishment to divide and will not be able to leave the primary tumor site (Folkman and Shing, J. Biol. Chem., 1992, 267:10931-10934) . Inhibition of angiogenesis in animal models of cancer has been shown to result in tumor growth suppression and prevention of metastatic growth (Herblin et al., Exp. Opin. Ther. Patents, 1994, 1-14). Many angiogenic inhibitors have been directed toward blocking initial cytokine-dependent induction of new vessel growth, e.g. antibodies to endothelial cell growth factors. However, these approaches are problematic because tumor and inflammatory cells can secrete multiple activators of angiogenesis (Brooks et al., Cell, 1994, 7_9_:1157-1164) . Therefore, a more general approach that would allow inhibition of angiogenesis due to a variety of stimuli would be of benefit. The integrin αvβ 3 is preferentially expressed on angiogenic blood vessels in chick and man (Brooks et al., Science, 1994, 264:569-571; Enenstein and Kramer, J. Invest. Derrnatol., 1994, 102:381-386). Integrin αvβ 3 is the most promiscuous member of the integrin family, allowing endothelial cells to interact with a wide variety of extracellular matrix components (Hynes, Cell, 1992, ϋ9_:11-25). These adhesive interactions are considered to be critical for angiogenesis since vascular cells must ultimately be capable of invading virtually all tissues. While integrin αyβ 3 promotes adhesive events important for angiogenesis, this receptor also transmits signals from the extracellular environment to the intracellular compartment (Leavesley et al., J. Cell Biol., 1993, 121:163-170, 1993) . For example, the interaction between the αvβ 3 integrin and extracellular matrix components promotes a calcium signal required for cell motility. During endothelium injury, the basement membrane zones of blood vessels express several adhesive proteins, including but not limited to von Willebrand factor, fibronectin, and fibrin. Additionally, several members of the integrin family of adhesion receptors are expressed on the surface of endothelial, smooth muscle and on other circulating cells. Among these integrins is ctvβ 3 , the endothelial cell, fibroblast, and smooth muscle cell receptor for adhesive proteins including von Willebrand factor, fibrinogen (fibrin) , vitronectin, thro bospondin, and osteopontin. These integrins initiate a calcium-dependent signaling pathway that can lead to endothelial cell, smooth muscle cell migration and, therefore, may play a fundamental role in vascular cell biology. Recently, an antibody to the ctvβ 3 integrin has been developed that inhibits the interaction of this integrin with agonists such as vitronectin (Brooks et al., Science, 1994, 264:569-571) . Application of this antibody has been shown to disrupt ongoing angiogenesis on the chick chorioallantoic membrane (CAM) , leading to rapid regression of histologically distinct human tumor transplanted onto the CAM (Brooks et al., Cell, 1994, 2 :1157-1164) . In this model, antagonists of the α v β 3 integrin induced apoptosis of the proliferating angiogenic vascular cells, leaving pre-existing quiescent blood vessels unaffected. Thus, α v β 3 integrin antagonists have -been shown to inhibit angiogenesis and are recognized as being useful as therapeutic agents for the treatment of human diseases such as cancer, restenosis, thromoembolic disorders, rheumatoid arthritis and ocular vasculopathies (Folkman and Shing, J. Biol. Chem., 1992, 2 l-10931-10934) . Increasing numbers of other cell surface receptors have been identified which bind to extracellular matrix ligands or other cell adhesion ligands thereby mediating cell-cell and cell-matrix adhesion processes. These receptors belong to a gene superfamily called integrins and are composed of heterodimeric transmembrane glycoproteins containing α- and β-subunits. Integrin subfamilies contain a common β-subunit combined with different α-subunits to form adhesion receptors with unique specificity. The genes for eight distinct β-subunits have been cloned and sequenced to date. The o- v β 3 heterodimer is a member of the β 3 integrin subfamily and has been described on platelets, endothelial cells, melanoma, smooth muscle cells, and osteoclasts (Horton and Davies, J. Bone Min. Res. 1989, 4:803-808; Davies et al. , J. Cell. Biol. 1989, 1___:1817- 1826; Horton, Int. J. Exp. Pathol. , 1990, 21:741-759). Like GPIIb/IIIa, the vitronectin receptor binds a variety of RGD-containing adhesive proteins such as vitronectin, fibronectin, VWF, fibrinogen, osteopontin, bone sialo protein II and thrombosponden in a manner mediated by the RGD sequence. A key event in bone resorption is the adhesion of osteoclasts to the matrix of bone. Studies with monoclonal antibodies have implicated the 01^ 3 receptor in this process and suggest that a selective α v β 3 antagonist would have utility in blocking bone resorption (Horton et al., J. Bone Miner. Res., 1993, 8:239-247; Helfrich et al. , J. Bone Miner. Res. , 1992, 7:335-343) . PCT Patent Application Publication Number W095/14683, published June 1, 1995 discloses isoxazoline and isoxazole fibrinogen receptor antagonists of general formula shown below: Copending, commonly assigned U.S. Patent Application Serial Number 08/455,768 filed 5/31/95 discloses integrin inhibitors of the general formula shown below: PCT Patent Application Publication Number WO95/32710, published December 7, 1995 discloses compounds for inhibition of osteoclast-mediated bone resorption of general formula shown below: X-Y-Z-Aryl-A-B wherein Aryl is a 6-membered aromatic ring system. None of the above references discloses or suggests the spirocyclic compounds of the present invention which are described in detail below. SUMMARY OF THE INVENTION The present invention provides novel nonpeptide compounds which bind to integrin receptors thereby altering cell-matrix and cell-cell adhesion processes. The compounds of the present invention are useful for the inhibition of cell adhesion and the treatment of angiogenic disorders, inflammation, bone degradation, cancer metastases, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis. One aspect of this invention provides novel compounds of Formula I (described below) which are useful as antagonists of the 0:^ 3 integrin, which is also referred to as the vitronectin receptor. The compounds of the present invention inhibit the binding of vitronectin or other RGD-containing ligands to αγβ 3 and inhibit cell adhesion. The present invention also includes pharmaceutical compositions containing such compounds of Formula I, and methods of using such compounds for the inhibition of angiogenesis, and/or for the treatment of disorders mediated by angiogenesis. Another aspect of the present invention comprises agents that inhibit the binding of vitronectin to the ot v β 3 receptor for the treatment (including prevention) of thrombosis which do not significantly alter hemostatic balance and do not significantly inhibit platelet aggregation and do not significantly inhibit coagulation. Also the compounds of the current invention can be used for the treatment or prevention of restenosis. The present invention also provides novel compounds, pharmaceutical compositions and methods which may be used in the treatment or prevention of other diseases which involve cell adhesion processes, including, but not limited to, rheumatoid arthritis, asthma, allergies, adult respiratory distress syndrome, graft versus host disease, organ transplantation, septic shock, psoriasis, eczema, contact dermatitis, osteoporosis, osteoarthritis, atherosclerosis, metastasis, wound healing, diabetic retinopathy, ocular vasculopathies, thrombosis, inflammatory bowel disease and other autoimmune diseases. Also included in the present invention are pharmaceutical kits comprising one or more containers containing pharmaceutical dosage units comprising a compound of Formula I, for the therapeutic inhibition of cell adhesion, the treatment of angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis. DETAILED DESCRIPTION OF THE INVENTION The present invention provides novel nonpeptide compounds of Formula I (described below) which bind to integrin receptors thereby altering cell-matrix and cell-cell adhesion processes. The compounds of the present invention are useful for the inhibition of cell adhesion and the treatment of angiogenic disorders, inflammation, bone degradation, cancer metastases, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis, in a mammal. One aspect of this invention provides novel compounds of Formula I which are useful as antagonists of the αγβ 3 or vitronectin receptor. The compounds of the present invention inhibit the binding of vitronectin and other RGD-containing ligands to ctvβ 3 and inhibit cell adhesion. The present invention also includes pharmaceutical compositions containing such compounds of Formula I, and methods of using such compounds for the inhibition of angiogenesis, and/or for the treatment of angiogenic disorders. [1] The present invention comprises spirocyclic compounds of Formula I: Rl-Q-W-X-Y (I) including stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, or pharmaceutically acceptable salt or prodrug forms thereof wherein: Q is selected from A is selected from -N(R 10 )-, -C(R 11 )- or -0-; A 1 is selected from -0- or -N(R 10 )-; Z is a spiro-fused 4-7 membered ring system (including the sprio atom) containing 0-2 heteroatoms selected from 0, S, or N, said ring system optionally being substituted on carbon with keto, or being substituted on carbon or nitrogen independently with 0-2 R 9 or R 10 or R 10a ; R 1 is selected from: NR 7 NR 7 NR 7 R 7 R 6 N-V- ^- f ?- N R 6 - - , R 8 R 7 N— C— - , R 8 R 7 N- "-NR 6 -V- ; B is independently selected from -CH 2 -, -0-, -N(R 2 )-, or -C(=0)-; B 1 is independently selected from -CH 2 - or -N(R 3 )-; D is -N(R 2 )-, -0-, -S-, -C(=0)- or -S0 2 -; E-F is -C(R 4 )=C(R 5 )-, -N=C(R 4 )-, -C(R 4 )=N-, or -C(R 4 ) 2 C(R 5 ) 2 -; J, K, L and M are independently selected from -C(R 4 )-, -C(R 5 )- or -N-, provided that at least one of J, K, L and M is not -N-; R 2 is selected from: H, Cι-C 6 alkyl, (Cι-C 6 alkyl) carbonyl, (Ci-Cβ alkoxy) carbonyl; (Cι-C 6 alkyl)aminocarbonyl, C 3 -C 6 alkenyl, C 3 -C 7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, heteroaryl (C1-C6 alkyl) carbonyl, heteroarylcarbonyl, aryl Ci-Cβ alkyl, (Ci-C δ alkyl) carbonyl, arylcarbonyl, Ci-C δ alkylsulfonyl, arylsulfonyl, aryl (Ci-Cβ alkyl)sulfonyl, heteroarylsulfonyl, heteroaryl (C1-C 6 alkyl) sulfonyl, aryloxycarbonyl, aryKCi-Cβ alkoxy) carbonyl, wherein said aryl groups are substituted with 0-2 substituents independently selected from the group consisting of C 1 -C 4 alkyl, C 1 -C 4 alkoxy, halo, CF 3 , and nitro; R 3 isselected from: H, Ci-C δ alkyl, C 3 -C 7 cycloalkyl, C 4 - C1 1 cycloalkylalkyl, aryl, aryl(Cι-C6 alkyl)-, or heteroaryl (C1-C6 alkyl) - ; R 4 and R 5 are independently selected from: H, C 1 -C 4 alkoxy, NR 2 R 3 , halogen, NO2, CN, CF 3 , Ci-Cβ alkyl, C 3 -Ce alkenyl, C 3 -C7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, aryl (Cι-C 6 alkyl)-, (Cι-C 6 alkyl) carbonyl, (Cχ-C 6 alkoxy) carbonyl, arylcarbonyl; alternatively, when substituents on adjacent atoms, R 4 and R 5 can be taken together with the carbon atoms to which they are attached to form a 5-7 membered carbocyclic or 5-7 membered heterocyclic aromatic or non-aromatic ring system, said carbocyclic or heterocyclic ring being optionally substituted with 0-2 groups independently selected from: C 1 -C 4 alkyl, C 1 -C 4 alkoxy, halo, cyano, a ino, CF3, or N0 2 ; R 6 is selected from: H, C 1 -C 4 alkyl, or benzyl; R 7 and R 8 are independently selected from: H, Ci-Cβ alkyl, C 3 -C 7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, aryl(Cι-C6 alkyl)-, or heteroaryl (C0-C 6 alkyl) - . U is selected from: -N(R 6 ) (CH 2 ) n -» -N(R 6 ) (CH 2 ) m N(R 7 )- -N(R 6 ) (CH 2 )nS(0) p - -N(R 6 )C(=0) (CH 2 ) n -; -N(R 6 ) (CH 2 ) m C(=0)-; V is selected from: - ( CH 2 ) m 0- ( CH2 ) n-. -(CH 2 )πvN(R 7 ) (CH 2 ) n -, -(CH 2 )mN(R 7 )C(=0) (CH 2 ) n -» -(CH 2 ) n C(=0)N(R 7 ) (CH 2 ) n -, -(CH 2 ) n C(=0) (CH 2 ) n -; R 9 is selected from H, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, aryl, aryl(Cι-C 6 alkyl)-, (C 1 -C 4 alkoxy) carbonyl, (C 1 -C 4 alkyl) carbonyl, C 1 -C 4 alkylsulfonyl, or C 1 -C 4 alkylaminosulfonyl; R 10 is selected from: H, C0 2 R 17 , C(=0)R 17 , C(=0)NR 17 R 20 , -S0 2 R 17 , -S0 2 NR 17 R 20 , Cι-C 6 alkyl substituted with 0- 1 R 15 , C 3 -C 6 alkenyl substituted with 0-1 R 15 , C 3 -C 7 cycloalkyl substituted with 0-1 R 15 , C 4 -C 11 cycloalkylalkyl substituted with 0-1 R 15 , aryl substituted with 0-1 R 15 or 0-2 R 11 , or aryl (Cι-C 6 alkyl)- substituted with 0-1 R 15 or 0-2 R 11 ,- R i oa i s selected from: CO2R 17 , C(=0)R 17 , C(=0)NR 17 R 20 , -S0 2 R 17 , -S0 2 NR 17 R 20 , Cι-C 6 alkyl substituted with 0- 1 R 15 , C3-C6 alkenyl substituted with 0-1 R 15 , C 3 -C 7 cycloalkyl substituted with 0-1 R 15 , C 4 -C 11 cycloalkylalkyl substituted with 0-1 R 15 , aryl substituted with 0-1 R 15 or 0-2 R 11 , or aryl(Cι-C 6 alkyl)- substituted with 0-1 Ris or 0-2 R 11 ; R 11 - is selected from H, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, aryl, aryl(Cι-C δ alkyl)-, (C 1 -C 4 alkoxy) carbonyl, (C 1 -C 4 alkyl) carbonyl, C 1 -C 4 alkylsulfonyl, or C 1 -C 4 alkylaminosulfonyl; W is selected from: C 1 -C 4 alkylene, -(C(R 12 ) 2 )qO(C ( R 12 ) 2 )q-, -(C(R 12 ) 2 )qC(=0) (C(R 12 ) 2 )q-, -(C(R 12 ) 2 ) q C(=0)N(Rl3)- 7 -C(=0)-N(R l3 )-(C(R l2 ) 2 )q-; X is -(C(R 12 ) 2 )qC(R 12 ) (R 14 )-C(R 12 ) (R 15 )-; alternatively, W and X can be taken together to be R 12 is selected from H, Cι-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, C 4 -C 10 cycloalkylalkyl, (C 1 -C 4 alkyl)carbonyl, aryl, or aryKCi-Ce alkyl)-; R 13 is selected from H, Cχ-C 6 alkyl, C 3 -C7 cycloalkylmethyl, or aryl(Cχ-C 6 alkyl)- R 14 is selected from: H, Cι-C 6 alkylthio(Cι-C 6 alkyl)-, aryl(Cι-Cι 0 alkylthioalkyl) -, aryl (C1-C10 alkoxyalkyl) -, C 1 -C 10 alkyl, C 1 -C10 alkoxyalkyl, Ci-Cβ hydroxyalkyl, C2-C10 alkenyl, C 2 -Cιo alkynyl, C 3 -C 10 cycloalkyl, C3-C10 cycloalkylalkyl, aryl (Ci-C δ alkyl) -, heteroaryl (C 1 -C 6 alkyl) -, aryl, heteroaryl, C0 R 17 , C(=0)R 17 , or C0NR 17 R 20 , provided that any of the above alkyl, cycloalkyl, aryl or heteroaryl groups may optionally be substituted independently with 0- 1 R 16 or 0-2 U; R 15 is selected from: H, R 16 , C1-C10 alkyl, C 1 -C 10 alkoxyalkyl, C 1 -C 10 alkyla inoalkyl, C 1 -C 10 dialkylaminoalkyl, (C 1 -C 1 0 alkyl)carbonyl, aryl (Co-Cβ alkyl)carbonyl, C 1 -C1 0 alkenyl, C 1 -C 1 0 alkynyl ,C 3 -C 10 cycloalkyl, C3-C10 cycloalkylalkyl, aryKCi-Cβ alkyl)-, heteroaryl (Ci-C δ alkyl) -, aryl, heteroaryl, C0 2 R 17 , C(=0)R 17 , CONR 17 R 20 , S0 2 R 17 , or S0 2 NR 17 R 2 °, provided that any of the above alkyl, cycloalkyl, aryl or heteroaryl groups may optionally be substituted independently with 0-2 R 11 ,- Y is selected from: -COR 19 , -S0 3 H, -PO 3 H, tetrazolyl, -CONHNHSO 2 CF 3 , -CONHSO2R 17 , -CONHS0 2 NHR 17 , -NHCOCF 3 , -NHCONHS0 2 R 17 , -NHS0 2 R 17 , -OPO3H2, -OSO3H, -PO 3 H 2 , -SO 3 H, -SO2NHCOR 17 , -S0 2 NHC0 2 R 17 , R 16 is selected from: -N(R 20 )-C(=O)-O-R 17 , -N(R 20 )-C(=O)-R 17 , -N(R 20 )-C(=O)-NH-R 17 , -N(R 20 )SO 2 -R 17 , or -N(R 20 )Sθ2-NR 20 R 17 ; R 17 is selected from: Ci-Cio alkyl, C 3 -Cn cycloalkyl, aryl(Cι-C 6 alkyl)-, (Ci-Cβ alkyl)aryl, heteroaryl(Ci-Cβ alkyl)-, (Cι-C 6 alkyl)heteroaryl, arylaryl (Ci-Cβ alkyl)-, heteroarylaryl (Ci-Cβ alkyl ) -, arylheteroaryl (Ci-Cβ alkyl)-, heteroarylheteroaryl (Ci-Ce alkyl) -, heteroaryl, or aryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents independently selected from the group consisting of: C 1 -C 4 alkyl, C 1 -C 4 alkoxy, aryl, halo, cyano, amino, CF 3 , and NO 2 ; R 18 is selected from: H, -C(=0)-0-R 17 , -C(=0)-R 17 , -C(=0)-NH-R 17 , -S0 2 -R 17 , or -SO 2 -NR 20 R 17 ; R 19 is selected from: hydroxy, C 1 -C 10 alkyloxy, C3 -C11 cycloalkyloxy , aryloxy, aryl (Cχ-C6 alkoxy)-, C 3 -C 10 alkylcarbonyloxyalkyloxy, C 3 -C 10 alkoxycarbonyloxyalkyloxy, C -Cιo alkoxycarbonylalkyloxy, C 5 -C 10 cycloalkylcarbonyloxyalkyloxy, C5-C 1 0 cycloalkoxycarbonyloxyalkyloxy, C 5 -C10 cycloalkoxycarbonylalkyloxy, C 7 -C 11 aryloxycarbonylalkyloxy, C 8 - χ 2 aryloxycarbonyloxyalkyloxy, 8 - 12 arylcarbonyloxyalkyloxy, C 5 -C1 0 alkoxyalkylcarbonyloxyalkyloxy, C 5 -C 10 (5-alkyl-l, 3-dioxa-cyclopenten-2-one- yDmethyloxy, C 10 -C 14 (5-aryl-l, 3-dioxa-cyclopenten-2-one- y1)methyloxy, or (R 11 ) (R 12 )N-(Cι-Cιo alkoxy)-; R 20 is selected from: H, Ci-Ce alkyl, C 3 -C7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, aryKCi-Cβ alkyl)-, or heteroaryl (Ci-Cβ alkyl)-- m is 1-2 n is 0-2 p is 0-2 q is 0-2 and r is 0-2 provided that: n, q, and r are chosen such that the number of in-chain atoms between R 1 and Y is in the range of 8-18. [2] Preferred compounds of the invention as described above are spirocyclic compounds of Formula I: R 1 -Q-W-X-Y (I) including stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, or pharmaceutically acceptable salt or prodrug forms thereof wherein: Q is selected from >10a R 1 is selected f rom: NR 7 NR 7 NR 7 R 8 — C-NR 6 -V— , R 8 R 7 N— C-V- , R 8 R 7 N— C-NR 6 "V- ; D is -N(R 2 )-, -0-, -S-, -C(=0)- or -S0 2 -; E-F is -C(R 4 )=C(R 5 )-, -N=C(R 4 )-, -C(R 4 )=N-, or -C(R ) 2 C(R 5 ) 2 -; J, K, L and M are independently selected from -C(R 4 )-, -C(R 5 )- or -N-, provided that at least one of J, K, L and M is not -N-; R 2 is selected from: H, Cι-C 6 alkyl, (C -C δ alkyl)carbonyl, (C -Cβ alkoxy) carbonyl; (Ci-Cβ alkyl)aminocarbonyl, C 3 -C 6 alkenyl, C 3 -C 7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, heteroaryl (Ci-Ce alkyl) carbonyl, heteroarylcarbonyl, aryl (Cι-C 6 alkyl)-, (Cι-C 6 alkyl) carbonyl, arylcarbonyl, Cχ-C 6 alkylsulfonyl, arylsulfonyl, aryKCi-Cβ alkyl)sulfonyl, heteroarylsulfonyl, heteroaryl (Ci-Cβ alkyl)sulfonyl, aryloxycarbonyl, or aryl (Ci-Ce alkoxy) carbonyl, wherein said aryl groups are substituted with 0-2 substituents independently selected from the group consisting of C 1 -C 4 alkyl, C 1 -C 4 alkoxy, halo, CF 3 , and nitro; R 3 is selected from: H, Ci-Cβ alkyl, C 3 -C7 cycloalkyl, C4-C11 cycloalkylalkyl, aryl, aryKCi-Cβ alkyl)-, or heteroaryl (Ci-Cβ alkyl) - ; R 4 and R 5 are independently selected from: H, C 1 -C 4 alkoxy, NR 2 R 3 , halogen, N0 , CN, CF 3 , Cι-C 6 alkyl, C3-C6 alkenyl, C3-C7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, aryl (Ci-Cβ alkyl)-, (Ci-Cβ alkyl) carbonyl, (Ci-Cβ alkoxy)carbonyl, arylcarbonyl, or alternatively, when substituents on adjacent atoms, R 4 and R 5 can be taken together with the carbon atoms to which they are attached to form a 5-7 membered carbocyclic or 5-7 membered heterocyclic aromatic or non-aromatic ring system, said carbocyclic or heterocyclic ring being optionally substituted with 0-2 groups independently selected from: C 1 -C 4 alkyl, C 1 -C 4 alkoxy, halo, cyano, amino, CF 3 , or N0 2 ; R 6 is selected from: H, C 1 -C 4 alkyl, or benzyl; R 7 and R 8 are independently selected from: H, Ci-Cβ alkyl, C3-C7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, aryl(Cι-C 6 alkyl)-, or heteroaryl { o~ alkyl)-. U is selected from: -N(R 6 ) (CH 2 )m0-, -N(R 6 ) (CH 2 )πv (R 7 )- -N(R 6 ) (CH 2 ) n S(0)p- -N(R 6 )C(=0) (CH 2 ) n -; V is selected from: - ( CH 2 ) π p- ( CH 2 ) n- > - -(CH 2 )mN(R 7 ) (CH 2 )n-, - ( CH 2 ) nS ( 0 ) p ( CH 2 ) n-, -(CH 2 ) m N(R 7 )C(=0) (CH 2 ) n -, - ( CH 2 ) n C ( =0 ) N ( R 7) ( CH 2 ) n -, -(CH 2 ) n C(=0) (CH 2 ) n -; R 9 is selected from H, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, aryl, aryKC -Ce alkyl)-, (C 1 -C4 alkoxy) carbonyl, (C 1 -C 4 alkyl)carbonyl, C 1 -C 4 alkylsulfonyl, or C 1 -C 4 alkylaminosulfonyl; R 10 is selected from: H, C0 2 R 17 , C(=0)R 17 , C(=0)NR 17 R 20 , -S0 2 R 17 , -S0 2 NR 17 R 20 , Ci-Cβ alkyl substituted with 0- 1 R 15 , C 3 -C6 alkenyl substituted with 0-1 R 15 , C 3 -C 7 cycloalkyl substituted with 0-1 R 15 , C 4 -C 11 cycloalkylalkyl substituted with 0-1 R 15 , aryl substituted with 0-1 R 15 or 0-2 R 11 , or aryl (Cι-C 6 alkyl)- substituted with 0-1 R 15 or 0-2 R 11 ; R i o is selected from: C0 2 R 17 , C(=0)R 17 , C(=0)NR 17 R 20 , -S0 2 R 17 , -S0 2 NR 17 R 20 , Ci-Cβ alkyl substituted with 0- 1 R 15 , C 3 -C 6 alkenyl substituted with 0-1 R 15 , C 3 -C 7 cycloalkyl substituted with 0-1 R 15 , C 4 -C 11 cycloalkylalkyl substituted with 0-1 R 15 , aryl substituted with 0-1 R 15 or 0-2 R ii , or aryl(Cι-C 6 ■ alkyl)- substituted with 0-1 R 15 or 0-2 R 11 ; R 11 is selected from H, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, aryl, aryl(Cι-C 6 alkyl)-, (C 1 -C 4 alkoxy) carbonyl, (C 1 -C 4 alkyl) carbonyl, C 1 -C 4 alkylsulfonyl, or C 1 -C 4 alkylaminosulfonyl; W is selected from: C 1 -C 4 alkylene, -(C(R 12 ) 2 ) q O(C(R i2 ) 2 ) q -, -(C(R 12 ) 2 ) q C(=0) (C(R 1 ) 2 ) q -, -(C(R 12 ) 2 ) q C(=0)N(R l3 )-, -C(=0 ) -N ( R l3) - ( C ( R l ) 2 ) q-; X is -(C(R l ) 2 )qC(R 12 ) (R 14 )-C(R 12 ) (R 15 -)-; alternatively, W and X can be taken together to be R 12 is selected from H, Ci-Cβ alkyl, C 2 -C 6 alkenyl, C 2 -C6 alkynyl, C 3 -C7 cycloalkyl, C 4 -C 10 cycloalkylalkyl, (C 1 -C 4 alkyl)carbonyl, aryl, or aryl(Cι-Cδ alkyl)-; R 13 is selected from H, Ci-C δ alkyl, C 3 -C7 cycloalkylmethyl, or aryl(Cι-C 6 alkyl)-; R 14 is selected from: H, Cι-C 6 alkylthio(Cι-C 6 alkyl)-, aryl(Cι-Cιo alkylthioalkyl) -, aryl (C 1 -C 10 alkoxyalkyl) -, C 1 -C 10 alkyl, C 1 -C 1 0 alkoxyalkyl, Ci-Cβ hydroxyalkyl, C 2 -Cιo alkenyl, C2-C10 alkynyl, C 3 -C 10 cycloalkyl, C3-C10 cycloalkylalkyl, aryl(Cι-C 6 alkyl)-, heteroaryl (Cι-C 6 alkyl) -, aryl, heteroaryl, C0 2 R 17 , C(=0)R 17 , or CONR 17 R 20 , provided that any of the above alkyl, cycloalkyl, aryl or heteroaryl groups may optionally be substituted independently with 0- 1 R 16 or 0-2 R 11 ; R 15 is selected from: H, R 16 , C1-C10 alkyl, C1-C10 alkoxyalkyl, 1-C10 alkylaminoalkyl, C1-C10 dialkylaminoalkyl, (C1-C10 alkyl) carbonyl, aryl (C 0 -C6 alkyl) carbonyl, C1-C10 alkenyl, C1-C10 alkynyl ,C3-C1 0 cycloalkyl, C3-C1 0 cycloalkylalkyl, aryl(Cι-C6 alkyl)-, heteroaryl (Cχ-C6 alkyl) -, aryl, heteroaryl, C0 2 R 17 , C(=0)R 17 , CONR 17 R 20 , S0 2 R 17 , or S0 2 NR 17 R 2 °, provided that any of the above alkyl, cycloalkyl, aryl or heteroaryl groups may optionally be substituted independently with 0-2 R ; Y is selected from: -COR 19 , -SO3H, -PO3H, tetrazolyl, -CONHNHSO2CF3, -CONHS0 2 R 17 , -CONHSO2NHR 17 , -NHCOCF3, -NHCONHS0 2 R 17 , -NHS0 2 R 17 , -OPO3H2, -OSO3H, -P0 3 H 2 , -SO3H, -S0 2 NHCOR 17 , -SO2NHCO2R 17 , , R 16 is selected from: -N(R 20 )-C(=O)-O-R 17 , -N(R 20 )-C(=O)-R 17 , -N(R 20 )-C(=O)-NH-R 17 , -N(R 20 )SO2-R 17 , or -N ( R 20 ) SO 2 -NR 0 R 17 ; R 17 is selected from: Ci-Cio alkyl, C3-C11 cycloalkyl, aryl (Ci-Cβ alkyl)-, (C -Cβ alkyl)aryl, heteroaryl (Ci-Cβ alkyl) -, (Ci-Cβ alkyl) eteroaryl, arylaryl (Ci-Cβ alkyl)-, heteroarylaryl (Ci-Cβ alkyl) - , arylheteroaryl (C -Cβ alkyl)-, heteroarylheteroaryl (Ci-Cβ alkyl)-, heteroaryl, or aryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents independently selected from the group consisting of: C1-C4 alkyl, C1-C4 alkoxy, aryl, halo, cyano, a ino, CF 3 , and NO2; R 18 is selected from: H, -C(=0) -O-R 17 , -C(=0)-R 17 , -C(=0)-NH-R 17 , -SO2-R 17 , or -SO 2 -NR 0 R 17 ; R 19 is selected from: hydroxy, C1-C10 alkyloxy, C3-C11 cycloalkyloxy, aryloxy, aryl(Cι-C6 alkoxy)-, C3-C10 alkylcarbonyloxyalkyloxy, C3-C10 alkoxycarbonyloxyalkyloxy, C2-C10 alkoxycarbonylalkyloxy, C5-C10 cycloalkylcarbonyloxyalkyloxy, C5-C10 cycloalkoxycarbonyloxyalkyloxy, C5-C10 cycloalkoxycarbonylalkyloxy, C7-C11 aryloxycarbonylalkyloxy, C8-C12 aryloxycarbonyloxyalkyloxy, C8-C12 arylcarbonyloxyalkyloxy, C5-C10 alkoxyalkylcarbonyloxyalkyloxy, C5-C 1 0 (5-alkyl-l, 3-dioxa-cyclopenten-2-one- yDmethyloxy, C10-C14 (5-aryl-l,3-dioxa-cyclopenten-2-one- y1) ethyloxy, or (R 11 ) (R 1 )N-(Cι-Cιo alkoxy)-; R 20 selected from: H, Ci-C δ alkyl, C 3 -C 7 cycloalkyl, C 4 - C 11 cycloalkylalkyl, aryl, aryl (C 1 -C 6 alkyl) -, or heteroaryl (Cχ-C6 alkyl)-- m is 1-2 n is 0-2 p is 0-2 q is 0-2 and r is 0-2 provided that: n, q, and r are chosen such that the number of in- chain atoms between R 1 and Y is in the range of 8- 18. [3] Further preferred compounds of the invention as described above are compounds of the Formula I including stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, or pharmaceutically acceptable salt or prodrug forms thereof wherein: Q is selected from: R 1 is selected from: ς o-.oo- .00 wherein the above heterocycles are optionally substituted with 0-2 substituents selected from the group consisting of: NH 2 , halogen, N0 2 , CN, CF 3 , C 1 -C 4 alkoxy, Ci-Cβ alkyl, and C3-C7 cycloalkyl; R 2 is selected from: H, C1-C4 alkyl or benzyl; U is -NH ( CH 2 ) n -; V is -(CH 2 ) n -; R 10 is selected from: H , C0 2 R 17 , C (=0) R 17 , C0NR 17 R 20 , -SO 2 R 17 , -S0 2 NR 17 R 20 , Ci-Cβ alkyl substituted with 0- 1 R 15 , C3-C6 alkenyl substituted with 0-1 R 15 , C 3 -C 7 cycloalkyl substituted with 0-1 R 15 , C 4 -C 11 cycloalkylalkyl substituted with 0-1 R 15 , aryl substituted with 0-1 R 15 or 0-2 R 11 , or aryl (Cι-C 6 alkyl ) - substituted with 0-1 R 15 or 0-2 R 11 ; R 10 is selected from: C0 2 R 17 , C(=0)R 17 , CONR 17 R 20 , -S0 2 R 17 , -S0 2 NR 17 R 2 °, Ci-Ce alkyl substituted with 0- 1 R 15 , C 3 -C 6 alkenyl substituted with 0-1 R 15 , C 3 -C 7 cycloalkyl substituted with 0-1 R 15 , C 4 -C 11 cycloalkylalkyl substituted with 0-1 R 15 , aryl substituted with 0-1 R 15 or 0-2 R 11 , or aryl(Cι-C 6 alkyl)- substituted with 0-1 R 15 or 0-2 R 11 ; R 11 is selected from H, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, aryl, aryl(Cι-C6 alkyl)-, (C 1 -C4 alkoxy) carbonyl, (C 1 -C 4 alkyl)carbonyl, C 1 -C 4 alkylsulfonyl, or C 1 -C 4 alkylaminosulfonyl; W is -C(=0)-N(R 13 )-; X is -CH (R 1 ) -CH (R 15 ) - ; R 13 is H or CH 3 ; - R 14 is selected from: H, Ci-Cio alkyl, aryl, or heteroaryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents independently selected from the group consisting of: C 1 -C 4 alkyl, C1-C4 alkoxy, aryl, halo, cyano, a ino, CF 3 , and N0 2 ; R 15 is H or R 16 ; Y is -C(=0)R 19 ; R 16 is selected from: -N(R 0 )-C(=0)-0-R 17 , -N(R 20 )-C(=0)-R 17 , -N(R 0 )-C(=O)-NH-R 17 , -N(R 20 )SO 2 -R 17 , or -N(R 20 )SO 2 -N(R 20 )R 17 ; R 17 is selected from: C 1 -C 10 alkyl, C3-C11 cycloalkyl, aryl (Cι-C 6 alkyl)-, (Ci-Ce alkyl)aryl, heteroaryl (Cι-C 6 alkyl)-, (Cι-C 6 alkyl)heteroaryl, arylaryl (Ci-Cβ alkyl)-, heteroarylaryKCi-Cβ alkyl)-, arylheteroaryl (Ci-Cε alkyl)-, heteroarylheteroaryl (Ci-Cβ alkyl)-, heteroaryl, or aryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents independently selected from the group consisting of: C 1 -C 4 alkyl, C 1 -C 4 alkoxy, aryl, halo, cyano, a ino, CF 3 , and N0 ; R 19 is selected from: hydroxy, Ci-Cio alkoxy, methylcarbonyloxymethoxy-, ethylcarbonyloxymethoxy-, t-butylcarbonyloxymethoxy-, cyclohexylcarbonyloxymethoxy- , 1- (methylcarbonyloxy) ethoxy- , 1- (ethylcarbonyloxy) ethoxy-, 1- (t-butylcarbonyloxy) ethoxy- , 1- (cyclohexylcarbonyloxy) ethoxy-, i-propyloxycarbonyloxymethoxy-, t-butyloxycarbonyloxymethoxy- , 1- (i-propyloxycarbonyloxy) ethoxy-, 1- (cyclohexyloxycarbonyloxy) ethoxy- , 1- ( t-butyloxycarbonyloxy) ethoxy-, dimethylaminoethoxy-, diethylaminoethoxy-, (5-methyl-1, 3-dioxacyclopenten-2-on-4-y1)methoxy-, (5- ( t-butyl) -1, 3-dioxacyclopenten-2-on-4- yl)methoxy-, (1,3-dioxa-5-phenyl-cyclopenten-2-on-4-yl)methoxy-, or 1- (2- (2-methoxypropyl ) carbonyloxy) ethoxy-; R 20 is H or CH 3; and n is 0-1, [4] Still further preferred compounds of the above invention as described above are compounds of the Formula I including stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, or pharmaceutically acceptable salt or prodrug forms thereof wherein: Q is selected from: R 1 is selected from: R 2 is selected from: H, C 1 -C 4 alkyl, or benzyl; U is -NH ( CH 2 ) n -; V is - ( CH 2 ) n -; R 10 is selected from: H, C0 2 R 17 , C(=0)R 17 , C (=0)NR 17 R 20 , -SO2R 17 , -S0 2 NR 17 R 20 , Cι-C 6 alkyl substituted with 0- 1 R 15 , C3-C 6 alkenyl substituted with 0-1 R 15 , C 3 -C 7 cycloalkyl substituted with 0-1 R 15 , C 4 -C 11 cycloalkylalkyl substituted with 0-1 R 15 , aryl substituted with 0-1 R 15 or 0-2 R 11 , or aryl(Cι-C 6 alkyl)- substituted with 0-1 R 15 or 0-2 R 11 ; R 10a is selected from: CO 2 R 17 , C(=0)R 17 , CONR 17 R 20 , -S0 2 R 17 , -S0 2 NR 17 R °, Cι-C 6 alkyl substituted with 0- 1 R 15 , C 3 -C 6 alkenyl substituted with 0-1 R 15 , C 3 -C 7 cycloalkyl substituted with 0-1 R 15 , C 4 -C 11 cycloalkylalkyl substituted with 0-1 R 15 , aryl substituted with 0-1 R 15 or 0-2 R 11 , or aryl(Cι-C 6 alkyl)- substituted with 0-1 R 15 or 0-2 R 11 ; R 11 -is selected from H, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, aryl, aryl(Cι-C6 alkyl)-, (C 1 -C 4 alkoxy) carbonyl , (C 1 -C 4 alkyl ) carbonyl , C 1 -C 4 alkylsulfonyl, or C 1 -C 4 alkylaminosulfonyl; W is -C(=0)-N(R 13 )-; X is -CH(R )-CH(R 15 )-; R 13 is H or CH 3 ; R 14 is selected from: H, C 1 -C 10 alkyl, aryl, or heteroaryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents independently selected from the group consisting of: C 1 -C 4 alkyl, C 1 -C 4 alkoxy, aryl, halo, cyano, amino, CF 3 , and N0 2 ; R 15 is H or R 16 ; Y is -C(=0)R 19 ; R 16 is selected from: -N (R 20 ) -C ( =O) -O-R 17 , -N (R 20 ) -C ( =O ) -R 17 , -N ( R 20 ) SO -R 17 , R 17 is selected from: Ci-Cio alkyl, C3-C11 cycloalkyl, aryl (Cι-C 6 alkyl)-, (C1-C6 alkyl)aryl, heteroaryl (Ci-Cβ alkyl)-, (Ci-Cβ alkyl)heteroaryl, arylaryl (Ci-Cβ alkyl)-, heteroarylaryl (Ci-Cδ alkyl)-, arylheteroaryl (C -Cβ alkyl)-, heteroarylheteroaryl(Ci-Cβ alkyl)-, heteroaryl, or aryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents independently selected from the group consisting of: C 1 -C 4 alkyl, C 1 -C 4 alkoxy, aryl, halo, cyano, amino, CF 3 , and NO 2 ; R 19 is selected from: hydroxy, C1-C10 alkoxy, methylcarbonyloxymethoxy-, ethylcarbonyloxymethoxy-, t-butylcarbonyloxymethoxy-, cyclohexylcarbonyloxymethoxy-, 1- (methylcarbonyloxy) ethoxy-, 1- (ethylcarbonyloxy)ethoxy-, 1- (t-butylcarbonyloxy) ethoxy-, 1- (cyclohexylcarbonyloxy)ethoxy-, i-propyloxycarbonyloxymethoxy-, t-butyloxycarbonyloxymethoxy-, 1- (i-propyloxycarbonyloxy) ethoxy-, 1- (cyclohexyloxycarbonyloxy) ethoxy-, 1- ( c-butyloxycarbonyloxy)ethoxy-, dimethylaminoethoxy-, diethylaminoethoxy-, (5-methyl-l, 3-dioxacyclopenten-2-on-4-yl)methoxy- , (5- (t-butyl) -1, 3-dioxacyclopenten-2-on-4- yl)methoxy-, ( 1, 3-dioxa-5-phenyl-cyclopenten-2-on-4-yl)methoxy-, or 1- (2- (2-methoxypropyDcarbonyloxy) ethoxy-; R 20 is H or CH 3 ; and n is 0-1. [5] Specifically preferred compounds of the above invention are compounds including enantiomeric or diasteriomeric forms thereof, or mixtures of enantiomeric or diastereomeric forms thereof, or pharmaceutically acceptable salt or prodrug forms thereof, selected from the group consisting of: (S) -2-phenylsulfonylamino-3- [ [ [8- (2- pyridinylaminomethyl) -] -l-oxa-2-azaspiro- [4,5] -dec-2-en-3-yl)carbonylamino]propionic acid, (S) -2-benzyloxycarbonylamino-3- [ [ [8- (2- pyridinylaminomethyl) -] -l-oxa-2-azaspiro- [4,5] -dec-2-en-3-yl] carbonylamino]propionic acid, (S)-2-[(2,4, 6-trimethylphenyl) sulfonyl]amino-3- [ [ [8- (2-pyridinylaminomethyl) -] -l-oxa-2- azaspiro- [4, 5] -dec-2-en-3- yl] carbonylamino]propionic acid, (S) -2- [ (3, 5-dimethylisoxazol4-yl) sulfonyl]amino-3- [ [ [8- (2-pyridinylaminomethyl) -] -l-oxa-2- azaspiro- [4, 5] -dec-2-en-3- yl] carbonylamino]propionic acid, (S) -2-phenylsulfonylamino-3- [ [ [8- [ (6-aminopyridin- 2-yl)methyl] -] -l-oxa-2, 8-diazaspiro- [4, 5] -dec- 2-en-3-yl] carbonylamino]propionic acid, (S) -2-phenylsulfonylamino-3- [ [ [8- [ (6-aminopyridin- 2-yl) ethyl] ] -l-oxa-2 , 8-diazaspiro- [4,4] -non- 2-en-3-yl] carbonylamino]propionic acid, (S) -2-phenylsulfonylamino-3- [ [ [8- (2- pyridinylaminomethyl) -] -l-oxa-2-azaspiro- [4,4] -non-2-en-3-yl] carbonylamino]propionic acid, (Ξ)-2-phenylsulfonylamino-3- [ [ [8- [2- (4,5- dihydroimidazol-2-yl) aminomethyl] -] -l-oxa-2- azaspiro- [4,5] -dec-2-en-3-yl] carbonylamino] - propionic acid, (S)-2- [ (2- ethylphenyl) sulfonyl] amino-3- [ [ [8- (2- pyridinylaminomethyl) -] -l-oxa-2-azaspiro- [4, 5] -dec-2-en-3-yl] carbonylamino]propionic acid, (S)-2- [ (2-chloro-4-methylphenyl) sulfonyl] amino-3- [ [ [8- (2-pyridinylaminomethyl) -] -l-oxa-2- azaspiro- [4,5] -dec-2-en-3- yl] carbonylamino]propionic acid, (S)-2- [ (4-biphenyl) sulfonyl] amino-3-[ [ [8- (2- pyridinylaminomethyl) -] -l-oxa-2-azaspiro- [4,5] -dec-2-en-3-yl] carbonylamino] propionic acid, (S) -2- [ (2-bromophenyl) sulfonyl]amino-3- [ [ [8- (2- pyridinylaminomethyl) -] -l-oxa-2-azaspiro- [4,5] -dec-2-en-3-yl] carbonylamino] propionic acid, (S) -2- [(2-naphthyl) sulfonyl] amino-3-[ [ [8- (2- pyridinylaminomethyl) -] -l-oxa-2-azaspiro- [4, 5] -dec-2-en-3-yl] carbonylamino] propionic acid, (S)-2-[ (1-naphthyl) sulfonyl]amino-3-[ [ [8- (2- pyridinylaminomethyl) -] -l-oxa-2-azaspiro- [4,5] -dec-2-en-3-yl] carbonylamino] ropionic acid. (S) -2-phenylsulfonylamino-3- [ [ [8- (2- imidazolylaminomethyl) -] -l-oxa-2-azaspiro- [4, 5] -dec-2-en-3-yl] carbonylamino] propionic acid, (S) -2-benzyloxycarbonylamino-3- [ [ [8- (2- imidazolylaminomethyl) -] -l-oxa-2-azaspiro- [4, 5] -dec-2-en-3-yl] carbonylamino]propionic acid, (S) -2- [ (2,4, 6-trimethylphenyl) sulfonyl] amino-3- [ [ [8- (2-imidazolylaminomethyl) -] -l-oxa-2- azaspiro- [4, 5] -dec-2-en-3- yl] carbonylamino]propionic acid, (S)-2- [ (2,6-dimethylphenyl)sulfonyl]amino-3-[ [ [8- (2-imidazolylaminomethyl) -] -l-oxa-2-azaspiro- [4, 5] -dec-2-en-3-yl] carbonylamino] propionic acid, (S) -2- [ (2, 6-dichlorophenyl) sulfonyl]amino-3- [ [ [8- (2-imidazolylaminomethyl) -] -1-oxa-2-azaspiro- [4, 5] -dec-2-en-3-yl] carbonylamino] propionic acid, (S) -2- [ (2, 6-dimethyl-4-phenyl)phenylsulfonyl]amino- 3- [ [ [8- (2-imidazolylaminomethyl) -] -l-oxa-2- azaspiro- [4, 5] -dec-2-en-3- yl] carbonylamino] ropionic acid, (S)-2-[ (2-naphthyl) sulfonyl] amino-3-[ [ [8- (2- imidazolylaminomethyl) -] -l-oxa-2-azaspiro- [4,5] -dec-2-en-3-yl] carbonylamino] propionic acid, (S)-2-[biphenylsulfonyl]amino-3-[ [ [8-(2- imidazolylaminomethyl) -] -l-oxa-2-azaspiro- [4,5] -dec-2-en-3-yl] carbonylamino] propionic acid, (S) -2-phenylsulfonylamino-3- [ [7-benzyloxycarbonyl- 8- (2-imidazolylaminomethyl) -l-oxa-2, 7- diazaspiro- [4,4] -non-2-en-3- yl] carbonylamino]propionic acid, (S) -2-benzyloxycarbonylamino-3- [ [7- benzyloxycarbonyl-8- (2-imidazolylaminomethyl) - l-oxa-2, 7-diazaspiro- [4,4] -non-2-en-3- yl] carbonylamino]propionic acid, (S) -2- [ (2,4,6-trimethylphenyl)sulfonyl]amino-3- [ [7- benzyloxycarbonyl-8- (2-imidazolylaminomethyl) - l-oxa-2, 7-diazaspiro- [4,4] -non-2-en-3- yl] carbonylamino]propionic acid, (S)-2-[ (2, 6-dimethylphenyl) sulfonyl] amino-3-[ [7- benzyloxycarbonyl-8- (2-imidazolylaminomethyl) - l-oxa-2 , 7-diazaspiro- [4, 4] -non-2-en-3- yl] carbonylamino]propionic acid, (S)-2-[ (2,6-dichlorophenyl)sulfonyl]amino-3-[ [7- benzyloxycarbonyl-8- (2-imidazolylaminomethyl) - l-oxa-2, 7-diazaspiro- [4,4] -non-2-en-3- yl] carbonylamino]propionic acid, (S) -2- [ (2, 6-dimethyl-4-phenyl)phenylsulfonyl]amino- 3- [ [7-benzyloxycarbonyl-8- (2- imidazolylaminomethyl) -l-oxa-2,7-diazaspiro- [4,4] -non-2-en-3-yl] carbonylamino]propionic acid, (S) -2- [ (2-naphthyl) sulfonyl] amino-3- [ [7- benzyloxycarbonyl-8- (2-imidazolylaminomethyl) - l-oxa-2, 7-diazaspiro- [4,4] -non-2-en-3- yl] carbonylamino]propionic acid, (S) -2- [biphenylsulfonyl]amino-3- [ [7- benzyloxycarbonyl-8- (2-imidazolylaminomethyl) - l-oxa-2, 7-diazaspiro- [4, 4] -non-2-en-3- yl] carbonylamino]propionic acid, (S)-2-phenylsulfonylamino-3- [ [8- (2- imidazolylaminomethyl) -l-oxa-2, 7-diazaspiro- [4,4] -non-2-en-3-yl] carbonylamino] propionic acid, (S) -2-benzyloxycarbonylamino-3- [ [8- (2- imidazolylaminomethyl) -l-oxa-2 , 7-diazaspiro- [4,4] -non-2-en-3-yl] carbonylamino] propionic acid, (S)-2- [ (2,4, 6-trimethylphenyl) sulfonyl] amino-3- [ [8- (2-imidazolylaminomethyl) -l-oxa-2,7- diazaspiro- [4,4] -non-2-en-3- yl] carbonylamino]propionic acid, (S) -2- [ (2, 6-dimethylphenyl) sulfonyl]amino-3- [ [8- (2- imidazolylaminomethyl) -l-oxa-2,7-diazaspiro- [4,4] -non-2-en-3-yl] carbonylamino] propionic acid, (S)-2-[ (2, 6-dichlorophenyl) sulfonyl] amino-3- [ [8- (2- imidazolylaminomethyl) -l-oxa-2, 7-diazaspiro- [4, 4] -non-2-en-3-yl] carbonylamino] propionic acid, (S) -2- [ (2, 6-dimethyl-4-phenyl)phenylsulfonyl]amino- 3- [ [8- (2-imidazolylaminomethyl) -l-oxa-2, 7- diazaspiro- [4,4] -non-2-en-3- yl] carbonylamino]propionic acid, (S)-2-[ (2-naphthyl) sulfonyl] amino-3- [ [8- (2- imidazolyla inomethyl ) -l-oxa-2, 7-diazaspiro- [4,4] -non-2-en-3-yl] carbonylamino]propionic acid, (S) -2- [biphenylsulfonyl]amino-3- [ [8- (2- imidazolylaminomethyl) -l-oxa-2, 7-diazaspiro- [4, 4] -non-2-en-3-yl] carbonylamino] ropionic acid, (S) -2-phenylsulfonylamino-3- [ [7-benzyloxycarbonyl- 8- (2-pyridinylaminomethyl) -l-oxa-2,7- diazaspiro- [4,4] -non-2-en-3- yl] carbonylamino]propionic acid, (S) -2-benzyloxycarbonylamino-3- [ [7- benzyloxycarbonyl-8- (2-pyridinylaminomethyl) - l-oxa-2, 7-diazaspiro- [4,4] -non-2-en-3- yl]carbonylamino]propionic acid, (S)-2-[ (2, 4, 6-trimethylphenyl) sulfonyl]amino-3- [ [7- benzyloxycarbonyl-8- (2-pyridinylaminomethyl) - l-oxa-2,7-diazaspiro- [4,4] -non-2-en-3- yl]carbonylamino]propionic acid, (S)-2-[ (2, 6-dimethylphenyl) sulfonyl]amino-3-[ [7- benzyloxycarbonyl-8- (2-pyridinylaminomethyl) - l-oxa-2, 7-diazaspiro- [4, 4] -non-2-en-3- yl]carbonylamino]propionic acid, (S)-2-[ (2,6-dichlorophenyl)sulfonyl]amino-3-[ [7- benzyloxycarbonyl-8- (2-pyridinylaminomethyl) - l-oxa-2, 7-diazaspiro- [4,4]-non-2-en-3- yl]carbonylamino]propionic acid, (S) -2- [ (2, 6-dimethyl-4-phenyDphenylsulfonyl]amino- 3- [ [7-benzyloxycarbonyl-8- (2- pyridinylaminomethyl) -l-oxa-2,7-diazaspiro- [4,4] -non-2-en-3-y1]carbonylamino]propionic acid, (S)-2-[ (2-naphthyl) sulfonyl] amino-3-[ [7- benzyloxycarbonyl-8- (2-pyridinylaminomethyl) - l-oxa-2,7-diazaspiro- [4,4] -non-2-en-3- yl]carbonylamino]propionic acid, (S)-2-[biphenylsulfonyl]amino-3- [ [7- benzyloxycarbonyl-8- (2-pyridinylaminomethyl) - l-oxa-2, 7-diazaspiro- [4,4] -non-2-en-3- yl] carbonylamino]propionic acid, (S) -2-phenylsulfonylamino-3- [ [7-benzyloxycarbonyl- 8- (4, 5-dihydroimidazol-2-yl)aminomethyl-l-oxa- 2, 7-diazaspiro- [4, 4] -non-2-en-3- yl] carbonylamino]propionic acid, (S) -2-benzyloxycarbonylamino-3- [ [7- benzyloxycarbonyl-8- (4,5-dihydroimidazol-2- yl)aminomethyl-l-oxa-2,7-diazaspiro- [4,4]-non- 2-en-3-yl]carbonylamino] ropionic acid, (S)-2- [ (2,4,6-trimethylphenyl)sulfonyl]amino-3- [ [7- benzyloxycarbonyl-8- (4,5-dihydroimidazol-2- yl)aminomethyl-l-oxa-2,7-diazaspiro- [4,4]-non- 2-en-3-yl]carbonylamino]propionic acid, (S) -2- [ (2,6-dimethylphenyl) sulfonyl]amino-3- [ [7- benzyloxycarbonyl-8- (4,5-dihydroimidazol-2- yl)aminomethyl-l-oxa-2,7-diazaspiro- [4,4]-non- 2-en-3-yl]carbonylamino]propionic acid, (S)-2-[ (2,6-dichlorophenyl)sulfonyl]amino-3- [ [7- benzyloxycarbonyl-8-(4,5-dihydroimidazol-2- yl)aminomethyl-l-oxa-2,7-diazaspiro- [4,4]-non- 2-en-3-yl]carbonylamino]propionic acid, (S)-2- [ (2,6-dimethyl-4-phenyDphenylsulfonyl]amino- 3- [ [7-benzyloxycarbonyl-8- (4,5- dihydroimidazol-2-yl)aminomethyl-l-oxa-2,7- diazaspiro- [4,4] -non-2-en-3- yl]carbonylamino]propionic acid, (S)-2-[ (2-naphthyl)sulfonyl]amino-3-[ [7- benzyloxycarbonyl-8- (4,5-dihydroimidazol-2- yl)aminomethyl-l-oxa-2,7-diazaspiro- [4,4] -non- 2-en-3-yl]carbonylamino]propionic acid, (S)-2- [biphenylsulfonyl]amino-3- [ [7- benzyloxycarbonyl-8-8- (4,5-dihydroimidazol-2- yl)aminomethyl-l-oxa-2,7-diazaspiro- [4,4]-non- 2-en-3-yl]carbonylamino]propionic acid, (S) -2-phenylsulfonylamino-3- [ [8- (4, 5- dihydroimidazol-2-y1)aminomethyl-1-oxa-2,7- diazaspiro- [4,4] -non-2-en-3- yl]carbonylamino]propionic acid, (S) -2-benzyloxycarbonylamino-3- [ [8- (4,5- dihydroimidazol-2-yl)aminomethyl-l-oxa-2,7- diazaspiro- [4, 4] -non-2-en-3- yl] carbonylamino]propionic acid, (S)-2- [ (2,4,6-trimethylphenyl)sulfonyl]amino-3- [ [8- (4, 5-dihydroimidazol-2-y1)aminomethyl-1-oxa- 2, 7-diazaspiro- [4,4] -non-2-en-3- yl]carbonylamino]propionic acid, (S) -2- [ (2, 6-dimethylphenyl) sulfonyl]amino-3- [ [8- (4, 5-dihydroimidazol-2-yl)aminomethyl-l-oxa- 2, 7-diazaspiro- [4,4] -non-2-en-3- yl]carbonylamino]propionic acid, (S)-2-[ (2, 6-dichlorophenyl) sulfonyl]amino-3- [ [8- (4, 5-dihydroimidazol-2-yl)aminomethyl-1-oxa- 2, 7-diazaspiro- [4,4] -non-2-en-3- yl]carbonylamino]propionic acid, (S)-2-[ (2, 6-dimethyl-4-phenyl)phenylsulfonyl]amino- 3- [ [8- (4, 5-dihydroimidazol-2-yl)aminomethyl-1- oxa-2,7-diazaspiro- [4, 4] -non-2-en-3- yl]carbonylamino]propionic acid, (S)-2-[ (2-naphthyl)sulfonyl]amino-3-[ [8- (4,5- dihydroimidazol-2-yl)aminomethyl-l-oxa-2,7- diazaspiro- [4,4] -non-2-en-3- yl] carbonylamino]propionic acid, (S) -2- [biphenylsulfonyl]amino-3- [ [8- (4, 5- dihydroimidazol-2-y1) aminomethyl-1-oxa-2,7- diazaspiro- [4,4] -non-2-en-3- yl]carbonylamino] ropionic acid, and (S)-2-[(2,4, 6-trimethylphenyl) sulfonyl] amino-3- [ [8- (2-benzimidazolyl)aminomethyl-l-oxa-2,7- diazaspiro- [4,4] -non-2-en-3- yl] carbonylamino]propionic acid. In the present invention it has been discovered that the compounds of Formula I above are useful as inhibitors of cell-matrix and cell-cell adhesion processes. The present invention includes novel compounds of Formula I and methods for using such compounds for the prevention or treatment of diseases resulting from abnormal cell adhesion to the extracellular matrix which comprises administering to a host in need of such treatment a therapeutically effective amount of such compound of Formula I. In the present invention it has also been discovered that the compounds of Formula I above are useful as inhibitors of <χvβ 3 - The compounds of the present invention inhibit the binding of vitronectin to α v β 3 and inhibit cell adhesion. The present invention also provides pharmaceutical compositions comprising a compound of Formula I and a pharmaceutically acceptable carrier. The compounds of Formula I of the present invention are useful for the treatment (including prevention) of angiogenic disorders. The term "angiogenic disorders" as used herein includes conditions involving abnormal neovascularization, such as tumor metastasis and ocular neovascularization, including, for example, diabetic retinopathy, neovascular glaucoma, age-related macular degeneration, and retinal vein occlusion, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I described above. The compounds of Formula I of the present invention may be useful for the treatment or prevention of other diseases which involve cell adhesion processes, including, but not limited to, inflammation, bone degradation, thromboembolic disorders, restenosis, rheumatoid arthritis, asthma, allergies, adult respiratory distress syndrome, graft versus host disease, organ transplantation rejection, septic shock, psoriasis, eczema, contact dermatitis, osteoporosis, osteoarthritis, atherosclerosis, inflammatory bowel disease and other autoimmune diseases. The compounds of Formula I of the present invention may also be useful for wound healing. The term "thromboembolic disorders" as used herein includes conditions involving platelet activation and aggregation, such as arterial or venous cardiovascular or cerebrovascular thromboembolic disorders, including, for example, thrombosis, unstable angina, first or recurrent myocardial infarction, ischemic sudden death, transient ische ic attack, stroke, atherosclerosis, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary and cerebral arterial thrombosis, myocardial infarction, cerebral embolism, kidney embolisms, pulmonary embolisms, or such disorders associated with diabetes, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I described above. The compounds of the present invention may be used for other ex vivo applications to prevent cellular adhesion in biological samples. The compounds of the present invention can also be administered in combination with one or more additional therapeutic agents selected from: anti-coagulant or coagulation inhibitory agents, such as heparin or warfarin; anti-platelet or platelet inhibitory agents, such as aspirin, piroxicam, or ticlopidine; thrombin inhibitors such as boropeptides, hirudin or argatroban; or thrombolytic or fibrinolytic agents, such as plasminogen activators, anistreplase, urokinase, or streptokinase. The compounds of Formula I of the present invention can be administered in combination with one or more of the foregoing additional therapeutic agents, thereby to reduce the doses of each drug required to achieve the desired therapeutic effect. Thus, the combination treatment of the present invention permits the use of lower doses of each component, with reduced adverse, toxic effects of each component. A lower dosage minimizes the potential of side effects of the compounds, thereby providing an increased margin of safety relative to the margin of safety for each component when used as a single agent. Such combination therapies may be employed to achieve synergistic or additive therapeutic effects for the treatment of thromboembolic disorders. By "therapeutically effective amount" it is meant an amount of a compound of Formula I that when administered alone or in combination with an additional therapeutic agent to a cell or mammal is effective to prevent or ameliorate the thromboembolic disease condition or the progression of the disease. By "administered in combination" it is meant that the compound of Formula I and one or more additional therapeutic agents are administered concurrently to the mammal being treated. When administered in combination each component may be administered at the same time or sequentially in any order at different points in time. Thus, each component may be administered separately but sufficiently closely in time so as to provide the desired therapeutic effect. The term anti-coagulant agents (or coagulation inhibitory agents) , as used herein, denotes agents that inhibit blood coagulation. Such agents include warfarin (available as COUMADIN ® ) and heparin. The term anti-platelet agents (or platelet inhibitory agents) , as used herein, denotes agents that inhibit platelet function such as by inhibiting the aggregation, adhesion or granular secretion of platelets. Such agents include the various known non-steroidal anti- inflammatory drugs such as aspirin, ibuprofen, naproxen, sulindac, indomethacin, mefenamate, droxicam, diclofenac, sulfinpyrazone, and piroxicam, including pharmaceutically acceptable salts or prodrugs thereof. Other suitable anti-platelet agents include ticlopidine, including pharmaceutically acceptable salts or prodrugs thereof. Ticlopidine is also a preferred compound since it is known to be gentle on the gastro-intestinal tract in use. Still other suitable platelet inhibitory agents include thromboxane-A2-receptor antagonists and thromboxane-A2-synthetase inhibitors, as well as pharmaceutically acceptable salts or prodrugs thereof. The phrase thrombin inhibitors (or anti-thrombin agents) , as used herein, denotes inhibitors of the serine protease thrombin. By inhibiting thrombin, various thrombin-mediated processes, such as thrombin-mediated platelet activation (that is, for example, the aggregation of platelets, and/or the granular secretion of plasminogen activator inhibitor-1 and/or serotonin) and/or fibrin formation are disrupted. Such inhibitors include boroarginine derivatives and boropeptides, hirudin and argatroban, including pharmaceutically acceptable salts and prodrugs thereof. Boroarginine derivatives and boropeptides include N-acetyl and peptide derivatives of boronic acid, such as C-terminal α-aminoboronic acid derivatives of lysine, ornithine, arginine, homoarginine and corresponding isothiouronium analogs thereof. The term hirudin, as used herein, includes suitable derivatives or analogs of hirudin, referred to herein as hirulogs, such as disulfatohirudin. Boropeptide thrombin inhibitors include compounds described in Kettner et al., U.S. Patent No. 5,187,157 and European Patent Application Publication Number 293 881 A2, the disclosures of which are hereby incorporated herein by reference. Other suitable boroarginine derivatives and boropeptide thrombin inhibitors include those disclosed in PCT Application Publication Number 92/07869 and European Patent Application Publication Number 471 651 A2, the disclosures of which are hereby incorporated herein by reference, in their entirety. The phrase thrombolytics (or fibrinolytic) agents (or thrombolytics or fibrinolytics) , as used herein, denotes agents that lyse blood clots (thrombi) . Such agents include tissue plasminogen activator, anistreplase, urokinase or streptokinase, including pharmaceutically acceptable salts or prodrugs thereof. Tissue plasminogen activator (tPA) is commercially available from Genentech Inc., South San Francisco, California. The term anistreplase, as used herein, refers to anisoylated plasminogen streptokinase activator complex, as described, for example, in European Patent Application No. 028,489, the disclosures of which are hereby incorporated herein by reference herein, in their entirety. The term urokinase, as used herein, is intended to denote both dual and single chain urokinase, the latter also being referred to herein as prourokinase. Administration of the compounds of Formula I of the invention in combination with such additional therapeutic agent, may afford an efficacy advantage over the compounds and agents alone, and may do so while permitting the use of lower doses of each. A lower dosage minimizes the potential of side effects, thereby providing an increased margin of safety. The compounds of the present invention are also useful as standard or reference compounds, for example as a quality standard or control, in tests or assays involving the binding of vitronectin or fibrinogen to o v β 3 . Such compounds may be provided in a commercial kit, for example, for use in pharmaceutical research involving αvβ 3 . The compounds of the present invention may also be used in diagnostic assays involving αvβ 3 . The compounds herein described may have asymmetric centers. Unless otherwise indicated, all chiral, diastereomeric and racemic forms are included in the present invention. Many geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. It will be appreciated that compounds of the present invention that contain asymmetrically substituted carbon atoms may be isolated in optically active or racemic forms. It is well known in the art how to prepare optically active forms, such as by resolution of racemic forms or by synthesis, from optically active starting materials. All chiral, diastereomeric, racemic forms and all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomer form is specifically indicated. When any variable (for example but not limited to, R 2 , R 4 , R 6 , R 7 , R 8 , R 12 ,and R 14 , n, etc.) occurs more than one time in any constituent or in any formula, its definition on each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown to be substituted with 0-2 R 4 , then said group may optionally be substituted with up to two R 4 and R 4 at each occurrence is selected independently from the defined list of possible R 4 . Also, by way of example, for the group -N(R 5a ) 2 , each of the two R 5 substituents on N is independently selected from the defined list of possible R 5 . Similarly, by way of example, for the group -C(R 7 ) 2 ~, each of the two R 7 substituents on C is independently selected from the. defined list of possible R 7 . When a bond to a substituent is shown to cross the bond connecting two atoms in a ring, then such substituent may be bonded to any atom on the ring. When a bond joining a substituent to another group is not specifically shown or the atom in such other group to which the bond joins is not specifically shown, then such substituent may form a bond with any atom on such other group. When a substituent is listed without indicating the atom via which such substituent is bonded to the rest of the compound of Formula I, then such substituent may be bonded via any atom in such substituent. For example, when the substituent is piperazinyl, piperidinyl, or tetrazolyl, unless specified otherwise, said piperazinyl, piperidinyl, tetrazolyl group may be bonded to the rest of the compound of Formula I via any atom in such piperazinyl, piperidinyl, tetrazolyl group. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. By stable compound or stable structure it is meant herein a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent. The term "substituted", as used herein, means that any one or more hydrogen on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound. When a substitent is keto (i.e., =0), then 2 hydrogens on the atom are replaced. As used herein, "alkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms (for example, "Co-Cio" denotes alkyl having 0 to 10 carbon atoms; thus, Co denotes a direct bond between the groups linked by the Co group) ; "haloalkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, substituted with 1 or more halogen (for example -C V F W where v = 1 to 3 and w = 1 to (2v+l) ) ; "alkoxy" represents an alkyl group of indicated number of carbon atoms attached through an oxygen bridge; "cycloalkyl" is intended to include saturated ring groups, including mono-,bi- or poly-cyclic ring systems, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and adamantyl; and "biycloalkyl" is intended to include saturated bicyclic ring groups such as [3.3.0]bicyclooctane, [4.3.0]bicyclononane, [4.4.O]bicyclodecane (decalin) , [2.2.2]bicyclooctane, and so forth. "Alkenyl" is intended to include hydrocarbon chains of either a straight or branched configuration and one or more unsaturated carbon-carbon bonds which may occur in any stable point along the chain, such as ethenyl, propenyl and the like; and "alkynyl" is intended to include hydrocarbon chains of either a straight or branched configuration and one or more triple carbon-carbon bonds which may occur in any stable point along the chain, such as ethynyl, propynyl and the like. The terms "alkylene", "alkenylene", "phenylene", and the like, refer to alkyl, alkenyl, and phenyl groups, respectively, which are connected by two bonds to the rest of the structure of Formula I. Such "alkylene", "alkenylene", "phenylene", and the like, may alternatively and equivalently be denoted herein as "- (alkyl) -", "- (alkyenyl) -" and "- (phenyl)-", and the like. "Halo" or "halogen" as used herein refers to fluoro, chloro, bromo and iodo; and "counterion" is used to represent a small, negatively charged species such as chloride, bromide, hydroxide, acetate, sulfate and the like. As used herein, "aryl" or "aromatic residue" is intended to mean phenyl or naphthyl; the term "arylalkyl" represents an aryl group attached through an alkyl bridge. As used herein, "carbocycle" or "carbocyclic residue" is intended to mean any stable 3- to 7- membered monocyclic or bicyclic or 7- to 14-membered bicyclic or tricyclic or an up to 26-membered polycyclic carbon ring, any of which may be saturated, partially unsaturated, or aromatic. Examples of such carbocyles include, but are not limited to, cyclopropyl, cyclopentyl, cyclohexyl, phenyl, biphenyl, naphthyl, indanyl, adamantyl, or tetrahydronaphthyl (tetralin) . As used herein, the term "heterocycle" or "heterocyclic" is intended to mean a stable 5- to 7- membered monocyclic or bicyclic or 7- to 10-membered bicyclic heterocyclic ring which may be saturated, partially unsaturated, or aromatic, and which consists of carbon atoms and from 1 to 4 heteroatoms independently selected from the group consisting of N, 0 and S and wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen may optionally be quaternized, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom which results in a stable structure. The heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable. Examples of such heterocycles include, but are not limited to, pyridyl (pyridinyl), pyrimidinyl, furanyl (furyl), thiazolyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, benzofuranyl, benzothiophenyl, indolyl, indolenyl, isoxazolinyl, isoxazolyl, quinolinyl, isoquinolinyl, benzimidazolyl, piperidinyl, 4-piperidonyl, pyrrolidinyl, 2-pyrrolidonyl, pyrrolinyl, tetrahydrofuranyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl or octahydroisoquinolinyl, azocinyl, triazinyl, 6H-1,2,5- thiadiazinyl, 2H, 6H-1 , 5, 2-dithiazinyl, thianthrenyl, pyranyl, isobenzofuranyl, chromenyl, xanthenyl, phenoxathiinyl, 2H- yrrolyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, isoxazolinyl, isoxazolyl, oxazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, isoindolyl, 3H-indolyl, indolyl, lH-indazolyl, purinyl, 4H-quinolizinyl, isoquinolinyl, quinolinyl, phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, pteridinyl, 4aH-carbazole, carbazole, β-carbolinyl, phenanthridinyl, acridinyl, perimidinyl, phenanthrolinyl, phenazinyl, phenarsazinyl, phenothiazinyl, furazanyl, phenoxazinyl, isochromanyl, chromanyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidinyl, piperazinyl, indolinyl, isoindolinyl, quinuclidinyl, morpholinyl or oxazolidinyl. Also included are fused ring and spiro compounds containing, for example, the above heterocycles. As used herein, the term "heteroaryl" refers to aromatic heterocyclic groups. Such heteroaryl groups are preferably 5-6 membered monocyclic groups or 8-10 membered fused bicyclic groups. Examples of such heteroaryl groups include, but are not limited to pyridyl (pyridinyl), pyrimidinyl, furanyl (furyl), thiazolyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, indolyl, isoxazolyl, oxazolyl, pyrazinyl, pyrimidinyl, pyridazinyl, benzofuranyl, benzothienyl, benzimidazolyl, quinolinyl, or isoquinolinyl. As used herein, "prodrugs" refer to any covalently bonded carriers which release the active parent drug according to Formula I in vivo when such prodrug is administered to a mammalian subject. Prodrugs of the compounds of Formula I are prepared by modifying functional groups present in the compounds in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compounds. Prodrugs include compounds of Formula I wherein hydroxyl, amino, sulfhydryl, or carboxyl groups are bonded to any group that, when administered to a mammalian subject, cleaves to form a free hydroxyl, amino, sulfhydryl, or carboxyl group respectively. Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups in the compounds of Formula I, and the like. As used herein, "pharmaceutically acceptable salts" refer to derivatives of the disclosed compounds wherein the parent compound of Formula I is modified by making acid or base salts of the compound of Formula I. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts of the compounds of Formula I include the conventional non- toxic salts or the quaternary ammonium salts of the compounds of Formula I formed, for example, from non- toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like. The pharmaceutically acceptable salts of the present invention can be synthesized from the compounds of Formula I which contain a basic or acidic moiety by conventional chemical methods. Generally, the salts are prepared by reacting the free base or acid with stoichiometric amounts or with an excess of the desired salt-forming inorganic or organic acid or base in a suitable solvent or various combinations of solvents. The pharmaceutically acceptable salts of the acids of Formula I with an appropriate amount of a base, such as an alkali or alkaline earth metal hydroxide e.g. sodium, potassium, lithium, calcium, or magnesium, or an organic base such as an amine, e.g., dibenzylethylenediamine, trimethyla ine, piperidine, pyrrolidine, benzylamine and the like, or a quaternary ammonium hydroxide such as tetramethylammonium hydroxide and the like. As discussed above, pharmaceutically acceptable salts of the compounds of the invention can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid, respectively, in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington 's Pharmaceutical Sciences , 17th ed. , Mack Publishing Company, Easton, PA, 1985, p. 1418, the disclosure of which is hereby incorporated by reference. The disclosures of all of the references cited herein are hereby incorporated herein by reference in their entirety. Synthesis The compounds of the present invention can be prepared in a number of ways well known to one skilled in the art of organic synthesis. The compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art. Preferred methods include, but are not limited to, those described below. All references cited herein are hereby incorporated in their entirety herein by reference. Compounds of Formula I wherein Q includes an isoxazoline ring as one ring of the spirocycle can be conveniently prepared by dipolar cycloaddition of nitrile oxides with appropriate dipolarophiles (for reviews of 1,3-dipolar cycloaddition chemistry, see 1,3- Dipolar Cycloaddition Chemistry (Padwa, ed.), Wiley, New York, 1984; Kanemasa and Tsuge, Heterocvcles 1990, 3_J 719) . The requisite nitrile oxides are in turn prepared from commercially available precursors or appropriately substituted aldehydes via the intermediate oximes. Scheme 1 illustrates one synthetic sequence which will provide compounds of Formula I of this invention. Scheme 1 Swβrn Oxidation ion R= Me or tBu Treatment of a methylenecycloalkylmethanol with ethyl chlorooximidoacetate in a suitable solvent, such as tetrahydrofuran or dichloromethane, in the presence of a mild base, such as sodium bicarbonate or triethylamine, provides a spirocycle intermediate, 1(a) . Alternately, the cycloaddition can be carried out by thermal decomposition of diethyl nitromalonate in refluxing mesitylene by the method of Shimizu et al. ( Bull Chem. Soc . Jpn . , 1985, ϋjl, 2519-2522). The hydroxyl group in 1(a) can be subsequently oxidized to the corresponding aldehyde by any of a number of known methods for carrying out this transformation, i.e., (See Manacuso & Swern, Synthesis, 1981, 165; Tidwell, Synthesis, 1990, 857; D.B. Dess & J.C. Martin, J. Org. Chem. , 1983, 4 4155; op cit. J. Amer. Chem. Soc , 199J., 22., 77; R.E. Ireland & L. Liu, J " . Org. Chem, 1993, 5_8_, 2899) . Reductive a ination of the resulting aldehyde with an appropriate aminoheterocycle, such as 2-aminopyridine, can be achieved using sodium triacetoxyborohydride (Abdel-Magid, A. F.; Maryanoff, C. A. Synlet t , 1990, __., 537) to provide a secondary amine. Optional protection of the nitrogen as its BOC derivative yields 1(c). Subsequent hydrolysis of the ethyl ester using conventional methods known to one skilled in the art of organic synthesis gives the corresponding acid 1(d). Coupling of compound 1(d) to an appropriately substituted a- or /J-amino ester, 1(e) affords compounds of formula 1(f). The coupling is carried out using any of the many methods for the formation of amide bonds known to one skilled in the art of organic synthesis. These methods include but are not limited to conversion of the acid to the corresponding acid chloride or fluoride, or use of standard coupling procedures such as the azide method, mixed carbonic acid anhydride (isobutyl chloroformate) method, carbodiimide (dicyclohexylcarbodiimide, diisopropylcarbodiimide, or water-soluble carbodiimides) method, active ester (p-nitrophenyl ester, N- hydroxysuccinic imido ester) method, carbonyldiimidazole method, or coupling with phosphorus reagents such as BOP-C1. Some of these methods (especially the carbodiimide) can be enhanced by the addition of 1- hydroxybenzotriazole. Deprotection of compound 1(f) is carried out using standard methods of removal of carboxy and amino protecting groups to provide target compounds of formula Kg) . Additional compounds of formula I can be prepared as shown in Scheme 2. Cycloaddition product, 1(a) can be converted to the corresponding amino compound by conversion to azide 2(a) using diphenylphosphoryl azide under Mitsunobu conditions (Mitsunobu, 0. Synthesis 1981, 1) and reduction of the resulting azide with triphenylphosphine (Staudinger, H.; Meyer, J. Helv. Chi . Acta . 1919, 2 , 635) Protection of the resulting amino group as its BOC derivative provides intermediate 2(b). Alternately, the amine function can be introduced prior to cycloaddition by conversion of the starting methylenecycloalkylmethanol to the corresponding tosylate, displacement of the tosyl group with sodium azide, reduction to the amine and treatment with di-t- butyldicarbonate. Subsequent 1,3 dipolarcycloaddition provides 2(a) . Ester hydrolysis and amide coupling as described above provides compounds of formula 2(d). Hydrolysis of the ester, removal of the BOC protecting group and treatment of the free amine with an appropriate heterocyclic isothiouronium salt, such as those listed in the scheme, provides compounds of Formula 2(f) . Scheme 2 Compounds of Formula I, wherein R 1 is a 7- azabenzimidazol-2-yl, group can also be prepared from cycloaddition product 1(a) as depicted in Scheme 3. Jones oxidation of the primary hydroxyl group provides acid 3(a) which is condensed with 2,3-diaminopyridine to provide the 7-azabenzimidazole derivative, 3(b). This intermediate is converted to compounds of the invention by the steps of ester hydrolysis, coupling to compounds of formula 1(e) and deprotection described in detail above. Scheme 3 3(e) The appropriately substituted racemic β-amino acids may be purchased commercially or, as is shown in Scheme 4, Method 1, prepared from the appropriate aldehyde, malonic acid and ammonium acetate according to the procedure of Johnson and Livak (J. Am. Chem. So , 1936, 5_&, 299) . Racemic β-substituted-β-amino esters may be prepared through the reaction of dialkylcuprates or alkyllithiums with 4-benzoyloxy-2-azetidinone followed by treatment with anhydrous ethanol (Scheme 4, Method 2) or by reductive amination of β-keto esters as is described in WO9316038. (Also see Rico et al., J. Org. Chem. 1993, 5J_, 7948-51.) Enantiomerically pure β- substituted-β-amino acids can be obtained through the optical resolution of the racemic mixture or can be prepared using numerous methods, including: Arndt- Eistert homologation of the corresponding α-amino acids as shown in Scheme 4, Method 3 (see Meier, and Zeller, Anσew. Chem. Int. Ed. Enσl. 1975, 11, 32; Rodriguez, et al. Tetrahedron Lett. 1990, _ L, 5153; Greenlee, J- Med. Chem. 1985, 2£, 434 and references cited within); and through an enantioselective hydrogenation of a dehydroamino acid as is shown in Scheme 4, Method 4 (see Asymmetric Synthesis, Vol. 5, (Morrison, ed. ) Academic Press, New York, 1985) . A comprehensive treatise on the preparation of β-amino acid derivatives may be found in patent application WO 93/07867, the disclosure of which is hereby incorporated by reference. Scheme 4 Method 1 Method 2 BocHN ^^COzMe R β The synthesis of N 2 -substituted diaminopropionic acid derivatives can be carried out via Hoffman rearrangement of a wide variety of asparagine derivatives as described in Synthesis, 266-267, (1981] or by manipulation of the commercially available 3- amino-2-benzyloxycarbonylaminopropιonic acid. Additional dipolarophiles useful for the preparation of the compounds of this invention are either commercially available or may be prepared by numerous methods. Synthesis of representative examples and their conversion into compounds of Formula I are illustrated in the following schemes. Heating a neat mixture of 8-aza-l,4- dioxaspiro(4, 5)decane and 2, 6-dibromopyridine provides bromopyridine intermediate 5(a) as shown in Scheme 5. Hydrolysis of the acetal protecting group gives the ketone, 5(b) which can then undergo olefination to compound 5(c). The olefination can be carried out by a number of methods known to one skilled in the art. (For suitable olefination methods, see S. H. Pine et al . , Synthesis 1991, 165; Bull. Chem Soc . Jpn . , 1980, 5_3_, 1698; or J. Org. Chem. 1968, H, 780.) The alkene is then subjected to the 1,3-dipolar cycloaddition conditions described above to provide the spirocyclic system, 5(d). Amination with potassium amide in liquid ammonia followed by protection of the resulting amine as its BOC derivative gives compound 5(e). This intermediate is then carried on to compounds of Formula 5(g) using the steps previously described. Scheme 5 COjEt 5(f) Preparation of the analogous (4,4) spiro system is outlined in Scheme 6. Hydrogenation of commercially available l-benzyl-3-hydroxypyrolidine and selective reprotection of the amine as the t-butylcarbamate provides 6(a) . Oxidation of the hydroxyl to the ketone 6(b) by Swern oxidation or other standard methods followed by olefination as described above provides alkene 6(c). This alkene is then subjected to 1,3- dipolar cycloaddition as previously described to provide the spirocycle 6(d). Ester hydrolysis and coupling to a suitable β-amino ester gives 6(e). Removal of the BOC protecting group and treament with 2-bromo-6-t- butoxycarbonylaminopyridine (Aust. J. Chem . 1982, 35, 202-5) gives intermediate 6(f). Finally, deprotection provides compounds of this invention of Formula 6(g). Scheme 6 oxidation 6(a) 6 < b ) PhaPCH Br Et0 2 CC(=NOH)CI KOtBu/THF TEA > C H 2 CI 2 6(c) 6 ( d ) A further class of spirocycles useful in the present invention is prepared as outlined in Scheme 7. Reduction of N-Cbz 4-hydroxyproline with borane-dimethyl sulfide complex in tetrahydrofuran provides diol 7(a). The primary hydroxyl is then selectively protected as its t-butyldimethylsilyl ether, 7(b). Oxidation of the remaining secondary alcohol using methods described above provides ketone 7(c) which can be converted to alkene 7(d) by olefination. Compound 7(d) then undergoes 1,3-dipolarcycloaddition to provide spirocycle 7(e). Deprotection of the silyl ether by treatment with fluoride ion followed by Swern oxidation of the resulting alcohol provides aldehyde 7(f). Reductive amination with 2-aminopyridine followed by Boc protection of the resulting secondary amine yields 7(g). Ester hydrolysis, coupling to the desired 2,3- diaminopropionate derivative and deprotection gives 7(h) . Alternately prior to deprotection the Cbz group can be selectively removed and alternate R 10 groups introduced using standard methods known to one skilled in the art to provide compounds 7(i). Scheme 7 r=1-2 7(a) ^ 7(c) 7(d) Compounds of Formula I wherein Q includes a 1,2,4- oxadiazoline as one ring of the spriocycle are prepared as shown in Scheme- 8. Protection of 4- methylenecyclohexylmethanol as its t-butyldimethylsilyl ether followed by ozonolysis of the double bond provides ketone 8(a). Treatment of compound 8(a) with a suitable amine provides an imine 8(b) which can undergo 1, 3-dipolarcycloaddition with a nitrile oxide to provide spirocycle 8(c). Further elaboration as described above would provide additional compounds of the present invention of Formula 8(b). Scheme a Swem 1 - Reductive ». ammation Oxidation 2. (BOCJaP/CHsCIa K β ) R= Me or tBu Additional spirocyclic compounds useful in the present invention can be prepared as outlined in Scheme 9 wherein 1,3-dipolarcycloaddition is carried using ethyl diazoacetate (E. Keller et al . , Tetrahedron, 1993, 12, 8899) to provide spirocycle 9(b) (R 10 = H) . The nitrogen of the resulting pyrazole ring may be optionally functionalized using standard methodology prior to carrying out the remaining steps leading to compounds of formula 9(g). Scheme 9 j , 3. TBAF 1 - Reductive amination 2 - (BOCJjO/CHgCIa Fully saturated spirocycles are obtained by 1,3- dipolarcycloadditon of α-methoxycarbonylnitrones to an appropriately substituted alkene as illustrated in Scheme 10. (Y. Inouye et al., Bull Chem. Soc. Jpn, 1979, 5 ., 3763; J. Hara et al . , ibid., 1981, 5 ., 3871) . Scheme 10 The detailed processes for preparing the compounds of Formula I are illustrated by the following Examples . It is , however, understood that this invention is not limited to the specific details of these examples. Melting points (mp) are uncorrected. Proton nuclear magnetic resonance spectra (NMR) were measured in chloroform-d (CDC1 3 ) unless otherwise specified and the peaks are reported in parts per million (ppm) downfield from tetramethylsilane (TMS) . The coupling patterns are reported as follows: s, singlet; d, doublet; t, triplet; q, quartet; m, ultiplet; bs, broad singlet; bm, broad multiplet. Infrared spectra are reported in reciprocal centimeters (cm " ) . All final compounds gave satisfactory nmr and HRMS data and were analyzed to be >98% pure by reverse phase analytical HPLC. F.xamnl es Exampl e TORI ( £ ) -2-benzvloxvcarbonvlamino-3- π 8- ( 2- nvridinvlamino methvl-l-oxa-2-azas ro- r4 . 51 -dec-2-en-3- vl 1 carbnπvl ami nol nronioni r acid Ethvl r ( 8-hvdrnxvmetbvl ) -l-oxa-2-a?.a.qniro- r4 . 1 -riec-2- en-3-yllπarboxyiat.e; 1(a) Method A: 4-Methylenecyclohexylmethanol (2.52g, 20mmol, Wiley Organics, 63% purity) and sodium bicarbonate (8.4g, lOOmmol) in 45ml of 2:1 THF:H 2 θ was cooled in an ice bath. Ethyl chlorooximidoacetate (5.00g, 33mmol) in 30ml 2:1 THF:H 2 θ was then added, and the mixture stirred at room temperature for 18 hours. The mixture was then diluted with ethyl acetate and washed with water. The aqueous layer was extracted with one more portion of ethyl acetate. The organic layers were combined, dried (MgSU 4 ) , filtered, concentrated and the residue purified by flash chromatography (silica gel column/1:1 EtOAc:Hexane) to afford 1(a) as a colorless oil (57.6% yield). HRMS calcd. for C12H19NO 4 ([M+H] + ): 242.139233; found: 242.140376. Method B: A mixture of 4-Methylenecyclohexylmethanol (lOg, mol, Wiley Organics, 63% purity, 0.051 mol) and diethylnitromalonate (14 ml, 0.08 mol) in 100 ml mesitylene was refluxed for 4-5 hrs under a nitrogen atmosphere with stirring. The resulting yellow solution was evaporated on a rotary evaporator in vacuo and the residue purified by flash chromatography (silica gel/70:30 Hexane/ethyl acetate) to provide 6.4 g of 1(a) (52%) as 3/2 mixture of diastereomers by nmr. Ethvl r (B-formvl)-l-oxa-2-azaspiro-T4.51-dec-2-Pn-3- yllcarboxyla e: Kb) : Oxalyl chloride (0.70ml, 8mmol) in 5ml CH 2 CI 2 was cooled to -78°C in dry ice-acetone bath and treated with dimethylsulfoxide (0.74ml, 10.4mmol) in 10ml CH 2 CI 2 and stirred at -78°C for 15 minutes. Intermediate 1(a) (992mg, 4mmol) in 10ml CH 2 CI 2 was then added, and the mixture stirred at -78°C for 1 hour. Triethylamine (2.0g, 20mmol) in 5 ml CH 2 CI 2 was then added, and the mixture stirred at -78°C for 15 minutes. The bath was removed and the mixture allowed to warm up over a 30 minute period, diluted with CH 2 CI 2 (50ml) and washed with water followed by brine. The organic layer was separated, dried over anhydrous magnesium sulfate, filtered and concentrated to afford 0.68g of 1(b) as a clear oil. HRMS calcd. for C 12 H 17 NO 4 <[M+H] + ): 240.123583; found: 240.123665. Ethvl f8- r (N-t-butoxycarbonyl)-(N-2- Dvridinvl)aminomethvll-l-oxa-2-azasniro-r4.51-dec-2-en- 3-vllcarboxvlate 1(e): The intermediate 1(b) (1.068g, 4 mmol crude) and acetic acid (240mg, 4mmol) in 15ml 1,2- dichloroethane were treated with sodium triacetoxyborohydride (1.19g, 5.6mmol), and the mixture stirred at room temperature for 18 hours. The mixture was diluted with ethyl acetate and washed with sat. sodium bicarbonate and then brine. The organic layer was separated, dried over anhydrous magnesium sulfate, filtered and concentrated to afford 1.32g of amine as an oil. HRMS calcd. for Cι 7 H 23 N 3 θ 3 ([M+H] + ) : 318.181767; found: 318.183254. The crude amine and triethylamine (l.Og, lOmmol) in 20ml dichloromethane were treated with di-t-butyldicarbonate (2.18g, lOmmol), and stirred at room temperature for 18 hours. The mixture was diluted with dichloromethane and washed with water and brine. The organic layer was separated, dried over anhydrous magnesium sulfate, filtered, concentrated and the residue purified by flash chromatography (silica gel/1:3 EtOAc:Hexane) to afford 845mg of 1(c) as a colorless oil (50.6% yield from 1(a)). HRMS calcd. for C 22 H 31 N 3 O 5 ([M+H] + ): 418.234197; found: 418.233666. rR- r (N-t-Bυtoxvcarbonvl - (N-2-r)vridinv3 ϊaminomethvll -1- oxa-2-azasmro-r4.51-dec-?.-en-3-vll arboxvlic acid l (ά) The intermediate 1(c) (209mg, 0.5mmol) in 4.5ml of 2:1 THF:H 2 θ was treated with lithium hydroxide monohydrate (25mg, 0.6mmol) and the mixture stirred at room temperature for 18 hours. The mixture was quenched with 0.6ml of 1 N HC1 and extracted with ethyl acetate (2x25ml) . The organic layer was separated, dried over anhydrous magnesium sulfate, filtered, concentrated to afford 199mg of 1(d) as a colorless foam. HRMS calcd. for C20H27N3O5 ([M+H] + ) : 390.202896; found: 390.202306. Methvl (S) -2-henzvloxvcarnonv1arni.no-3- r ffi- FN- (f.- butoxvcarbonvl)-N-(2-nvridinvl)amino1methvl-l-oxa-2- azasniro- f4. 1 -dec-2-en-3-v!1 arbonvlaminolπropionate 1(f) (R 15 = NHCbz, R = Me) : The intermediate 1(d) (199mg, 0.5mmol crude) , 1(e) (R 15 = HCbz, R = Me, 144mg, 0.5mmol) and BOP Reagent (265 mg, 0.6 mmol) in 3ml DMF were treated with 4-N-methylmorpholine (152 mg, 1.5 mmol) in 2ml DMF and the mixture stirred at room temperature for 18 hours. The mixture was diluted with ethyl acetate and washed with sat. sodium bicarbonate, water and then brine. The organic layer was separated, dried over anhydrous magnesium sulfate, filtered, concentrated and the residue purified by flash chromatography (silica gel column/1:1 EtOAc:Hexane followed by 10:1:10 EtOAc:EtOH:Hexane) to afford 213mg of 1(f) (R 15 = NHCbz, R = Me) as a white solid (68.3% yield from 1(c)) . HRMS calcd. for C32H41 5O8 ([M+H] + ) : 624.303339; found: 624.303031. (S)-2-benzvloxvcarbonvlamino-3-r f8- (2- nvridinvlamino)methvl-l-oxa-2-azaspiro-r4.51-dec-2-en-3- vllcarbonylamino1propionic acid 1(g) (R 15 = NHCbz) : The intermediate 1(f) (205mg, 0.33mmol crude) in 4ml of 1:1 MeOH:H2θ was treated with lithium hydroxide monohydrate (21mg, 0.5mmol) and the mixture stirred at room temperature for 18 hours. The mixture was neutralised with 0.5ml of 1 N HC1 and extracted with EtOAc. The organic layer was separated, dried over anhydrous magnesium sulfate, filtered, concentrated to afford 205mg of the free acid as a white solid. HRMS calcd. for C31H39N5O8 ([M+H] + ) : 610.287689; found: 610.290115. Crude acid was treated with 3ml of 4M HC1 in dioxane and stirred at room temperature for 18 hours. The mixture was concentrated in vacuo and the residue purified by preparative HPLC (C18/80% CH 3 CN:20% H 2 O:0.05% TFA) to afford 132mg of a white solid. The compound was lyophilyzed from 2ml of 1:1 CH3C :H 2 0 to afford 107mg of Kg) (R 15 = NHCbz) as a white solid (52.0% yield from 1(f)) . 1 H NMR (DMSO-D6; Mixture of diastereoisomers) d 7.8 (m, 2H) , 7.35 (bs, 5H) , 6.8 (m, 2H) , 5.11 (s, 2H) , 4.44 (s, IH) , 3.4 (bm, 2H) , 3.2 ( , 2H) , 2.8 (s, 2H) ,2.0 - 1.2 (bm, 8H) ; HRMS calcd. for C 26 H3 1 5 O 6 ([M+H] + ) : 510.235259; found: 510.236039. Similarly prepared from 1(d) were the following: Example 1111 (S)-2-phenvlsulfonvlamino-3-rr8-^- pvridinvlamino methvl-l-oxa-2-a aspirn-r4.51-dec-2-en-3- yl1carbonyiaπύr-olpropionic acid X H NMR (DMSO-D6) d 8.8 (bs,lH), 8.23 (t, IH, J = 6), 8.18 (d, IH, J = 9), 7.85-7.40 (m, 5H) , 7.03 (d, IH, J = 9), 6.8 (t, IH, J = 7), 3.93 (dd, IH, J = 13, 7), 3.38 (m, IH) , 3.19 (bm, 3H) , 2.8 (s, 2H) , 1.85-1.2 (bm, 8H) ; MS calcd. for C2 4 H 29 N 5 O 6 S ([M+H] + ) : 516.2; found: 516.1. Example 1121 (£)-2-r(2.5-dimethvlisoxazol-2-vl)sn1fonvl1amino-3-rr8- (2-pvridinv1amino)methvl-l-oxa-2-azaspiro-r4.51-dec-2- en-3-vl1 arbonvl ino propioni acid ! H NMR (DMSO-D6) d 8.8 (bs,lH), 8.54 (d, IH, J = 9) , 8.27 (t, IH, J = 6), 7.86 (m, IH) , 7.03 (d, IH, J = 9), 3.94 (m, IH) , 3.44 (m, IH) , 3.19 (bm, 3H) , 2.8 (s, 2H) , 2.45 (s, 3H) , 2.5 (s, 3H) , 2.9 - 1.2 (bm, 8H) ; MS calcd. for C2 3 H 3 oN 6 0 7 S ([M+H] + ) : 535.2; found: 535.1. Example 3055 (S) -2- f ( 2 .4. -trimethvlphenvl , sul fonvl 1 mino-3- r T7- bpnzv1oxvcarbnnv1-a-(2-imidazo1v1amino)methvl-l-oxa-2.7- diazaspiro- fd. 1 -non-2-en-3-vl 1 carbonvlaminolpropionic acid Part A: N-Chz-4-hvdroxv-L-prolinol: A solution of N- Cbz-4-hydroxy-L-proline (50 gm, 0.188 mol) in tetrahydrofuran (400 ml) was cooled to 0 °C in an ice bath under nitrogen and a solution of borane dimethylsulfide complex (2.0M in THF, 122 ml, 0.244 mol) was added dropwise over lh. The resulting mixture is then allowed to stir overnight at room temperature, the reaction mixture was recooled to 0 °C and a second portion of borane-dimethylsulfide complex was added as described above. Reaction was again stirred at room temperature overnight, then cooled to 0 °C and quenched by addition of approximately 200ml of 1:1 methanol/water. Solvents were removed on rotary evaporator and residue diluted with water and extracted 4X with ethyl acetate. The combined extracts were washed with saturated aqueous sodium bicarbonate solution (2X) and brine (IX) then dried over anhydrous magnesium sulfate, filtered and evaporated to a clear oil (46.77 g, 99%) which was used without purification in part B below. Part R. l-benzvloxvcarbonvl-2-(S)-t- bntvl imethylsilvloxvmethvl-4-hvdroxvpyrrolidine: A mixture of the compound of Part A above (46.77 g, 0.186 mol), triethylamine (51.8 g, 0.372 mol) , and t- butyldimethyIsilylchloride (30.86 g, 0.205 mol) in methylene chloride (375 ml) was stirred under nitrogen overnight at room temperature. An additional aliquot of silyl chloride (5 g, 0.033 mol) was added and stirring continued for 4-5 h. Reaction mixture was transferred to a separatory funnel and washed with water (4X) and brine (IX) then dried over anhydrous sodium sulfate, filtered and solvent removed in vacuo . The residue was chromatographed on silica gel (hexane - hexane/ethyl acetate 8:2 - hexane/ethyl acetate 7:3) to provide the silyl ether (47.11 g, 69%) Part C. 1-bPnzvloxvcarbonvl-2(S)-t- butvldi methvlsilvlnxvτπethvl-4-Pvrro i inone: To a solution of oxalyl chloride (12.4 ml, 0.142 mol) in methylene chloride (330 ml) precooled to -70 °C in an acetone/dry ice bath was added a solution of anhydrous dimethylsulfoxide (20.60ml, 0.29 mol) in methylene chloride (66 ml) dropwise under nitrogen over 30 min at T < -65°C. The resulting mixture was stirred 15 min, followed by dropwise addition of a solution of the compound of part B above in methylene chloride (130 ml) over 45 min at T < -65°C. The reaction was stirred for 30 min followed by dropwise addition of triethylamine (119.2 ml, 0.855 mol) over 30 min again at T < -65°C. The cooling bath was removed and the reaction temperature was allowed to rise to 5-10°C, and then quenched by addition of 645 ml of 10% aqueous potassium hydrogen sulfate solution. The mixture was then transferred to a separatory funnel and layers separated. The aqueous was extracted with methylene chloride and the combined organic layers are washed with 10% citric acid solution (3X) and brine (IX) then dried over anhydrous sodium sulfate, filtered and concentrated to a clear oil (46.8 g, 100%) which was used without purification in part D below. Part D. 1-benzvloxvcarbonvl-2(S)-t- butvldimethylsilvloxvmethvl-4-methvlenepvrrolidine: Methyltriphenylphosphonium bromide (68,98 g, 0.193 mol) is added to a suspension of potassium t-butoxide (20.27 g, 0.181 mol) in anhydrous ether (700 ml) with stirring at 0°C under nitrogen. The resulting bright yellow solution is stirred for an additional 15 min. To this is added a solution of the compound of part D above (46.8 g, 0.129 mol) in ether (100 ml) . The mixture is allowed to assume room temperature and stirred overnight. The resulting mixture was cooled in an ice bath and quenched by addition 700 ml of a saturated solution of ammonium chloride. The phases were separated and aqueous reextracted 2X with ether. The combined organics were washed with brine and dried over anhydrous sodium sulfate, filtered and evaporated in vacuo . The crude product was purified by flash chromatography (silica gel, hexane-ether 9:1) to provide the olefin (42.6 g, 91%) as a pale yellow oil. Part E: 7-henzvloxvcarbonvl-8-t-butvldimethvlsilv1oxy- methvl-3-ethoxvcarbonvl-l-oxa-2.7-diazaspiro-r4.41-non- 2-ene: The compound of part D above (13.04 g, 0.036 mol) was dissolved in methylene chloride (50 ml), treated with ethyl chlorooximidoacetate (8.18 g., 0.054 mol), and the mixture was cooled to 0°C followed by dropwise addition of triethylamine (7.53 ml, 0.054 mol). The reaction was allowed to come to room temperature over several hours then stirred overnight. An additional 1.5 eq. of the chlorooxi e was then added, and the mixture was cooled to 0°C and treated with triethylamine (1.5 eq) as described above. Resulting mixture was stirred at room temperature for 48 h, then diluted with additional methylene chloride and washed with 10% aqueous citric acid (3X) , and brine (IX) then dried over anhydrous sodium sulfate, filtered and evaporated in vacuo. The crude was charged to silica gel and eluted first with Hexane/ether(80:20) to provide unreacted starting material (6.64 g, 51%) and then with hexane/ethyl acetate (75:25) to provide the two diastereomers of the product (S,S isomer, 5.54 g, 32%; S,R isomer, 1.34 g, 8%). Anal. Calcd. for C 2 H 36 N 2 θ6Si: C, 60.48; H, 7.61; N, 5.89. Found: C, 60.46; H, 7.33; N, 5.96. Part F: 7-henzvloxvcarbonvl-8-t-bntvldimethvlsilvloxv- rnethyl-3-ca bnxv-l-oxa-2.7-diazaspiro- f4.41-non-2-ene: The compound of Part E above (18.7 g, 0.038 mol) was dissolved in methanol (200 ml) and treated at room temperature with a solution of lithium hydroxide monohydrate (2.4 g, 0.057 mol) in water (50 ml). The whole was stirred for 5 h and then solvent removed in vacuo. Water was added and the pH of the solution was adjusted to 4.4 with 10% aq. citric acid solution. The resulting mixture was extracted 3X with ethyl acetate with adjustment of pH back to 4.4 between extractions. The combined extracts were washed with brine and dried over anhydrous sodium sulfate, filtered and evaporated. The residue was dried under vacuum to provide the acid (16.2 g, 95%) as a foam which was used without purification in Part G below. MS(esi) m/z 449.4 (M+H)+, 335.2 (M+H-TBMDS)* Part G: t-Butvl (S)-2- f (2. . -trimethvlphenvl )sirifonvl 1- amino-3- f r7-benzvloxvcarbonvl-8- (t-butvldimethvlsi1vl- oxv)methv1-1-oxa-2.7-diazaspiro- T4. 1-non-2-en-3- yllcarbonylamino1 ropionic acid: A mixture of the compound of Part F above (10 g, 0.022 mol), t-butyl 3- amino-2-(2,4, 6-trimethylphenylsulfonylamino)propionate (7.6 g, 0.022 mol), N-methylmorpholine (5.4 ml, (0.049 mol) and Castro's reagent (14.8 g, 0.033 mol) in N,N- dimethylformamide (100 ml)was stirred under nitrogen at room temperature overnight. The DMF was removed in vacuo and the residue diluted with 500 ml water and extracted 3X with ethyl acetate. The combined extracts were washed with water (2X) , 10% citric acid (IX), saturated sodium bicarbonate (IX) and brine (IX) then dried over anhydrous sodium sulfate, filtered and evaporated. The coupling product was purified by filtration through a pad of silica gel eluted with hexane/ethyl acetate (4:1) to provide the product as a white foam (15 g , 88%). MS(esi) m/z 773.4 (M+H) + 795.4 (M+Na) + . Part H: t-Butvl (S) -2- ( .4.6-trimethvlphenvl)sulfonvl - aminn-3- I r7-henzyloxvcarbonvl-8-hvdroxvmethvl-l-oxa- .7- diazaspjro- T .41-non-2-en-3-v!1carbonvlaminoloronionic acid: The compound of Part G above (2.8 g, 3.62 mmol) was dissolved in tetrahydrofuran (12 ml) and treated with tetra-n-butylammonium floride (5.8 ml of a 1.0 M solution in THF, 5.8 mmol) . The resulting solution was stirred overnight at room temperature. Reaction was quenched by addition of water and THF removed on rotary evaporator. The remaining aqueous was extracted 3X with ethyl acetate. The combined extracts were washed with water and brine, dried over anhydrous sodium sulfate, filtered and evaporated. Chromatography on silica gel (hexane/ethyl acetate 1:1 followed by methylene chloride/methanol 95:5) provided the alcohol (2.02 g., 85%) ms m/z 659.3 (M+H) + . Par T: t-Bntvl (S) -2- \ ( 2 .4.6-trimethvlphenvl)sillfonvl 1- amino-3-r r7-benzvloxvcarbonvl-8-formvl-l-oxa-2.7- diazaspiro-f4,41-non-2-en-3-vllcarbonylamino1propionic acid: A solution of the compound of Part H above (0.8 g, 1.21 mmol) in anhydrous methylene chloride (1 ml) was added dropwise to a a solution of Dess-Martin periodinane (0.59g, 1.30 mmol) in approximately 4 ml of dry methylene chloride at room temperature under nitrogen. The resulting mixture was stirred for 1 hr, the diluted with ethyl acetate and poured into a solution of saturated sodium bicarbonate (20 ml) containing 5 g sodium thiosulfate. This was stirred for 10 min. The phases were separated, aqueous reextracted with ethyl acetate, and combined organics washed with saturated sodium bicarbonate, water and brine, then dried over anhydrous magnesium sulfate, filtered and evaporated to give the aldehyde as a clear oil (0.74 g, 93%) . Part J: t-Butyl (S) -2- r (2.4,6-trimethylphenyl)sulfonyll- amino- -f f7-benzvloxvcarbonvl-8- (imidazol-2- vlamino)me hvl-l-oxa-2.7-diazaspiro- T .41-non-2-en-3- yllcarbonvlaminol ropionic acid: To a solution of the compound of Part I above (0.73 g, 1.11 mmol) in benzene was added anhydrous magnesium sulfate (0.588 g, 4.88 mmol) and 2-amino-l-tritylimidazole (0.398 g, 1.22 mmol) and the whole was refluxed for 4 hrs under nitrogen. The mixture was cooled to room temperature, filtered under nitrogen and benzene removed in vacuo. The residue was taken up in 1,2-dichloroethane, treated under nitrogen at room temperature with sodium triacetoxyborohydride (0.588 g, 2.78 mmol), and the whole was stirred overnight. The reaction was quenched by addition of water and then diluted with ethyl acetate. Aqueous was reextracted with ethyl acetate, and combined organic layers were washed with saturated sodium bicarbonate, water and brine, then dried over anhydrous magnesium sulfate, filtered and evaporated. Filtration through silica gel provided the desired product (0.682 g, 63%) as an off-white foam which was used without further purification in part K below. Part K; (■q,-2-r(2.4.6-trimethvlphenvl)sulfonvl1-amino-3- r r7-benzvloχycarhonv1-8- Hmidazol-2-vlamino)methvl-1- oxa- .7-riiazaspiro- f . 1-non-2-en-3-vl1carbonvlamino1- propionic acid: The compound of part J above (0.3 g, 0.31 mmol) was dissolved in 20% acetic acid in methanol (10 ml) and refluxed for 24 h under nitrogen. The reaction was cooled to room temperature, methanol removed by evaporation and residue diluted with ethyl acetate. This solution was washed with saturated sodium bicarbonate (2X) , water and brine then dried over anhydrous magnesium sulfate, filtered and evaporated. Filtration through silica gel (eluted with (i)methylene chloride/methanol 95:5; (2) methylene chloride/methanol/conc. ammonium hydroxide 95:5:0/5; (3) 90/10/1) provided the intermediate detritylated t-butyl ester 0.139 mg, 62%). This was taken up in methylene chloride (8 ml) and trifluoroacetic acid (2 ml) was added. The solution was stirred for 72 h, then evaporated and triturated with ether. The resulting solid was purified by prep HPLC (C18, gradient from 100% A to 100% B: A=90/10/0.05 H 2 0/CH 3 CN/TFA; B=90/10/0.05 CH3CN/H2O/TFA) to provide the title compound (0.078g, 50%) . MS m/z 690.4 (M+Na) + 668.4 (M+H) + . Example 3063: (fi) -2- \ ( 2.4.6-trimethvlphenvl) sulf nvl 1 - amino-3-r ffi- (imidazol-2-v1 mino τrιethvl-l-oxa-2.7- diazaspiro- f , 41 -non-2-en-3-vll carbonylamino1 -nrnπinni c acid The compound of Example 3055, Part J, (0.1 g, 0.1 mmol) was taken up in neat trifluoroacetic acid (3 ml) and the mixture refluxed for 1.5 h. Reaction was cooled to room temperature and TFA removed in vacuo. The residue was purified by prep HPLC using the system described under Ex. 3055, Part K above to provide the title compound (0.043 g, 80%) . MS m/z 534.4 (M+H) + . Using the methods described above and modifications thereof known to one skilled in the art of organic synthesis, additional compounds of the present invention can be prepared, including, but not limited to the representative compounds listed in the Tables below. Utility The compounds of Formula I of the present invention possess activity as antagonists of integrins such as, for example, the o-vp3 or vitronectin receptor, α βs or c.5βl, and as such have utility in the treatment and diagnosis of cell adhesion, angiogenic disorders, inflammation, bone degradation, cancer metastases, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis. The integrin antagonist activity of the compounds of the present invention is demonstrated using assays which measure the binding of a specific integrin to a native ligand, for example, using the ELISA assay described below for the binding of vitronectin to the αγβ 3 receptor. The compounds of the present invention possess selectivity for the αvβ3 receptor relative to the GPIIb/IIIa receptor as demonstrated by their lack of activity in standard assays of platelet aggregation, such as the platelet aggregation assay described below. One of the major roles of integrins in vivo is to mediate cellular interactions with adjacent cells. Cell based adhesion assays can be used to mimic these interactions in vitro. A cell based assay is more representative of the in vivo situation than an ELISA since the receptor is maintained in membranes in the native state. The compounds of the present invention have activity in cell-based assays of adhesion, for example as demonstrated in using the cell adhesion assays described below. The compounds of Formula I of the present invention may be useful for the treatment or prevention of other diseases which involve cell adhesion processes, including, but not limited to, osteoporosis, rheumatoid arthritis, autoimmune disorders, bone degradation, rheumatoid arthritis, asthma, allergies, adult respiratory distress syndrome, graft versus host disease, organ transplantation, septic shock, psoriasis, eczema, contact dermatitis, osteoarthritis, atherosclerosis, metastasis, wound healing, inflammatory bowel disease and other angiogenic disorders. The compounds of Formula I have the ability to suppress/inhibit angiogenesis in vi vo, for example, as demonstrated using animal models of ocular neovascularization. The compounds provided by this invention are also useful as standards and reagents in determining the ability of a potential pharmaceutical to inhibit integrin-ligand binding. These may be provided in a commercial kit comprising a compound of this invention. As used herein "μg" denotes microgram, "mg" denotes milligram, "g" denotes gram, "μL" denotes microliter, "mL" denotes illiliter, "L" denotes liter, M nM" denotes nanomolar, "μM" denotes micromolar, "mM" denotes millimolar, "M" denotes molar and "nm" denotes nanometer. "Sigma" stands for the Sigma-Aldrich Corp. of St. Louis, MO. The utility of the compounds of the present invention may be assessed by testing in one or more of the following assays as described in detail below: Purified ctvβ 3 (human placenta) - Vitronectin ELISA, «vβ 3 -Vitronectin Binding Assay, Human Aortic Smooth Muscle Cell Migration Assay, In Vivo Angiogenesis Model, Pig Restenosis Model, Mouse Retinopathy Model. A compound of the present invention is considered to be active if it has an IC 50 or Ki value of less than about 10 μM for the inhibition of α v β 3 -Vitronectin Binding Assay, with compounds preferably having Ki values of less than about 0.1 μM. Tested compounds of the present invention are active in the αvβ 3 -Vitronectin Binding Assay as well as in cell-based assays of integrin adhesion mediated by the ctvβ 3 -receptor. The ocvβ3 receptor was isolated from human placental extracts prepared using octylglucoside. The extracts were passed over -an affinity column composed of anti-α v β 3 monoclonal antibody (LM609) to Affigel. The column was subsequently washed extensively at pH 7 and pH 4.5 followed by elution at pH 3. The resulting sample was concentrated by wheat germ agglutinin chromatography to provide gave two bands on SDS gel which were confirmed as αvβ 3 by western blotting. Affinity purified protein was diluted at different levels and plated to 96 well plates. ELISA was performed using fixed concentration of biotinylated vitronectin (approximately 80 nM/well) . This receptor preparation contains the ctvβ3 with no detectable levels of α v βs according to the gel (αvβ3) and according to effects of blocking antibodies for the a^3 or ayβs in the ELISA. A submaximal concentration of biotinylated vitronectin was selected based on cone, response curve with fixed receptor cone, and variable concentrations of biotinylated vitronectin. α^-Vitronec in Binding Assay The purified receptor is diluted with coating buffer (20 mM Tris HCl, 150 mM NaCl, 2.0 mM CaCl2, 1.0 mM MgCl 2 -6H 2 θ, 1.0 mM MnCl 2 ' H 2 θ) and coated (100 μL/well) on Costar (3590) high capacity binding plates overnight at 4°C. The coating solution is discarded and the plates washed once with blocking/binding buffer (B/B buffer, 50 mM Tris HCl, 100 mM NaCl, 2.0 mM CaCl 2 ,1.0 mM MgCl 2 *6H 2 θ,1.0 mM MnCl 2 -4H 0). Receptor is then blocked (200 μL/well) with 3.5% BSA in B/B buffer for 2 hours at room temperature. After washing once with 1.0% BSA in B/B buffer, biotinylated vitronectin (100 μD and either inhibitor (11 μL) or B/B buffer w/1.0% BSA (11 μL)is added to each well. The plates are incubated 2 hours at room temperature. The plates are washed twice with B/B buffer and incubated 1 hour at room temperature with anti-biotin alkaline phosphatase (100 μL/well) in B/B buffer containing 1.0% BSA. The plates are washed twice with B/B buffer and alkaline phosphatase substrate (100 μL) is added. Color is developed at room temperature. Color development is stopped by addition of 2N NaOH (25 μL/well) and absorbance is read at 405 nm. The IC 50 is the concentration of test substance needed to block 50% of the vitronectin binding to the receptor. Tnteαrin Cell-Based Adhesion Assays In the adhesion assays, a 96 well plate was coated with the ligand (i.e., fibrinogen) and incubated overnight at 4° C. The following day, the cells were harvested, washed and loaded with a fluorescent dye. Compounds and cells were added together and then were immediately added to the coated plate. After incubation, loose cells are removed from the plate, and the plate (with adherent cells) is counted on a fluorometer. The ability of test compounds to inhibit cell adhesion by 50% is given by the IC50 value and represents a measure of potency of inhibition of integrin mediated binding. Compounds were tested for their ability to block cell adhesion using assays specific for αvβ 3 , αvβs and αsβi integrin interactions. Platelet Aggregation Assay Venous blood was obtained from anesthetized mongrel dogs or from healthy human donors who were drug- and aspirin-free for at least two weeks prior to blood collection. Blood was collected into citrated Vacutainer tubes. The blood was centrifuged for 15 minutes at 150 x g (850 RPM in a Sorvall RT6000 Tabletop Centrifuge with H-1000 B rotor) at room temperature, and platelet- rich plasma (PRP) was removed. The remaining blood was centrifuged for 15 minutes at 1500 x g (26,780 RPM) at room temperature, and platelet-poor plasma (PPP) was removed. Samples were assayed on a PAP-4 Platelet Aggregation Profiler, using PPP as the blank (100% transmittance) . 200 μL of PRP (5xl0 8 platelets/mL) were added to each micro test tube, and transmittance was set to 0%. 20 μL of ADP (10 μM) was added to each tube, and the aggregation profiles were plotted (% transmittance versus time) . Test agent (20 μL) was added at different concentrations prior to the addition of the platelet agonist. Results are expressed as % inhibition of agonist-induced platelet aggregation. Human Aortic Smooth Muscle Cell Migration Assay A method for assessing a^ 3 -mediated smooth muscle cell migration and agents which inhibit αvβ 3 -mediated smooth muscle cell migration is described in Liaw et al., J. Clin . Invest . (1995) 95: 713-724). In Vivo Angiogenesis Model A quantitative method for assessing angiogenesis and antiangiogenic agents is described in Passaniti et al., Laboratory Investigation (1992) 67: 519-528 Pig Restenosis Model A method for assessing restenosis and agents which inhibit restenosis is described in Schwartz et al., J. Am. College of Cardiology (1992) 19: 267-274. Mouse Retinopathy Model A method for assessing retinopathy and agents which inhibit retinopathy is described in Smith et al., Invest. Ophthal . & Visual Science (1994) 35: 101-111. Dosage and Formulation The compounds of this invention can be administered by any means that produces contact of the active agent with the agent's site of action, the α v β 3 integrin, in the body of a mammal. They can be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents, such as a antiplatelet agent such as aspirin, piroxicam, or ticlopidine which are agonist-specific, or an anti-coagulant such as warfarin or heparin, or a thrombin inhibitor such as a boropeptide, hirudin or argatroban, or a thrombolytic agent such as tissue plasminogen activator, anistreplase, urokinase or streptokinase, or combinations thereof. The compounds of the invention, or compounds of the invention in combination with other therapeutic agents, can be administered alone, but generally administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice. The dosage of the novel cyclic compounds of this invention administered will, of course, vary depending upon known factors, such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration; the age, health and weight of the recipient; the nature and extent of the symptoms; the kind of concurrent treatment; the frequency of treatment; and the effect desired. A daily dosage of active ingredient can be expected to be about 0.001 to 10 milligrams per kilogram of body weight. Dosage forms (compositions suitable for administration) contain from about 0.1 milligram to about 100 milligrams of active ingredient per unit. In these pharmaceutical compositions the active ingredient will ordinarily be present in an amount of about 0.5-95% by weight based on the total weight of the composition. The active ingredient can be administered orally in solid dosage forms, such as capsules, tablets, and powders, or in liquid dosage forms, such as elixirs, syrups, and suspensions. It can also be administered parenterally, in sterile liquid dosage forms. Gelatin capsules contain the active ingredient and powdered carriers, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract. Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance. In general, water, a suitable oil, saline, aqueous dextrose (glucose) , and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions. Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances. Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents. Also used are citric acid and its salts and sodium EDTA. In addition, parenteral solutions can contain preservatives, such as benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol. Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, Mack Publishing Company, a standard reference text in this field. Useful pharmaceutical dosage-forms for administration of the compounds of this invention can be illustrated as follows: Capsules A large number of unit capsules are prepared by filling standard two-piece hard gelatin capsules each with 10 milligrams of powdered active ingredient, 150 milligrams of lactose, 50 milligrams of cellulose, and 6 milligrams magnesium stearate. Soft Gelatin Capsules A mixture of active ingredient in a digestable oil such as soybean oil, cottonseed oil or olive oil is prepared and injected by means of a positive displacement pump into gelatin to form soft gelatin capsules containing 10 milligrams of the active ingredient. The capsules are washed and dried. Tablets A large number of tablets are prepared by conventional procedures so that the dosage unit was 10 milligrams of active ingredient, 0.2 milligrams of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 275 milligrams of microcrystalline cellulose, 11 milligrams of starch and 98.8 milligrams of lactose. Appropriate coatings may be applied to increase palatability or delay absorption. The combination products of this invention, such as the novel αvβ3 antagonist compounds of this invention in combination with an anti-coagulant agent such as warfarin or heparin, or an anti-platelet agent such as aspirin, piroxicam or ticlopidine, or a thrombin inhibitor such as a boropeptide, hirudin or argatroban, or a thrombolytic agent such as tissue plasminogen activator, anistreplase, urokinase or streptokinase, or combinations thereof, can be in any dosage form, such as those described above, and can also be administered in various ways, as described above. In a preferred embodiment, the combination products of the invention are formulated together, in a single dosage form (that is, combined together in one capsule, tablet, powder, or liquid, etc.). When the combination products are not formulated together in a single dosage form, the αvβ 3 antagonist compounds of this invention and the anti-coagulant agent, anti-platelet agent, thrombin inhibitor, and/or thrombolytic agent may be administered at the same time (that is, together) , or in any order, for example the compounds of this invention are administered first, followed by administration of the anti-coagulant agent, anti-platelet agent, thrombin inhibitor, and/or thrombolytic agent. When not administered at the same time, preferably the administration of the compound of this invention and any anti-coagulant agent, anti-platelet agent, thrombin inhibitor, and/or thrombolytic agent occurs less than about one hour apart, more preferably less than about 30 minutes apart, even more preferably less than about 15 minutes apart, and most preferably less than about 5 minutes apart. Preferably, administration of the combination products of the invention is oral. The terms oral agent, oral inhibitor, oral compound, or the like, as used herein, denote compounds which may be orally administered. Although it is preferable that the αγβ3 antagonist compounds of this invention and the anti-coagulant agent, anti-platelet agent, thrombin inhibitor, and/or thrombolytic agent are both administered in the same fashion (that is, for example, both orally) , if desired, they may each be administered in different fashions (that is, for example, one component of the combination product may be administered orally, and another component may be administered intravenously) . The dosage of the combination products of the invention may vary depending upon various factors such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration, the age, health and weight of the recipient, the nature and extent of the symptoms, the kind of concurrent treatment, the frequency of treatment, and the effect desired, as described above. As discussed above, where two or more of the foregoing therapeutic agents are combined or co-administered with the compounds of this invention, generally the amount of each component in a typical daily dosage and typical dosage form may be reduced relative to the usual dosage of the agent when administered alone, in view of the additive or synergistic effect which would be obtained as a result of addition of further agents in accordance with the present invention. Particularly when provided as a single dosage form, the potential exists for a chemical interaction between the combined active ingredients (for example, a novel compound of this invention and an anti-coagulant such as warfarin or heparin, or a novel compound of this invention and an anti-platelet agent such as aspirin, piroxica or ticlopidine, or a novel compound of this invention and a thrombin inhibitor such as a boropeptide, hirudin or argatroban, or a novel compound of this invention and a thrombolytic agent such as tissue plasminogen activator, anistreplase, urokinase or streptokinase, or combinations thereof) . For this reason, the preferred dosage forms of the combination products of this invention are formulated such that although the active ingredients are combined in a single dosage form, the physical contact between the active ingredients is minimized (that is, reduced) . In order to minimize contact, one embodiment of this invention where the product is orally administered provides for a combination product wherein one active ingredient is enteric coated. By enteric coating one of the active ingredients, it is possible not only to minimize the contact between the combined active ingredients, but also, it is possible to control the release of one of these components in the gastrointestinal tract such that one of these components is not released in the stomach but rather is released in the intestines. Another embodiment of this invention where oral administration is desired provides for a combination product wherein one of the active ingredients is coated with a sustained-release material which effects a sustained-release throughout the gastrointestinal tract and also serves to minimize physical contact between the combined active ingredients. Furthermore, the sustained-released component can be additionally enteric coated such that the release of this component occurs only in the intestine. Still another approach would involve the formulation of a combination product in which the one component is coated with a sustained and/or enteric release polymer, and the other component is also coated with a polymer such as a low viscosity grade of hydroxypropyl methylcellulose (HPMC) or other appropriate materials as known in the art, in order to further separate the active components. The polymer coating serves to form an additional barrier to interaction with the other component. Dosage forms of the combination products of the present invention wherein one active ingredient is enteric coated can be in the form of tablets such that the enteric coated component and the other active ingredient are blended together and then compressed into a tablet or such that the enteric coated component is compressed into one tablet layer and the other active ingredient is compressed into an additional layer. Optionally, in order to further separate the two layers, one or more placebo layers may be present such that the placebo layer is between the layers of active ingredients. In addition, dosage forms of the present invention can be in the form of capsules wherein one active ingredient is compressed into a tablet or in the form of a plurality of microtablets, particles, granules or non-perils, which are then enteric coated. These enteric coated microtablets, particles, granules or non- perils are then placed into a capsule or compressed into a capsule along with a granulation of the other active ingredient. These as well as other ways of minimizing contact between the components of combination products of the present invention, whether administered in a single dosage form or administered in separate forms but at the same time by the same manner, will be readily apparent to those skilled in the art, once armed with the present disclosure. Pharmaceutical kits useful in, for example, the inhibition of thrombus formation, the prevention of blood clots, and/or the treatment of thromboembolic disorders, which comprise a therapeutically effective amount of a compound according to the method of the present invention along with a therapeutically effective amount of an anti-coagulant agent such as warfarin or heparin, or an antiplatelet agent such as aspirin, piroxicam or ticlopidine, or a thrombin inhibitor such as a boropeptide, hirudin or argatroban, or a thrombolytic agent such as tissue plasminogen activator, anistreplase, urokinase or streptokinase, or combinations thereof, in one or more sterile containers, are also within the ambit of the present invention. Sterilization of the container may be carried out using conventional sterilization methodology well known to those skilled in the art. The sterile containers of materials may comprise separate containers, or one or more multi-part containers, as exemplified by the UNIVIAL™ two-part container (available from Abbott Labs, Chicago, Illinois) , as desired. The compounds according to the method of the invention and the anti-coagulant agent, anti-platelet agent, thrombin inhibitor, thrombolytic agent, and/or combinations thereof, may be separate, or combined into a single dosage form as described above. Such kits may further include, if desired, one or more of various conventional pharmaceutical kit components, such as for example, one or more pharmaceutically acceptable carriers, additional vials for mixing the components, etc., as will be readily apparent to those skilled in the art. Instructions, either as inserts or as labels, indicating quantities of the components to be administered, guidelines for administration, and/or guidelines for mixing the components, may also be included in the kit. Representative compounds of the present invention are listed in the Tables below. Table 1 E 1 E 14 E 15 Ω.. 1001 imidazol-2-yl - aminomethyl 1002 imidazol-2-yl- NHC0 2 Bn aminomethyl 1003 imidazol-2-yl- HC0 2 CH 2 C6H4-(2- aminomethyl CH 3 ) 1004 imidazol-2-yl- HC0 2 CH 2 C 6 H4- ( 3 - aminomethyl CH 3 ) 1005 imidazol-2-yl- NHC0 2 CH 2 C 6 H 4 - aminome hyl (4-CH3) 1006 imidazol-2-yl- NHC0 CH 2 (2- aminomethyl pyridinyl) 1007 i idazol-2-yl- NHCO2CH 2 (3- aminomethyl pyridinyl) 1008 imidazol-2-yl- NHCO2CH 2 (4- -urtinome hyl pyridinyl) 1009 imidazol-2-yl- NHCO2CH 2 (2- aminoraethyl thiazolyl) 1010 imidazol-2-yl- NHCO2CH2 (4- ciminomethyl thiazolyl) 1011 imidazol-2-yl- NHCO2CH 2 (5- aminomethyl thiazolyl) 1012 imidazol-2-yl- NHCO2CH2 (4- aminome yl isoxazolyl) 1013 imidazol-2-yl- HCO2CH2 (2- aminome hyl thienyl) 1014 imidazol-2-yl- NHCO2CH2 (5- aminomethyl isoxazolyl) 1015 imidazol-2-yl- H HCθ2n-Bu aminome hyl 1016 imidazol-2-yl- NHCθ2i-Bu aminomethyl 1017 imidazol-2-yl- NHC02t-Bu aminome hyl 1018 imidazol-2-yl- NHCOCH2Ph aminomechyl 1019 imidazol-2-yl- HCOCH 2 C6H4_(2- aminomethyl CH3) 1020 imidazol-2-yl- NHCOCH2C6H4~(3- aminomethyl CH3) 1021 imidazol-2-yl- NHCOCH2C6H4~(4- aminome hyl CH3) 1022 imidazol-2-yl- NHCOCH2(2- aminomethyl pyridinyl) 1023 imidazol-2-yl- NHCOCH2 (3- aminomethyl pyridinyl) 1024 imidazol-2-yl- NHCOCH2 (4- aminome hyl pyridinyl) 1025 imidazol-2-yl- NHCOCH2 (2- aminome hyl thiazolyl) 1026 imidazol-2-yl- NHCOCH2 (4- arainomethyl thiazolyl) 1027 imidazol-2-yl- HCOCH2 (5- cuninome hyl thiazolyl) 1028 imidazol-2-yl- NHCOCH2 (4- aminome hyl isoxazol) 1029 imidazol-2-yl- HCOCH2 (2- aminome hyl thienyl) 1030 imidazol-2-yl- NHCOn-Bu aminomethyl 1031 imidazol-2-yl- NHCOt-Bu aminome hyl 1032 imidazol-2-yl- HS0 2 Ph 505.2 aminomethyl 1033 imidazol-2-yl- NHS0 2 C 6 H4-(2- aminome hyl CH 3 ) 1034 imidazol-2-yl- HS0 C6H4-(3- aminorae hyl CH 3 ) 1035 imidazol-2-yl- NHS0 2 C6H4-(4- aminome hyl CH 3 ) 1036 imidazol-2-yl- NHS0 2 (2-pyridyl) am nomethyl 1037 imidazol-2-yl- NHS0 2 (3-pyridyl) aminome hyl 1038 imidazol-2-yl- HS0 2 (4-pyridyl) aminome hyl 1039 imidazol-2-yl- NHS0 2 (2-thiaz- aminomethyl olyl) 1040 imidazol-2-yl- NHS0 2 (3- aminomethyl thiazolyl) 1041 iπιidazol-2-yl- NHS0 2 (4- aminome hyl isoxazolyl) 1042 imidazol-2-yl- NHS0 2 [4-(3,5- aminomethyl dimethyl) isoxaz olyl] 1043 imidazol-2-yl- HS0 2 C6H4-(2- aminome hyl Br) 1044 imidazol-2-yl- NHS0 2 C6H4-(3- aminomet yl Br) 1045 imidazol-2-yl- NHS0 2 C 6 H4-(4- aminomethyl Br) 1046 imidazol-2-yl- NHSO2C6H4- (2-F) aminomet yl 1047 imidazol-2-yl- NHS0 C6H4-(3-F) aminome hyl 1048 imidazol-2-yl- NHSO2C6H4- (4-F) aminomethyl 1049 imidazol-2-yl- HS0 2 (2- 555.2 aminome hyl naph hyl ) 1050 imidazol-2-yl- NHSO2Q- aminome hyl naphthyl) 1051 imidazol-2-yl- NHS0 2 CH=CHPh aminome hyl 1052 imidazol-2-yl- HS0 2 CH 2 Ph aminomethyl 1053 imidazol-2-yl- HSθ2CH 2 CH=CH-Ph aminome hyl 1054 imidazol-2-yl- NHSθ2-n-Bu aminomethyl 1055 imidazol-2-yl- HS0 2 -i-Bu arαinomethyl 1056 imidazol-2-yl- NHS0 -t-Bu aminomethyl 1057 imidazol-2-yl- NHS0 2 NHPh aminomethyl 1058 imidazol-2-yl- H NHS0 2 NHC6H4-(2- aminomethyl CH3) 1059 imidazol-2-yl- NHS0 2 HC6H4-(3- aminome hyl CH3) 1060 imidazol-2-yl- NHS0 2 NHC6H4-(4- aminomethyl CH3) 1061 imidazol-2-yl- HS0 2 NH(2- aminomethyl pyridyl) 1062 imidazol-2-yl- HS0 2 H(3- arαinomethyl pyridyl) 1063 imidazol-2-yl- NHS0 NH<4- aminomethyl pyridyl) 1064 imidazol-2-yl- HS0 2 H(2- aminomethyl thiazolyl) 1065 imidazol-2-yl- NHS0 2 H(4- aminomethyl thiazolyl) 1066 imidazol-2-yl- NHS0 2 H(4- amino ethyl isoxazolyl) 1067 imidazol-2-yl- NHS0 2 [4-(3,5- aminomethyl dimethyl) isoxaz olyl] 1068 imidazol-2-yl- HS0 2 NHC6H4-(2- aminomethyl Br) 1069 imidazol-2-yl- HSO2 HC6H4- (3- aminome hyl Br) 1070 imidazol-2-yl- NHS0 NHC6H4-(4- aminome hyl Br) 1071 imidazol-2-yl- NHS0 NHC6H4-(3- aminomethyl F) 1072 imidazol-2-yl- NHS0 2 NHC6H4-(4- aminome hyl F) 1073 imidazol-2-yl- NHS0 2 NH(2- aminomethyl naphthyl) 1074 imidazol-2-yl- NHS0 2 NH(1- aminomethyl naph hyl) 1075 imidazol-2-yl- NHS0 2 NHCH=CH-Ph aminomethyl 1076 imidazol-2-yl- HS0 2 NHCH 2 Ph aminomethyl 1077 imidazol-2-yl- NHS0 NHCH 2 CH=CH- aminomethyl Ph 1078 imidazol-2-yl- NHS0 2 NH-n-Bu aminomethyl 1079 imidazol-2-yl- NHS0 2 NH-i-Bu aminomethyl 1080 imidazol-2-yl- NHS0 2 H-t-Bu amino e hyl 1081 pyridin-2-yl- NHC0 2 Bn 510.2 aminomethyl 1082 pyridin-2-yl- NHC02CH 2 C 6 H4-(2- aminome hyl CH 3 ) 1083 pyridin-2-yl- NHCO2CH2C6H4- aminome hyl (3-CH3) 1084 pyridin-2-yl- NHC02CH 2 C6H4- aminome hyl (4-CH3) 1085 pyridin-2-yl- HC02CH (2- aminorαethyl pyridinyl) 1086 pyridin-2-yl- NHCO2CH2 (3- aminomethyl pyridinyl) 1087 pyridin-2-yl- HCO2CH2 (4- arαinome hyl pyridinyl) 1088 pyridin-2-yl- NHCO2CH2 (2- aminomethyl Chiazolyl) 1089 pyridin-2-yl- NHCO2CH2 (4- aminomethyl thiazolyl) 1090 pyridin-2-yl- HCθ2CH 2 (5- aminomethyl thiazolyl) 1091 pyridin-2-yl- NHCO2CH2 (4- aminomethyl isoxazolyl) 1092 pyridin-2-yl- NHCO2CH2 (2- aminomethyl thienyl) 1093 pyridin-2-yl- NHC02n-B ciminomethyl 1094 pyridin-2-yl- NHC02i-Bu aminomethyl 1095 pyridin-2-yl- HC02t-Bu aminor e hyl 1096 pyridin-2-yl- NHC0CH 2 Ph aminomethyl 1097 pyridin-2-yl- NHCOCH2C6H4- (2- aminomethyl CH3) NHCOCH2-C6H4- (3-CH3) NHCOCH C6H4_(4- CH3) NHCOCH2 (2- pyridinyl) NHCOCH 2 (3- pyridinyl) HCOCH2 (4- pyridinyl) HC0CH 2 (2- thiazolyl) NHCOCH 2 (4- thiazolyl) NHCOCH2 (5- thiazolyl) NHCOCH 2 (4- isoxazolyl) NHCOCH2 (2- thienyl) NHCOn-Bu HCOt-Bu NHS0 2 Ph 516.1 HS0 2 C6H4-(2- CH3) NHS0 2 C6H4-(3- CH3) NHS0 2 C 6 H4-(4- CH3) 1115 pyridin-2-yl- NHS0 (2-pyridyl) aminome hyl 1116 pyridin-2-yl- NHS0 2 (3-pyridyl) aminome hyl 1117 pyridin-2-yl- NHS0 2 (4-pyridyl) aminome hyl 1118 pyridin-2-yl- HS0 2 (2- aminome yl thiazolyl) 1119 pyridin-2-yl- NHS0 2 (4- aminomethyl thiazolyl) 1120 pyridin-2-yl- NHS0 2 (4- aminomethyl isoxazolyl) 1121 pyridin-2-yl- NHS0 2 -[4-(3,5- 535.1 aminomethyl dimethyl) isoxaz olyl] 1122 pyridin-2-yl- NHS0 2 C6H4-(2- aminome hyl Br) 1123 pyridin-2-yl- NHS0 2 C 6 H4-(3- aminome hyl Br) 1124 pyridin-2-yl- HS0 2 CβH4-(4- aminomethyl Br) 1125 pyridin-2-yl- NHS0 2 C6H4- (2-F) aminomethyl 1126 pyridin-2-yl- HS0 2 C6H4-(3-F) a inomethyl 1127 pyridin-2-yl- NHS0 2 C 6 H4-(4-F) aminome hyl 1128 pyridin-2-yl- NHS0 2 (2- aminomethyl naph hyl) 1129 pyridin-2-yl- NHS0 2 d- aminome hyl naph hyl) 1130 pyridin-2-yl- NHS0 2 CH=CH-Ph aminome hyl 1131 pyridin-2-yl- NHS0 2 CH 2 Ph aminomethyl 1132 pyridin-2-yl- NHS0 -CH 2 CH=CH- a nomethyl Ph 1133 pyridin-2-yl- NHS02-n-Bu aminomethyl 1134 pyridin-2-yl- NHS0 -i-Bu am nome hyl 1135 pyridin-2-yl- NHS0 2 -t-Bu aminomethyl 1136 pyridin-2-yl- NHS0 2 NHPh aminomethyl 1137 pyridin-2-yl- NHSO 2 NHC6H4- (2- aminome hyl CH3) 1138 pyridin-2-yl- HS0 2 HC6H4-(3- aminome hyl CH3) 1139 pyridin-2-yl- HS0 2 NHC6H4-(4- aminomethyl CH 3 ) 1140 pyridin-2-yl- HS0 NH(2- aminomethyl pyridyl) 1141 pyridin-2-yl- NHS0 2 NH(3- aminomethyl pyridyl) 1142 pyridin-2-yl- NHS0 2 NH(4- aminomethyl pyridyl) 1143 pyridin-2-yl- NHS0 2 NH(2- aminomethyl thiazolyl) 1144 pyridin-2-yl- NHS0 2 H-(4- aminomethyl thiazolyl) 1145 pyridin-2-yl- NHS0 2 NH(4- aminome hyl isoxazolyl) 1146 pyridin-2-yl- HS0 2 -[4-(3,5- aminomethyl dimethyl)isoxaz olyll 1147 pyridin-2-yl- NHS0 NHC6H4-(2- aminome hyl Br) 1148 pyridin-2-yl- HSO 2 NHC 6 H4- (3- aminomethyl Br) 1149 pyridin-2-yl- HSO 2 NHC 6 H4- (4- aminomethyl Br) 1150 pyridin-2-yl- NHSO2NHC 6 H4- (3- aminomethyl F) 1151 pyridin-2-yl- HSO 2 NHC6H4- (4- aminomethyl F) 1152 pyridin-2-yl- NHS0 2 NH(2- aminomethyl naph hyl) 1153 pyridin-2-yl- HS0 2 NH)1- aminome hyl naphthyl) 1154 pyridin-2-yl- NHS0 2 NHCH=CH-Ph aminome hyl 1155 pyridin-2-yl- HS0 2 NHCH 2 Ph aminome hyl 1156 pyridin-2-yl- HS0 2 NHCH 2 CH=CH- aminomethyl Ph 1157 pyridin-2-yl- NHS0 2 NH-n-Bu aminomethyl 1158 pyridin-2-yl- NHSθ 2 NH-i-Bu aminomethyl 1159 pyridin-2-yl- NHS0 2 H-t-Bu aminomethyl 1160 tetrahydropyrimidin NHCOOBn -2-ylaminomethyl 1161 tetrahydropyrimidin NHCO2CH 2 C6H4- -2-ylaminomethyl (2-CH3) 1162 tetrahydropyrimidin NHCO2CH2C6H4- -2-y1aminomethy1 O-CH3) 1163 tetrahydropyrimidin NHCO2CH 2 C6H4- -2-ylaminomethyl (4-CH 3 ) 1164 tetrahydropyrimidin NHCO2CH 2 (2- -2-ylaminomethyl pyridinyl) 1165 tetrahydropyrimidin NHCO2CH 2 (3- -2-ylaminomethyl pyridinyl) 1166 tetrahydropyrimidin HCO2CH 2 (4- -2-ylaminomethyl pyridinyl) 1167 tetrahydropyrimidin NHCO2CH 2 (2- -2-y1aminomet y1 thiazolyl) 1168 tetrahydropyrimidin NHCO2CH 2 (4- -2-ylaminomethyl thiazolyl) 1169 tetrahydropyrimidin HCO2CH 2 (5- -2-ylaminomethyl thiazolyl) 1170 tetrahydropyrimidin NHCO2CH2 (4- -2-ylaminomethyl isoxazolyl) 1171 tetrahydropyrimidin HCO2CH 2 (2- -2-yl minomethyl thienyl) 1172 tetrahydropyrimidin NHCθ2n-Bu -2-ylaminomethyl 1173 tetrahydropyrimidin HC02i-Bu -2-ylaminomethyl 1174 tetrahydropyrimidin NHC02t-Bu -2-ylaminomethyl 1175 tetrahydropyrimidin NHSθ2Ph 521.3 -2-ylaminomethyl 1176 tetrahydropyrimidin HS0 2 C6H4-(2- -2-ylaminomethyl CH3) 1177 tetrahydropyrimidin NHS0 2 C6H4-(3- -2-ylaminomethyl CH3) 1178 tetrahydropyrimidin NHS0 2 C6H4-(4- -2-ylaminomethyl CH3) 1179 tetrahydropyrimidin HS0 2 (2-pyridyl) -2-ylaminomethyl 1180 tetrahydropyrimidin NHS0 2 (3-pyridyl) -2-ylaminomethyl 1181 tetrahydropyrimidin NHS0 2 (4-pyridyl) -2-ylaminomethyl 1182 tetrahydropyrimidin HS0 2 (2- -2-y1 minomethy1 thiazolyl) 1183 tetrahydropyrimidin NHS0 2 (4- -2-ylaminomethyl thiazolyl) 1184 tetrahydropyrimidin NHS0 2 (4- -2-yl minomethyl isoxazolyl) 1185 tetrahydropyrimidin NHS0 2 -[4-(3,5- -2-ylaminomethyl dimethyl)isoxaz olyl] 1186 tetrahydropyrimidin NHSθ2C6H4-(2- -2-ylaminomethyl Br) 1187 tetrahydropyrimidin HS0 2 C6H4-(3- -2-ylaminomethyl Br) 1188 tetrahydropyrimidin NHS0 C6H4-(2-F) -2-ylaminomethyl 1189 tetrahydropyrimidin HS0 2 C6H4-(3-F) -2-ylaminomethyl 1190 tetrahydropyrimidin NHS0 C 6 H4-(4-F) -2-ylaminomethyl 1191 tetrahydropyrimidin NHS0 2 (2- -2-ylaminomethyl naphthyl) 1192 tetrahydropyrimidin NHS0 2 d- -2-ylaminomethyl naph hyl) 1193 tetrahydropyrimidin NHS0 2 CH=CHPh -2-ylaminomethyl 1194 tetrahydropyrimidin NHS0 2 CH 2 Ph -2-ylaminomethyl 1195 tetrahydropyrimidin NHS0 2 CH 2 CH=CHPh -2-ylaminomethyl 1196 tetrahydropyrimidin NHS0 2 -n-Bu -2-ylaminomethyl 1197 tetrahydropyrimidin NHS0 2 -i-Bu -2-ylaminomethyl 1198 imidazolin-2-yl- NHCOOBn aminomethyl 1199 imidazolin-2-yl- NHC02CH 2 C6H4-(2- aminomethyl CH3) 1200 imidazolin-2-yl- NHCθ2CH C6H4_(3- aminomethyl CH 3 ) 1201 imidazolin-2-yl- NHCθ2CH C6H4-(4- aminomethyl CH3) 1202 imidazolin-2-yl- NHCO2CH2 (2- aminome hyl pyridinyl) 1203 imidazolin-2-yl- HCO2CH2 (3- aminomethyl pyridinyl) 1204 imidazolin-2-yl- NHC02CH 2 (4- aminomethyl pyridinyl) 1205 imidazolin-2-yl¬ NHCO2CH2 (2- aminomethyl thiazolyl) 1206 imidazolin-2-yl- NHCO2CH2 (4- aminome hyl thiazolyl) 1207 imidazolin-2-yl- NHCO2CH2 (5- a inomethyl thiazolyl) 1208 imidazolin-2-yl- NHCO2CH2 (4- aminomethyl isoxazolyl) 1209 imidazolin-2-yl- NHCO2CH2 (2- aminomethyl thienyl) 1210 imidazolin-2-yl- NHC02n-Bu aminomethyl 1211 imidazolin-2-yl- HCθ2i-Bu aminomethyl 1212 imidazolin-2-yl- HC02t-Bu aminomethyl 1213 imidazolin-2-yl- HS0 Ph 507.3 aminomethyl 1214 imidazolin-2-yl- NHS0 2 C6H4-(2- aminomethyl CH3) 1215 imidazolin-2-yl¬ NHS0 2 C6H4-(3- aminomethyl CH3) 1216 imidazolin-2-yl- NHS0 2 C6H4-(4- aminomethyl CH 3 ) 1217 imidazolin-2-yl- HS0 2 (2-pyridyl) aminomethyl 1218 imidazolin-2-yl- HS0 (3-pyridyl) aminomethyl 1219 imidazolin-2-yl- NHS0 2 (4-pyridyl) aminomethyl 1220 imidazolin-2-yl- HS0 2 (2-thiaz- aminomethyl olyl) 1221 imidazolin-2-yl- NHS0 (4- aminomethyl isoxazolyl) 1222 imidazolin-2-yl- NHS0 2 -[4-(3,5- aminomethyl dimethyl)isoxaz olyl] 1223 imidazolin-2-yl¬ NHS0 2 C6H4-(2- aminomethyl Br) 1224 imidazolin-2-yl- HS0 C6H4-(3- aminome hyl Br) 1225 imidazolin-2-yl- NHS0 2 C6H4-(2-F) aminomethyl 1226 imidazolin-2-yl- NHSO 2 C 6 H4- (3-F) aminomethyl 1227 imidazolin-2-yl- NHS0 2 C δ H4-(4-F) aminomethyl 1228 imidazolin-2-yl- HS0 2 (2- aminomethyl naphthyl) 1229 imidazolin-2-yl¬ NHS0 2 (1- aminomethyl naphthyl) 1230 imidazolin-2-yl- NHS0 2 CH=CHPh aminome hyl 1231 imidazolin-2-yl- HS0 CH 2 Ph aminomethyl 1232 imidazolin-2-yl- HS0 2 CH CH=CHPh aminomethyl 1233 imidazolin-2-yl- HSθ2-n-Bu aminomethyl 1234 imidazolin-2-yl- NHS0 2 -i-Bu aminomethyl 1235 benzimidazol-2-yl- NHS0 2 Ph aminomethyl 1236 benzimidazol-2-yl- NHS0 2 C6H4-(2- aminomethyl CH3) 1237 benzimidazol-2-yl- NHS0 2 C 6 H4-(3- aminomethyl CH3) 1238 benzimidazol-2-yl- NHS0 2 CβH4-(4- aminomethyl CH3) 1239 benzimidazol-2-yl¬ NHS0 2 (2-pyridyl) aminomethyl 1240 benzimidazol-2-yl- NHS0 2 (3-pyridyl) aminomethyl 1241 benzimidazol-2-yl- HS0 (4-pyridyl) aminomethyl 1242 benzimidazol-2-yl¬ HS0 2 (2- aminomethyl thiazolyl) 1243 benzimidazol-2-yl¬ NHS0 2 (4- aminomethyl isoxazolyl) 1244 benzimidazol-2-yl- NHS0 2 -[4-(3,5- a inomethyl dimethyl)isoxaz olyl] 1245 benzimidazol-2-yl- HS0 2 C6H4-(2- aminomethyl Br) 1246 benzimidazol-2-yl- NHSO 2 C6H4-O- aminomethyl Br) 1247 benzimidazol-2-yl- NHS0 2 C6H4-(2-F) aminomethyl 1248 benzimidazol-2-yl- HS0 2 C6H4-(3-F) aminomethyl 1249 benzimidazol-2-yl- NHS0 2 C6H4-(4-F) aminomethyl 1250 benzimidazol-2-yl- NHC0 CH 2 Ph aminomethyl 1251 benzimidazol-2-yl- NHC02n-Bu aminomethyl 1252 benzimidazol-2-yl¬ NHC0 2 i-B aminomethyl 1253 2-aminopyridin-6- NHS0 2 Ph ylmethyl 1254 2-aminopyridin-6- NHS0 C6H4-(2- ylmethyl CH 3 ) 1255 2-aminopyridin-6- NHSO 2 C6H -O- ylmethyl CH3) 1256 2-aminopyridin-6- HS0 2 C6H4-(4- ylmethyl CH3) 1257 2-aminopyridin-6- NHS0 2 (2-pyridyl) ylmethyl 1258 2-aminopyridin-6- NHS0 2 (3-pyridyl) ylmethyl 1259 2-aminopyridin-6- H NHS0 2 (4-pyridyl) ylmethyl 1260 2-aminopyridin-6- NHS0 (2- ylmethyl thiazolyl) 1261 2-aminopyridin-6- NHS0 2 (4- ylmethyl isoxazolyl) 1262 2-aminopyridin-6- HS0 2 -[4-(3,5- 535.1 ylmethyl dimethyl)isoxaz olyl] 1263 2-aminopyridin-6- NHS0 2 C6H4-(2- ylmethyl Br) 1264 2-aminopyridin-6- NHS0 2 C6H4-(3- ylmethyl Br) 1265 2-aminopyridin-6- NHS0 2 C6H4-(2-F) ylmethyl 1266 2-aminopyridin-6- NHS0 2 C6H4-(3-F) ylmethyl 1267 2-aminopyridin-6- NHSO2C6H4- (4-F) ylmethyl 1268 2-aminopyridin-6- HC0 2 CH 2 Ph ylmethyl 1269 2-aminopyridin-6~ NHC02n-Bu ylmethyl 1270 2-aminopyridin-6- NHC02i-Bu ylmethyl 1271 7-azabenimidazol-2- NHS0 2 Ph yi 1272 7-azabenimidazol-2- NHS0 2 C6H4-(2- yi CH3) 1273 7-azabenimidazol-2- NHS0 2 C6H4-(3- yi CH3) 1274 7-azabenimidazol-2- HSθ 2 C6H4-(4- yi CH3) 1275 7-azabenimidazol-2- HS0 2 (2- yi naph hyl) 1276 7-azabenimidazol-2- NHS0 2 (1- yi naphthyl) 1277 7-azabenimidazol-2- NHS0 2 (biphenyl) yi 1278 7-azabenimidazol-2- HSO 2 C6H4- 569.4 yi (2,4,6-(CH 3 ) 3 ) 1279 7-azabenimidazol-2- NHS0 2 (2-thienyl) yi 1280 7-azabenimidazol-2- NHS0 -[4-(3,5- yi dimethyl)isoxaz olyl] 1281 7-azabenimidazol-2- NHS0 2 C6H4-(2- yi Br) 1282 7-azabenimidazol-2- HS0 2 C6H4-(3- yi Br) 1283 7-azabenimidazol-2- NHS0 2 C 6 H4- (2-F) yi 1284 7-azabenimidazol-2- HS0 2 C 6 H4- (3-F) yi 1285 7-azabenimidazol-2- NHS0 2 C6H4-(4-F) yi 1286 7-azabenimidazol-2- NHC0 CH 2 Ph yi 1287 7-azabenimidazol-2- NHC02n-Bu yi 1288 7-azabenimidazol-2- NHC02i-Bu yi 1289 4,5,6,7-tetrahydro- HS0 2 Ph 561.4 benzimidazol-2-yl¬ aminomethyl 1290 4,5,6,7-tetrahydro- HS0 C6H4-(2- benzimidazol-2-yl- CH 3 ) aminomethyl 1291 4,5,6,7-tetrahydro- NHS0 2 C 6 H4-(3- benzimidazol-2-yl- CH 3 ) aminomethyl 1292 4,5,6,7-tetrahydro- NHS0 C6H4-(4- benzimidazol-2-yl¬ CH3) aminomethyl 1293 4,5,6,7-tetrahydro- NHS0 2 (2- benzimidazol-2-y1- naph hyl) aminomethyl 1294 4,5,6,7-tetrahydro- NHS0 2 (1- benzimidazol-2-yl- naphthyl) aminomethyl 1295 4,5,6,7-tetrahydro- HSO2(biphenyl) benzimidazol-2-y1- aminomethyl 1296 4,5,6,7-tetrahydro- HSO2C6H4- benzimidazol-2-yl¬ (2,4,6-(0.3)3) aminomethyl 1297 4,5,6,7-tetrahydro- NHS0 2 (2-thienyl) benzimidazol-2-yl- aminomethyl 1298 4,5,6,7-tetrahydro- HS0 2 -[4-(3,5- benzimidazol-2-yl¬ dimethyl) isoxaz aminomethyl olyl] 1299 4, 5,6, 7-tetrahydro- NHS0 2 C6H4~(2- benzimidazol-2-yl- Br) aminomethyl 1300 4, 5,6, 7-tetrahydro- NHS0 2 C 6 H4-(3- benzimidazol-2-yl¬ Br) aminomethyl 1301 4,5,6,7-tetrahydro- NHS0 2 C6H4-(2-F) benzimidazol-2-yl¬ aminomethyl 1302 4,5,6,7-tetrahydro- NHSO2C6H4- (3-F) benzimidazol-2-yl¬ aminomethyl 1303 4,5, 6,7-tetrahydro- NHS0 C6H4-(4-F) benzimidazol-2-yl- aminomethyl 1304 4,5,6,7-tetrahydro- NHC0 2 CH 2 Ph benzimidazol-2-yl¬ aminomethyl 1305 4,5, 6,7-tetrahydro- HC02n-Bu benzimidazol-2-yl- aminomethyl 1306 4,5,6,7-tetrahydro- NHC02i-Bu benzimidazol-2-yl¬ aminomethyl 1307 4-oxo-3,4,5,6- NHS0 2 Ph 549.3 tetrahydro- pyrimidin-2-yl- aminomethyl 1308 4-oxo-3,4,5,6- HS0 2 C6H4-(2- tetrahydro- CH3) pyrimidin-2-yl¬ aminomethyl 1309 4-oxo-3,4,5,6- NHS0 2 C6H4-(3- tetrahydro- CH3) pyrimidin-2-yl¬ aminomethyl 1310 4-oxo-3,4,5,6- NHS0 2 C6H4-(4- tetrahydro- CH3) pyrimidin-2-yl¬ aminomethyl 1311 4-oxo-3,4,5,6- NHS0 2 (2- tetrahydro- naphthyl) pyrimidin-2-yl¬ aminomethyl 1312 4-oxo-3,4,5,6- NHS0 2 (1- tetrahydro- naphthyl) pyrimidin-2-yl¬ aminomethyl 1313 4-oxo-3,4,5,6- NHS0 2 (biphenyl) tetrahydro- pyrimidin-2-yl¬ aminomethyl 1314 4-oxo-3,4,5,6- NHSO2C6H4- tetrahydro- (2,4,6-(CH 3 ) 3 ) pyrimidin-2-yl¬ aminomethyl 1315 4-oxo-3,4,5,6- NHSθ2 (2-thienyl ) tetrahydro- pyrimidin-2-yl¬ aminomethyl 1316 4-oxo-3,4,5,6- NHS0 2 -[4-(3,5- tetrahydro- dimethyl) isoxaz pyrimidin-2-yl- olyl) a inomethyl 1317 4-oxo-3,4,5,6- NHS0 2 C6H4-(2- tetrahydro- Br) pyrimidin-2-yl¬ aminomethyl 1318 4-oxo-3,4,5,6- HS02C6H4-(3- tetrahydro- Br) pyrimidin-2-yl- aminomethyl 1319 4-oxo-3,4,5,6- NHS0 2 C6H4-(2-F) tetrahydro- pyrimidin-2-yl- aminomethyl 1320 4-oxo-3,4,5,6- NHSO2C6H4- (3-F) tetrahydro- pyrimidin-2-yl¬ aminomethyl 1321 4-oxo-3,4,5,6- NHS0 2 C6H4-(4-F) tetrahydro- pyrimidin-2-yl¬ aminomethyl 1322 4-oxo-3,4,5,6- HC0 2 CH 2 Ph tetrahydro- pyrimidin-2-yl¬ aminomethyl 1323 4-oxo-3,4,5,6- HC0 2 n-Bu tetrahydro- pyrimidin-2-yl¬ aminomethyl 1324 4-oxo-3,4,5,6- HCO21-BU tetrahydro- pyrimidin-2-yl- - aminomethyl 1325 2-iminoazepin-7- NHS0 2 Ph ylmethyl 1326 l,2-pyrazol-3- NHS0 2 Ph ylaminomethyl 1327 l,2,4-triazol-5- NHS0 2 Ph y1aminomethy1 1328 imidazol-4- NHS0 2 Ph - ylaminomethyl 1329 1,3,4-oxadiazol- NHS0 2 Ph 2ylaminomethyl 1330 l,2,4-thiadiazol-5- NHS0 2 Ph y1aminomethy1 1331 1.2.5-oxadiazol-3- HS0 2 Ph ylaminomethyl 1332 1.2.4-oxadiazol-5- HS0 2 Ph ylaminomethyl 1333 2-iminoazepin-7- NHS0 2 (4- ylmethyl isoxazolyl) 1334 l,2-pyrazol-3- NHS0 (4- ylaminomethyl isoxazolyl) 1335 l,2,4-triazol-5- HS0 2 (4- ylaminomethyl isoxazolyl) 1336 imidazol-4- HS0 2 (4- ylaminomethyl isoxazolyl) 1337 1,3,4-oxadiazol- HS0 2 (4- 2ylaminomethyl isoxazolyl) 1338 l,2,4-thiadiazol-5- NHS0 2 (4- ylaminomethyl isoxazolyl) 1339 1.2.5-oxadiazol-3- NHS0 (4- y1aminomethy1 isoxazolyl) 1340 1.2.4-oxadiazol-5- 1 HS0 2 (4- ylaminomethyl isoxazolyl) 1341 2-iminoazepin-7- 1 NHS0 2 -(4-(3,5- ylmethyl dimethyl) isoxaz olylj 1342 l,2-pyrazol-3- 1 HS0 2 -[4-(3,5- ylaminomethyl dimethyl) isoxaz olyl] 1343 l,2,4-triazol-5- 1 NHS0 2 -[4-(3,5- ylaminomethyl dimethyl) isoxaz olyl] 1344 imidazol-4- 1 HS0 2 -[4-(3,5- l minomethyl dimethyl) isoxaz olyl] 1345 1,3, -oxadiazol- 1 HS0 2 -[4-(3,5- 2ylaminomethyl dimethyl)isoxaz olyl] 1346 l,2,4-thiadiazol-5- 1 HS0 2 -[4-(3,5- ylaminomethyl dimethyl)isoxaz olyl] 1347 1.2.5-oxadiazol-3- 1 HS0 2 -[4-(3,5- ylaminome hyl dimethyl) isoxaz olyl] 1348 1.2.4-oxadiazol-5- 1 NHS0 2 -[4-(3,5- ylaminome hyl dimethyl)isoxaz olyl] 1349 imidazol-2-yl- 1 3-pyridinyl H aminomethyl 1350 pyridin-2- 1 3-pyridinyl ylaminomethyl 1351 imidazolin-2-yl- 1 3-pyridinyl aminomethyl 1352 tetrahydropyrimidin 1 3-pyridinyl -2-ylaminomethyl 1353 benzimidazol-2-yl- 1 3-pyridinyl H aminomethyl 1354 2-aminopyridin-6- 1 3-pyridinyl H ylmethyl 1355 2-iminoazepin-7- 1 3-pyridinyl H ylmethyl 1356 l,2-pyrazol-3- 1 3-pyridinyl H ylaminomethyl 1357 l,2,4-triazol-5- 1 3-pyridinyl H ylaminomethyl 1358 imidazol-4- 1 3-pyridinyl H ylaminomethyl 1359 1,3,4-oxadiazol- 1 3-pyridinyl H 2ylaminomethyl 1360 l,2,4-thiadiazol-5- 1 3-pyridinyl H ylaminomethyl 1361 1.2.5-oxadiazol-3- 1 3-pyridinyl H ylaminomethyl 1362 1.2.4-oxadiazol-5- 1 3-pyridinyl H ylaminomethyl 1363 imidazol-2-yl- 1 (3,4- H aminomethyl methylene- dioxy)phenyl 1364 pyridin-2- 1 (3,4- H ylaminomethyl methylene- dioxy) henyl 1365 imidazolin-2-yl- 1 (3,4- H aminomethyl methylene- dioxy)phenyl 1366 tetrahydropyrimidin 1 (3,4- H -2-ylaminomethyl methylene- dioxy)phenyl 1367 benzimidazol-2-yl- 1 (3,4- H aminomethyl methylene- dioxy)phenyl 1368 2 -aminopyridin-6- 1 (3,4- ylmethyl methylene- dioxy)phenyl 1369 2-iminoazepin-7- 1 (3,4- ylmethyl methylene- dioxy)phenyl 1370 l , 2-pyrazol -3 - 1 (3,4- y 1 ami nome t hy 1 methylene- dioxy)phenyl 1371 l , 2 , 4-triazol-5- 1 (3,4- ylaminomethyl methylene- dioxy)phenyl 1372 imidazol-4- 1 (3,4- ylaminomethyl methylene- dioxy)phenyl 1373 1,3,4-oxadiazol- 1 (3,4- 2ylaminomethyl methylene- dioxy)phenyl 1374 l,2,4-thiadiazol-5 - 1 (3,4- ylaminomethyl methylene- dioxy)phenyl 1375 1,2,5-oxadiazol-3- - 1 (3,4- ylaminomethyl methylene- dioxy)phenyl 1376 1.2.4-oxadiazol-5- 1 (3,4- ylaminomethyl methylene- dioxy)phenyl 1377 imidazol-2-yl¬ 1 3-pyridinyl HS0 2 Ph aminomethyl 1378 pyridin-2- 1 3-pyridinyl NHS0 2 Ph ylaminomethyl 1379 imidazol-2-yl¬ 1 (3,4- NHS0 Ph aminomethyl methylene- dioxy)phenyl 1380 pyridin-2-ylamino 1381 imidazol-2-yl-amino 1382 pyridin-2-ylamino 1383 imidazolin-2-yl- amino 1384 tetrahydropyrimidin -2-ylamino 1385 benzimidazol-2-yl- amino 1386 2-aminopyridin-6- ylmethyl 1387 2-iminoazepin-7-yl 1388 l,2-pyrazol-3- ylamino 1389 l,2,4-triazol-5- NHS0 Ph ylamino 1390 imidazol-4-ylamino 1391 1,3,4-oxadiazol- 2ylaminomethyl 1392 l,2,4-thiadiazol-5- y1aminomethy1 1393 1.2.5-oxadiazol-3- y1aminomethy1 1394 1.2.4-oxadiazol-5- ylaminomethyl 1395 imidazol-2-yl- aminoethyl 1396 pyridin-2- ylaminoethyl 1397 imidazolin-2-yl- aminoethyl 1398 tetrahydropyrimidin -2-ylaminoethyl 1399 benzimidazol-2-yl- NHS0 2 Ph aminoethyl 1400 2-ammopyrιdιn-6- NHS0 2 Ph ylethyl 1401 2-ιmιnoazepιn-7- NHS0 2 Ph ylethyl 1402 l,2-pyrazol-3- NHS0 2 Ph ylaminoethyl 1403 l,2,4-trιazol-5- HS0 2 Ph ylarmnoethyl 1404 ιmιdazol-4- NHS0 2 Ph ylaminoethyl 1405 1,3,4-oxadιazol- NHS0 Ph 2ylamιnoethyl 1406 l,2,4-thιadιazol-5- NHS0 2 Ph ylaminoethyl 1407 1,2, 5-oxadιazol-3- HS0 2 Ph ylaminoethyl 1408 l,2,4-oxadιazol-5- NHS0 2 Ph ylaminoethyl 1409 ιmιdazol-2-yl- NHS0 2 Ph aminomethyl 1410 pyπdιn-2- NHS0 2 Ph ylammomethyl 1411 ιmιdazolιn-2-yl- NHS0 2 Ph ei inomethyl 1412 tetrahydropyrimidin NHS0 2 Ph -2-ylaminomethyl 1413 benzιmιdazol-2-yl- NHS0 2 Ph aminomethyl 1414 7-azabenιmιdazol-2- HS0 Ph yi 1415 4,5,6,7-tetrahydro- NHS0 2 Ph benzimidazol-2-yl- aminomethyl 1416 4-oxotetrahydro- NHS0 2 Ph pyrimidin-2-yl¬ aminomethyl 1417 2-_uniπopyridin-6- HS0 2 Ph ylmethyl 1418 2-iminoazepin-7- NHS0 2 Ph ylmethyl 1419 l,2-pyrazol-3- NHS0 2 Ph y1aminomethy1 1420 l,2,4-triazol-5- NHS0 2 Ph ylaminomethyl 1421 imidazol-4- NHS0 Ph y1aminomethy1 1422 1,3,4-oxadiazol- NHS02P 2ylaminomethyl 1423 l,2,4-thiadiazol-5- HS02Ph ylaminomethyl 1424 1.2.5-oxadiazol-3- NHSθ 2 Ph ylaminomethyl 1425 1.2.4-oxadiazol-5- HS0 Ph y1 minomethy1 1426 imidazol-2-yl¬ NHS0 2 Ph aminomethyl 1427 pyridin-2- NHS0 2 Ph ylaminomethyl 1428 imidazolin-2-yl- NHS0 2 Ph aminomethyl 1429 tetrahydropyrimidin NHS0 2 Ph -2-ylaminomethyl 1430 benzimidazol-2-yl- NHS0 2 Ph aminomethyl 1431 7-azabenimidazol-2- NHS0 2 Ph yi 1432 4,5,6,7-tetrahydro- 0 NHS02Ph benzimidazol-2-yl- aminomethyl 1433 4-oxotetrahydro- 0 NHSθ2Ph pyrimidin-2-yl¬ aminomethyl 1434 2-aminopyridin-6- 0 NHS0 Ph ylmethyl 1435 2-iminoazepin-7- 0 HS0 2 Ph ylmethyl 1436 l,2-pyrazol-3- 0 NHS02Ph ylaminomethyl 1437 l,2,4-triazol-5- 0 NHS02Ph ylaminomethyl 1438 imidazol-4- 0 NHS0 2 Ph ylaminomethyl 1439 1,3,4-oxadiazol- 0 NHS0 2 Ph 2yl minomethyl 1440 l,2,4-thiadiazol-5- 0 NHS0 2 Ph ylaminomethyl 1441 l,2,5-oxadiazol-3- 0 NHS0 2 Ph ylaminomethyl 1442 1.2.4-oxadiazol-5- 0 NHS0 2 Ph ylaminomethyl 1443 benzimidazol-2- 1 NHS0 2 (2,4,6- 597.4 ylaminomethyl trimethyl phenyl) 1444 2- 1 NHS0 2 (2,4,6- 608.5 quinolinylaminometh trimethyl yi phenyl) 1445 benzimidazol-2- 1 HS0 2 (2,4,6- 611.3 y1aminocarbony1 trimethyl phenyl) 1446 benzimidazol-2-yl 1447 imidazol-2- 1 ylaminocarbonyl 1448 imidazol-2- 1 ylaminocarbonyl 1449 imidazol-2- 1 ylaminocarbonyl 1450 pyridin-2- 1 ylaminomethyl 1451 imidazol-2- 1 ylaminomethyl 1452 imidazol-2- 1 ylaminomethyl 1453 imidazol-2- 1 HS0 2 [(2,6- ' 649.1 ylaminomethyl dichloro-4- phenyl)phenyl] 1454 imidazol-2- 1 HS0 2 [(2,6- 609.2 ylaminomethyl dimethyl-4- phenyl)phenyl] 1455 imidazol-2- 1 NHS0 2 (2,6- 533.2 ylaminomethyl dimethylphenyl) 1456 imidazol-2- 1 NHS0 (2-chloro- 553.2 ylaminomethyl 6-methylphenyl) 1457 imidazol-2- 1 NHS0 2 (2,6- 573.1 ylaminomethyl dichlorophenyl) Table 2 E .. E la E 14 E 15 US. Ms.. 2001 2-aminopyridin-6-yl 0 2002 2-aminopyridin-6-yl 0 2003 2-aminopyridin-6-yl 0 2004 2-aminopyridin-6-yl 0 2005 2-aminopyridin-6-yl 0 2006 2-aminopyridin-6-yl 0 2007 2-aminopyridin-6-yl 0 2008 2-aminopyridin-6-yl 0 2009 2-aminopyridin-6-yl 0 2010 2-aminopyridin-6-yl 0 2011 2-aminopyridin-6-yl 0 2012 2-aminopyridin-6-yl 0 2013 2-aminopyridin-6-yl 0 2014 2-aminopyridin-6-yl 0 2015 2-aminopyridin-6-yl 0 2016 2-aminopyridin-6-yl 0 2017 2-aminopyridin-6-yl 0 NHC02t-Bu 2018 2-aminopyridin-6-yl 0 HCOCH 2 Ph 2019 2-aminopyridin-6-yl 0 NHCOCH 2 C6H4_(2-CH3) 2020 2-aminopyridin-6-yl 0 H HCOCH C6H4-(3-CH3) 2021 2-aminopyridin-6-yl 0 H NHCOCH 2 C 6 H4-(4-CH3) 2022 2-aminopyridin-6-yl 0 H NHCO(CH 2 ) 2 Ph 2023 2-aminopyridin-6-yl 0 H NHCOn-Bu 2024 2-aminopyridin-6-yl 0 H NHCOt-Bu 2025 2-aminopyridin-6-yl 0 H NHS0 2 Ph 2026 2-aminopyridin-6-yl 0 H NHS0 2 C6H4-(2-CH3) 2027 2-aminopyridin-6-yl 0 H HS0 2 C6H4- (3-CH 3 ) 2028 2-aminopyridin-6-yl 0 H HS0 2 C6H4-(4-CH3) 2029 2-aminopyridin-6-yl 0 HS0 2 (2-pyridyl) 2030 2-aminopyridin-6-yl 0 H NHS0 2 (3-pyridyl) 2031 2-aminopyridin-6-yl 0 NHS0 2 (4-pyridyl) 2032 2-aminopyridin-6-yl 0 NHSO2 (2-thiaz-olyl) 2033 2-aminopyridin-6-yl 0 H NHS0 2 (3-thiazolyl) 2034 2-aminopyridin-6-yl 0 H NHS0 2 (4-isoxazolyl) 2035 2-aminopyridin-6-yl 0 H NHS0 2 [4-(3,5- dimethyl) isoxazolyl] 2036 2-aminopyridin-6-yl 0 H HSO2C6H4- (2-Br) 2037 2-aminopyridin-6-yl 0 H NHSO2C6H4- (3-Br) 2038 2-aminopyridin-6-yl 0 H NHS0 2 C6H4-(4-Br) 2039 2-aminopyridin-6-yl 0 H NHSO2C6H4- (2-F) 2040 2-aminopyridin-6-yl 0 H HS0 2 C6H4-(3-F) 2041 2-aminopyridin-6-yl 0 H NHSO2C6H4- (4-F) 2042 2-aminopyridin-6-yl 0 H NHS0 2 (2-naphthyl) 2043 2-aminopyridin-6-yl 0 H NHS0 2 (1-naphthyl) 2044 2-aminopyridin-6-yl 0 H NHS0 2 CH=CHPh 2045 2-aminopyridin-6-yl 0 H NHSθ2CH 2 Ph 2046 2-aminopyridin-6-yl 0 H NHS0 CH 2 CH=CH-Ph 2047 2-aminopyridin-6-yl 0 H HS0 -n-B 2048 2-aminopyridin-6-yl 0 H NHSθ2-i-Bu 2049 2-aminopyridin-6-yl 0 H NHS02-t-Bu 2050 2-aminopyridin-6-yl 0 H HS0 HPh 2051 2-aminopyridin-6-yl 0 H NHSO2NHC6H4- (2-CH3) 2052 2-aminopyridin-6-yl 0 H NHSO2NHC6H4- (3-CH3) 2053 2-aminopyridin--6-yl 0 H NHS0 2 NHC6H4- (4-CH3) 2054 2-aminopyridin-6-yl 0 H HS0 2 NH(2-pyridyl) 2055 2-aminopyridin-6-yl 0 H NHS0 2 H ( 3 -pyridyl ) 2056 2-aminopyridin-6-yl 0 H HS0 2 H ( 4 -pyridyl ) 2057 2-aminopyridin-6-yl 0 H NHS0 2 NH ( 2 -thiazolyl ) 2058 2-aminopyridin-6-yl 0 H NHS0 NH ( 4 -thiazolyl ) 2059 2-aminopyridin-6-yl 0 H NHS0 2 NH (4 - isoxazolyl) 2060- 2-aminopyridin-6-yl 0 H HS0 2 [4-(3,5- dimethyl)isoxazolyl] 2061 2-aminopyridin-6- NHS0 2 NHC6H4-(2-Br) 2062 2-aminopyridin-6- NHS0 2 NHC6H4-(3-Br) 2063 2-aminopyridin-6- NHS0 2 NHC6H4-(4-Br) 2064 2-aminopyridin-6- NHS0 2 HCβH4-(3-F) 2065 2-aminopyridin-6- NHS0 2 NHC6H4-(4-F) 2066 2-aminopyridin-6- HS0 2 H(2-naphthyl) 2067 2-aminopyridin-6- NHS0 2 NH(1-naphthyl) 2068 2-aminopyridin-6- NHS0 2 HCH=CH-Ph 2069 2-aminopyridin-6- NHS0 HCH Ph 2070 2-aminopyridin-6- NHS0 2 NHCH 2 CH=CH-Ph 2071 2-aminopyridin-6- NHS0 2 NH-n-Bu 2072 2-aminopyridin-6- NHS0 2 NH-i-Bu 2073 2-aminopyridin-6- NHS0 2 NH-t-Bu 2074 2-aminopyridin-6- NHC0 Bn 497.2 2075 2-aminopyridin-6- NHCO2CH 2 C6H4-(2-CH3) 2076 2-aminopyridin-6- NHC02CH 2 C6H4-(3-CH3) 2077 2-aminopyridin-6- NHC02CH 2 C6H4-(4-CH3) 2078 2-aminopyridin-6- NHCO2CH2 (2- pyridinyl) 2079 2-aminopyridin-6-yl 1 NHCO2CH2O- pyridinyl) 2080 2-aminopyridin-6-yl 1 H NHCO2CH2 (4- pyridinyl) 2081 2-aminopyridin-6-yl 1 H HC02CH (2- thiazolyl) 2082 2-aminopyridin-6-yl 1 H NHC02CH 2 (4- thiazolyl) 2083 2-aminopyridin-6-yl 1 H HC02CH 2 (5- thiazolyl) 2084 2-aminopyridin-6-yl 1 H NHC0 2 CH 2 (4- isoxazolyl) 2085 2-aminopyridin-6-yl 1 H HCO2CH2 (2-thienyl) 2086 2-aminopyridin-6-yl 1 H NHC02n-Bu 2087 2-aminopyridin-6-yl 1 H NHCθ2i-Bu 2088 2-aminopyridin-6-yl 1 H HC02t-Bu 2089 2-aminopyridin-6-yl 1 H NHCOCH 2 Ph 2090 2-aminopyridin-6-yl 1 H NHCOCH2C6H4-(2-CH3) 2091 2-a inopyridin-6-yl 1 H NHCOCH -C6H4-(3-CH3) 2092 2-aminopyridin-6-yl 1 H HCOCH2C6H4-(4-CH3) 2093 2-aminopyridin-6-yl 1 H NHCOCH2 (2-pyridinyl) 2094 2-aminopyridin-6-yl 1 H NHCOCH2 (3-pyridinyl) 2095 2-aminopyridin-6-yl 1 H NHCOCH2 (4-pyridinyl) 2096 2-aminopyridin-6-yl 1 H HCOCH2 (2-thiazoly1) 2097 2-aminopyridin-6-yl 1 H NHCOCH2 (4-thiazolyl) 2098 2-aminopyridin-6-yl 1 2099 2-aminopyridin-6-yl 1 2100 2-aminopyridin-6-yl 1 2101 2-aminopyridin-6-yl 1 2102 2-aminopyridin-6-yl 1 2103 2-aminopyridin-6-yl 1 2104 2-aminopyridin-6-yl 1 2105 2-aminopyridin-6-yl 1 2106 2-aminopyridin-6-yl 1 2107 2-aminopyridin-6-yl 1 NHS0 2 ( 3 -pyridyl) HS0 2 ( 4 -pyridyl) NHSO2 (2-thiazolyl) NHS0 2 (4-thiazolyl) NHSO2 ( 4 - isoxazolyl ) NHS0 -[4-(3,5- dimethyl) isoxazolyl] NHS0 2 C6H4-(2-Br) NHS0 2 C6H4-(3-Br) NHS0 2 C 6 H4-(4-Br) HS0 2 C 6 H4-(2-F) HS0 2 C6H4-(3-F) HS0 2 C 6 H4-(4-F) HS0 2 (2-naphthyl) HS0 2 (1-naphthyl) HS02CH=CH-Ph HS0 2 CH 2 Ph NHS0 2 -CH 2 CH=CH-Ph NHS0 2 -n-Bu NHS0 2 -i-Bu NHS0 2 -t-Bu NHSθ2 H h NHS0 2 NHC6H4- (2-CH3) NHS0 2 NHC6ft4- (3-CH3) NHS0 2 NHC6H4-(4-CH3) NHS0 H(2-pyridyl) NHS0 2 NH(3-pyridyl) NHS0 2 NH(4-pyridyl) HS0 2 NH(2-thiazolyl) NHS0 2 NH-(4- thiazolyl) 2137 2-aminopyridin-6-yl 1 HS0 2 NH(4- isoxazolyl) 2138 2-aminopyridin-6-yl 1 H NHS0 2 -[4-(3,5- dimethyl) isoxazolyl] 2139 2-aminopyridin-6-yl 1 H HS0 2 NHC6H4~ (2-Br) 2140 2-aminopyridin-6-yl 1 H NHS0 2 HC6H4-(3-Br) 2141 2-aminopyridin-6-yl 1 H NHS0 2 NHC6H4-(4-Br) 2142 2-aminopyridin-6-yl 1 H NHS0 2 NHC6H4-(3-F) 2143 2-aminopyridin-6-yl 1 H NHS0 2 NHC6H4-(4-F) 2144 2-aminopyridin-6-yl 1 H NHS0 NH(2-naphthyl) 2145 2-aminopyridin-6-yl 1 H NHS0 2 NH) 1-naphthyl) 2146 2-aminopyridin-6-yl 1 H NHS0 2 NHCH=CH-Ph 2147 2-aminopyridin-6-yl 1 H NHS0 2 NHCH 2 Ph 2148 2-aminopyridin-6-yl 1 H NHS0 2 NHCH 2 CH=CH-Ph 2149 2-aminopyridin-6-yl 1 H NHS0 2 H-n-Bu 2150 2-aminopyridin-6-yl 1 H NHS0 2 NH-i-B 2151 2-aminopyridin-6-yl 1 H NHS0 2 NH-t-Bu 2152 2-aminoimidazol- 0 H NHCOOBn 5-yl 2153 2-aminoimidazol- 0 H NHC02CH 2 C6H4-(2-CH3) 5-yl 2154 2-aminoimidazol- 0 H NHC02CH2C6H4-(3-CH3) 5-yl 2155 2-aminoimidazol- 0 H NHCO2CH 2 C6H4- (4-CH3) 5-yl 2156 2-aminoimidazol- 0 H NHC02CH 2 (2- 5-yl pyridinyl) 2157 2-aminoimidazol- 0 H NHC02CH 2 (3- 5-yl pyridinyl) 2158 2-aminoimidazol- 0 H NHC02CH 2 (4- 5-yl pyridinyl) 2159 2-aminoimidazol- 0 H NHC0 2 CH 2 (2- 5-yl thiazolyl) 2160 2-aminoimidazol- 0 H NHC02CH 2 (4- 5-yl thiazolyl) 2161 2-aπunoιmιdazol- 0 H NHC02CH 2 (5- 5-yl thiazolyl) 2162 2-amιnoimidazol- 0 H NHC02CH 2 (4- 5-yl isoxazolyl) 2163 2-ammoιmιdazol- 0 H NHCO2CH2 (2-thιenyl) 5-yl 2164 2-amιnoimidazol- 0 H NHC02n-Bu 5-yl 2165 2-amιnoimidazol- 0 H NHC02i-Bu 5-yl 2166 2-amιnoimidazol- 0 H NHC02t-Bu 5-yl 2167 2-ammoιmidazol- 0 H NHS0 2 Ph 5-yl 2168 2-aminoimidazol- 0 H NHS0 2 C6H4-(2-CH3) 5-yl 2169 2-aminoιmidazol- 0 H NHSO2C6H4-O-CH3) 5-yl 2170 2-aminoimidazol- H NHS0 2 C6H4-(4-CH3; 5-yl 2171 2-aminoιmidazol- 0 H HS0 2 (2-pyridyl) 5-yl 2172 2-amιnoimidazol- 0 H NHS0 2 (3-pyridyl) 5-yl 2173 2-amιnoimidazol- 0 H NHS0 2 (4-pyridyl) 5-yl 2174 2-aminoimidazol- 0 H NHS0 2 (2-thιazolyl) 5-yl 2175 2-amιnoιmιdazol- 0 H NHSθ2(4-thiazolyl) 5-yl 2176 2-amιnoimιdazol- 0 H HSO2 (4-isoxazolyl) 5-yl 2177 2-ammoimidazol- 0 H NHS0 2 -[4-(3,5- 5-yl dimethyl) isoxazolyl] 2178 2-aminoimidazol- 0 H NHS0 2 C6H4-(2-Br) 5-yl 2179 2-aminoimidazol- 0 H HS0 2 C 6 H4-(3-Br) 5-yl 2180 2-aminoimidazol- 0 H NHS0 2 C 6 H 4 -(2-F) 5-yl 2181 2-aminoimidazol- 0 H NHS0 2 C6H4-(3-F) 5-yl 2182 2-aminoimidazol- 0 H NHS0 2 C6H4-(4-F) 5-yl 2183 2-aminoimidazol- 0 H HS0 2 (2-naphthyl) 5-yl 2184 2-aminoimidazol- 0 H NHS0 2 (1-naphthyl) 5-yl 2185 2-aminoimidazol- 0 H NHS0 2 CH=CHPh 5-yl 2186 2-aminoimidazol- 0 H NHS0 2 CH 2 Ph 5-yl 2187 2-aminoimidazol- 0 H HS0 2 CH 2 CH=CHPh 5-yl 2188 2-aminoimidazol- 0 H NHS0 2 -n-Bu 5-yl 2189 2-aminoimidazol- 0 H NHS0 -i-Bu 5-yl 2190 2-aminoimidazol- 1 H NHCOOBn 5-yl 2191 2-aminoimidazol- 1 H NHC02CH 2 C6H4_(2-CH3) 5-yl 2192 2-aminoimidazol- 1 H NHC02CH 2 C 6 H4-(3-CH3) 5-yl 2193 2-aminoimidazol- 1 H NHC02CH 2 C6H4-(4-CH3) 5-yl 2194 2-aminoimidazol- 1 H HC02CH 2 (2- 5-yl pyridinyl) 2195 2-amιnoιmιdazol- HC02CH 2 (3- 5-yl pyridinyl) 2196 2-amιnoιmιdazol- HC02CH 2 (4- 5-yl pyridmyl) 2197 2-amιnoιmιdazol- NHCO2CH2 (2- 5-yl thiazolyl) 2198 2-amιnoιmιdazol- NHCO2CH2 (4- 5-yl thiazolyl) 2199 2-amιnoιraιdazol- NHC02CH 2 (5- 5-yl thiazolyl) 2200 2-amιnoιmιdazol- NHCO2CH2 (4- 5-yl lsoxazolyl) 2201 2-amιnoιmιdazol- HCO2CH2 (2-thιenyl) 5-yl 2202 2-amιnoιmιdazol- 1 H NHC02n-Bu 5-yl 2203 2-amιnoιmιdazol- 1 H HCθ2i-Bu 5-yl 2204 2-amιπoιmιdazol- 1 H NHC02t-Bu 5-yl 2205 2 -ammoιmιdazol- 1 H NHS0 2 Ph 5-yl 2206 2-amιnoιmιdazol- 1 H NHS0 2 C 5 H4-(2-CH 3 ) 5-yl 2207 2-amιnoιmιdazol- 1 H NHS0 2 CδH4-(3-CH3) 5-yl 2208 2 -amιnoιrαιdazol- 1 H NHSO2C6H4- (4-CH3) 5-yl 2209 2-amιnoιmιdazol- 1 H NHS0 2 (2-pyridyl) 5-yl 2210 2-amιnoιmιdazol- 1 H NHS0 (3-pyridyl) 5-yl 2211 2-ammoιmιdazol - NHS0 2 (4-pyridyl] 5-yl 2212 2-aminoimidazol- 1 H NHS0 2 (2-thiaz-olyl) 5-yl 2213 2-aminoimidazol- 1 H NHS0 2 (4-isoxazolyl) 5-yl 2214 2-aminoimidazol- 1 H HS0 2 -[4-(3,5- 5-yl dimethyl ) isoxazolyl ] 2215 2-aminoimidazol- 1 H NHS0 2 C 6 H4-(2-Br) 5-yl 2216 2-aminoimidazol- 1 H NHS0 C6H4-(3-Br) 5-yl 2217 2-aminoimidazol- 1 H NHS0 2 C 6 H -(2-F) 5-yl 2218 2-aminoimidazol- 1 H NHS0 2 CβH4-(3-F) 5-yl 2219 2-aminoimidazol- NHS0 2 C6H4-(4-F) 5-yl 2220 2-aminoimidazol- 1 H NHS0 (2-naphthyl) 5-yl 2221 2-aminoimidazol- 1 H NHS0 2 (1-naphthyl) 5-yl 2222 2-arninoimidazol- HS0 2 CH=CHPh 5-yl 2223 2-aminoimidazol- 1 H NHS0 2 CH Ph 5-yl 2224 2-aminoimidazol- 1 H NHS0 2 CH 2 CH=CHPh 5-yl 2225 2-aminoimidazol- 1 H NHS0 2 -n-Bu 5-yl 2226 2-aminoimidazol- 1 H HS0 2 -i-Bu 5-yl 2227 2-aminoimidazol- 1 H NHSθ2Ph 5-yl 2228 2-aminoimidazol- 1 H HS0 2 C 6 H4-(2-CH3) 5-yl 2229 2-aminoimidazol- 1 H NHS0 2 C6H4-(3-CH3) 5-yl 2230 2-aminoimidazόl- 1 H HS0 2 C 6 H4-(4-CH3) 5-yl 2231 2-aminoimidazol- 1 H HS0 2 (2-pyridyl) 5-yl 2232 2-aminoimidazol- 1 H NHS0 2 (3-pyridyl) 5-yl 2233 2-aminoimidazol- 1 H NHS0 2 (4-pyridyl) 5-yl 2234 2-aminoimidazol- 1 H NHS0 (2-thiazolyl) 5-yl 2235 2-aminoimidazol- 1 H NHSθ2(4-isoxazolyl) 5-yl 2236 2-aminoimidazol- 1 H NHS0 2 -[4-(3,5- 5-yl dimethyl)isoxazolyl] 2237 2-aminoimidazol- 1 H NHS0 2 C6H4-(2-Br) 5-yl 2238 2-aminoimidazol- 1 H NHS0 2 C6H4-(3-Br) 5-yl 2239 2-aminoimidazol- 1 H NHS0 2 C6H4-(2-F) 5-yl 2240 2-aminoimidazol- 1 H NHS0 2 C6H4-(3-F) 5-yl 2241 2-aminoimidazol- 1 H NHS0 2 CβH4-(4-F) 5-yl 2242 2-aminoimidazol- 1 H NHC0 2 CH2Ph 5-yl 2243 2-aminoimidazol- 1 H NHCθ2n-Bu 5-yl 2244 2-aminoimidazol- 1 H HCθ2i-Bu 5-yl 2245 2-aminothiazol-4-yl 0 H HS0 2 Ph 2246 2-aminothiazol-4-yl 0 H NHS0 2 C6H4-(2-CH3) 2247 2-aminothiazol-4-yl 0 H HSO2C6H4- (3-CH3) 2248 2-aminothiazol-4-yl 0 H NHS0 2 C6H4-(4-CH3) 2249 2-aminothiazol-4-yl 0 H NHS0 (2-pyridyl) 2250 2-aminothiazol-4-yl 0 H NHS0 2 (3-pyridyl) 2251 2-aminothiazol-4-yl 0 H HS0 2 (4-pyridyl) 2252 2-aminothiazol-4-yl 0 H NHS0 2 (2-thiazolyl) 2253 2-aminothiazol-4-yl 0 H NHS0 2 (4-isoxazolyl) 2254 2-aminothiazol-4-yl 0 H HS0 2 -[4-(3,5- di ethyl) isoxazolyl] 2255 2-aminothiazol-4-yl 0 H HS0 2 C6H4-(2-Br) 2256 2-aminothiazol-4-yl 0 H HS0 2 C6H4-(3-Br) 2257 2-aminothiazol-4-yl 0 H NHS0 2 C6H4-(2-F) 2258 2-aminothiazol-4-yl 0 H NHS0 2 C6H4-(3-F) 2259 2-aminothiazol-4-yl 0 H NHS0 2 C6H4-(4-F) 2260 2-aminothiazol-4-yl 0 H NHC0 CH 2 Ph 2261 2-aminothiazol-4-yl 0 H NHCθ2n-Bu 2262 2-aminothiazol-4-yl 0 H NHC02i-Bu 2263 2-aminothiazol-4-yl 1 H NHS0 2 Ph 2264 2-aminothiazol-4-yl 1 H NHS0 2 C6H4-(2-CH3) 2265 2-aminothiazol-4-yl 1 H NHSO2C6H4- (3-CH3) 2266 2-aminothiazol-4-yl 1 H NHS0 2 CβH4- (4-CH3) 2267 2-aminothiazol-4-yl 1 H NHS0 2 (2-pyridyl) 2268 2-aminothiazol-4-yl 1 H HS0 2 (3-pyridyl) 2269 2-aminothiazol-4-yl 1 H NHS0 (4-pyridyl) 2270 2-aminothiazol-4-yl 1 H NHS0 2 (2-thiazolyl) 2271 2-aminothiazol-4-yl 1 H HSO2 (4-isoxazolyl) 2272 2-aminothiazol-4-yl 1 H NHS0 2 -[4-(3,5- dimethyl) isoxazolyl] 2273 2-aminothiazol-4-yl 1 H NHSO2C6H4- (2-Br) 2274 2-aminothiazol-4-yl 1 H NHSO2C6H4- (3-Br) 2275 2-aminothiazol-4-yl 1 H NHSO2C6H4- (2-F) 2276 2-aminothiazol-4-yl 1 H NHS0 C 6 H4-(3-F) 2277 2-aminothiazol-4-yl 1 H NHS0 2 C6H4-(4-F) 2278 2-aminothiazol-4-yl 1 H NHC0 2 CH Ph 2279 2-aminothiazol-4-yl 1 H NHC02n-Bu 2280 2-aminothiazol-4-yl 1 H NHC02i-Bu 2281 2-aminopyridin-6- 0 H HS0 2 Ph ylmethyl 2282 2-aminopyridin-6- 0 H NHSO2C6H4- (2-CH3) ylmethyl 2283 2-aminopyridin-6- 0 H HS0 2 C 6 H4-(3-CH3) ylmethyl 2284 2-aminopyridin-6- 0 H HS0 2 C6H4-(4-CH3) ylmethyl 2285 2-aminopyridin-6- 0 H NHS0 2 (2-naphthyl) ylmethyl 2286 2-aminopyridin-6- 0 H NHS0 2 (1-naphthyl) ylmethyl 2287 2-aminopyridin-6- 0 H HS0 2 (biphenyl) ylmethyl 2288 2-aminopyridin~6- 0 H NHS0 (2,4,6- ylmethyl trimethylphenyl) 2289 2-aminopyridin-6- 0 H NHS0 2 (2-thienyl) ylmethyl 2290 2-aminopyridin-6- 0 H NHS0 2 -(4-(3,5- ylmethyl dimethyl) isoxazolyl] 2291 2-aminopyridin-6- 0 H NHS0 2 C 6 H4-(2-Br) ylmethyl 2292 2-aminopyridin-6- 0 H NHS0 2 C6H4-(3-Br) ylmethyl 2293 2-aminopyridin-6- 0 H NHS0 2 C6H -(2-F) ylmethyl 2294 2-aminopyridin-6- 0 H NHS0 2 C6H4~ (3-F) ylmethyl 2295 2-aminopyridin-6- 0 H HS0 2 C6H - (4-F) ylmethyl 2296 2-aminopyridin-6- 0 H HC0 CH 2 Ph ylmethyl 2297 2-aminopyridin-6- NHC02n-Bu ylmethyl 2298 2-aminopyridin-6- 0 H NHCθ2i-Bu ylmethyl 2299 2-aminopyridin-6- 1 1 HH NHS0 2 Ph ylmethyl 2300 2-aminopyridin-6- 1 H NHS0 2 C6H4- (2-CH3) ylmethyl 2301 2-aminopyridin-6- 1 H NHS0 2 C6H4-(3-CH3) ylmethyl 2302 2-aminopyridin-6- 1 H NHS0 2 C6H4-(4-CH3) ylmethyl 2303 2-aminopyridin-6- 1 H NHS0 2 (2-naphthyl) ylmethyl 2304 2-aminopyridin-6- 1 H HS0 2 (1-naphthyl) ylmethyl 2305 2-aminopyridin-6- 1 H NHS0 2 (biphenyl) ylmethyl 2306 2-aminopyridin-6- 1 H NHS0 2 (2,4,6- ylmethyl trimethylphenyl) 2307 2-aminopyridin-6- 1 H NHS0 (2-thienyl) yl ethyl 2308 2-aminopyridin-6- 1 H NHS0 2 -[4-(3,5- ylmethyl dimethy1) isoxazolyl] 2309 2-aminopyridin-6- 1 H NHS0 2 C6H4- (2-Br) ylmethyl 2310 2-aminopyridin-6- 1 1 HH HS0 2 C6H4- (3-Br) ylmethyl 2311 2-aminopyridin-6- 1 1 HH NHS0 2 C 5 H4-(2-F) ylmethyl 2312 2-aminopyridin-6- 1 H HS0 2 C 6 H4-(3-F) ylmethyl 2313 2-aminopyridin-6- 1 H NHS0 2 C6H4-(4-F) ylmethyl 2314 2-aminopyridin-6- 1 NHC0 2 CH 2 Ph ylmethyl 2315 2-aminopyridin-6- 1 H HC02n-Bu ylmethyl 2316 2-aminopyridin-6- 0 H NHS0 2 Ph ylcarbonyl 2317 2-aminopyridin-6- 0 H HS0 2 C6H4-(2-CH 3 ) ylcarbonyl 2318 2-aminopyridin-6- 0 H HS0 2 C 6 H4-(3-CH3) ylcarbonyl 2319 2-aminopyridin-6- H NHS0 2 C 6 H4-(4-CH3) ylcarbonyl 2320 2-aminopyridin-6- 0 H NHSθ2(2-naphthyl) ylcarbonyl 2321 2-aminopyridin-6- 0 H NHSO2 (1-naphthyl) ylcarbonyl 2322 2-aminopyridin-6- HS0 2 (biphenyl) ylcarbonyl 2323 2-aminopyridin-6- 0 H NHS0 (2,4,6- ylcarbonyl trimethylphenyl) 2324 2-aminopyridin-6- 0 H NHS0 2 (2-thienyl) ylcarbonyl 2325 2-aminopyridin-6- H NHS0 2 -[4-(3,5- ylcarbonyl dimethyl) isoxazolyl; 2326 2-aminopyridin-6- H HS0 2 C 6 H4-(2-Br) ylcarbonyl 2327 2-aminopyridin-6- 0 H NHS0 2 CeH4-(3-Br) ylcarbonyl 2328 2-aminopyridin-6- 0 H HS0 2 C 6 H4-(2-F) ylcarbonyl 2329 2-aminopyridin-6- 0 H NHS0 2 C 6 H4-(3-F) ylcarbonyl 2330 2-aminopyridin-6- 0 H NHS0 2 C6H4-(4-F) ylcarbonyl 2331 2-aminopyridin-6- 0 H NHC0 2 CH Ph ylcarbonyl 2332 2-aminopyridin-6- 0 H NHCθ2n-Bu ylcarbonyl 2333 2-aminopyridin-6- 0 H NHCθ2i-Bu ylcarbonyl 2334 2-aminopyridin-6- 1 H HS0 2 Ph ylcarbonyl 2335 2-aminopyridin-6- 1 H NHS0 2 C 6 H4-(2-CH3) ylcarbonyl 2336 2-aminopyridin-6- 1 H NHS0 2 C 6 H4-(3-CH3) ylcarbonyl 2337 2-aminopyridin-6- 1 H NHS0 2 C6H4-(4-CH3) ylcarbonyl 2338 2-aminopyridin-6- 1 H HS0 2 (2-naphthyl) ylcarbonyl 2339 2-aminopyridin-6- 1 H NHS0 2 (1-naphthyl) ylcarbonyl 2340 2-aminopyridin-6- 1 H NHS0 2 (biphenyl) ylcarbonyl 2341 2-aminopyridin-6- 1 H HS0 2 (2,4,6- ylcarbonyl trimethylphenyl) 2342 2-aminopyridin-6- 1 H NHS0 (2-thienyl) ylcarbonyl 2343 2-aminopyridin-6- 1 H NHS0 2 -[4-(3,5- ylcarbonyl dimethyl) isoxazolyl] 2344 2-aminopyridin-6- 1 H NHS0 2 C 6 H4- (2-Br) ylcarbonyl 2345 2-aminopyridin-6- 1 H NHS0 2 C 6 H4-(3-Br) ylcarbonyl 2346 2-aminopyridin-6- 1 H NHS0 2 C6H4-(2-F) ylcarbonyl 2347 2-aminopyridin-6- 1 H NHS0 2 C6H4- (3-F) ylcarbonyl 2348 2-aminopyridin-6- 1 H NHS0 2 C6H4-(4-F) ylcarbonyl 2349 2-aminopyridin-6- HC0 2 CH Ph ylcarbonyl 2350 2-aminopyridin-6- NHC0 2 n-Bu ylcarbonyl 2351 2-aminoimidazol-5- NHS0 2 Ph ylmethyl 2352 2-aminoimidazol-5- 1 H NHS0 2 C 6 H4 - ( 2 -CH3 ) ylmethyl 2353 2-aminoimidazol-5- 1 H NHS0 2 C6H4 ~ ( 3 -CH3 ) ylmethyl 2354 2-aminoimidazol-5- 1 H NHS0 2 CeH4 - ( 4 -CH3 ) ylmethyl 2355 2-aminoimidazol-5- 1 H NHS0 2 (2-naphthyl) ylmethyl 2356 2-aminoimidazol-5- 1 H NHS0 2 (1-naphthyl) ylmethyl 2357 2-aminoimidazol-5- 1 H NHS0 2 (biphenyl) ylmethyl 2358 2-aminoimidazol-5- 1 H NHS0 2 (2,4,6- ylmethyl trimethylphenyl) 2359 2-aminoimidazol-5- 1 H HS0 2 (2-thienyl) ylmethyl 2360 2-aminoimidazol-5- 1 H NHS0 2 -[4-(3,5- ylmethyl dimethyl) isoxazolyl] 2361 2-aminoimidazol-5- 1 H HS0 2 C 6 H4- (2-Br) ylmethyl 2362 2-aminoimidazol-5- 1 H NHS0 2 C6H4- (3-Br) ylmethyl 2363 2-aminoimidazol-5- 1 H NHS0 C 6 H4-(2-F) ylmethyl 2364 2-aminoimidazol-5- 1 H NHS0 2 C 6 H4-(3-F) ylmethyl 2365 2-aminoimidazol-5- 1 H NHS0 2 C 6 H4- (4-F) ylmethyl 2366 2-aminoimidazol-5- 1 H NHC0 2 CH 2 Ph ylmethyl 2367 2-aminoimidazol-5- 1 H NHC02n-Bu ylmethyl 2368 2-amino-l,3,4- 0 H NHS0 2 Ph triazol-5-yl- carbonyl 2369 4-imidazolyl- 0 H NHS0 2 Ph carbonyl 2370 2-aminoimidazol-5- 0 H NHS0 2 Ph ylmethyl Table 3 US. B 14 E' 15 (M-rH) NHS0 2 Ph HS0 2 Ph NHS0 Ph NHS0 2 Ph NHSθ2Ph NHS0 2 Ph NHS0 2 Ph H NHS0 2 Ph 3009 2- C0 2 -i-Bu H NHS0 2 Ph pyridinylamino- methyl 3010 2- C0 -t-Bu H NHS0 2 Ph pyridinylamino¬ methyl 3011 2- HS0 2 Ph pyridinylamino- methyl 3012 2- -(CH 2 )4NH2 H NHS0 2 Ph pyridinylamino- methyl 3013 2- COPh H NHS0 Ph pyridinylamino- methyl 3014 2- cyclopropyl- NHS0 2 Ph pyridinylamino- methyl methyl 3015 2- S0 2 -n-Bu H HSθ2Ph pyridinylamino- methyl 3016 2- Cbz NHS0 2 -(2,4,6- 679.4 pyridinylamino- trimethylphen methyl yi ) 3017 2- Sθ2P NHS0 2 -(2,4,6- pyridinylamino- tri ethylphen methyl yi ) 3018 2- CO(CH 2 ) 2 Ph NHS0 2 -(2,4,6- pyridinylamino- trimethylphen methyl yi ) 3019 2- Bn NHS0 2 -(2,4,6- pyridinylamino- tri ethylphen methyl yi ) 3020 2- n-Bu NHS0 2 -(2,4,6- pyridinylamino- trimethylphen ethyl yi ) 3021 2- C0 2 -n-Bu NHS0 - (2,4,6- pyridinylamino¬ trimethylphen methyl yi ) 3022 2- C0 2 -i-Bu NHS0 2 - (2,4,6- pyridinylamino- trimethylphen methyl yi ) 3023 2- C0 2 -t-Bu HS0 2 -(2,4,6- pyridinylamino- trimethylphen methyl yi ) 3024 2- NHS0 2 -(2,4,6- 545.5 pyridinylamino¬ trimethylphen methyl yi ) 3025 2- -(CH 2 ) NH 2 NHS0 -(2,4,6- pyridinylamino- trimethylphen methyl yi ) 3026 2- COPh NHS0 2 -(2,4,6- pyridinylamino¬ trimethylphen methyl yi) 3027 2- Sθ2~n-Bu NHS0 -(2,4,6- pyridinylamino¬ rimethylphen methyl yi ) 3028 2- Cbz NHCbz pyridinylamino- ethyl 3029 2- S0 2 Ph NHCbz pyridinylamino¬ methyl 3030 2- 0 CO(CH 2 ) 2 Ph NHCbz pyridinylamino- methyl 3031 2- 0 Bn H NHCbz pyridinylamino¬ methyl 3032 2- 0 n-Bu H NHCbz pyridinylamino¬ methyl 3033 2- 0 C0 2 -n-Bu H NHCbz pyridinylamino¬ methyl 3034 2- 0 C0 2 -i-Bu H NHCbz pyridinylamino¬ methyl 3035 2- 0 C0 2 -t-Bu H NHCbz pyridinylamino¬ methyl 3036 2- 0 NHCbz r ridinylamino- methyl 3037 2- 0 - ( CH 2 ) 4 NH 2 H NHCbz pyridinylamino¬ methyl 3038 2- 0 COPh H NHCbz pyridinylamino¬ methyl 3039 2- 0 S0 -n-Bu H NHCbz pyridinylamino¬ methyl 3040 2- 0 Cbz H NHS0 2 Ph imidazolylamino¬ methyl 3041 2- 0 S0 2 Ph H NHS0 2 Ph imidazolylamino¬ methyl 3042 2- 0 CO(CH ) 2 Ph H NHS0 2 Ph imidazolylamino¬ methyl 3043 2- 0 Bn H NHS0 Ph imidazolylamino¬ methyl 3044 2- 0 n-Bu H NHS02Ph imidazolylamino¬ methyl 3045 2- 0 COCH 2 (3- NHS0 2 Ph imidazolylamino¬ indolyl) methyl 3046 2- 0 S0 2 - NHS0 2 Ph imidazolylamino¬ (biphenyl) methyl 3047 2- 0 C0 2 -n-Bu H NHS0 2 Ph imidazolylamino¬ methyl 3048 2- 0 C0 2 -i-Bu H NHS0 2 Ph imidazolylamino¬ methyl 3049 2- 0 C0 2 -t-Bu H NHS0 2 Ph imidazolylamino¬ methyl 3050 2- 0 NHS02Ph 492.3 imidazolylamino¬ methyl 3051 2- 0 -(CH 2 ) 4 NH H NHS0 2 Ph imidazolylamino¬ methyl 3052 2- 0 COPh H NHS0 Ph imidazolylamino¬ methyl 3053 2- 0 cyclopropyl- NHS0 2 Ph imidazolylamino- methyl methyl 3054 2- 0 S0 2 -n-Bu NHS0 2 Ph imidazolylamino¬ methyl 3055 2- 0 Cbz NHS0 2 -(2,4,6- 668.4 imidazolylamino¬ trimethylphen methyl yi ) 3056 2- 0 S0 2 Ph NHS0 2 - (2,4,6- imidazolylamino¬ trimethylphen methyl yi) 3057 2- 0 CO(CH 2 ) 2 Ph NHS0 2 - (2,4,6- imidazolylamino¬ trimethylphen methyl yi ) 3058 2- 0 Bn NHS0 2 -(2,4,6- imidazolylamino¬ trimethylphen methyl yi) 3059 2- 0 n-Bu NHSO2- (2,4,6- imidazolylamino¬ trimethylphen methyl yi ) 3060 2- 0 C0 2 -n-Bu NHS0 2 -(2,4,6- imidazolylamino¬ trimethylphen methyl yi ) 3061 2- 0 C0 2 -i-Bu NHS0 2 -(2,4,6- imidazolylamino¬ trimethylphen methyl yi ) 3062 2- 0 C0 2 -t-Bu NHS0 -(2,4,6- imidazolylamino¬ trimethylphen methyl yi ) 3063 2- O H NHS0 2 -(2,4,6- 534.4 imidazolylamino¬ trimethylphen methyl yi ) 3064 2- 0 -(CH 2 ) 4 NH 2 NHS0 2 -(2,4,6- imidazolylamino¬ trimethylphen methyl yi ) 3065 2- 0 COPh NHS0 - (2,4,6- imidazolylamino¬ trimethylphen methyl yi ) 3066 2- 0 S0 2 -n-Bu NHS0 2 -(2,4,6- imidazolylamino¬ trimethylphen methyl yi) 3067 2- 0 Cbz NHCbz imidazolylamino¬ methyl 3068 2- 0 S0 2 Ph H NHCbz imidazolylamino¬ methyl 3069 2- 0 CO(CH 2 )2Ph NHCbz imidazolylamino¬ methyl 3070 2 - 0 Bn NHCbz imidazolylamino¬ methyl 3071 2- 0 n-Bu NHCbz imidazolylamino¬ methyl 3072 2- 0 Cθ2-n-Bu NHCbz imidazolylamino¬ methyl 3073 2- 0 C0 -i-Bu NHCbz imidazolylamino- methyl 3074 2- 0 C0 2 -t-Bu NHCbz imidazolylamino¬ methyl 3075 2- NHCbz imidazolyl ami no- methyl 3076 2- 0 -(CH 2 ) 4 NH 2 H NHCbz imidazol lamino¬ methyl 3077 2- COPh NHCbz imidazolylamino- methyl 3078 2- 0 S0 2 -n-Bu H NHCbz imidazolylamino- methyl 3079 2-imidazolinyl- 0 Cbz NHS02Ph aminomethyl 3080 2-imidazolinyl- 0 S0 2 Ph NHS0 2 Ph aminomethyl 3081 2-imidazolinyl- 0 CO(CH 2 ) 2 Ph NHS0 2 Ph aminomethyl 3082 2-imidazolinyl- 0 Bn NHS0 Ph aminomethyl 3083 2-imidazolinyl- 0 n-Bu NHS0 2 Ph aminomethyl 3084 2-imidazolinyl- 0 COCH 2 (3- NHS0 2 Ph aminomethyl indolyl) 3085 2-imidazolinyl- 0 S0 2 - NHS0 2 Ph aminomethyl ( iphenyl) 3086 2-imidazolinyl- 0 Cθ2-n-Bu NHS0 2 Ph aminomethyl 3087 2-imidazolinyl- 0 Cθ2~i-Bu NHS0 2 Ph aminomethyl 3088 2-imidazolinyl- 0 Cθ2~t-Bu NHS0 2 Ph aminome yl 3089 2-imidazolinyl- 0 H NHS0 2 Ph aminome hyl 3090 2 - imidazol inyl - 0 -(CH 2 ) 4 NH 2 H NHS0 Ph aminomethyl 3091 2-imidazolinyl- 0 COPh H NHS0 2 Ph aminomethyl 3092 2-imidazolinyl- 0 cyclopropyl- H NHS0 2 Ph aminomethyl methyl 3093 2-imidazolinyl- 0 S0 2 -n-Bu H NHS0 2 Ph aminomethyl 3094 2-imidazolinyl- 0 Cbz H NHS0 2 -(2,4,6- aminomethyl trimethylphen yi ) 3095 -2 -imidazol inyl - 0 S0 Ph H NHS0 2 -(2,4,6- aminomethyl trimethylphen yi ) 3096 2 -imidazolinyl - 0 CO (CH 2 ) 2 Ph H NHΞ0 2 -(2,4,6- aminomethyl trimethylphen yi) 3097 2-imidazolinyl- 0 Bn H NHS0 2 -(2,4,6- aminomethyl trimethylphen yi ) 3098 2-imidazolinyl- 0 n-Bu H NHS0 2 - (2,4,6- aminomethyl trimethylphen yi ) 3099 2-imidazolinyl- 0 C0 -n-Bu H NHS0 2 -(2,4,6- aminomethyl trimethy1phen yi ) 3100 2-imidazolinyl- 0 C0 2 -i-Bu H NHS0 2 -(2,4,6- aminomethyl trimethylphen yi ) 3101 2-imidazolinyl- 0 C0 2 -t-Bu H NHS0 2 -(2,4,6- όimi nomet hyl trimethylphen yi ) 3102 2-imidazolinyl- 0 H NHS0 2 - (2,4,6- 536.3 aminomethyl trimethylphen yi ) 3103 2 - imidazol inyl - 0 - ( CH 2 ) 4 NH 2 H NHS0 2 - (2,4,6- aminomethyl trimethylphen yi ) 3104 2-imidazolinyl- 0 COPh H NHS0 2 -(2,4,6- aminomethyl trimethylphen yi ) 3105 2-imidazolinyl- 0 S0 2 -n-Bu H NHS0 2 -(2,4,6- aminomethyl trimethylphen yi ) 3106 2-imidazolinyl- 0 Cbz H NHCbz aminomethyl 3107 2-imidazolinyl- 0 S0 Ph H NHCbz aminomethyl 3108 2-imidazolinyl- 0 CO(CH 2 ) Ph H NHCbz aminomethyl 3109 2-imidazolinyl- 0 Bn H NHCbz aminomethyl 3110 2-imidazolinyl- 0 n-Bu NHCbz aminomethyl 3111 2-imidazolinyl- 0 C0 -n-Bu NHCbz aminomethyl 3112 2-imidazolinyl- 0 C0 -i-Bu NHCbz aminomethyl 3113 2-imidazolinyl- 0 C0 2 -t-Bu NHCbz aminomethyl 3114 2-imidazolinyl- 0 H NHCbz aminome hyl 3115 2-imidazolinyl- 0 -(CH 2 ) 4 NH 2 H NHCbz aminomethyl 3116 2-imidazolinyl- COPh NHCbz aminomethyl 3117 2-imidazolinyl- 0 S0 2 -n-Bu H NHCbz a inomethyl 3118 Cbz H NHS0 2 Ph 3119 NHS0 2 Ph 3120 NHS0 2 Ph 3121 NHS0 2 Ph 3122 NHS0 2 Ph 3123 NHS0 2 Ph 3124 NHS0 2 Ph 3125 NHS0 2 Ph 3126 NHS0 2 Ph 3127 NHS0 2 Ph 3128 NHS0 2 Ph 3129 2- (CH 2 ) 4 NH NHS0 2 Ph benzimidazolyl- aminomethyl 3130 2- COPh NHS0 2 Ph benzimidazolyl¬ aminomethyl 3131 2- 0 cyclopropyl- NHS0 Ph benzimidazolyl¬ methyl aminomethyl 3132 2- 0 S0 2 -n-Bu NHS0 2 Ph benzimidazolyl¬ aminomethyl 3133 2- 0 Cbz NHS0 2 -(2,4,6- 718.4 benzimidazolyl¬ trimethy lphen aminomethyl yi ) 3134 2- 0 S0 2 Ph NHS0 2 -(2,4,6- benzimidazolyl¬ trimethylphen aminomethyl yl ) 3135 2- 0 CO(CH 2 ) 2 Ph NHS0 2 -(2,4,6- benzimidazolyl¬ trimethylphen aminomethyl yi ) 3136 2- 0 Bn NHS02~(2,4,6- benzimidazolyl¬ trimethylphen aminomethyl yi ) 3137 2- 0 n-Bu NHS0 2 -(2,4,6- benzimidazolyl- trimethylphen a inome hyl yi ) 3138 2- 0 Cθ2-n-Bu NHS0 2 -(2,4,6- benzimidazolyl¬ trimethylphen aminomethyl yi ) 3139 2- 0 C0 2 -i-Bu NHS0 2 -(2,4,6- benzimidazolyl- trimethy lphen aminomethyl yi ) 3140 2- C0 2 -t-Bu NHS0 2 - (2,4,6- benzimidazolyl- trimethylphen aminomethyl yi ) 3141 2- NHS0 2 -(2,4,6- 584.2 benzimidazolyl- trimethy1phen aminomethyl yi ) 3142 2- (CH 2 ) 4 NH 2 NHS0 2 -(2,4,6- benzimidazolyl- tri ethylphen aminomethyl yi ) 3143 2- COPh NHS0 2 -(2,4,6- benzimidazolyl- trimethylphen - aminomethyl yi ) 3144 2- S0 2 -n-Bu NHS0 2 -(2,4,6- benzimidazolyl- trimethylphen aminomethyl yi ) 3145 2- Cbz NHCbz benzimidazolyl- aminomethyl 3146 2- S0 2 Ph NHCbz benzimidazolyl¬ aminomethyl 3147 2- 0 CO(CH ) 2 Ph NHCbz benzi idazolyl- aminomethyl 3148 2- Bn NHCbz benzimidazolyl- aminomethyl 3149 2- n-Bu NHCbz benzimidazolyl- aminomethyl 3150 2- C0 2 -n-Bu NHCbz benzimidazolyl- aminomethyl 3151 2- C0 2 -i-Bu NHCbz benzimidazolyl- aminomethyl 3152 2- Cθ2"t-Bu NHCbz benzimidazolyl- a inomethyl 3153 2- NHCbz benzimidazolyl¬ aminomethyl 3154 2- 0 -(CH 2 ) 4 NH 2 H NHCbz benzimidazolyl- aminomethyl 3155 2- 0 COPh H NHCbz benzimidazolyl- aminomethyl 3156 2- 0 S0 2 -n-Bu H NHCbz benzimidazolyl- aminomethyl 3157 7-aza-2- 0 Cbz H NHS0 2 Ph benzimidazolyl 3158 7-aza-2- 0 S0 2 Ph H NHS0 2 Ph benzimidazolyl 3159 7-aza-2- 0 CO(CH 2 ) 2 Ph H NHS0 2 Ph benzimidazolyl 3160 7-aza-2- 0 Bn H NHS0 2 Ph benzimidazolyl 3161 7-aza-2- 0 n-Bu H NHS0 2 Ph benzimidazolyl 3162 7-aza-2- 0 COCH (3- H NHS0 2 Ph benzimidazolyl indolyl) 3163 7-aza-2- 0 S02- H NHS0 2 Ph benzimidazolyl (biphenyl) 3164 7-aza-2- 0 C0 -n-Bu H NHS0 2 Ph benzimidazolyl 3165 7-aza-2- C0 2 -i-Bu H NHS0 2 Ph benzimidazolyl 3166 7-aza-2- C0 2 -t-Bu H NHS0 Ph benzimidazolyl 3167 7-aza-2- H NHS0 Ph benzimidazolyl 3168 7-aza-2- 0 -(CH 2 ) 4 NH 2 H NHS0 2 Ph benzimidazolyl 3169 7-aza-2- 0 COPh H NHS0 2 Ph benzimidazolyl 3170 7-aza-2- 0 cyclopropyl- H NHS0 Ph benzimidazolyl methyl 3171 7-aza-2- 0 S0 2 -n-Bu H NHS0 2 Ph benzimidazolyl 3172 7-aza-2- 0 Cbz H NHS0 2 -(2,4,6- benzimidazolyl trimethylphen yi) 3173 7-aza-2- S0 2 Ph H NHS0 2 -(2,4,6- benzimidazolyl trimethylphen yi) 3174 7-aza-2- 0 CO(CH 2 ) 2 Ph H NHS0 2 -(2,4,6- benzimidazolyl trimethylphen yi ) 3175 7-aza-2- 0 Bn H NHS0 -(2,4,6- benzimidazolyl trimethylphen yi ) 3176 7-aza-2- 0 n-Bu H NHS0 2 - (2,4,6- benzimidazolyl trimethylphen yi ) 3177 7-aza-2- 0 C0 2 -n-Bu H NHS0 2 -(2,4,6- benzimidazolyl trimethylphen yi ) 3178 7-aza-2- 0 C0 2 -i-Bu H NHS0 2 -(2,4,6- benzimidazolyl trimethylphen yi ) 3179 7-aza-2- 0 C0 2 -t-Bu NHS0 2 - (2,4,6- benzimidazolyl trimethylphen yi ) 3180 7-aza-2- 0 H NHS0 2 - (2,4,6- benzimidazolyl trimethylphen yi ) 3181 7-aza-2- 0 (CH 2 ) 4 NH 2 NHS0 2 -(2,4,6- benzimidazolyl tri ethylphen yi ) 3182 7-aza-2- 0 COPh NHS0 -(2,4,6- benzimidazolyl trimethylphen yi ) 3183 7-aza-2- 0 S0 2 -n-Bu NHS0 2 -(2,4,6- benzimidazolyl trimethylphen yi ) 3184 7-aza-2- 0 Cbz NHCbz benzimidazolyl 3185 7-aza-2- 0 S0 2 Ph NHCbz benzimidazolyl 3186 7-aza-2- 0 CO(CH 2 ) 2 Ph NHCbz benzimidazolyl 3187 7-aza-2- 0 Bn NHCbz benzimidazolyl 3188 7-aza-2- 0 n-Bu NHCbz benzimidazolyl 3189 7-aza-2- 0 C0 -n-Bu NHCbz benzimidazolyl 3190 7-aza-2- 0 C0 2 -i-Bu NHCbz benzimidazolyl 3191 7-aza-2- 0 C0 2 -t-Bu NHCbz benzimidazolyl 3192 7-aza-2- 0 H NHCbz benzimidazolyl 3193 7-aza-2- 0 -(CH 2 ) NH 2 NHCbz benzimidazolyl 3194 7-aza-2- 0 COPh NHCbz benzimidazolyl 3195 7-aza-2- 0 S0 2 -n-Bu NHCbz benzimidazolyl 3196 tetrahydropyrimi 0 Cbz NHS0 2 Ph din-2- ylaminomethyl 3197 tetrahydropyrimi 0 Sθ 2 P NHS0 2 Ph din-2- ylaminomethyl 3198 tetrahydropyrimi 0 CO(CH 2 )2Ph NHS0 2 Ph din-2- ylaminome hyl 3199 tetrahydropyrimi 0 Bn NHS0 2 Ph din-2- ylaminomethyl 3200 tetrahydropyrimi 0 n-Bu NHS0 Ph din-2- ylaminomethyl 3201 tetrahydropyrimi 0 COCH 2 (3- NHS0 2 Ph din-2- indolyl) ylaminomethyl 3202 tetrahydropyrimi 0 S02- NHS0 2 Ph din-2- (biphenyl) ylaminomethyl 3203 tetrahydropyrimi 0 C0 2 -n-Bu H NHS0 2 Ph din-2- ylaminomethyl 3204 tetrahydropyrimi 0 C0 2 -i-Bu H NHS0 2 Ph din-2- ylaminomethyl 3205 tetrahydropyrimi 0 C0 2 -t-Bu NHS0 Ph din-2- y1aminomethy1 3206 tetrahydropyrimi 0 H NHS0 Ph din-2- ylaminomethyl 3207 tetrahydropyrimi 0 -(CH 2 ) 4 NH 2 NHS0 2 Ph din-2- ylaminomethyl 3208 tetrahydropyrimi 0 COPh NHS0 2 Ph din-2- ylaminomethyl 3209 tetrahydropyrimi 0 cyclopropyl- NHS0 2 Ph din-2- methyl ylaminome hyl 3210 tetrahydropyrimi 0 S0 2 -n-Bu NHS0 2 Ph din-2- ylaminomethyl 3211 tetrahydropyrimi 0 Cbz NHS0 2 -(2,4,6- din-2- trimethylphen yl minomethyl yi ) 3212 tetrahydropyrimi 0 S0 2 Ph NHS0 2 -(2,4,6- din-2- trimethylphen ylaminomethyl yi ) 3213 tetrahydropyrimi 0 CO (CH 2 ) 2Ph NHS0 2 -(2,4,6- din-2- trimethylphen ylaminomethyl yi ) 3214 tetrahydropyrimi 0 Bn NHS0 2 -(2,4,6- din-2- trimethylphen ylaminomethyl yi ) 3215 tetrahydropyrimi 0 n-Bu NHS0 2 -(2,4,6- din-2- trimethylphen ylaminomethyl yi ) 3216 tetrahydropyrimi 0 C0 2 -n-B NHS0 2 -(2,4,6- din-2- trimethylphen ylaminomethyl yi ) 3217 tetrahydropyrimi 0 C0 2 -i-Bu NHS0 2 -(2,4,6- din-2- trimethylphen ylaminomethyl yi ) 3218 tetrahydropyrimi 0 C0 2 -t-Bu NHS0 2 -(2,4,6- din-2- trimethylphen ylaminomethyl yi ) 3219 tetrahydropyrimi 0 H NHS0 2 -(2,4,6- din-2- trimethylphen ylaminomethyl yi ) 3220 tetrahydropyrimi 0 -(CH 2 ) 4 NH 2 NHS0 2 -(2,4,6- din-2- trimethylphen y1aminomethy1 yi ) 3221 tetrahydropyrimi 0 COPh NHS0 -(2,4,6- din-2- trimethylphen ylaminomethyl yi ) 3222 tetrahydropyrimi 0 S0 2 -n-Bu NHS0 2 -(2,4,6- din-2- trimethylphen ylaminomethyl yi ) 3223 tetrahydropyrimi 0 Cbz NHCbz din-2- ylaminomethyl 3224 tetrahydropyrimi 0 S0 2 Ph NHCbz din-2- yl minomethyl 3225 tetrahydropyrimi 0 CO(CH 2 ) 2 Ph H NHCbz din-2- ylaminomethyl 3226 tetrahydropyrimi 0 Bn NHCbz din-2- ylaminomethyl 3227 tetrahydropyrimi 0 n-Bu NHCbz din-2- ylaminomethyl 3228 tetrahydropyrimi 0 C0 2 -n-Bu NHCbz din-2- ylaminomethyl 3229 tetrahydropyrimi 0 C0 2 -i-Bu NHCbz din-2- ylaminome hyl 3230 tetrahydropyrimi 0 C0 -t-Bu NHCbz din-2- ylaminomethyl 3231 tetrahydropyrimi 0 NHCbz din-2- ylaminomethyl 3232 tetrahydropyrimi 0 (CH 2 ) 4 NH 2 NHCbz din-2- ylaminome hyl 3233 tetrahydropyrimi 0 COPh NHCbz din-2- ylaminomethyl 3234 tetrahydropyrimi 0 S0 2 -n-Bu NHCbz din-2- y1aminomethy1 3235 2- 1 Cbz NHSθ2Ph pyridinylamino¬ methyl 3236 2- 1 Sθ2P NHSθ2P pyridinylamino¬ methyl 3237 2- CO(CH ) 2 Ph H NHS0 2 Ph pyridinylamino- methyl 3238 2- Bn NHS0 2 Ph pyridinylamino- methyl 3239 2- n-Bu H NHS0 Ph pyridinylamino- methyl 3240 2- 1 C0CH 2 (3- NHS0 2 Ph pyridinylamino- indolyl) methyl 3241 2- 1 S02- NHS0 2 Ph pyridinylamino- (biphenyl) methyl 3242 2- Cθ2-n-Bu H NHSθ2Ph pyridinylamino- ethyl 3243 2- Cθ2-i-Bu H NHSθ2Ph pyridinylamino¬ methyl 3244 2- C0 2 -t-Bu H NHS0 2 Ph pyridinylamino- methyl 3245 2- NHS0 2 Ph pyridinylamino- methyl 3246 2- (CH 2 ) 4 NH 2 H NHS0 2 Ph pyridinylamino- methyl 3247 2- COPh H NHS0 Ph pyridinylamino- methyl 3248 2- 1 cyclopropyl- NHS0 2 Ph pyridinylamino- methyl methyl 3249 2- S0 -n-Bu H NHSθ2Ph pyridinylamino- methyl 3250 2- 1 Cbz NHS0 2 - (2,4,6- pyridinylamino¬ trimethylphen methyl yl) 3251 2- 1 S0 2 Ph NHS0 2 -(2,4,6- pyridinylamino¬ trimethylphen methyl yi) 3252 2- 1 CO(CH 2 ) 2 Ph NHS0 2 -(2,4,6- pyridinylamino¬ trimethylphen methyl yi ) 3253 2- 1 Bn NHS0 2 - (2,4,6- pyridinylamino¬ trimethylphen methyl y ) 3254 2- 1 n-Bu NHS0 2 -(2,4,6- pyridinylamino¬ trimethylphen methyl yi) 3255 2- 1 C0 2 -n-Bu NHS0 2 -(2,4,6- pyridinylamino¬ trimethylphen methyl yi ) 3256 2- 1 C0 -i-Bu NHS0 2 -(2,4,6- pyridinylamino¬ trimethylphen methyl yi ) 3257 2- 1 C0 2 -t-Bu NHS0 2 -(2,4,6- pyridinylamino¬ trimethylphen methyl yi ) 3258 2- 1 H NHS0 2 -(2,4,6- pyridinylamino¬ trimethylphen methyl yi ) 3259 2- 1 -(CH 2 ) 4 NH 2 NHS0 -(2,4,6- pyridinylamino¬ trimethylphen methyl yi ) 3260 2- 1 COPh NHS0 2 -(2,4,6- pyridinylamino¬ trimethylphen methyl yi ) 3261 2- S0 2 -n-Bu NHS0 2 - (2,4,6- pyridinylamino- tri ethylphen methyl yi ) 3262 2- Cbz NHCbz pyridinylamino- methyl 3263 2- S0 2 Ph H NHCbz pyridinylamino- methyl 3264 2- CO ( CH 2 )2Ph H NHCbz pyridinylamino¬ methyl 3265 2- Bn H NHCbz pyridinylamino¬ methyl 3266 2- n-Bu H NHCbz pyridinylamino- methyl 3267 2- C0 -n-Bu H NHCbz pyridinylamino- me hyl 3268 2- C0 -i-Bu H NHCbz pyridinylamino- methyl 3269 2- C0 2 -t-Bu H NHCbz pyridinylamino- methyl 3270 2- NHCbz pyridinylamino- ethyl 3271 2- (CH 2 ) 4 NH 2 H NHCbz pyridinylamino- methyl 3272 2- 1 COPh H NHCbz pyridinylamino¬ methyl 3273 2- 1 S0 2 -n-Bu H NHCbz pyridinylamino¬ methyl 3274 2- 1 Cbz H NHS0 2 Ph imidazolylamino¬ methyl 3275 2- 1 S0 2 Ph H NHS0 2 Ph imidazolylamino¬ methyl 3276 2- 1 CO(CH 2 ) 2 Ph H NHSQ 2 Ph imidazolylamino¬ methyl 3277 2- 1 Bn H NHS0 2 Ph imidazolylamino¬ methyl 3278 2- 1 n-Bu H NHS0 2 Ph imidazolylamino¬ methyl 3279 2- 1 COCH 2 (3- NHS0 2 Ph imidazolylamino¬ indolyl) methyl 3280 2- 1 S0 2 - NHS0 2 Ph imidazolylamino¬ (biphenyl) methyl 3281 2- 1 C0 2 -n-Bu H NHS0 2 Ph imidazolylamino¬ methyl 3282 2- 1 C0 2 -i-Bu H NHS0 2 Ph imidazolylamino¬ methyl 3283 2- 1 C0 2 -t-Bu NHS0 Ph imidazolylamino¬ methyl 3284 2- 1 H NHS0 2 Ph imidazolylamino¬ methyl 3285 2- 1 -(CH 2 ) NH 2 NHS0 2 Ph imidazolylamino¬ methyl 3286 2- 1 COPh NHS0 Ph imidazolylamino¬ methyl 3287 2- 1 cyclopropyl- NHS0 2 Ph imidazolylamino- methyl methyl 3288 2- 1 S0 2 -n-Bu NHS0 2 Ph imidazolylamino¬ methyl 3289 2- 1 Cbz NHS0 2 -(2,4,6- imidazolylamino¬ trimethylphen methyl yi ) 3290 2- 1 S0 2 Ph NHS0 2 -(2,4,6- imidazolylamino¬ trimethylphen methyl yi ) 3291 2- 1 CO(CH 2 ) 2 Ph NHS0 2 -(2,4,6- imidazolylamino¬ trimethylphen methyl yi ) 3292 2- 1 Bn NHS0 2 -(2,4,6- imidazolylamino¬ trimethylphen methyl yi ) 3293 2- 1 n-Bu NHS0 2 -(2,4,6- imidazolylamino¬ trimethylphen methyl yi ) 3294 2- 1 C0 2 -n-Bu NHS0 2 - (2,4,6- imidazolylamino¬ trimethylphen methyl yi ) 3295 2- 1 Cθ2-i-Bu NHS0 -(2,4,6- imidazolylamino¬ trimethylphen methyl yi ) 3296 2- 1 C0 2 -t-Bu NHS0 2 - (2,4,6- imidazolylamino¬ tri ethylphen methyl yi ) 3297 2- 1 NHS0 2 - (2,4,6- imidazolylamino¬ trimethylphen methyl yi ) 3298 2- 1 -(CH 2 ) 4 NH 2 NHS0 2 -(2,4,6- imidazolylamino¬ trimethylphen methyl yi ) 3299 2- 1 COPh NHS0 2 - (2,4,6- imidazolylamino¬ trimethylphen methyl yi ) 3300 2- 1 S0 2 -n-Bu NHS0 2 -(2,4,6- imidazolylamino¬ trimethylphen methyl yi ) 3301 2- 1 Cbz NHCbz imidazolylamino¬ methyl 3302 2- 1 S0 2 Ph NHCbz imidazolylamino¬ methyl 3303 2- 1 CO(CH 2 )2Ph NHCbz imidazolylamino¬ methyl 3304 2- 1 Bn NHCbz imidazolylamino¬ methyl 3305 2- n-Bu NHCbz imidazolylamino¬ methyl 3306 2- Cθ2-n-Bu NHCbz i idazolylamino¬ methyl 3307 2- Cθ2-i-Bu NHCbz imidazolylamino¬ methyl 3308 2- Cθ2-t-Bu NHCbz imidazolylamino- methyl 3309 2- NHCbz imidazolylamino- methyl 3310 2- -(CH 2 ) 4 NH 2 H NHCbz imidazolylamino- methyl 3311 2- COPh H NHCbz imidazolylamino- methyl 3312 2- S02~n-Bu H NHCbz imidazolylamino- methyl 3313 2-imidazolinyl- Cbz H NHS0 2 Ph aminomethyl 3314 2-imidazolinyl- S0 2 Ph H NHS0 Ph aminomethyl 3315 2-imidazolinyl- CO(CH 2 ) 2 Ph H NHS0 2 Ph aminomethyl 3316 2-imidazolinyl- Bn H NHS0 Ph aminomethyl 3317 2-imidazolinyl- n-Bu H NHSθ Ph aminomet yl 3318 2 - imidazol inyl - 1 COCH 2 (3- NHS0 Ph aminomethyl indolyl) 3319 2 - imidazol inyl - 1 S0 2 - NHS0 2 Ph aminomethyl (biphenyl) 3320 2 - imidazol inyl - 1 C0 2 -n-Bu NHS0 2 Ph aminomethyl 3321 2-imidazolinyl- 1 C0 2 -i-Bu NHS0 2 Ph aminomethyl 3322 2-imidazolinyl- 1 C0 2 -t-Bu NHS0 2 Ph aminomethyl 3323 2-imidazolinyl- 1 H NHS0 2 Ph aminomethyl 3324 2-imidazolinyl- 1 -(CH 2 ) 4 NH H NHS0 2 Ph aminomethyl 3325 2-imidazolinyl- 1 COPh H NHS0 2 Ph aminomethyl 3326 2-imidazolinyl- 1 cyclopropyl- H NHS0 2 Ph aminomethyl methyl 3327 2-imidazolinyl- 1 S0 2 -n-Bu NHS0 2 Ph aminomethyl 3328 2-imidazolinyl- 1 Cbz NHS0 2 - ( 2 , 4 , 6- aminomethyl trimethylphen yi ) 3329 2 - imidazol inyl - 1 S0 2 Ph NHS0 -(2,4,6- aminomethyl trimethylphen yi ) 3330 2-imidazolinyl- 1 CO(CH 2 ) 2 Ph NHS0 -(2,4,6- aminomethyl trimethylphen yi ) 3331 2-imidazolinyl- 1 Bn NHS0 2 -(2,4,6- aminomethyl trimethylphen yi ) 3332 2-imidazolinyl- 1 n-Bu NHS0 2 -(2,4,6- aminomethyl trimethylphen yi ) 3333 2-imidazolinyl- 1 C0 2 -n-Bu NHS0 2 -(2,4,6- aminomethyl trimethylphen yi) 3334 2-imidazolinyl- 1 C0 2 -i-Bu NHS0 2 -(2,4,6- aminomethyl trimethylphen yi ) 3335 2-imidazolinyl- 1 C0 2 -t-Bu NHS0 2 -(2,4,6- aminomethyl trimethylphen yi ) 3336 2-imidazolinyl- 1 H NHS0 2 - (2,4,6- aminomethyl trimethylphen yi ) 3337 2-imidazolinyl- 1 -(CH 2 ) 4 NH 2 NHS0 2 -(2,4,6- aminomethyl trimethylphen yi ) 3338 2-imidazolinyl- 1 COPh NHS0 2 -(2,4,6- aminomethyl trimethylphen yi ) 3339 2-imidazolinyl- S0 2 -n-Bu NHS0 2 -(2,4,6- aminomethyl trimethylphen yi ) 3340 2-imidazolinyl- Cbz NHCbz aminomet yl 3341 2-imidazolinyl- S0 2 Ph NHCbz aminomethyl 3342 2-imidazolinyl- CO(CH 2 ) Ph NHCbz aminomethyl 3343 2-imidazolinyl- Bn NHCbz aminomethyl 3344 2-imidazolinyl- n-Bu NHCbz aminomethyl 3345 2-imidazolinyl- C0 2 -n-Bu NHCbz aminomethyl 3346 2-imidazolinyl- C0 2 -i-Bu NHCbz aminomethyl 3347 2-imidazolinyl- C0 2 -t-Bu NHCbz aminomethyl 3348 2-imidazolinyl- NHCbz aminomethyl 3349 2-imidazolinyl- -(CH 2 ) 4 NH 2 NHCbz aminomethyl 3350 2-imidazolinyl- COPh NHCbz aminomethyl 3351 2-imidazolinyl- S0 -n-Bu NHCbz aminomethyl 3352 2- Cbz NHS0 2 Ph benzimidazolyl- aminome hyl 3353 2- S0 2 Ph NHS0 2 Ph benzimidazolyl- aminomethyl 3354 2- CO(CH 2 ) 2 h H NHS0 2 Ph benzimidazolyl- aminome hyl 3355 2- Bn NHS0 Ph benzimidazolyl¬ aminomet yl 3356 2- n-Bu NHS0 2 Ph benzimidazolyl¬ aminomethyl 3357 2- COCH 2 (3- NHS0 2 Ph benzimidazolyl- indolyl) aminomethyl 3358 2- S02- NHS0 2 Ph benzimidazolyl¬ (biphenyl) aminomethyl 3359 2- C0 2 -n-Bu H NHS0 2 Ph benzimidazolyl¬ aminomethyl 3360 2- C0 2 -i-Bu NHS0 Ph benzimidazolyl- aminomethyl 3361 2- C0 -t-Bu NHS0 2 Ph benzimidazolyl- aminomethyl 3362 2- NHS0 2 Ph benzimidazolyl- aminomethyl 3363 2- -(CH 2 ) 4 NH 2 NHS0 2 Ph benzimidazolyl¬ aminomethyl 3364 2- COPh NHS0 2 Ph benzimidazolyl- aminomethyl 3365 2- 1 cyclopropyl- NHS0 2 Ph benzimidazolyl¬ methyl aminomet yl 3366 2- 1 S0 2 -n-Bu NHS0 2 Ph benzimidazolyl- aminome hyl 3367 2- Cbz NHS0 2 -(2,4,6- benzimidazolyl- trimethylphen aminomethyl yi ) 3368 2- S0 2 Ph NHS0 -(2,4,6- benzimidazolyl- trimethylphen aminomethyl yi ) 3369 2- CO(CH ) Ph NHS0 2 - (2,4,6- benzimidazolyl¬ trimethylphen aminomethyl yi ) 3370 2- Bn NHS0 2 - (2,4,6- benzimidazolyl- trimethylphen aminomethyl yi ) 3371 2- n-Bu NHS0 2 -(2,4,6- benzimidazolyl¬ trimethylphen aminomethyl yi ) 3372 2- C0 2 -n-Bu NHS0 2 - (2,4,6- benzimidazolyl¬ trimethylphen aminomethyl yi ) 3373 2- C0 2 -i-Bu NHS0 - (2,4,6- benzimidazolyl- trimethylphen aminomethyl yi ) 3374 2- C0 2 -t-Bu NHS0 -(2,4,6- benzimidazolyl- trimethylphen aminomethyl yi ) 3375 2- NHS0 2 - (2,4,6- benzimidazolyl¬ trimethylphen aminomethyl yi ) 3376 2- (CH 2 ) 4 NH 2 NHS0 2 - (2,4,6- benzimidazolyl- trimethylphen aminomethyl yi ) 3377 2- COPh NHS0 2 - (2,4,6- benzimidazolyl- trimethylphen a inomethyl yi ) 3378 2- S02~n-Bu NHS0 2 -(2,4,6- benzimidazolyl- trimethylphen aminomethyl yi ) 3379 2- Cbz NHCbz benzimidazolyl¬ aminomethyl 3380 2- S0 2 Ph NHCbz benzimidazolyl¬ aminomethyl 3381 2- CO(CH 2 ) 2 Ph NHCbz benzimidazolyl- aminome hyl 3382 2- Bn NHCbz benzimidazolyl- aminomethyl 3383 2- n-Bu NHCbz benzimidazolyl- aminomethyl 3384 2- C0 2 -n-Bu NHCbz benzimidazolyl¬ aminomethyl 3385 2- C0 2 -i-Bu NHCbz benzimidazolyl¬ aminomethyl 3386 2- C0 2 -t-Bu NHCbz benzimidazolyl- aminomethyl 3387 2- NHCbz benzimidazolyl- aminomethyl 3388 2- -(CH 2 ) 4 NH 2 NHCbz benzimidazolyl¬ aminomethyl 3389 2- COPh NHCbz benzimidazolyl¬ aminomethyl 3390 2- S0 2 -n-Bu NHCbz benzimidazolyl- aminomethyl 3391 7-aza-2- Cbz NHS0 2 Ph benzimidazolyl 3392 7-aza-2- S0 2 Ph NHS0 2 Ph benzimidazolyl 3393 7-aza-2- CO(CH 2 ) 2 Ph NHS0 Ph benzimidazolyl 3394 7-aza-2- Bn NHS0 2 Ph benzimidazolyl 3395 7-aza-2- 1 n-Bu H NHS0 2 Ph benzimidazolyl 3396 7-aza-2- 1 COCH 2 (3- H NHS0 2 Ph benzimidazolyl indolyl) 3397 7-aza-2- 1 S02- H NHS0 2 Ph benzimidazolyl (biphenyl) 3398 7-aza-2- 1 C0 2 -n-Bu H NHS0 2 Ph benzimidazolyl 3399 7-aza-2- 1 C0 2 -i-Bu H NHS0 Ph benzimidazolyl 3400 7-aza-2- 1 C0 2 -t-Bu H NHS0 2 Ph benzimidazolyl 3401 7-aza-2- 1 H H NHS0 Ph benzimidazolyl 3402 7-aza-2- 1 -(CH 2 ) 4 NH 2 H NHS0 2 Ph benzimidazolyl 3403 7-aza-2- 1 COPh H NHS0 2 Ph benzimidazolyl 3404 7-aza-2- 1 cyclopropyl - H NHS0 2 Ph benzimidazolyl methyl 3405 7-aza-2- 1 S0 2 -n-Bu H NHS0 2 Ph benzimidazolyl 3406 7-aza-2- 1 Cbz H NHS0 2 -(2,4,6- benzimidazolyl trimethylphen yi ) 3407 7 -aza-2 - 1 S0 2 Ph H NHS0 2 -(2,4,6- benzimidazolyl trimethylphen yi) 3408 7-aza-2- 1 CO(CH ) 2 Ph H NHS0 2 -(2,4,6- benzimidazolyl trimethylphen yi) 3409 7-aza-2- 1 Bn H NHS0 2 -(2,4,6- benzimidazolyl trimethylphen yi ) 3410 7-aza-2- 1 n-Bu NHS0 2 -(2,4,6- benzimidazolyl trimethylphen yi) 3411 7-aza-2- 1 C0 2 -n-Bu NHS0 2 - (2,4,6- benzimidazolyl trimethylphen yi) 3412 7-aza-2- 1 C0 2 -i-Bu NHS0 2 -(2,4,6- benzimidazolyl trimethylphen yi ) 3413 7-aza-2- 1 C0 2 -t-Bu NHS0 - (2,4,6- benzimidazolyl trimethylphen yi) 3414 7-aza-2- 1 NHS0 2 -(2,4,6- benzimidazolyl trimethylphen yi ) 3415 7-aza-2- 1 -(CH 2 ) 4 NH 2 NHS0 2 -(2,4,6- benzimidazolyl trimethylphen yi ) 3416 7-aza-2- 1 COPh NHS0 2 -(2,4,6- benzimidazolyl trimethylphen yi ) 3417 7-aza-2- 1 S0 2 -n-Bu NHS0 2 - (2,4,6- benzimidazolyl trimethylphen yi) 3418 7-aza-2- 1 Cbz NHCbz benzimidazolyl 3419 7-aza-2- 1 Sθ2P NHCbz benzimidazolyl 3420 7-aza-2- 1 CO(CH 2 )2Ph NHCbz benzimidazolyl 3421 7-aza-2- 1 Bn NHCbz benzimidazolyl 3422 7-aza-2- 1 n-Bu NHCbz benzimidazolyl 3423 7-aza-2- 1 C0 2 -n-Bu H NHCbz benzimidazolyl 3424 7-aza-2- 1 C0 2 -i-Bu H NHCbz benzimidazolyl 3425 7-aza-2- 1 C0 -t-Bu H NHCbz benzimidazolyl 3426 7-aza-2- NHCbz benzimidazolyl 3427 7-aza-2- -(CH 2 ) 4 NH 2 NHCbz benzimidazolyl 3428 7-aza-2- COPh NHCbz benzimidazolyl 3429 7-aza-2- S0 2 -n-Bu NHCbz benzimidazolyl 3430 tetrahydropyrimi 1 Cbz NHS0 2 Ph din-2- y1aminomethy1 3431 tetrahydropyrimi 1 S0 2 Ph H NHS0 2 Ph din-2- ylaminomethyl 3432 tetrahydropyrimi 1 CO(CH 2 ) Ph H NHS0 2 Ph din-2- ylaminomethyl 3433 tetrahydropyrimi 1 Bn NHS0 2 Ph din-2- y1aminomethy1 3434 tetrahydropyrimi 1 n-Bu H NHS0 2 Ph din-2- ylaminomethyl 3435 tetrahydropyrimi 1 COCH2 (3- H NHS0 2 Ph din-2- indolyl) laminome hyl 3436 tetrahydropyrimi 1 S02- H NHS02Ph din-2- (biphenyl) ylaminomethyl 3437 tetrahydropyrimi 1 C0 2 -n-Bu NHS0 2 Ph dιn-2- ylaminomethyl 3438 tetrahydropyrimi 1 CO2-1-BU NHS0 2 Ph dιn-2- ylaminomethyl 3439 tetrahydropyrimi 1 C0 2 -t-Bu NHS0 2 Ph dm-2- ylaminomethyl 3440 tetrahydropyrimi 1 H NHS0 2 Ph dm-2- -ylaminomethyl 3441 tetrahydropyrimi 1 (CH 2 ) 4 NH2 NHS0 2 Ph dιn-2- ylaminomethyl 3442 tetrahydropyrimi 1 COPh NHS0 2 Ph dm-2- y1aminomethy1 3443 tetrahydropyrimi 1 cyclopropyl- NHS0 2 Ph dιn-2- methyl ylaminomethyl 3444 tetrahydropyrimi 1 S0 2 -n-Bu NHS0 2 Ph dιn-2- ylaminomethyl 3445 tetrahydropyrimi 1 Cbz NHS0 -(2,4,6- dιn-2- tπmethylphen ylaminomethyl yi ) 3446 tetrahydropyrimi 1 S0 2 Ph NHS0 2 -(2,4,6- dιn-2- trimethylphen ylaminoraethyl yi) 3447 tetrahydropyrimi 1 CO (CH 2 ) 2 Ph NHS0 2 -(2,4,6- dm-2- trimethylphen ylaminomethyl yi ) 3448 tetrahydropyrimi 1 Bn NHS0 2 - £2,4,6- din-2 - trimethylphen ylaminomethyl yi ) 3449 tetrahydropyrimi 1 n-Bu NHS0 2 - (2,4,6- din-2- trimethylphen y1aminomethy1 yi ) 3450 tetrahydropyrimi 1 C0 2 -n-Bu NHS0 2 -(2,4,6- din-2- trimethylphen y1aminomethy1 yi ) 3451 tetrahydropyrimi 1 C0 2 -i-Bu NHS0 2 -(2,4,6- din-2- trimethylphen yl minom thyl yi) 3452 tetrahydropyrimi 1 C0 -t-Bu NHS0 2 -(2,4,6- din-2- trimeth lphen ylaminomethyl yi ) 3453 tetrahydropyrimi 1 H NHS0 2 -(2,4,6- din-2- trimethylphen yl minometh l yi ) 3454 tetrahydropyrimi 1 -(CH 2 ) 4 NH 2 NHS0 2 -(2,4,6- din-2- trimethylphen ylaminomethyl yi ) 3455 tetrahydropyrimi 1 COPh NHS0 2 -(2,4,6- din-2- trimethylphen ylaminomethyl yi) 3456 tetrahydropyrimi 1 S0 2 -n-Bu NHS0 2 -(2,4,6- din-2- trimethylphen ylaminomethyl yi ) 3457 tetrahydropyrimi 1 Cbz NHCbz din-2- ylaminomethyl 3458 tetrahydropyrimi 1 S0 2 Ph NHCbz din-2- ylaminome hyl 3459 tetrahydropyrimi 1 CO(CH ) 2 Ph NHCbz din-2- ylaminomethyl 3460 tetrahydropyrimi 1 Bn NHCbz din-2- ylaminomethyl 3461 tetrahydropyrimi 1 n-Bu NHCbz din-2- ylaminomethyl 3462 tetrahydropyrimi 1 C0 2 -n-Bu NHCbz din-2- ylaminomethyl 3463 tetrahydropyrimi 1 C0 -i-Bu NHCbz din-2- ylaminomethyl 3464 tetrahydropyrimi 1 C0 2 -t-Bu NHCbz din-2- ylaminome hyl 3465 tetrahydropyrimi 1 NHCbz din-2- ylaminomethyl 3466 tetrahydropyrimi 1 -(CH 2 ) 4 NH 2 NHCbz din-2- ylaminomethyl 3467 tetrahydropyrimi 1 COPh NHCbz din-2- ylaminome hyl 3468 imidazol-2- 0 C0 2 Me NHS0 2 -(2,4,6- 592.4 ylaminomethyl trimethylphen yi ) 3469 benzamidazol-2- 0 Bn NHS0 2 -(2,4,6- 674.3 ylaminomethyl trimethylphen yi ) 3470 benzamιdazol-2- 0 C0 2 Me H NHS0 2 -(2,4,6- 642.3 ylaminomethyl trimethylphen yi ) 3471 benzamιdazol-2- 0 C0 2 Bu H NHSθ2-(2,4,6- 684.4 y1aminomethy1 trimethylphen yi ) 3472 imidazol-2- 0 C0 2 CH 2 (3- H NHS0 2 -(2,4,6- 669.4 ylaminomethyl pyr) trimethylphen yi ) 3473 ιmιdazol-2- 0 H H NHS0 2 -(2,6- 520.3 ylaminomethyl trimethylphen yi ) 3474 ιmιdazol-2- 0 H H NHS0 2 biphenyl 568.3 ylaminomethyl 3475 ιmιdazolm-2- 0 Cbz H NHS0 2 (2- 678.1 ylaminomethyl naphthyl 3476 ιmidazolιn-2- 0 H H NHS0 2 biphenyl 570.2 ylaminomethyl Table 4 B 1 B 10 E 14 E 15 4001 2-pyridinylamino- 0 Cbz H NHS0 2 Ph methyl 4002 2 -pyridinylamino¬ 0 S0 2 Ph H NHS0 2 Ph methyl 4003 2 -pyridinylamino¬ 0 CO(CH 2 )2Ph H NHS0 2 Ph methyl 4004 2-pyridinylamino- 0 Bn H NHS0 2 Ph me hyl 4005 2-pyridinylamino- 0 n-Bu H NHS0 2 Ph methyl 4006 2 -pyridinylamino¬ 0 COCH 2 (3- H NHS0 2 Ph methyl indolyl) 4007 2 -pyridinylamino¬ 0 S02- H NHS0 2 Ph methyl (biphenyl) 4008 2 -pyridinylamino¬ 0 C0 2 -n-Bu H NHS0 2 Ph methyl 4009 2 -pyridinylamino¬ 0 C0 2 -i-Bu H NHS0 2 Ph methyl 4010 2 -pyridinylamino¬ 0 C0 2 -t-Bu H NHS0 2 Ph methyl 4011 2 -pyridinylamino¬ NHS0 2 Ph methyl 4012 2 -pyridinylamino¬ (CH 2 ) 4 NH 2 NHS0 2 Ph methyl 4013 2-pyridinylamino¬ 0 COPh NHS0 Ph methyl 4014 2-pyridinylamino¬ 0 cyclopropy NHS0 2 Ph methyl 1-methyl 4015 2-pyridinylamino¬ 0 S0 2 -n-Bu NHS0 Ph methyl 4016 2-pyridinylamino- 0 Cbz NHS0 2 - (2,4,6- methyl trimethylphenyl) 4017 2-pyridinylamino¬ 0 S0 2 Ph NHS0 2 -(2,4,6- methyl trimethylphenyl) 4018 2-pyridinylamino¬ 0 CO(CH 2 ) 2 Ph NHS0 2 - (2,4,6- methyl trimethylphenyl) 4019 2-pyridinylamino¬ 0 Bn NHS0 2 -(2,4,6- methyl trimethylphenyl) 4020 2-pyridinylamino¬ 0 n-Bu NHS0 2 -(2,4,6- methyl trimethylphenyl) 4021 2-pyridinylamino¬ 0 C0 -n-Bu NHS0 2 -(2,4,6- methyl trimethylphenyl) 4022 2-pyridinylamino¬ 0 C0 2 -i-Bu NHS0 2 -(2,4,6- methyl trimethylphenyl) 4023 2-pyridinylamino- 0 C0 -t-Bu NHS0 2 -(2,4,6- methyl trimethylphenyl) 4024 2-pyridinylamino¬ 0 H H NHS0 2 -(2,4,6- methyl trimethylphenyl) 4025 2-pyridinylamino¬ 0 -<CH 2 ) 4 NH 2 H NHS0 2 -(2,4,6- methyl trimethylphenyl) 4026 2-pyridinylamino¬ 0 COPh NHS0 2 - (2,4,6- methyl trimethylphenyl) 4027 2-pyridinylamino¬ 0 S0 2 -n-Bu H NHS0 2 -(2,4,6- methyl trimethylphenyl) 4028 2-pyridinylamino- 0 Cbz NHCbz methyl 4029 2-pyridinylamino¬ 0 S0 2 Ph NHCbz methyl 4030 2-pyridinylamino¬ 0 CO(CH 2 ) 2 Ph H NHCbz methyl 4031 2-pyridinylamino¬ 0 Bn H NHCbz methyl 4032 2-pyridinylamino¬ 0 n-Bu H NHCbz methyl 4033 2-pyridinylamino¬ 0 C0 2 -n-Bu H NHCbz methyl 4034 2-pyridinylamino¬ 0 C0 2 -i-Bu H NHCbz methyl 4035 2-pyridinylamino- 0 C0 2 -t-Bu H NHCbz ethyl 4036 2-pyridinylamino¬ NHCbz methyl 4037 2-pyridinylamino- 0 -(CH 2 ) 4 NH 2 H NHCbz methyl 4038 2-pyridinylamino¬ 0 COPh H NHCbz methyl 4039 2-pyridinylamino¬ 0 S0 2 -n-Bu H NHCbz methyl 4040 2-imidazolylamino¬ 0 Cbz H NHS0 2 Ph methyl 4041 2-imidazolylamino¬ 0 S0 2 Ph H NHS0 2 Ph methyl 4042 2-imidazolylamino¬ 0 CO(CH 2 ) 2 Ph H NHS0 2 Ph methyl 4043 2-imidazolylamino¬ Bn NHS0 2 Ph methyl 4044 2-imidazolylamino¬ 0 n-Bu NHS0 Ph methyl 4045 2-imidazolylamino¬ 0 COCH 2 (3- NHS0 2 Ph methyl indolyl) 4046 2-imidazolylamino- 0 S02- NHS0 2 Ph methyl (biphenyl) 4047 2-imidazolylamino¬ 0 C0 2 -n-Bu NHS0 Ph methyl 4048 2-imidazolylamino¬ 0 C0 -i-Bu NHS0 Ph methyl 4049 2-imidazolylamino¬ 0 C0 2 -t-Bu NHS0 2 Ph methyl 4050 2-imidazolylamino¬ H NHS0 2 Ph methyl 4051 2-imidazolylamino¬ 0 - ( CH 2 ) 4 NH 2 H NHS0 2 Ph methyl 4052 2-imidazolylamino¬ 0 COPh H NHS0 2 Ph methyl 4053 2-imidazolylamino¬ 0 cyclopropy H NHS0 2 Ph methyl 1-methyl 4054 2-imidazolylamino¬ 0 Sθ2-n-Bu H NHSθ2Ph methyl 4055 2-imidazolylamino¬ 0 Cbz H NHS0 2 -(2,4,6- methyl trimethylphenyl) 4056 2-imidazolylamino- 0 S0 2 Ph H NHS0 2 -(2,4,6- methyl trimethylphenyl) 4057 2-imidazolylamino¬ 0 CO(CH )2Ph H NHS0 2 -(2,4,6- methyl trimethylphenyl) 4058 2-imidazolylamino- Bn H NHS0 2 -(2,4,6- methyl trimethylphenyl) 4059 2-imidazolylamino¬ n-Bu NHS0 2 -(2,4,6- methyl trimethylphenyl) 4060 2-imidazolylamino¬ C0 2 -n-Bu NHS0 2 -(2,4,6- methyl trimethylphenyl) 4061 2-imidazolylamino¬ C0 -i-Bu NHS0 2 -(2,4,6- methyl trimethylphenyl) 4062 2-imidazolylamino¬ C0 2 -t-Bu NHS0 -(2,4,6- methyl trimethylphenyl) 4063 2-imidazolylamino- H NHSθ2-(2,4,6- methyl trimethylphenyl) 4064 2-imidazolylamino¬ 0- -(CH 2 ) NH 2 H NHS0 2 -(2,4,6- methyl trimethylphenyl) 4065 2-imidazolylamino- 0 COPh H NHS0 2 -(2,4,6- methyl trimethylphenyl) 4066 2-imidazolylamino- 0 Sθ 2 -n-Bu H NHS0 2 -(2,4,6- methyl trimethylphenyl) 4067 2-imidazolylamino¬ 0 Cbz H NHCbz methyl 4068 2-imidazolylamino- 0 S0 2 Ph H NHCbz methyl 4069 2-imidazolylamino- 0 CO(CH 2 ) 2 Ph H NHCbz methyl 4070 2-imidazolylamino¬ 0 Bn H NHCbz methyl 4071 2-imidazolylamino¬ 0 n-Bu H NHCbz methyl 4072 2-imidazolylamino¬ 0 C0 2 -n-Bu H NHCbz methyl 4073 2-imidazolylamino¬ 0 C0 2 -i-Bu NHCbz methyl 4074 2-imidazolylamino¬ 0 C0 2 -t-Bu NHCbz methyl 4075 2-imidazolylamino¬ 0 H NHCbz methyl 4076 2-imidazolylamino¬ 0 -(CH 2 ) NH 2 H NHCbz methyl 4077 2-imidazolylamino- 0 COPh NHCbz methyl 4078 2-imidazolylamino¬ 0 S0 2 -n-Bu H NHCbz methyl 4079 2-imidazolinyl- 0 Cbz NHS0 2 Ph aminomethyl 4080 2-imidazolinyl- 0 S0 2 Ph NHS0 2 Ph aminomethyl 4081 2-imidazolinyl- 0 CO(CH ) 2 Ph H NHS02Ph aminomethyl 4082 2-imidazolinyl- 0 Bn H NHS0 Ph aminomethyl 4083 2-imidazolinyl- 0 n-Bu H NHS0 2 Ph aminomethyl 4084 2-imidazolinyl- 0 COCH 2 (3- H NHS0 2 Ph aminomethyl indolyl) 4085 2-imidazolinyl- 0 S02- H NHS02Ph aminomethyl (biphenyl) 4086 2-imidazolinyl- 0 C0 2 -n-Bu H NHS0 2 Ph aminomethyl 4087 2-imidazolinyl- 0 C0 2 -i-Bu H NHS0 2 Ph aminomethyl 4088 2-imidazolinyl- 0 C0 2 -t-Bu H NHSθ2Ph aminomethyl 4089 2-imidazolinyl- NHS0 2 Ph aminomethyl 4090 2-imidazolinyl- 0 -(CH 2 ) 4 NH 2 H NHS0 2 Ph aminomethyl 4091 2-imidazolinyl- 0 COPh H NHS0 2 Ph aminomethyl 4092 2-imidazolinyl- 0 cyclopropy H NHS0 Ph aminomethyl 1-methyl 4093 2-imidazolinyl- 0 S0 2 -n-Bu H NHS0 2 Ph aminomethyl 4094 2-imidazolinyl- 0 Cbz H NHS0 2 -(2,4,6- aminomethyl tri ethylphenyl) 4095 2-imidazolinyl- 0 S0 2 Ph H NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 4096 2-imidazolinyl- 0 CO(CH 2 ) 2 Ph H NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 4097 2-imidazolinyl- 0 Bn H NHS0 2 -(2,4,6- aminomethyl tri ethylphenyl) 4098 2-imidazolinyl- 0 n-Bu NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 4099 2-imidazolinyl- 0 C0 2 -n-Bu NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 4100 2-imidazolinyl- 0 C0 2 -i-Bu NHS0 2 -(2,4,6- aminome hyl trimethylphenyl) 4101 2-imidazolinyl- 0 C0 2 -t-Bu NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 4102 2-imidazolinyl- 0 H NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 4103 2-imidazolinyl- 0 -(CH 2 ) NH 2 NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 4104 2-imidazolinyl- 0 COPh H NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 4105 2-imidazolinyl- S0 2 -n-Bu NHS0 2 - (2,4,6- aminomethyl trimethylphenyl) 4106 2-imidazolinyl- Cbz NHCbz aminomethyl 4107 2-imidazolinyl- S0 2 Ph NHCbz aminomethyl 4108 2-imidazolinyl- 0 CO(CH 2 )2Ph NHCbz aminomethyl 4109 2-imidazolinyl- Bn NHCbz aminomethyl 4110 2-imidazolinyl- n-Bu NHCbz aminomethyl 4111 2-imidazolinyl- Cθ2~n-Bu NHCbz aminomethyl 4112 2-imidazolinyl- Cθ2~i-Bu NHCbz aminomethyl 4113 2-imidazolinyl- Cθ2-t-Bu NHCbz aminomethyl 4114 2-imidazolinyl- NHCbz aminomethyl 4115 2-imidazolinyl- 0 -(CH 2 ) NH 2 H NHCbz aminomethyl 4116 2-imidazolinyl- 0 COPh H NHCbz aminomethyl 4117 2-imidazolinyl- 0 S0 2 -n-Bu H NHCbz aminomethyl 4118 2-benzimidazolyl- 0 Cbz H NHS0 2 Ph aminomethyl 4119 2-benzimidazolyl- 0 S0 2 Ph H NHS0 2 Ph aminomethyl 4120 2-benzimidazolyl- 0 CO(CH 2 ) 2 Ph H NHS0 2 Ph aminomethyl 4121 2-benzimidazolyl- 0 Bn H NHS0 2 Ph a inomethyl 4122 2-benzimidazolyl- 0 n-Bu H NHS0 2 Ph aminomethyl 4123 2-benzimidazolyl- 0 COCH 2 (3- H NHS0 2 Ph aminomethyl indolyl) 4124 2-benzimidazolyl- 0 S02- H NHS0 2 Ph aminomethyl (biphenyl) 4125 2-benzimidazolyl¬ 0 C0 2 -n-Bu H NHS0 2 Ph aminomethyl 4126 2-benzimidazolyl- 0 C0 -i-Bu H NHS0 2 Ph aminomethyl 4127 2-benzimidazolyl- 0 C0 2 -t-Bu H NHS0 2 Ph aminomethyl 4128 2-benzimidazolyl- NHS0 2 Ph aminomethyl 4129 2-benzimidazolyl¬ 0 -(CH 2 ) 4 NH 2 H NHSθ2Ph aminomethyl 4130 2-benzimidazolyl- 0 COPh H NHS0 2 Ph aminomethyl 4131 2-benzimidazolyl- 0 cyclopropy H NHS0 2 Ph aminomethyl 1-methyl 4132 2-benzimidazolyl¬ 0 Sθ 2 -n-Bu H NHS0 2 Ph aminomethyl 4133 2-benzimidazolyl- 0 Cbz H NHS0 2 -(2,4,6- aminomethyl tπraethylphenyl) 4134 2-benzimidazolyl- 0 S0 2 Ph H NHS0 -(2,4,6- aminomethyl trimethylphenyl) 4135 2-benzimidazolyl- 0 CO(CH 2 )2Ph H NHS0 2 -(2,4,6- aminomethyl tπmethylphenyl) 4136 2-benzimidazolyl- 0 Bn H NHS0 2 -(2,4,6- aminomethyl tπmethylphenyl) 4137 2-benzιmιdazolyl- 0 n-Bu H NHS0 2 -(2,4,6- ammomethyl tnmethylphenyl) 4138 2-benzimidazolyl- 0 Cθ 2 -n-Bu H NHS0 2 -(2,4,6- aminomethyl tπmethylphenyl) 4139 2-benzimidazolyl- 0 CO2-I-BU H NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 4140 2-benzιmιdazolyl- 0 Cθ2~t-Bu H NHSO 2 -(2,4,6- aπunomethyl trimethylphenyl) 4141 2-benzimidazolyl¬ 0 H NHS0 2 -(2,4,6- aminomethyl tπmethylphenyl) 4142 2-benzimidazolyl- 0 -(CH 2 ) 4 NH 2 H NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 4143 2-benzιmιdazolyl- 0 COPh NHSO2-(2,4,6- a inomet yl tπmethylphenyl) 4144 2-benzimidazolyl¬ 0 Sθ2-n-Bu H NHSO 2 -(2,4,6- aminome hyl trimethylphenyl) 4145 2-benzimidazolyl¬ 0 Cbz NHCbz aminomethyl 4146 2-benzιmιdazolyl- 0 S0 2 Ph NHCbz aminomethyl 4147 2-benzimidazolyl- 0 CO(CH 2 ) 2 Ph H NHCbz aminomethyl 4148 2-benzimidazolyl¬ Bn NHCbz aminomethyl 4149 2-benzimidazolyl- n-Bu NHCbz aminome hyl 4150 2-benzimidazolyl- C0 -n-Bu NHCbz aminomethyl 4151 2-benzimidazolyl¬ C0 2 -i-Bu NHCbz aminomethyl 4152 2-benzimidazolyl- C0 2 -t-Bu NHCbz aminomethyl 4153 2-benzimidazolyl¬ NHCbz aminomethyl 4154 2-benzimidazolyl- 0 -(CH 2 ) 4 NH 2 H NHCbz aminomethyl 4155 2-benzimidazolyl- 0 COPh H NHCbz aminomethyl 4156 2-benzimidazolyl- 0 Sθ2-n-Bu H NHCbz aminomethyl 4157 7-aza-2- 0 Cbz H NHS0 Ph benzimidazolyl 4158 7-aza-2- 0 S0 2 Ph H NHS0 2 Ph benzimidazolyl 4159 7-aza-2- 0 CO(CH 2 )2Ph H NHS0 2 Ph benzimidazolyl 4160 7-aza-2- 0 Bn H NHS0 2 Ph benzimidazolyl 4161 7-aza-2- 0 n-Bu H NHSθ2Ph benzimidazolyl 4162 7-aza-2- 0 COCH 2 (3- H NHS0 Ph benzimidazolyl indolyl) 4163 7-aza-2- 0 S02- H NHS0 2 Ph benzimidazolyl (biphenyl) 4164 7-aza-2- 0 Cθ2-n-Bu H NHS0 Ph benzimidazolyl 4165 7-aza-2- 0 C0 2 -i-Bu H NHS0 Ph benzimidazolyl 4166 7-aza-2- 0 C0 2 -t-Bu NHS0 2 Ph benzimidazolyl 4167 7-aza-2- NHS0 2 Ph benzimidazolyl 4168 7-aza-2- 0 -(CH ) 4 NH 2 H NHS0 2 Ph benzimidazolyl 4169 7-aza-2- 0 COPh H NHS0 2 Ph benzimidazolyl 4170 7-aza-2- 0 cyclopropy H NHS0 2 Ph benzimidazolyl 1-methyl 4171 7-aza-2- 0 S0 2 -n-Bu H NHS0 2 Ph benzimidazolyl 4172 7-aza-2- 0 Cbz H NHS0 2 -(2,4,6- benzimidazolyl trimethylphenyl) 4173 7-aza-2- 0 S0 2 Ph H NHS0 2 - (2,4,6- benzimidazolyl trimethylphenyl) 4174 7-aza-2- 0 CO(CH 2 ) 2 Ph H NHS0 2 -(2,4,6- benzimidazolyl trimethylphenyl) 4175 7-aza-2- 0 Bn NHS0 2 - (2,4,6- benzimidazolyl trimethylphenyl) 4176 7-aza-2- 0 n-Bu NHS0 -(2,4,6- benzimidazolyl trimethylphenyl) 4177 7-aza-2- 0 C0 2 -n-Bu NHS0 - (2,4,6- benzimidazolyl trimethylphenyl) 4178 7-aza-2- 0 C0 2 -i-Bu NHS0 - (2,4,6- benzimidazolyl trimethylphenyl) 4179 7-aza-2- 0 C0 2 -t-Bu NHS0 2 -(2,4,6- benzimidazolyl trimethylphenyl) 4180 7-aza-2- 0 H NHS0 -(2,4,6- benzimidazolyl trimethylphenyl) 4181 7-aza-2- 0 -(CH 2 ) 4 NH 2 H NHS0 -(2,4,6- benzimidazolyl trimethylphenyl) 4182 7-aza-2- 0 COPh NHS0 2 - (2,4,6- benzimidazolyl trimethylphenyl) 4183 7-aza-2- 0 S0 2 -n-Bu H NHS0 2 -(2,4,6- benzimidazolyl trimethylphenyl; 4184 7-aza-2- Cbz H NHCbz benzimidazolyl 4185 7-aza-2- 0 S0 2 Ph H NHCbz benzimidazolyl 4186 7-aza-2- 0 CO(CH 2 ) 2 Ph NHCbz benzimidazolyl 4187 7-aza-2- 0 Bn NHCbz benzimidazolyl 4188 7-aza-2- n-Bu NHCbz benzimidazolyl 4189 7-aza-2- 0 C0 2 -n-Bu H NHCbz benzimidazolyl 4190 7-aza-2- 0 C0 2 -i-Bu H NHCbz benzimidazolyl 4191 7-aza-2- 0 C0 -t-Bu H NHCbz benzimidazolyl 4192 7-aza-2- O H H NHCbz benzimidazolyl 4193 7-aza-2- 0 -(CH 2 ) 4 NH 2 H NHCbz benzimidazolyl 4194 7-aza-2- 0 COPh H NHCbz benzimidazolyl 4195 7-aza-2- 0 S0 2 -n-Bu H NHCbz benzimidazolyl 4196 tetrahydropyrimidin 0 Cbz H NHS0 2 Ph -2-ylaminomethyl 4197 tetrahydropyrimidin 0 S0 2 Ph H NHS0 2 Ph -2-ylaminomethyl 4198 tetrahydropyrimidin 0 CO(CH 2 ) 2 Ph H NHS0 2 Ph -2-ylaminomethyl 4199 tetrahydropyrimidin 0 Bn H NHS0 2 Ph -2-ylaminomethyl 4200 tetrahydropyrimidin 0 n-Bu NHS0 2 Ph -2-ylaminomethyl 4201 tetrahydropyrimidin 0 C0CH 2 (3- NHS0 2 Ph -2-ylaminomethyl indolyl) 4202 tetrahydropyrimidin 0 0 S02- NHS0 2 Ph -2-ylaminomethyl (biphenyl) 4203 tetrahydropyrimidin 0 0 C0 2 -n-Bu NHS0 2 Ph -2-ylaminomethyl 4204 tetrahydropyrimidin 0 C0 2 -i-Bu NHS0 2 Ph -2-ylaminomethyl 4205 tetrahydropyrimidin 0 C0 2 -t-Bu NHS0 2 Ph - -2-ylaminomethyl 4206 tetrahydropyrimidin 0 NHS0 2 Ph -2-ylaminomethyl 4207 tetrahydropyrimidin 0 -(CH 2 )4NH 2 H NHS0 2 Ph -2-ylaminomethyl 4208 tetrahydropyrimidin 0 COPh H NHS0 2 Ph -2-ylaminomethyl 4209 tetrahydropyrimidin 0 cyclopropy H NHS0 2 Ph -2-ylaminomethyl 1-methyl 4210 tetrahydropyrimidin 0 S02~n-Bu H NHS0 2 Ph -2-ylaminomethyl 4211 tetrahydropyrimidin 0 Cbz H NHS0 2 -(2,4,6- -2-ylaminomethyl trimethylphenyl) 4212 tetrahydropyrimidin 0 S0 2 Ph H NHS0 2 -(2,4,6- -2-ylaminomethyl trimethylphenyl) 4213 tetrahydropyrimidin 0 C0(CH 2 ) 2 Ph H NHS0 2 -(2,4,6- -2-ylaminomethyl trimethylphenyl) 4214 tetrahydropyrimidin 0 Bn H NHS0 -(2,4,6- -2-ylaminomethyl trimethylphenyl) 4215 tetrahydropyrimidin 0 n-Bu H NHS0 2 -(2,4,6- -2-ylaminomethyl trimethylphenyl) 4216 tetrahydropyrimidin 0 C0 2 -n-Bu H NHS0 2 -(2,4,6- -2-ylaminomethyl trimethylphenyl) 4217 tetrahydropyrimidin 0 C0 2 -i-Bu NHS0 2 - (2,4,6- -2-ylaminomethyl trimethylphenyl) 4218 tetrahydropyrimidin 0 C0 2 -t-Bu NHS0 2 -(2,4,6- -2-ylaminomethyl trimethylphenyl) 4219 tetrahydropyrimidin 0 H NHS0 2 -(2,4,6- -2-ylaminomethyl trimethylphenyl) 4220 tetrahydropyrimidin 0 -(CH 2 ) 4 NH 2 NHSO2- (2,4,6- -2-ylaminomethyl trimethylphenyl) 4221 tetrahydropyrimidin 0 COPh NHS0 2 -(2,4,6- -2-ylaminomethyl trimethylphenyl) 4222 tetrahydropyrimidin 0 S0 2 -n-Bu NHS0 2 -(2,4,6- -2-ylaminomethyl trimethylphenyl) 4223 tetrahydropyrimidin 0 Cbz NHCbz -2-ylaminomethyl 4224 tetrahydropyrimidin 0 S0 Ph NHCbz -2-ylaminomethyl 4225 tetrahydropyrimidin 0 C0(CH 2 ) 2 Ph NHCbz -2-ylaminomethyl 4226 tetrahydropyrimidin 0 Bn NHCbz -2-ylaminomethyl 4227 tetrahydropyrimidin 0 n-Bu NHCbz -2-ylaminomethyl 4228 tetrahydropyrimidin 0 C0 2 -n-Bu NHCbz -2-ylaminomethyl 4229 tetrahydropyrimidin 0 C0 2 -i-Bu NHCbz -2-ylaminomethyl 4230 tetrahydropyrimidin 0 C0 2 -t-Bu NHCbz -2-ylaminomethyl 4231 tetrahydropyrimidin 0 H NHCbz -2-ylaminomethyl 4232 tetrahydropyrimidin 0 -(CH 2 ) 4 NH 2 NHCbz -2-ylaminomethyl 4233 tetrahydropyrimidin 0 COPh NHCbz -2-ylaminomethyl 4234 tetrahydropyrimidin 0 Sθ2~n~Bu NHCbz -2 -ylaminomethyl 4235 2-pyridinylamino- 1 Cbz NHS0 2 Ph methyl 4236 2-pyridinylamino- 1 S0 2 Ph NHS0 2 Ph methyl 4237 2-pyridinylamino- 1 C0(CH 2 ) 2 Ph NHS0 2 Ph methyl 4238 2-pyridinylamino- 1 Bn NHS0 2 Ph methyl 4239 2-pyridinylamino- 1 n-Bu H NHS0 Ph methyl 4240 2-pyridinylamino- 1 COCH 2 (3- H NHS0 2 Ph methyl indolyl) 4241 2-pyridinylamino- 1 S02- H NHS0 2 Ph methyl (biphenyl) 4242 2-pyridinylamino- 1 C0 2 -n-Bu H NHS0 2 Ph methyl 4243 2-pyridinylamino- 1 C0 2 -i-Bu H NHS0 2 Ph methyl 4244 2-pyridinylamino- 1 C0 2 -t-Bu H NHS0 2 Ph methyl 4245 2-pyridinylamino- 1 H H NHS0 2 Ph methyl 4246 2-pyridinylamino¬ 1 -(CH 2 ) NH 2 H NHS0 2 Ph methyl 4247 2-pyridinylamino- 1 COPh NHS0 2 Ph methyl 4248 2-pyridinylamino- 1 cyclopropy NHS0 2 Ph methyl 1-methyl 4249 2-pyridinylamino- 1 S02~n-Bu NHS0 Ph methyl 4250 2-pyridinylamino- 1 Cbz NHS0 2 -(2,4,6- methyl trimethylphenyl) 4251 2-pyridinylamino¬ 1 S0 2 Ph H NHS0 2 -(2,4,6- methyl trimethylphenyl) 4252 2-pyridinylamino¬ 1 C0(CH 2 ) 2 Ph H NHS0 2 - (2,4,6- methyl trimethylphenyl) 4253 2-pyridinylamino¬ 1 Bn H NHS0 2 - (2,4,6- methyl trimethylphenyl) 4254 2-pyridinylamino¬ 1 n-Bu H NHS0 -(2,4,6- methyl trimethylphenyl) 4255 2-pyridinylamino¬ 1 C0 2 -n-Bu H NHS0 2 -(2,4,6- methyl trimethylphenyl) 4256 2-pyridinylamino¬ 1 C0 2 -i-Bu H NHS0 2 -(2,4,6- methyl trimethylphenyl) 4257 2-pyridinylamino¬ 1 C0 2 -t-Bu H NHS0 2 -(2,4,6- methyl trimethylphenyl) 4258 2-pyridinylamino- NHS0 2 -(2,4,6- methyl tri ethylphenyl) 4259 2-pyridinylamino¬ 1 -(CH 2 ) 4 NH 2 H NHS0 2 -(2,4,6- methyl trimethylphenyl) 4260 2-pyridinylamino¬ 1 COPh H NHS0 - (2,4,6- methyl trimethylphenyl) 4261 2-pyridinylamino- 1 S0 2 -n-Bu H NHS0 2 -(2,4,6- methyl trimethylphenyl) 4262 2-pyridinylamino¬ 1 Cbz H NHCbz methyl 4263 2-pyridinylamino¬ 1 S0 2 Ph H NHCbz methyl 4264 2-pyridinylamino¬ 1 C0(CH 2 ) 2 Ph H NHCbz methyl 4265 2-pyridinylamino¬ 1 Bn H NHCbz methyl 4266 2-pyridinylamino¬ 1 n-Bu H NHCbz methyl 4267 2-pyridinylamino¬ 1 C0 2 -n-Bu H NHCbz methyl 4268 2 -pyridinylamino¬ 1 C0 2 -i-Bu H NHCbz methyl 4269 2 -pyridinylamino¬ 1 C0 2 -t-Bu H NHCbz methyl 4270 2 -pyridinylamino¬ NHCbz methyl 4271 2-pyridinylamino- 1 -(CH 2 ) 4 NH 2 H NHCbz methyl 4272 2-pyridinylamino- 1 COPh H NHCbz methyl 4273 2 -pyridinylamino¬ 1 S0 -n-Bu H NHCbz methyl 4274 2 -imidazolylamino¬ 1 Cbz H NHS0 2 Ph methyl 4275 2 -imidazolylamino¬ 1 S0 2 Ph H NHS0 2 Ph methyl 4276 2-imidazolylamino- 1 C0(CH 2 ) Ph H NHS0 2 Ph methyl 4277 2-imidazolylamino- 1 Bn H NHS0 2 Ph methyl 4278 2 -imidazolylamino¬ 1 n-Bu H NHS0 2 Ph methyl 4279 2 -imidazolylamino¬ 1 C0CH 2 (3- H NHS0 2 Ph methyl indolyl) 4280 2 -imidazolylamino¬ 1 S0 2 - H NHS0 2 Ph methyl (biphenyl) 4281 2-imidazolylamino- 1 C0 2 ~n-Bu H NHS0 Ph methyl 4282 2-imidazolylamino- 1 C02-i-Bu H NHS0 2 Ph methyl 4283 2 -imidazolylamino¬ 1 C0 2 -t-Bu H NHS0 2 Ph methyl 4284 2-imidazolylamino- NHS0 2 Ph methyl 4285 2-imidazolylamino- 1 -(CH 2 ) 4 NH 2 H NHS0 2 Ph methyl 4286 2 -imidazolylamino¬ 1 COPh H NHS0 2 Ph methyl 4287 2 -imidazolylamino¬ 1 cyclopropy H NHS0 2 Ph methyl 1-methyl 4288 2 -imidazolylamino¬ 1 S02-n-Bu H NHS0 2 Ph methyl 4289 2-imidazolylamino- 1 Cbz H NHS0 -(2,4,6- methyl trimethylphenyl) 4290 2 -imidazolylamino¬ 1 S0 Ph H NHS0 2 - (2,4,6- methyl trimethylphenyl) 4291 2 -imidazolylamino¬ 1 C0(CH 2 ) 2 Ph H NHS0 2 -(2,4,6- methyl trimethylphenyl) 4292 2 -imidazolylamino¬ 1 Bn H NHS0 2 -(2,4,6- methyl trimethylphenyl) 4293 2 -imidazolylamino¬ 1 n-Bu H NHS0 2 -(2,4,6- methyl trimethylphenyl) 4294 2 -imidazolylamino¬ 1 C0 2 -n-Bu H NHS0 2 -(2,4,6- methyl trimethylphenyl) 4295 2 -imidazolylamino¬ 1 C0 2 -i-Bu H NHS0 2 - (2,4,6- methyl trimethylphenyl) 4296 2 -imidazolylamino¬ 1 C0 2 -t-Bu H NHS0 2 -(2,4,6- methyl trimethylphenyl) 4297 -imidazolylamino¬ NHS0 - (2,4,6- methyl trimethylphenyl) 4298 2 -imidazolylamino¬ (CH 2 ) 4 NH 2 NHS0 2 - (2,4,6- methyl trimethylphenyl) 4299 2-imidazolylamino- COPh NHS0 2 -(2,4,6- methyl trimethylphenyl) 4300 2-imidazolylamino- 1 S0 2 -n-Bu H NHS0 2 - (2,4,6- methyl trimethylphenyl) 4301 2-imidazolylamino- Cbz NHCbz methyl 4302 2-imidazolylamino¬ 1 S0 2 Ph H NHCbz methyl 4303 2-imidazolylamino- 1 C0(CH 2 ) 2 Ph H NHCbz methyl 4304 2-imidazolylamino¬ 1 Bn H NHCbz methyl 4305 2-imidazolylamino- 1 n-Bu H NHCbz methyl 4306 2-imidazolylamino- 1 C0 2 -n-Bu H NHCbz methyl 4307 2-imidazolylamino¬ 1 C0 -i-Bu H NHCbz methyl 4308 2-imidazolylamino- 1 C0 2 -t-Bu H NHCbz methyl 4309 2-imidazolylamino¬ NHCbz methyl 4310 2-imidazolylamino¬ 1 -(CH 2 ) 4 NH 2 H NHCbz methyl 4311 2-imidazolylamino¬ 1 COPh H NHCbz methyl 4312 2-imidazolylamino¬ 1 Sθ 2 -n-Bu H NHCbz methyl 4313 2-imidazolinyl- 1 Cbz H NHS0 2 Ph aminomethyl 4314 2-imidazolinyl- 1 S0 2 Ph H NHS0 2 Ph aminomethyl 4315 2-imidazolinyl- 1 CO(CH 2 ) 2 Ph H NHS0 2 Ph aminomethyl 4316 2-imidazolinyl- 1 Bn H NHS0 2 Ph aminomethyl 4317 2-imidazolinyl- 1 n-Bu H NHS02P ami omethyl 4318 2-imidazolinyl- 1 C0CH 2 (3- H HS02Ph aminomethyl indolyl) 4319 2-imidazolinyl- 1 S0 2 - H NHS0 2 Ph aminomethyl (biphenyl) 4320 2-imidazolinyl- 1 C0 2 -n-Bu H NHS0 Ph aminomethyl 4321 2-imidazolinyl- 1 C0 -i-Bu H NHS0 2 Ph aminomethyl 4322 2-imidazolinyl- Cθ 2 -t-Bu NHS0 2 Ph aminomethyl 4323 2-imidazolinyl- NHS0 Ph a inomethyl 4324 2-imidazolinyl- 1 -(CH 2 ) 4 NH 2 H NHS0 2 Ph aminomethyl 4325 2-imidazolinyl- 1 COPh H NHS0 2 Ph aminomethyl 4326 2-imidazolinyl- 1 cyclopropy H NHS0 Ph aminomethyl 1-methyl 4327 2-imidazolinyl- 1 S0 2 -n-Bu H NHS0 2 Ph aminomethyl 4328 2-imidazolinyl- 1 Cbz H NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 4329 2-imidazolinyl- 1 S0 2 Ph H NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 4330 2-imidazolinyl- 1 C0(CH 2 )2Ph H NHSO 2 -(2,4,6- aminomethyl trimethylphenyl) 4331 2-imidazolinyl- 1 Bn H NHSO 2 -(2,4,6- aminomethyl trimethylphenyl) 4332 2-imidazolinyl- 1 n-Bu H NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 4333 2-imidazolinyl- 1 C0 2 -n-Bu H NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 4334 2-imidazolinyl- 1 C0 2 -i-Bu H NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 4335 2-imidazolinyl- 1 C0 2 -t-Bu H NHS0 2 -(2,4,6- aminome hyl trimethylphenyl) 4336 2-imidazolinyl- NHS0 2 -(2,4,6- aminomethyl tπmethylphenyl ) 4337 2-ιmιdazolmyl- -(CH 2 ) 4 NH 2 NHS0 2 - (2,4,6- aminomethyl tπmethylphenyl ) 4338 2-imιdazolinyl- COPh NHS0 2 -(2,4,6- ammomethyl trimethylphenyl) 4339 2-imιdazolmyl- S0 2 -n-Bu NHS0 2 - (2,4,6- aminomethyl trimethylphenyl) 4340 2-imidazolinyl- Cbz NHCbz ammomethyl 4341 2 -imidazol myl - S0 2 Ph NHCbz aminomethyl 4342 2-imidazolιnyl- 1 C0(CH ) 2 Ph NHCbz aminomethyl 4343 2-imidazolmyl- Bn NHCbz aminomethyl 4344 2-imidazolmyl- n-Bu H NHCbz aminomethyl 4345 2-imidazolinyl- C0 -n-Bu NHCbz aminomethyl 4346 2-imidazolmyl- C0 2 -ι-Bu NHCbz aminomethyl 4347 2-imidazolinyl- C0 2 -t-Bu NHCbz aminomethyl 4348 2-imidazolmyl- NHCbz aminomethyl 4349 2-imidazolinyl- ( CH 2 ) 4 NH 2 NHCbz aminomethyl 4350 2-imidazolinyl- COPh NHCbz aminomethyl 4351 2-imidazolinyl- S0 2 -n-Bu NHCbz aminomethyl 4352 2-benzimidazolyl¬ Cbz NHS0 2 Ph aminomethyl 4353 2-benzimidazolyl- 1 S0 2 Ph H NHS0 2 Ph aminomethyl 4354 2-benzimidazolyl- 1 C0(CH ) 2 Ph H NHS0 2 Ph aminomethyl 4355 2-benzimidazolyl- 1 Bn H NHS0 2 Ph aminomethyl 4356 2-benzimidazolyl- 1 n-Bu H NHS0 2 Ph aminomethyl 4357 2-benzimidazolyl- 1 COCH 2 (3- H NHS0 2 Ph aminomethyl indolyl) 4358 2-benzimidazolyl- 1 S02- H NHS0 2 Ph aminomethyl (biphenyl) 4359 2-benzimidazolyl- 1 C0 2 -n-Bu H NHS0 2 Ph aminomethyl 4360 2-benzimidazolyl- 1 C0 2 -i-Bu H NHS0 2 Ph aminomethyl 4361 2-benzimidazolyl¬ 1 C0 2 -t-Bu H NHS0 Ph aminomethyl 4362 2-benzimidazolyl- NHS0 2 Ph a inomethyl 4363 2-benzimidazolyl- 1 -(CH 2 ) 4 NH 2 H NHS0 2 Ph aminomethyl 4364 2-benzimidazolyl- 1 COPh H NHS0 Ph aminomethyl 4365 2-benzimidazolyl- 1 cyclopropy H NHS0 2 Ph aminomethyl 1-methyl 4366 2-benzimidazolyl¬ 1 S0 2 -n-Bu H NHS02Ph aminomethyl 4367 2-benzimidazolyl- 1 Cbz H NHS0 -(2,4,6- aminomethyl trimethylphenyl) 4368 2-benzimidazolyl- 1 S0 2 Ph H NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 4369 2-benzimidazolyl- 1 CO(CH 2 ) 2 Ph H NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 4370 2-benzimidazolyl- 1 Bn H NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 4371 2-benzimidazolyl- 1 n-Bu H NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 4372 2-benzimidazolyl- 1 Cθ2-n-Bu H NHS0 2 - (2,4,6- aminome hyl trimethylphenyl) 4373 2-benzimidazolyl- 1 C0 -i-Bu H NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 4374 2-benzimidazolyl- 1 C0 2 -t-Bu H NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 4375 2-benzimidazolyl- NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 4376 2-benzimidazolyl- 1 -(CH 2 ) NH 2 H NHS0 2 - (2,4,6- aminomethyl tri ethylphenyl) 4377 2-benzimidazolyl¬ 1 COPh H NHS0 -(2,4,6- aminomethyl trimethylphenyl) 4378 2-benzimidazolyl¬ 1 S0 2 -n-Bu H NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 4379 2-benzimidazolyl- 1 Cbz H NHCbz aminomet yl 4380 2-benzimidazolyl- 1 S0 2 Ph H NHCbz aminomethyl 4381 2-benzimidazolyl- 1 C0(CH ) 2 Ph H NHCbz aminomethyl 4382 2-benzimidazolyl- 1 Bn H NHCbz aminomethyl 4383 2-benzimidazolyl- 1 n-Bu H NHCbz aminomethyl 4384 2-benzimidazolyl- 1 C0 2 -n-Bu H NHCbz aminomethyl 4385 2-benzimidazolyl- 1 C0 2 -i-Bu H NHCbz aminomethyl 4386 2-benzimidazolyl- 1 C0 2 -t-Bu H NHCbz aminomethyl 4387 2-benzimidazolyl- NHCbz aminomethyl 4388 2-benzimidazolyl- 1 -(CH 2 ) 4 NH 2 H NHCbz aminomethyl 4389 2-benzimidazolyl- 1 COPh H NHCbz aminomethyl 4390 2-benzimidazolyl• 1 S02~n-Bu H NHCbz aminomethyl 4391 7-aza-2- 1 Cbz H NHS0 2 Ph benzimidazolyl 4392 7-aza-2- 1 S0 2 Ph H NHS0 2 Ph benzimidazolyl 4393 7-aza-2- 1 CO(CH 2 ) 2 Ph H NHS0 2 Ph benzimidazolyl 4394 7-aza-2- 1 Bn H NHS0 2 Ph benzimidazolyl 4395 7-aza-2- 1 n-Bu H NHS0 2 Ph benzimidazolyl 4396 7-aza-2- 1 C0CH 2 (3- H NHS0 2 Ph benzimidazolyl indolyl) 4397 7-aza-2- 1 S02- H HS02Ph benzimidazolyl (biphenyl) 4398 7-aza-2- 1 C0 -n-Bu H NHS0 2 Ph benzimidazolyl 4399 7-aza-2- 1 C0 2 -i-Bu H NHS0 2 Ph benzimidazolyl 4400 7-aza-2- 1 C0 2 -t-Bu H NHS0 2 Ph benzimidazolyl 4401 7-aza-2- NHS0 2 Ph benzimidazolyl 4402 7-aza-2- -(CH 2 ) 4 NH 2 NHS0 2 Ph benzimidazolyl 4403 7-aza-2- COPh NHS0 2 Ph benzimidazolyl 4404 7-aza-2- 1 cyclopropy H NHS0 2 Ph benzimidazolyl 1-methyl 4405 7-aza-2- 1 S0 2 -n-Bu H NHS0 Ph benzimidazolyl 4406 7-aza-2- 1 Cbz H NHS0 2 - (2,4,6- benzimidazolyl trimethylphenyl) 4407 7-aza-2- 1 S0 2 Ph H NHS0 2 -(2,4,6- benzimidazolyl trimethylphenyl) 4408 7-aza-2- 1 C0(CH 2 ) 2 Ph H NHS0 2 -(2,4,6- benzimidazolyl trimethylphenyl) 4409 7-aza-2- 1 Bn H NHS0 2 -(2,4,6- benzimidazolyl trimethylphenyl) 4410 7-aza-2- 1 n-Bu H NHS0 2 - (2,4,6- benzimidazolyl tri ethylphenyl) 4411 7-aza-2- 1 C0 2 -n-Bu H NHS0 -(2,4,6- benzimidazolyl trimethylphenyl) 4412 7-aza-2- 1 C0 2 -i-Bu H NHS0 2 -(2,4,6- benzimidazolyl trimethylphenyl) 4413 7-aza-2- 1 C0 2 -t-Bu H NHS0 2 -(2,4,6- benzimidazolyl trimethylphenyl) 4414 7-aza-2- NHS0 2 -(2,4,6- benzimidazolyl trimethylphenyl) 4415 7-aza-2- 1 -(CH 2 ) 4 NH 2 H NHS0 2 -(2,4,6- benzimidazolyl trimethylphenyl) 4416 7-aza-2- 1 COPh H NHS0 2 -(2,4,6- benzimidazolyl trimethylphenyl) 4417 7-aza-2- 1 S0 -n-Bu H NHS0 2 - (2,4,6- benzimidazolyl trimethylphenyl) 4418 7-aza-2- 1 Cbz H NHCbz benzimidazolyl 4419 7-aza-2- 1 S0 2 Ph H NHCbz benzimidazolyl 4420 7-aza-2- 1 C0(CH 2 ) 2 Ph H NHCbz benzimidazolyl 4421 7-aza-2- Bn H NHCbz benzimidazolyl 4422 7-aza-2- n-Bu H NHCbz benzimidazolyl 4423 7-aza-2- Cθ2-n-Bu H NHCbz benzimidazolyl 4424 7-aza-2- C0 2 -i-Bu H NHCbz benzimidazolyl 4425 7-aza-2- C0 2 -t-Bu H NHCbz benzimidazolyl 4426 7-aza-2- H H NHCbz benzimidazolyl 4427 7-aza-2- -(CH 2 ) 4 NH 2 H NHCbz benzimidazolyl 4428 7-aza-2- COPh H NHCbz benzimidazolyl 4429 7-aza-2- S0 2 -n-Bu H NHCbz benzimidazolyl 4430 tetrahydropyrimidin Cbz H NHS0 2 Pn -2-ylaminomethyl 4431 tetrahydropyrimidin S0 2 Ph H NHS0 Ph -2-ylaminomethyl 4432 tetrahydropyrimidin CO(CH 2 ) 2 Ph H NHS0 2 Ph -2-ylaminomethyl 4433 tetrahydropyrimidin Bn H NHS0 Ph -2-ylaminomethyl 4434 tetrahydropyrimidin n-Bu H NHS0 Ph -2-ylaminomethyl 4435 tetrahydropyrimidin C0CH 2 (3- H NHS0 2 Ph -2-ylaminomethyl indolyl) 4436 tetrahydropyrimidin S02- H NHS0 2 Ph -2-ylaminomethyl (biphenyl) 4437 tetrahydropyrimidin C0 2 -n-Bu H NHS0 2 Ph -2-ylaminomethyl 4438 tetrahydropyrimidin 1 C0 2 -i-Bu NHS0 Ph -2 -ylaminomethyl 4439 tetrahydropyrimidin 1 C0 -t-Bu NHS0 2 Ph -2 -ylaminomethyl 4440 tetrahydropyrimidin 1 H NHS0 2 Ph -2-ylaminomethyl 4441 tetrahydropyrimidin 1 -(CH 2 ) 4 NH2 NHS0 2 Ph -2-ylaminomethyl 4442 tetrahydropyrimidin 1 COPh NHS0 2 Ph -2-ylaminomethyl 4443 tetrahydropyrimidin 1 cyclopropy NHS0 2 Ph -2-ylaminomethyl 1-methyl 4444 tetrahydropyrimidin 1 Sθ2-n-Bu NHS0 2 Ph -2-ylaminomethyl 4445 tetrahydropyrimidin 1 Cbz NHS0 - (2,4,6- -2-ylaminomethyl trimethylphenyl) 4446 tetrahydropyrimidin 1 Sθ2Ph NHS0 2 -(2,4,6- -2-ylaminomethyl trimethylphenyl) 4447 tetrahydropyrimidin 1 C0(CH ) Ph NHS0 2 -(2,4,6- -2-ylaminomethyl trimethylphenyl) 4448 tetrahydropyrimidin 1 Bn NHS0 2 - (2,4,6- -2-ylaminomethyl trimethylphenyl) 4449 tetrahydropyrimidin 1 n-Bu NHS0 2 -(2,4,6- -2-ylaminomethyl trimethylphenyl) 4450 tetrahydropyrimidin 1 Cθ2~n-Bu NHS0 2 -(2,4,6- -2-ylaminomethyl trimethylphenyl) 4451 tetrahydropyrimidin 1 Cθ2~i-Bu NHS0 2 - (2,4,6- -2-ylaminomethyl trimethylphenyl) 4452 tetrahydropyrimidin 1 Cθ2-t-Bu NHS0 2 -(2,4,6- -2-ylaminomethyl trimethylphenyl) 4453 tetrahydropyrimidin 1 H NHS0 2 -(2,4,6- -2-ylaminomethyl trimethylphenyl) 4454 tetrahydropyrimidin 1 - (CH2 > 4 NH 2 NHS0 2 -(2,4,6- -2-y1aminomethy1 trimethylphenyl) 4455 tetrahydropyrimidin 1 COPh NHS0 2 -(2,4,6- -2-ylaminomethyl trimethylphenyl) 4456 tetrahydropyrimidin 1 S0 2 -n-Bu NHS0 2 -(2,4,6- -2-ylaminomethyl trimethylphenyl) 4457 tetrahydropyrimidin 1 Cbz NHCbz -2-ylaminomethyl 4458 tetrahydropyrimidin 1 S0 2 Ph NHCbz -2-ylaminomethyl 4459 tetrahydropyrimidin 1 C0(CH 2 ) 2 Ph NHCbz -2-ylaminomethyl 4460 tetrahydropyrimidin 1 Bn NHCbz -2-ylaminomethyl 4461 tetrahydropyrimidin 1 n-Bu NHCbz -2-ylaminomethyl 4462 tetrahydropyrimidin 1 C0 2 -n-Bu NHCbz -2-ylaminomethyl 4463 tetrahydropyrimidin 1 C0 2 -i-Bu NHCbz -2-ylaminomethyl 4464 tetrahydropyrimidin 1 C0 2 -t-Bu NHCbz -2-ylaminomethyl 4465 tetrahydropyrimidin 1 H NHCbz -2-ylaminomethyl 4466 tetrahydropyrimidin 1 (CH 2 ) 4 NH 2 NHCbz -2-ylaminomethyl 4467 tetrahydropyrimidin 1 COPh NHCbz -2-ylaminomethyl Table 5 E . R l E 10a B 14 E 15 5001 2 -pyridinylamino¬ 0 Cbz H NHS0 2 Ph methyl 5002 2 -pyridinylamino¬ 0 S02Ph H NHS0 2 Ph methyl 5003 2 -pyridinylamino¬ 0 C0(CH 2 ) 2 Ph H NHS0 2 Ph methyl 5004 2 -pyridinylamino¬ 0 Bn H NHS0 2 Ph methyl 5005 2 -pyridinylamino¬ 0 n-Bu H NHS0 2 Ph methyl 5006 2 -pyridinylamino¬ 0 C0CH 2 (3- H NHS0 2 Ph methyl indolyl) 5007 2-pyridinylamino- 0 S02-(bi H NHS0 2 Ph methyl phenyl) 5008 2 -pyridinylamino¬ 0 C0 2 -n-Bu H NHS0 2 Ph methyl 5009 2 -pyridinylamino¬ 0 C0 -i-Bu H NHS0 2 Ph methyl 5010 2 -pyridinylamino¬ 0 C0 2 -t-Bu H NHS0 2 Ph methyl 5011 2 -pyridinylamino¬ 0 -(CH 2 ) 4 NH 2 H NHS0 2 Ph methyl 5012 2 -pyridinylamino¬ 0 COPh H NHS0 Ph methyl 5013 2-pyridinylamino¬ 0 cyclo H NHS0 2 Ph methyl propyl- methyl 5014 2-pyridinylamino¬ 0 S0 2 -n-Bu H NHS0 2 Ph methyl 5015 2-pyridinylamino¬ 0 Cbz H NHS0 2 -(2,4,6- methyl trimethylphenyl) 5016 2-pyridinylamino¬ 0 S0 Ph H NHS0 2 -(2,4,6- methyl trimethylphenyl) 5017 2-pyridinylamino¬ 0 C0 ( CH 2 ) 2 Ph H NHS0 2 -(2,4,6- methyl trimethylphenyl) 5018 2-pyridinylamino¬ 0 Bn H NHS0 -(2,4,6- methyl trimethylphenyl) 5019 2-pyridinylamino¬ 0 n-Bu H NHS0 2 - (2,4,6- methyl trimethylphenyl) 5020 2-pyridinylamino¬ 0 C0 2 -n-Bu H NHS0 2 - (2,4,6- methyl trimethylphenyl) 5021 2-pyridinylamino¬ 0 C02-i-Bu H NHS0 2 -(2,4,6- methyl trimethylphenyl) 5022 2-pyridinylamino¬ 0 C0 -t-Bu H NHS0 2 -(2,4,6- methyl trimethylphenyl) 5023 2-pyridinylamino¬ 0 -(CH 2 ) 4 NH 2 H NHS0 2 -(2,4,6- methyl trimethylphenyl) 5024 2-pyridinylamino¬ 0 COPh H NHS0 2 - (2,4,6- methyl trimethylphenyl) 5025 2-pyridinylamino¬ 0 S0 2 -n-Bu H NHS0 2 -(2,4,6- methyl trimethylphenyl) 5026 2-pyridinylamino¬ 0 Cbz H NHCbz methyl 5027 2-pyridinylamino¬ 0 S0 2 Ph H NHCbz methyl 5028 2-pyridinylamino¬ 0 C0(CH 2 ) 2 Ph H NHCbz methyl 5029 2-pyridinylamino¬ 0 Bn H NHCbz methyl 5030 2-pyridinylamino- 0 n-Bu H NHCbz ethyl 5031 2-pyridinylamino¬ 0 C0 2 -n-Bu H NHCbz methyl 5032 2-pyridinylamino¬ 0 C0 2 -i-Bu H NHCbz methyl 5033 2-pyridinylamino¬ 0 C0 2 -t-Bu H NHCbz methyl 5034 2-pyridinylamino¬ 0 -(CH 2 ) 4 NH 2 H NHCbz methyl 5035 2-pyridinylamino¬ 0 COPh H NHCbz methyl 5036 2-pyridinylamino- 0 Sθ2-n-Bu H NHCbz methyl 5037 2-imidazolylamino¬ 0 Cbz H NHS0 2 Ph methyl 5038 2-imidazolylamino¬ 0 S0 2 Ph H NHS0 2 Ph methyl 5039 2-imidazolylamino¬ 0 C0(CH 2 ) Ph H NHS0 2 Ph methyl 5040 2-imidazolylamino¬ 0 Bn H NHS0 Ph methyl 5041 2-imidazolylamino¬ 0 n-Bu H NHS0 2 Ph methyl 5042 2-imidazolylamino- 0 COCH 2 (3- H NHS0 2 Ph methyl indolyl) 5043 2-imidazolylamino¬ 0 S02-(bi H NHS0 2 Ph methyl phenyl) 5044 2-imidazolylamino¬ 0 Cθ2-n-Bu H NHS0 2 Ph methyl 5045 2-imidazolylamino¬ 0 C0 2 -i-Bu H NHS0 Ph methyl 5046 2-imidazolylamino¬ 0 C0 2 -t-Bu H NHS0 2 Ph methyl 5047 2-ιmιdazolylamιno- 0 - ( CH ) 4 NH2 H NHS0 2 Ph methyl 5048 2 -imidazolylamino¬ 0 COPh H NHS0 2 Ph methyl 5049 2 -imidazolylamino¬ 0 cyclo H NHS0 2 Ph methyl propyl- methyl 5050 2-ιmιdazolylammo- 0 S0 2 -n-Bu H NHS0 2 Ph methyl 5051 2 -imidazolylamino¬ 0 Cbz H NHS0 2 -(2,4,6- methyl tπmethylphenyl) 5052 2 -imidazolylamino¬ 0 S0 Ph H NHS0 2 - (2,4,6- methyl tπmethylphenyl) 5053 2 -imidazolylamino¬ 0 C0(CH 2 ) 2 Ph H NHS0 2 -(2,4,6- methyl tπmethylphenyl) 5054 2 -imidazolylamino¬ 0 Bn H NHS0 2 -(2,4,6- methyl tπmethylphenyl) 5055 2-ιmιdazolylamιno- 0 n-Bu H NHS0 2 -(2,4,6- methyl trimethylphenyl) 5056 2 -imidazolylamino¬ 0 C0 2 -n-Bu H NHS0 2 -(2,4,6- methyl trimethylphenyl) 5057 2 -imidazolylamino¬ 0 C0 2 -ι-Bu H NHS0 2 -(2,4,6- methyl trimethylphenyl) 5058 2 -imidazolylamino¬ 0 C0 2 -t-Bu H NHS0 2 -(2,4,6- methyl tπmethylphenyl) 5059 2 -imidazolylamino¬ 0 -(CH 2 ) NH 2 H NHS0 2 -(2,4,6- methyl tπmethylphenyl) 5060 2 -imidazolylamino¬ 0 COPh H NHSO2-(2,4,6- methyl trimethylphenyl) 5061 2 - imidazolylamino¬ 0 S0 2 -n-Bu H NHSO2- (2,4,6- methyl tri ethylphenyl ) 5062 2 -imidazolylamino¬ 0 Cbz NHCbz methyl 5063 2 -imidazolylamino¬ 0 S0 2 Ph NHCbz methyl 5064 2-imidazolylamino- 0 C0(CH 2 ) 2 Ph H NHCbz methyl 5065 2-imidazolylamino¬ 0 Bn H NHCbz methyl 5066 2-imidazolylamino¬ 0 n-Bu H NHCbz methyl 5067 2-imidazolylamino- 0 C0 2 -n-Bu H NHCbz methyl 5068 2-imidazolylamino¬ 0 C0 2 -i-Bu H NHCbz methyl 5069 2-imidazolylamino- 0 C0 2 -t-Bu H NHCbz methyl 5070 2-imidazolylamino¬ 0 -(CH 2 ) 4 NH 2 H NHCbz methyl 5071 2-imidazolylamino¬ 0 COPh H NHCbz methyl 5072 2-imidazolylamino¬ 0 S0 2 -n-Bu H NHCbz methyl 5073 2-imidazolinyl- 0 Cbz H NHS0 2 Ph aminomethyl 5074 2-imidazolinyl- 0 S0 2 Ph H NHS0 Ph aminomethyl 5075 2-imidazolinyl- 0 CO(CH 2 ) 2 Ph H NHS0 2 Ph aminomethyl 5076 2-imidazolinyl- 0 Bn H NHS0 Ph aminomethyl 5077 2-imidazolinyl- 0 n-Bu H NHS0 Ph aminomethyl 5078 2-imidazolinyl- 0 C0CH 2 (3- H NHS0 Ph aminomethyl indolyl) 5079 2-imidazolinyl- 0 S02-(bi H NHS0 2 Ph aminomethyl phenyl) 5080 2-imidazolinyl- 0 C02-n-Bu H NHS0 2 Ph aminomethyl 5081 2-imidazolinyl- 0 C0 -i-Bu NHS0 2 Ph aminomethyl 5082 2-imidazolinyl- 0 C0 2 -t-Bu NHS0 2 Ph aminomethyl 5083 2-imidazolinyl- 0 -(CH 2 ) 4 NH 2 NHS0 2 Ph aminomethyl 5084 2-imidazolinyl- 0 COPh NHS0 2 Ph aminomethyl 5085 2-imidazolinyl- 0 cyclo NHS0 2 Ph aminomethyl propyl- methyl 5086 2-imidazolinyl- 0 S02-n-Bu NHS0 2 Ph aminomethyl 5087 2-imidazolinyl- 0 Cbz H NHS0 2 - (2,4,6- aminomethyl trimethylphenyl) 5088 2-imidazolinyl- 0 S0 2 Ph H NHS0 2 - (2,4,6- aminomethyl trimethylphenyl) 5089 2-imidazolinyl- 0 C0 (CH 2 ) 2Ph H NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 5090 2-imidazolinyl- 0 Bn H NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 5091 2-imidazolinyl- 0 n-Bu H NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 5092 2-imidazolinyl- 0 C02-n-Bu H NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 5093 2-imidazolinyl- 0 C02-i-Bu H NHS0 2 - (2,4,6- aminomethyl trimethylphenyl) 5094 2-imidazolinyl- 0 C02~t-Bu H NHS0 2 - (2,4,6- aminomethyl trimethylphenyl) 5095 2-imidazolinyl- 0 -(CH 2 ) 4 NH 2 H NHSO2- (2,4,6- aminomethyl trimethylphenyl) 5096 2-iraidazolinyl- 0 COPh H NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 5097 2-imidazolinyl- 0 Sθ2~n-Bu H NHS0 2 - (2,4,6- aminomethyl trimethylphenyl) 5098 2-imidazolinyl- 0 Cbz H NHCbz aminomethyl 5099 2-imidazolinyl- 0 S0 2 Ph H NHCbz aminomethyl 5100 2-imidazolinyl- 0 C0(CH 2 ) 2 Ph H NHCbz aminomethyl 5101 2-imidazolinyl- 0 Bn H NHCbz aminome hyl 5102 2-imidazolinyl- 0 n-Bu H NHCbz aminomethyl 5103 2-imidazolinyl- 0 C0 -n-Bu H NHCbz aminomethyl 5104 2-imidazolinyl- 0 C0 2 -i-Bu H NHCbz aminome hyl 5105 2-imidazolinyl- 0 C0 2 -t-Bu H NHCbz aminome hyl 5106 2-imidazolinyl- 0 -(CH 2 ) NH 2 H NHCbz aminomethyl 5107 2-imidazolinyl- 0 COPh H NHCbz aminomethyl 5108 2-imidazolinyl- 0 S0 -n-Bu H NHCbz aminomethyl 5109 2-benzimidazolyl- 0 Cbz H NHS0 2 Ph aminomethyl 5110 2-benzimidazolyl- 0 S0 2 Ph H NHS0 2 Ph aminome hyl 5111 2-benzimidazolyl- 0 C0(CH 2 ) 2 Ph H NHS0 2 Ph aminomethyl 5112 2-benzimidazolyl- 0 Bn H NHS0 2 Ph aminomethyl 5113 2-benzimidazolyl- 0 n-Bu H NHS0 2 Ph aminomethyl 5114 2-benzimidazolyl- 0 C0CH 2 (3- H NHS0 Ph aminomethyl indolyl) 5115 2-benzimidazolyl- aminomethyl 5116 2-benzimidazolyl¬ aminomethyl 5117 2-benzimidazolyl- aminome hyl 5118 2-benzimidazolyl¬ aminome hyl 5119 2-benzimidazolyl- aminomethyl 5120 2-benzimidazolyl¬ aminomethyl 5121 2-benzimidazolyl- aminomethyl 5122 2-benzimidazolyl¬ aminomethyl 5123 2-benzimidazolyl- Cbz H NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 5124 2-benzimidazolyl¬ 0 S0 2 Ph H NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 5125 2-benzimidazolyl- 0 C0(CH ) 2 Ph H NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 5126 2-benzimidazolyl- 0 Bn H NHS02-(2,4,6- aminomethyl trimethylphenyl) 5127 2-benzimidazolyl- 0 n-Bu H NHSO 2 -(2,4,6- aminomethyl trimethylphenyl) 5128 2-benzimidazolyl- 0 C0 2 -n-Bu H NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 5129 2-benzimidazolyl- 0 C0 2 -i-Bu H NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 5130 2-benzimidazolyl- 0 C0 2 -t-Bu H NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 5131 2-benzimidazolyl- 0 -(CH 2 ) 4 NH 2 H NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 5132 2-benzimidazolyl ■ 0 COPh H NHS0 - (2,4,6- aminomethyl trimethylphenyl) 5133 2-benzimidazolyl- 0 Sθ2~n-Bu H NHS0 2 -(2,4,6- aminomethyl tπmethylphenyl) 5134 2-benzimidazolyl¬ 0 Cbz H NHCbz aminomethyl 5135 2-benzιmιdazolyl- 0 S02Ph H NHCbz aminomethyl 5136 2-benzιmιdazolyl- 0 C0(CH 2 ) 2 Ph H NHCbz aminomethyl 5137 2-benzimidazolyl- 0 Bn H NHCbz aminomethyl 5138 2-benzιmιdazolyl- 0 n-Bu H NHCbz aminomethyl 5139 2-benzimidazolyl¬ 0 C0 2 -n-Bu H NHCbz aminomethyl 5140 2-benzimidazolyl- 0 C0 2 -ι-Bu H NHCbz aminomethyl 5141 2-benzimidazolyl- 0 C0 2 -t-Bu H NHCbz aminomethyl 5142 2-benzimidazolyl- 0 -(CH 2 ) 4 NH 2 H NHCbz aminomethyl 5143 2-benzιmιdazolyl- 0 COPh H NHCbz aminomethyl 5144 2-benzimidazolyl- 0 S0 2 -n-Bu H NHCbz aminomethyl 5145 7-aza-2- 0 Cbz H NHS0 2 Ph benzimidazolyl 5146 7-aza-2- 0 S0 2 Ph H NHS0 2 Ph benzimidazolyl 5147 7-aza-2- 0 C0(CH 2 ) 2 Ph H NHS0 2 Ph benzimidazolyl 5148 7-aza-2- 0 Bn H NHS0 2 Ph benzimidazolyl 5149 7-aza-2- 0 n-Bu H NHS0 Ph benzimidazolyl 5150 7-aza-2- 0 C0CH 2 (3- H NHS0 2 Ph benzimidazolyl indolyl) 5151 7-aza-2- 0 S02-(bi H NHS0 2 Ph benzimidazolyl phenyl) 5152 7-aza-2- 0 C0 2 -n-Bu H NHS0 2 Ph benzimidazolyl 5153 7-aza-2- 0 C0 2 -i-Bu H NHS0 2 Ph benzimidazolyl 5154 7-aza-2- 0 C0 2 -t-Bu H NHS0 2 Ph benzimidazolyl 5155 7-aza-2- 0 -(CH 2 ) 4 NH 2 H NHS0 2 Ph benzimidazolyl 5156 7-aza-2- 0 COPh H NHS02Ph benzimidazolyl 5157 7-aza-2- 0 cyclo H NHS0 Ph benzimidazolyl propyl- methyl 5158 7-aza-2- 0 S02~n-Bu H NHS0 2 Ph benzimidazolyl 5159 7-aza-2- 0 Cbz H NHS0 2 -(2,4,6- benzimidazolyl trimethylphenyl) 5160 7-aza-2- 0 S0 2 Ph H NHS0 2 - (2,4,6- benzimidazolyl trimethylphenyl) 5161 7-aza-2- 0 C0(CH ) 2 Ph H NHS0 2 -(2,4,6- benzimidazolyl trimethylphenyl) 5162 7-aza-2- 0 Bn H NHS0 2 -(2,4,6- benzimidazolyl trimethylphenyl) 5163 7-aza-2- 0 n-Bu H NHS0 2 -(2,4,6- benzimidazolyl trimethylphenyl) 5164 7-aza-2- 0 C0 2 -n-Bu H NHS0 2 - (2,4,6- benzimidazolyl trimethylphenyl) 5165 7-aza-2- 0 C0 2 -i-Bu H NHS0 2 - (2,4,6- benzimidazolyl trimethylphenyl) 5166 7-aza-2- 0 C0 2 -t-Bu H NHS0 2 -(2,4,6- benzimidazolyl trimethylphenyl) 5167 7-aza-2- 0 -(CH 2 ) NH 2 H NHS0 - (2,4,6- benzimidazolyl trimethylphenyl) 5168 7-aza-2- 0 COPh H NHS0 2 -(2,4,6- benzimidazolyl tri ethylphenyl) 5169 7-aza-2- 0 S0 2 -n-Bu H NHS0 2 -(2,4,6- benzimidazolyl trimethylphenyl) 5170 7-aza-2- 0 Cbz H NHCbz benzimidazolyl 5171 7-aza-2- 0 S0 2 Ph H NHCbz benzimidazolyl 5172 7-aza-2- 0 C0(CH 2 ) 2 Ph H NHCbz benzimidazolyl 5173 7-aza-2- 0 Bn H NHCbz benzimidazolyl 5174 7-aza-2- 0 n-Bu H NHCbz benzimidazolyl 5175 7-aza-2- 0 C0 2 -n-Bu H NHCbz benzimidazolyl 5176 7-aza-2- 0 C0 2 -i-Bu H NHCbz benzimidazolyl 5177 7-aza-2- 0 C0 2 -t-Bu H NHCbz benzimidazolyl 5178 7-aza-2- 0 -(CH 2 ) 4 NH 2 H NHCbz benzimidazolyl 5179 7-aza-2- 0 COPh H NHCbz benzimidazolyl 5180 7-aza-2- 0 S0 2 -n-Bu H NHCbz benzimidazolyl 5181 tetrahydropyrimidin 0 Cbz H NHS0 2 Ph -2-ylaminomethyl 5182 tetrahydropyrimidin 0 S0 2 Ph H NHS0 2 Ph -2-ylaminomethyl 5183 tetrahydropyrimidin 0 C0(CH 2 ) 2 Ph H NHS0 2 Ph -2-ylaminomethyl 5184 tetrahydropyrimidin 0 Bn H NHS0 2 Ph -2-ylaminomethyl 5185 tetrahydropyrimidin 0 n-Bu H NHS0 2 Ph -2-ylaminomethyl 5186 tetrahydropyrimidin 0 C0CH 2 (3- H NHS0 2 Ph -2-ylaminomethyl indolyl) 5187 tetrahydropyrimidin 0 S02-(bi H NHS0 2 Ph -2-ylaminomethyl phenyl) 5188 tetrahydropyrimidin 0 C0 -n-Bu H NHS0 Ph -2-ylaminomethyl 5189 tetrahydropyrimidin NHS0 2 Ph -2-ylaminomethyl 5190 tetrahydropyrimidin NHS0 2 Ph -2-ylaminomethyl 5191 tetrahydropyrimidin NHS0 2 Ph -2-ylaminomethyl 5192 tetrahydropyrimidin NHS0 2 Ph -2-ylaminomethyl 5193 tetrahydropyrimidin NHS0 2 Ph -2-ylaminomethyl 5194 tetrahydropyrimidin NHS0 2 Ph -2-ylaminomethyl 5195 tetrahydropyrimidin 0 Cbz H NHS0 2 -(2,4,6- -2-ylaminomethyl trimethylphenyl) 5196 tetrahydropyrimidin 0 S0 2 Ph H NHS0 2 -(2,4,6- -2-ylaminomethyl trimethylphenyl) 5197 tetrahydropyrimidin 0 C0(CH 2 ) 2 Ph H NHS0 2 -(2,4,6- -2-ylaminomethyl trimethylphenyl) 5198 tetrahydropyrimidin Bn H NHS0 2 -(2,4,6- -2-ylaminomethyl trimethylphenyl) 5199 tetrahydropyrimidin 0 n-Bu NHS0 2 -(2,4,6- -2-ylaminomethyl trimethylphenyl) 5200 tetrahydropyrimidin 0 Cθ2-n-Bu NHS0 2 - (2,4,6- -2-ylaminomethyl trimethylphenyl) 5201 tetrahydropyrimidin 0 C0 2 -i-Bu NHS0 2 - (2,4,6- -2-ylaminomethyl trimethylphenyl) 5202 tetrahydropyrimidin 0 C0 2 -t-Bu NHS0 2 - (2,4,6- -2-ylaminomethyl trimethylphenyl) 5203 tetrahydropyrimidin 0 -(CH 2 ) 4 NH 2 NHS0 2 - (2,4,6- -2-ylaminomethyl trimethylphenyl) 5204 tetrahydropyrimidin 0 COPh NHS0 2 - (2,4,6- -2-ylaminomethyl trimethylphenyl) 5205 tetrahydropyrimidin 0 S02-n-Bu NHS0 2 -(2,4,6- -2-ylaminomethyl trimethylphenyl) 5206 tetrahydropyrimidin 0 Cbz NHCbz -2-ylaminomethyl 5207 tetrahydropyrimidin 0 S0 2 Ph NHCbz -2-ylaminomethyl 5208 tetrahydropyrimidin 0 C0(CH 2 ) 2 Ph NHCbz -2-ylaminomethyl 5209 tetrahydropyrimidin 0 Bn NHCbz -2-ylaminomethyl 5210 tetrahydropyrimidin 0 n-Bu NHCbz -2-y1aminomethy1 5211 tetrahydropyrimidin 0 C0 2 -n-Bu NHCbz -2-ylaminomethyl 5212 tetrahydropyrimidin 0 C0 2 -i-Bu NHCbz -2-ylaminomethyl 5213 tetrahydropyrimidin 0 C0 2 -t-Bu NHCbz -2-ylaminomethyl 5214 tetrahydropyrimidin 0 - ( CH 2 > 4 NH2 NHCbz -2-ylaminomethyl 5215 tetrahydropyrimidin 0 COPh NHCbz -2-ylaminomethyl 5216 tetrahydropyrimidin 0 S02-n-Bu NHCbz -2-ylaminomethyl 5234 2-pyridinylamino¬ Bn NHS0 2 - (2,4,6- methyl trimethylphenyl) 5235 2-pyridinylamino¬ n-Bu H NHS0 2 -(2,4,6- methyl tri ethylphenyl) 5236 2-pyridinylamino¬ 1 C0 -n-Bu H NHS0 2 -(2,4,6- methyl trimethylphenyl) 5237 2-pyridinylamino¬ 1 C0 2 -i-Bu H NHS0 2 - (2,4,6- methyl trimethylphenyl) 5238 2-pyridinylamino- 1 C0 -t-Bu H NHS0 -(2,4,6- methyl trimethylphenyl) 5239 2-pyridinylamino¬ 1 -(CH 2 ) 4 NH 2 H NHS0 2 - (2,4,6- methyl trimethylphenyl) 5240 2-pyridinylamino¬ 1 COPh H NHS0 2 -(2,4,6- methyl trimethylphenyl) 5241 2-pyridinylamino¬ 1 S0 2 -n-Bu H NHS0 2 -(2,4,6- methyl trimethylphenyl) 5242 2-pyridinylamino¬ 1 Cbz H NHCbz methyl 5243 2-pyridinylamino¬ 1 S0 2 Ph H NHCbz methyl 5244 2-pyridinylamino¬ 1 C0(CH 2 ) 2 Ph H NHCbz methyl 5245 2-pyridinylamino¬ 1 Bn H NHCbz methyl 5246 2-pyridinylamino¬ 1 n-Bu H NHCbz methyl 5247 2-pyridinylamino¬ 1 C0 2 -n-Bu H NHCbz methyl 5248 2-pyridinylamino¬ 1 C0 2 -i-Bu H NHCbz methyl 5249 2-pyridinylamino¬ 1 C02-t-Bu H NHCbz methyl 5250 2-pyridinylamino¬ 1 -(CH 2 ) 4 NH 2 H NHCbz methyl 5268 2-imidazolylamino¬ 1 S0 2 Ph H NHS0 2 -(2,4,6- methyl trimethylphenyl) 5269 2-imidazolylamino- 1 C0(CH 2 ) 2 Ph H NHS0 - (2,4,6- methyl trimethylphenyl) 5270 2-imidazolylamino¬ 1 Bn H NHS0 2 - (2,4,6- methyl trimethylphenyl) 5271 2-imidazolylamino¬ 1 n-Bu H NHS0 2 -(2,4,6- methyl trimethylphenyl) 5272 2-imidazolylamino¬ 1 C0 2 -n-Bu H NHS0 2 - (2,4,6- methyl trimethylphenyl) 5273 2-imidazolylamino¬ 1 C0 2 -i-Bu H NHS0 2 -(2,4,6- methyl trimethylphenyl) 5274 2-imidazolylamino¬ 1 C0 2 -t-Bu H NHS0 2 - (2,4,6- methyl trimethylphenyl) 5275 2-imidazolylamino¬ 1 -(CH 2 ) 4 NH 2 H NHS0 2 -(2,4,6- methyl trimethylphenyl) 5276 2-imidazolylamino¬ 1 COPh H NHS0 2 - (2,4,6- methyl trimethylphenyl) 5277 2-imidazolylamino¬ 1 S0 -n-Bu H NHS0 2 -(2,4,6- methyl trimethylphenyl) 5278 2-imidazolylamino¬ 1 Cbz H NHCbz methyl 5279 2-imidazolylamino¬ 1 S0 2 Ph H NHCbz methyl 5280 2-imidazolylamino¬ 1 C0(CH 2 ) 2 Ph H NHCbz methyl 5281 2-imidazolylarπino- 1 Bn H NHCbz methyl 5282 2-imidazolylamino¬ 1 n-Bu H NHCbz methyl 5283 2-imidazolylamino¬ 1 C02-n-Bu H NHCbz methyl 5284 2-imidazolylamino¬ 1 C0 2 -i-Bu H NHCbz methyl 5285 2-imidazolylamino¬ 1 C0 2 -t-Bu H NHCbz methyl 5286 2-imidazolylamino¬ 1 -(CH 2 ) 4 NH 2 H NHCbz methyl 5287 2-imidazolylamino¬ 1 COPh H NHCbz methyl 5288 2-imidazolylamino- 1 S0 2 -n-Bu H NHCbz methyl 5289 2-imidazolinyl- 1 Cbz H NHS0 2 Ph am nomethyl 5290 2-imidazolinyl- 1 S0 2 Ph H NHS0 2 Ph aminomethyl 5291 2-imidazolinyl- 1 CO(CH 2 ) 2 Ph H NHS0 2 Ph aminomethyl 5292 2-imidazolinyl- 1 Bn H NHS0 2 Ph aminomethyl 5293 2-imidazolinyl- 1 n-Bu H NHS0 2 Ph aminomethyl 5294 2-imidazolinyl- 1 COCH 2 (3- H NHS0 2 Ph aminomethyl indolyl) 5295 2-imidazolinyl- 1 S02-(bi H NHS0 Ph aminomethyl phenyl) 5296 2-imidazolinyl- 1 C0 2 -n-Bu H NHS0 2 Ph aminomethyl 5297 2-imidazolinyl- 1 C0 -i-Bu H NHS0 2 Ph a inomethyl 5298 2-imidazolinyl- 1 C0 2 -t-Bu H NHS0 2 Ph aminomethyl 5299 2-imidazolinyl- 1 -(CH 2 ) 4 NH 2 H NHS0 2 Ph aminomethyl 5300 2-imidazolinyl- 1 COPh H NHS0 Ph aminomethyl 5301 2-imidazolinyl- 1 cyclo H NHS0 2 Ph aminomethyl propyl- methyl 5302 2 -imidazol inyl - 1 S0 2 -n-Bu H NHS0 2 Ph aminomethyl 5303 2-imidazolinyl- 1 Cbz H NHS0 -(2,4,6- aminomethyl trimethylphenyl) 5304 2-imidazolinyl- 1 S0 Ph H NHS0 2 -(2,4,6- a inomethyl trimethylphenyl) 5305 2-imidazolinyl- 1 C0(CH 2 ) 2 Ph H NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 5306 2-imidazolinyl- 1 Bn H NHSO 2 -(2,4,6- aminomethyl trimethylphenyl) 5307 2-imidazolinyl- 1 n-Bu H NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 5308 2-imidazolinyl- 1 C0 2 -n-Bu H NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 5309 2-imidazolinyl- 1 C0 -i-Bu NHS0 2 -(2,4,6- a inomethyl trimethylphenyl) 5310 2-imidazolinyl- 1 C0 2 -t-Bu NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 5311 2-imidazolinyl- 1 -(CH 2 ) 4 NH 2 NHSO2-(2,4,6- aminome hyl trimethylphenyl) 5312 2-imidazolinyl- 1 COPh NHSO 2 -(2,4,6- aminomethyl trimethylphenyl) 5313 2-imidazolinyl- 1 S0 2 -n-Bu NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 5314 2-imidazolinyl- 1 Cbz NHCbz aminomethyl 5315 2-imidazolinyl- S0 2 Ph NHCbz aminomethyl 5316 2-imidazolinyl- 1 C0(CH 2 ) Ph H NHCbz aminomethyl 5317 2-imidazolinyl- Bn NHCbz aminomethyl 5318 2-imidazolinyl- n-Bu NHCbz aminomethyl 5319 2-imidazolinyl- 1 C0 2 -n-Bu H NHCbz aminome hyl 5320 2-imidazolinyl- 1 C0 2 -i-Bu H NHCbz aminomethyl 5321 2-imidazolinyl- 1 C0 2 -t-Bu H NHCbz aminomethyl 5322 2-imidazolinyl- 1 -(CH 2 ) 4 NH 2 H NHCbz aminomethyl 5323 2-imidazolinyl- 1 COPh H NHCbz aminomethyl 5324 2-imidazolinyl- 1 S0 2 -n-Bu H NHCbz aminomethyl 5325 2-benzimidazolyl- 1 Cbz H NHS0 2 Ph aminomet yl 5326 2-benzimidazolyl- 1 S0 2 Ph NHS0 2 Ph aminomethyl 5327 2-benzimidazolyl- 1 C0(CH 2 ) 2 Ph NHS0 2 Ph aminome hyl 5328 2-benzimidazolyl- 1 Bn NHS0 2 Ph aminomethyl 5329 2-benzimidazolyl- n-Bu H NHS0 2 Ph aminomethyl 5330 2-benzimidazolyl- 1 COCH 2 (3- NHS0 2 Ph aminomethyl indolyl) 5331 2-benzimidazolyl- 1 S02-(bi NHS0 Ph aminomethyl phenyl) 5332 2-benzimidazolyl¬ 1 C0 2 -n-Bu H NHS0 2 Ph aminomethyl 5333 2-benzimidazolyl- 1 C0 2 -i-Bu H NHS0 2 Ph aminomethyl 5334 2-benzimidazolyl- 1 C0 2 -t-Bu H NHS0 2 Ph aminomethyl 5335 2-benzimidazolyl- 1 -(CH 2 ) 4 NH 2 H NHS0 2 Ph aminomethyl 5336 2 -benz imidazolyl¬ 1 COPh H NHS0 Ph aminomethyl 5337 2 -benz imidazolyl¬ 1 cyclo H NHS0 2 Ph aminomethyl propyl- methyl 5338 2 -benzimidazolyl - 1 S0 2 -n-Bu H NHS0 2 Ph aminomethyl 5339 2-benzimidazolyl- 1 Cbz H NHS0 2 - (2,4,6- aminomethyl trimethylphenyl) 5340 2-benzimidazolyl- 1 S0 2 Ph H NHS0 2 - (2,4,6- aminomethyl trimethylphenyl) 5341 2-benzimidazolyl¬ 1 C0(CH 2 ) 2 Ph H NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 5342 2-benzimidazolyl- 1 Bn H NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 5343 2-benzimidazolyl¬ 1 n-Bu H NHS0 - (2,4,6- aminome hyl trimethylphenyl) 5344 2-benzimidazolyl¬ 1 C0 2 -n-Bu H NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 5345 2-benzimidazolyl- 1 C0 2 -i-Bu H NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 5346 2-benzimidazolyl- 1 C0 2 -t-Bu H NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 5347 2-benzimidazolyl- 1 -(CH 2 ) 4 NH 2 H NHS0 - (2,4,6- aminomethyl trimethylphenyl) 5348 2-benzimidazolyl- 1 COPh H NHS0 2 - (2,4,6- aminomethyl trimethylphenyl) 5349 2-benzimidazolyl- 1 S0 2 -n-Bu H NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 5350 2-benzimidazolyl- 1 Cbz H NHCbz aminomethyl 5351 2-benzimidazolyl¬ 1 S0 2 Ph H NHCbz aminomethyl 5352 2-benzimidazolyl- 1 CO(CH 2 ) 2 Ph H NHCbz aminomethyl 5353 2-benzimidazolyl- 1 Bn H NHCbz aminomethyl 5354 2-benzimidazolyl¬ 1 n-Bu H NHCbz aminomethyl 5355 2-benzimidazolyl¬ 1 C0 2 -n-Bu H NHCbz aminomethyl 5356 2-benzimidazolyl- 1 C0 2 -i-Bu H NHCbz aminomethyl 5357 2-benzimidazolyl¬ 1 C0 2 -t-Bu H NHCbz aminomethyl 5358 2-benzimidazolyl- 1 -(CH 2 ) 4 NH 2 H NHCbz aminomethyl 5359 2-benzimidazolyl- 1 COPh H NHCbz aminomethyl 5360 2-benzimidazolyl- 1 S0 2 -n-Bu H NHCbz aminomethyl 5361 7-aza-2- 1 Cbz H NHS0 2 Ph benzimidazolyl 5362 7-aza-2- 1 S0 2 Ph H NHS0 2 Ph benzimidazolyl 5363 7-aza-2- 1 C0(CH 2 ) 2 Ph H NHS0 2 Ph benzimidazolyl 5364 7-aza-2- 1 Bn H NHS0 2 Ph benzimidazolyl 5365 7-aza-2- 1 n-Bu H NHS0 2 Ph benzimidazolyl 5366 7-aza-2- 1 C0CH (3- H NHS0 2 Ph benzimidazolyl indolyl) 5367 7-aza-2- 1 S02-(bi H NHS0 2 Ph benzimidazolyl phenyl) 5368 7-aza-2- 1 C0 -n-Bu H NHS0 2 Ph benzimidazolyl 5369 7-aza-2- 1 C0 2 -i-Bu H NHS0 2 Ph benzimidazolyl 5370 7-aza-2- 1 C0 2 -t-Bu H NHS0 2 Ph benzimidazolyl 5371 7-aza-2- 1 -(CH 2 ) 4 NH 2 H NHS0 2 Ph benzimidazolyl 5372 7-aza-2- 1 COPh H NHS0 2 Ph benzimidazolyl 5373 7-aza-2- 1 cyclo H NHS0 2 Ph benzimidazolyl propyl- methyl 5374 7-aza-2- 1 S0 2 -n-Bu H NHS0 2 Ph benzimidazolyl 5375 7-aza-2- 1 Cbz H NHS0 2 - (2,4,6- benzimidazolyl trimethylphenyl) 5376 7-aza-2- 1 S0 Ph H NHS0 2 -(2,4,6- benzimidazolyl trimethylphenyl) 5377 7-aza-2- 1 CO(CH 2 ) 2 Ph H NHS0 2 -(2,4,6- benzimidazolyl trimethylphenyl) 5378 7-aza-2- 1 Bn H NHS0 2 -(2,4,6- benzimidazolyl trimethylphenyl) 5379 7-aza-2- 1 n-Bu H NHS0 -(2,4,6- benzimidazolyl trimethylphenyl) 5380 7-aza-2- 1 C0 2 -n-Bu H NHS0 2 - (2,4,6- benzimidazolyl trimethylphenyl) 5381 7-aza-2- 1 C0 2 -i-Bu H NHS0 2 - (2,4,6- benzimidazolyl trimethylphenyl) 5382 7-aza-2- 1 C0 2 -t-Bu H NHS0 - (2,4,6- benzimidazolyl trimethylphenyl) 5383 7-aza-2- 1 -(CH 2 ) 4 NH 2 H NHS0 2 -(2,4,6- benzimidazolyl trimethylphenyl) 5384 7-aza-2- 1 COPh H NHS0 2 -(2,4,6- benzimidazolyl trimethylphenyl) 5385 7-aza-2- 1 S0 2 -n-Bu H NHS0 2 - (2,4,6- benzimidazolyl trimethylphenyl) 5386 7-aza-2- 1 Cbz H NHCbz benzimidazolyl 5387 7-aza-2- 1 S0 2 Ph H NHCbz benzi idazolyl 5388 7-aza-2- 1 C0(CH 2 ) 2 Ph H NHCbz benzimidazolyl 5389 7-aza-2- Bn H NHCbz benzimidazolyl 5390 7-aza-2- 1 n-Bu H NHCbz benzimidazolyl 5391 7-aza-2- 1 C0 2 -n-Bu H NHCbz benzimidazolyl 5392 7-aza-2- 1 C0 2 -i-Bu H NHCbz benzimidazolyl 5393 7-aza-2- 1 C0 2 -t-Bu H NHCbz benzimidazolyl 5394 7-aza-2- 1 -(CH 2 ) 4 NH 2 H NHCbz benzimidazolyl 5395 7-aza-2- 1 COPh H NHCbz benzimidazolyl 5396 7-aza-2- 1 S0 2 -n-Bu H NHCbz benzimidazolyl 5397 tetrahydropyrimidin 1 Cbz H NHS0 2 Ph -2-ylaminomethyl 5398 tetrahydropyrimidin 1 S0 2 Ph H NHS0 2 Ph -2-ylaminomethyl 5399 tetrahydropyrimidin 1 C0(CH 2 ) 2 Ph H NHS0 2 Ph -2-ylaminomethyl 5400 tetrahydropyrimidin 1 Bn H NHS0 2 Ph -2-ylaminomethyl 5401 tetrahydropyrimidin n-Bu NHS0 Ph -2-ylaminomethyl 5402 tetrahydropyrimidin C0CH 2 (3- NHS0 2 Ph -2-y1aminomethy1 indolyl) 5403 tetrahydropyrimidin S02-(bi NHS0 2 Ph -2-y1 minomethy1 phenyl) 5404 tetrahydropyrimidin 1 C0 -n-Bu H NHS0 2 Ph -2-ylaminomethyl 5405 tetrahydropyrimidin 1 C0 2 -i-Bu H NHS0 2 Ph -2-ylaminomethyl 5406 tetrahydropyrimidin 1 C0 2 -t-Bu H NHS0 2 Ph -2-ylaminomethyl 5407 tetrahydropyrimidin 1 -(CH 2 ) NH 2 H NHS0 2 Ph -2-ylaminomethyl 5408 tetrahydropyrimidin 1 COPh H NHS0 Ph -2-ylaminomethyl 5409 tetrahydropyrimidin 1 cyclo H NHS0 Ph - -2-ylaminomethyl propyl- methyl 5410 tetrahydropyrimidin 1 S0 2 -n-Bu H NHS0 2 Ph -2-ylaminomethyl 5411 tetrahydropyrimidin 1 Cbz H NHS0 2 -(2,4,6- -2-ylaminomethyl trimethylphenyl) 5412 tetrahydropyrimidin 1 S0 2 Ph H NHS0 2 -(2,4,6- -2-ylaminomethyl tri ethy1pheny1) 5413 tetrahydropyrimidin 1 C0(CH 2 ) Ph H NHS0 2 -(2,4,6- -2-ylaminomethyl trimethylphenyl) 5414 tetrahydropyrimidin 1 Bn H NHSO2-(2,4,6- -2-ylaminomethyl trimethylphenyl) 5415 tetrahydropyrimidin 1 n-Bu H NHS0 2 -(2,4,6- -2-ylaminomethyl trimethylphenyl) 5416 tetrahydropyrimidin 1 C0 2 -n-Bu H NHS0 2 -(2,4,6- -2-ylaminomethyl trimethylphenyl) 5417 tetrahydropyrimidin 1 C0 2 -i-Bu H NHS0 2 -(2,4,6- -2-ylaminomethyl trimethylphenyl) 5418 tetrahydropyrimidin 1 C0 -t-Bu H NHS0 -(2,4,6- -2-ylaminomet yl trimethylphenyl) 5419 tetrahydropyrimidin 1 -(CH 2 ) 4 NH 2 H NHS0 2 -(2,4,6- -2-ylaminomethyl trimethylphenyl) 5420 tetrahydropyrimidin 1 COPh H NHS0 2 -(2,4,6- -2-ylaminomethyl trimethylphenyl) 5421 tetrahydropyrimidin 1 S0 2 -n-Bu H NHS0 2 - (2,4,6- -2-ylaminomethyl trimethylphenyl) 5422 tetrahydropyrimidin 1 Cbz H NHCbz -2-ylaminomethyl 5423 tetrahydropyrimidin 1 S0 2 Ph H NHCbz -2-ylaminomethyl 5424 tetrahydropyrimidin 1 C0 (CH 2 ) 2 Ph H NHCbz -2-ylaminomethyl 5425 tetrahydropyrimidin 1 Bn H NHCbz -2-ylaminomethyl 5426 tetrahydropyrimidin 1 n-Bu H NHCbz -2-ylaminomethyl 5427 tetrahydropyrimidin 1 C0 2 -n-Bu H NHCbz -2-ylaminomethyl 5428 tetrahydropyrimidin 1 C0 2 - i-Bu H NHCbz -2-y1aminome hy1 5429 tetrahydropyrimidin 1 C0 2 -t-Bu H NHCbz -2-ylaminomethyl 5430 tetrahydropyrimidin 1 - (CH 2 ) 4 NH 2 H NHCbz -2-ylaminomethyl 5431 tetrahydropyrimidin 1 COPh H NHCbz -2-ylaminomethyl 5432 tetrahydropyrimidin 1 S0 -n-Bu H NHCbz -2 -ylaminomethyl Table 6 £__. B 1 β 10a £ 14 B 15 Ho.- 6001 2 -pyridinylamino¬ Cbz NHS0 2 Ph methyl 6002 2 -pyridinylamino¬ 0 S0 2 Ph NHS0 2 Ph methyl 6003 2 -pyridinylamino¬ 0 CO(CH 2 ) Ph NHS0 2 Ph methyl 6004 2 -pyridinylamino¬ 0 Bn NHS0 Ph methyl 6005 2 -pyridinylamino¬ 0 n-Bu NHS0 2 Ph methyl 6006 2-pyridinylamino- 0 COCH (3- NHS0 2 Ph methyl indolyl) 6007 2 -pyridinylamino¬ 0 S02- NHS0 2 Ph methyl ( biphenyl) 6008 2 -pyridinylamino¬ 0 C0 2 -n-Bu NHS0 2 Ph methyl 6009 2 -pyridinylamino¬ 0 C0 2 -i-Bu NHS0 2 Ph methyl 6010 2 -pyridinylamino¬ 0 C0 2 -t-Bu NHS0 Ph methyl 6011 2 -pyridinylamino¬ 0 -(CH ) 4 NH 2 NHS0 Ph methyl 6012 2 -pyridinylamino¬ 0 COPh NHS0 2 Ph methyl 6013 2-pyridinylamino¬ 0 cyclopropyl- H NHS0 2 Ph methyl methyl 6014 2-pyrιdιnylaπuno- 0 S0 2 -n-Bu H NHS0 2 h methyl 6015 2-pyridinylamino¬ 0 Cbz H NHS0 2 - (2,4,6- methyl trimethylphenyl) 6016 2-pyridinylamino¬ 0 S0 2 Ph H NHS0 2 - (2,4,6- methyl trimethylphenyl) 6017 2-pyridinylamino¬ 0 C0(CH 2 ) 2 Ph H NHS0 2 - (2,4,6- methyl trimethylphenyl) 6018 2-pyridinylamino¬ 0 Bn H NHS0 2 -(2,4,6- methyl trlmethylphenyl) 6019 2-pyridinylamino¬ 0 n-Bu H NHS0 2 - (2,4,6- methyl tπmethylphenyl) 6020 2-pyridinylamino¬ 0 C0 2 -n-Bu H NHS0 2 -(2,4,6- methyl trimethylphenyl) 6021 2-pyridinylamino¬ 0 C0 -ι-Bu H NHS0 2 -(2,4,6- methyl tπmethylphenyl) 6022 2-pyridinylamino¬ 0 C0 2 -t-Bu H NHS0 2 -(2,4,6- methyl trimethylphenyl) 6023 2-pyridinylamino¬ 0 -(CH 2 ) 4 NH 2 H NHS0 2 - (2,4,6- methyl trimethylphenyl) 6024 2-pyridinylamino¬ 0 COPh H NHS0 2 -(2,4,6- methyl trimethylphenyl) 6025 2-pyridinylamino¬ 0 S0 2 -n-Bu H NHS0 2 -(2,4,6- methyl trimethylphenyl) 6026 2-pyridinylamino¬ 0 Cbz H NHCbz methyl 6027 2-pyridinylamino¬ 0 S0 2 Ph H NHCbz methyl 6028 2-pyridinylamino¬ 0 C0(CH 2 ) 2 Ph H NHCbz methyl 6029 2-pyridinylamino¬ 0 Bn NHCbz methyl 6030 2 -pyridinylamino¬ 0 n-Bu H NHCbz methyl 6031 2-pyridinylamino- 0 C0 -n-Bu H NHCbz methyl 6032 2 -pyridinylamino¬ 0 C0 -i-Bu H NHCbz methyl 6033 2-pyridinylamino- 0 C0 2 -t-Bu H NHCbz methyl 6034 2-pyridinylamino- 0 -(CH 2 ) NH 2 H NHCbz methyl 6035 2 -pyridinylamino¬ 0 COPh H NHCbz methyl 6036 2 -pyridinylamino¬ 0 S0 2 -n-Bu H NHCbz methyl 6037 2-imidazolylamino- 0 Cbz H NHS0 2 Ph methyl 6038 2 -imidazolylamino¬ 0 S0 2 Ph H NHS0 2 Ph methyl 6039 2-imidazolylamino- 0 C0(CH 2 ) 2 Ph H NHS0 2 Ph ethyl 6040 2 -imidazolylamino¬ 0 Bn H NHS0 Ph methyl 6041 2-imidazolylamino- 0 n-Bu H NHS0 2 Ph ethyl 6042 2 -imidazolylamino¬ 0 C0CH 2 (3- H NHS0 2 Ph methyl indolyl) 6043 2-imidazolylamino- 0 S02- H NHS0 2 Ph methyl (biphenyl) 6044 2-imidazolylamino- 0 C0 -n-Bu H NHS0 2 Ph methyl 6045 2 -imidazolylamino¬ 0 C02-i-Bu H NHS0 2 Ph methyl 6046 2-imidazolylamino¬ 0 C02-t-Bu H NHS0 Ph methyl 6047 2-imidazolylamino- 0 -(CH 2 ) 4 NH 2 H NHS0 2 Ph methyl 6048 2-imidazolylamino- 0 COPh H NHS0 2 Ph methyl 6049 2-imidazolylamino¬ 0 cyclopropyl- H NHS0 Ph methyl methyl 6050 2-imidazolylamino¬ 0 S0 2 -n-Bu H NHS0 2 Ph methyl 6051 2-imidazolylamino¬ 0 Cbz H NHS0 2 -(2,4,6- methyl trimethylphenyl) 6052 2-imidazolylamino- 0 S0 2 Ph H NHS0 2 -(2,4,6- methyl trimethylphenyl) 6053 2-imidazolylamino¬ 0 C0(CH 2 ) 2 Ph H NHS0 -(2,4,6- methyl trimethylphenyl) 6054 2-imidazolylamino- 0 Bn NHS0 2 -(2,4,6- methyl trimethylphenyl) 6055 2-imidazolylamino¬ 0 n-Bu H NHS0 2 -(2,4,6- methyl trimethylphenyl) 6056 2-imidazolylamino¬ 0 C0 2 -n-Bu H NHS0 2 -(2,4,6- methyl trimethylphenyl) 6057 2-imidazolylamino¬ 0 C0 2 -i-Bu H NHS0 2 - (2,4,6- methyl trimethylphenyl) 6058 2-imidazolylamino¬ 0 C0 2 -t-Bu H NHS0 -(2,4,6- methyl trimethylphenyl) 6059 2-imidazolylamino¬ 0 -(CH 2 ) 4 NH 2 H NHS0 2 -(2,4,6- methyl trimethylphenyl) 6060 2-imidazolylamino¬ 0 COPh H NHS0 2 -(2,4,6- methyl trimethylphenyl) 6061 2-imidazolylamino 0 S0 2 -n-Bu H NHS0 2 -(2,4,6- methyl trimethylphenyl) 6062 2-imidazolylamino - 0 Cbz H NHCbz methyl 6063 2-imidazolylamino 0 S0 Ph H NHCbz methyl 6064 2-imidazolylamino- 0 C0(CH 2 ) 2 Ph H NHCbz methyl 6065 2-imidazolylamino¬ 0 Bn H NHCbz methyl 6066 2-imidazolylamino- 0 n-Bu H NHCbz methyl 6067 2-imidazolylamino¬ 0 C0 2 -n-Bu H NHCbz methyl 6068 2-imidazolylamino- 0 C0 2 -i-Bu H NHCbz methyl 6069 2-imidazolylamino¬ 0 C0 2 -t-Bu H NHCbz methyl 6070 2-imidazolylamino- 0 -(CH 2 ) 4 NH 2 H NHCbz methyl 6071 2-imidazolylamino- 0 COPh H NHCbz ethyl 6072 2-imidazolylamino¬ 0 S0 2 -n-Bu H NHCbz methyl 6073 2-imidazolinyl- 0 Cbz H NHS0 2 Ph aminomethyl 6074 2-imidazolinyl- 0 S0 Ph H NHS0 2 Ph aminomethyl 6075 2-imidazolinyl- 0 C0(CH ) 2 Ph H NHS0 2 Ph aminomethyl 6076 2-imidazolinyl- 0 Bn NHS0 2 Ph aminomethyl 6077 2-imidazolinyl- 0 n-Bu NHS0 2 Ph aminome yl 6078 2-imidazolinyl- 0 C0CH 2 (3- NHS0 Ph aminomethyl indolyl) 6079 2-imidazolinyl- 0 S02- NHS0 2 Ph aminomethyl (biphenyl) 6080 2-imidazolinyl- 0 C0 2 -n-Bu NHS0 2 Ph aminomethyl 6081 2-ιπudazolmyl- 0 C0 2 -ι-Bu H NHS0 2 Ph ami nomet hyl 6082 2-ιπudazolmyl- 0 C0 2 -t-Bu H NHS0 2 Ph ami nomet hyl 6083 2 -ιmιdazolmyl- 0 -(CH 2 ) 4 NH 2 H NHS0 2 Ph ami nomet hyl 6084 2-ιmιdazolmyl- 0 COPh H NHS0 2 Ph ami nomet hyl 6085 2 -ιmιdazolιnyl- 0 cyclopropyl- H NHS0 Ph aminomethyl methyl 6086 2-imidazolmyl- 0 S0 2 -n-Bu H NHS0 2 Ph aminomethyl 6087 2-ιmιdazolιnyl- 0 Cbz H NHS0 -(2,4,6- ami nomet hyl tπmethylphenyl) 6088 2-ιmιdazolmyl- 0 S0 2 Ph H NHS0 2 -(2,4,6- am omethyl trimethylphenyl) 6089 2-ιmιdazolmyl- 0 C0(CH 2 ) 2 Ph H NHS0 2 -(2,4,6- ami nome hyl trimethylphenyl) 6090 2-ιmιdazolιnyl- 0 Bn H NHS0 2 - (2,4,6- ami nomet hyl tπmethylphenyl) 6091 2-ιmιdazolmyl- 0 n-Bu H NHS0 2 -(2,4,6- ami nomet hyl trimethylphenyl) 6092 2-imidazolinyl- 0 C0 2 -n-Bu H NHS0 - (2,4,6- aminomethyl tπmethylphenyl) 6093 2 -ιmιdazolιnyl- 0 C0 -ι-Bu H NHS0 2 - (2,4,6- ami nomet hyl trimethylphenyl) 6094 2-ιmιdazol nyl- 0 C0 2 -t-Bu H NHS0 2 - (2,4,6- aminomethyl tπmethylphenyl) 6095 2-ιmιdazolιnyl- 0 -(CH 2 ) NH 2 H NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 6096 2-imidazolinyl- 0 COPh H NHS0 2 - (2,4,6- aminomethyl trimethylphenyl) 6097 2-imidazolinyl- 0 S0 2 -n-Bu H NHS0 2 - (2,4,6- aminomethyl tπmethylphenyl) 6098 2-imidazolinyl- 0 Cbz H NHCbz aminomethyl 6099 2-imidazolinyl- 0 S0 2 Ph H NHCbz aminomethyl 6100 2-imidazolinyl- 0 C0(CH 2 ) 2 Ph H NHCbz aminomethyl 6101 2-imidazolinyl- 0 Bn H NHCbz aminomethyl 6102 2-imidazolinyl- 0 n-Bu H NHCbz aminomethyl 6103 2-imidazolinyl- 0 C0 2 -n-Bu H NHCbz aminomethyl 6104 2-imidazolinyl- 0 C0 2 -i-Bu H NHCbz a inomethyl 6105 2-imidazolinyl- 0 C0 2 -t-Bu H NHCbz a inomethyl 6106 2-imidazolinyl- 0 -(CH 2 ) 4 NH 2 H NHCbz aminomethyl 6107 2-imidazolinyl- 0 COPh H NHCbz aminomethyl 6108 2-imidazolinyl- 0 S0 2 ~n-Bu H NHCbz aminomethyl 6109 2-benzimidazolyl- 0 Cbz H NHS0 2 Ph aminomethyl 6110 2-benzimidazolyl- 0 Sθ 2 Ph H NHS02Ph aminomethyl 6111 2-benzimidazolyl¬ 0 CO(CH 2 ) 2 Ph H NHS0 2 Ph aminomethyl 6112 2-benzimidazolyl- 0 Bn H NHS0 2 Ph aminomethyl 6113 2-benzimidazolyl- 0 n-Bu H NHS0 Ph aminomethyl 6114 2-benzimidazolyl- 0 COCH 2 (3- H NHS0 2 Ph aminomethyl indolyl) 6115 2-benzimidazolyl- 0 S02- H NHS0 2 Ph aminomethyl (biphenyl) 6116 2-benzimidazolyl- 0 C0 2 -n-Bu H NHS0 2 Ph aminomethyl 6117 2-benzimidazolyl- 0 C0 -i-Bu H NHS0 Ph aminomethyl 6118 2-benzimidazolyl- 0 C0 -t-Bu H NHS0 2 Ph aminomethyl 6119 2-benzimidazolyl- 0 -(CH 2 ) 4 NH 2 H NHS0 2 Ph aminomethyl 6120 2-benzimidazolyl- 0 COPh H NHS0 Ph aminomethyl 6121 2-benzimidazolyl¬ 0 cyclopropyl- H NHS0 2 Ph aminomethyl methyl 6122 2-benzimidazolyl- 0 S0 2 -n-Bu H NHS0 2 Ph aminomethyl 6123 2-benzimidazolyl- 0 Cbz H NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 6124 2-benzimidazolyl¬ 0 S0 2 Ph H NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 6125 2-benzimidazolyl¬ 0 CO(CH 2 ) 2 Ph H NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 6126 2-benzimidazolyl- 0 Bn H NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 6127 2-benzimidazolyl- 0 n-Bu H NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 6128 2-benzimidazolyl- 0 C0 2 -n-Bu H NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 6129 2-benzimidazolyl- 0 C0 -i-Bu H NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 6130 2-benzimidazolyl- 0 C0 2 -t-Bu H NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 6131 2-benzimidazolyl- 0 -(CH 2 ) 4 NH 2 H NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 6132 2-benzimidazolyl- COPh NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 6133 2-benzimidazolyl- S0 2 -n-Bu NHS0 2 - (2,4,6- aminomethyl trimethylphenyl) 6134 2-benzimidazolyl- Cbz NHCbz aminomethyl 6135 2-benzimidazolyl- S0 2 Ph NHCbz aminomethyl 6136 2-benzimidazolyl- 0 C0(CH 2 ) 2 Ph NHCbz aminomethyl 6137 2-benzimidazolyl- Bn NHCbz aminomethyl 6138 2-benzimidazolyl- n-Bu NHCbz aminome hyl 6139 2-benzimidazolyl¬ C0 2 -n-Bu NHCbz aminomethyl 6140 2-benzimidazolyl- C0 2 -i-Bu NHCbz aminomethyl 6141 2-benzimidazolyl- C02-t-Bu NHCbz aminomethyl 6142 2-benzimidazolyl¬ -(CH 2 ) 4 NH 2 NHCbz aminometh l 6143 2-benzimidazolyl- COPh NHCbz aminomethyl 6144 2-benzimidazolyl- S0 2 -n-Bu NHCbz aminomethyl 6145 7-aza-2- Cbz NHS0 2 Ph benzimidazolyl 6146 7-aza-2- S0 2 Ph NHS0 2 Ph benzimidazolyl 6147 7-aza-2- 0 CO(CH 2 ) 2 Ph NHS0 2 Ph benzimidazolyl 6148 7-aza-2- Bn NHS0 2 Ph benzimidazolyl 6149 7-aza-2- 0 n-Bu H NHS0 2 Ph benzimidazolyl 6150 7-aza-2- 0 C0CH 2 (3- H NHS0 2 Ph benzimidazolyl indolyl) 6151 7-aza-2- 0 S02- H NHS0 2 Ph benzimidazolyl (biphenyl) 6152 7-aza-2- 0 C0 2 -n-Bu H NHS0 2 Ph benzimidazolyl 6153 7-aza-2- 0 C0 2 -i-Bu H NHS0 2 Ph benzimidazolyl 6154 7-aza-2- 0 C0 2 -t-Bu H NHS0 2 Ph benzimidazolyl 6155 7-aza-2- 0 -(CH 2 ) 4 NH 2 H NHS0 Ph benzimidazolyl 6156 7-aza-2- 0 COPh H NHS0 2 Ph benzimidazolyl 6157 7-aza-2- 0 cyclopropyl- H NHS0 2 Ph benzimidazolyl methyl 6158 7-aza-2- 0 S0 2 -n-Bu H NHS0 2 Ph benzimidazolyl 6159 7-aza-2- 0 Cbz H NHS0 2 -(2,4,6- benzimidazolyl trimethylphenyl) 6160 7-aza-2- 0 S0 2 Ph H NHS0 -(2,4,6- benzimidazolyl tπmethylphenyl) 6161 7-aza-2- 0 CO(CH 2 ) 2 Ph H NHS0 -(2,4,6- benzimidazolyl trimethylphenyl) 6162 7-aza-2- 0 Bn H NHS0 2 - (2,4,6- benzimidazolyl tπmethylphenyl) 6163 7-aza-2- 0 n-Bu H NHS0 - (2,4,6- benzimidazolyl trimethylphenyl) 6164 7-aza-2- 0 C0 -n-Bu H NHS0 2 -(2,4,6- benzimidazolyl trimethylphenyl) 6165 7-aza-2- 0 C0 2 -ι-Bu H NHS0 - (2,4,6- benzimidazolyl trimethylphenyl) 6166 7-aza-2- 0 C0 2 -t-Bu H NHS0 2 -(2,4,6- benzimidazolyl tπmethylphenyl ) 6167 7-aza-2- 0 -(CH ) 4 NH 2 H NHS0 2 -(2,4,6- benzimidazolyl tπmethy lphenyl ) 6168 7-aza-2- 0 COPh H NHS0 2 -(2,4,6- benzimidazolyl trimethylphenyl ) 6169 7-aza-2- 0 S0 2 -n-Bu H NHS0 2 - (2,4,6- benzimidazolyl tπmethylphenyl ) 6170 7-aza-2- 0 0 Cbz H NHCbz benzimidazolyl 6171 7-aza-2- 0 0 S0 2 Ph H NHCbz benzimidazolyl 6172 7-aza-2- 0 0 C0(CH ) 2 Ph H NHCbz benzimidazolyl 6173 7-aza-2- 0 0 Bn H NHCbz benzimidazolyl 6174 7-aza-2- 0 0 n-Bu H NHCbz benzimidazolyl 6175 7-aza-2- 0 0 C0 2 -n-Bu H NHCbz benzimidazolyl 6176 7-aza-2- 0 0 C0 2 -ι-Bu H NHCbz benzimidazolyl 6177 7-aza-2- 0 0 C0 2 -t-Bu H NHCbz benzimidazolyl 6178 7-aza-2- 0 0 -(CH 2 ) 4 NH 2 H NHCbz benzimidazolyl 6179 7-aza-2- 0 COPh H NHCbz benzimidazolyl 6180 7-aza-2- 0 S0 2 -n-Bu H NHCbz benzimidazolyl 6181 tetrahydropyrimidin 0 Cbz H NHS0 2 Ph -2-ylaminomethyl 6182 tetrahydropyrimidin 0 S0 2 Ph H NHS0 2 Ph -2 -ylaminomethyl 6183 tetrahydropyrimidin 0 C0(CH 2 ) 2 Ph H NHS0 Ph -2-ylaminomethyl 6184 tetrahydropyrimidin 0 Bn H NHS0 2 Ph -2-ylaminomethyl 6185 tetrahydropyrimidin 0 n-Bu H NHS0 2 Ph -2-ylaminomethyl 6186 tetrahydropyrimidin 0 C0CH 2 (3- H NHS0 2 Ph -2-ylaminomethyl indolyl) 6187 tetrahydropyrimidin 0 S02- H NHS0 2 Ph -2-ylaminomethyl (biphenyl) 6188 tetrahydropyrimidin 0 C0 2 -n-Bu H NHS0 2 Ph -2-ylaminomethyl 6189 tetrahydropyrimidin 0 C0 2 -i-Bu H NHS0 2 Ph -2-ylaminomethyl 6190 tetrahydropyrimidin 0 C0 -t-Bu H NHS0 2 Ph -2-ylaminomethyl 6191 tetrahydropyrimidin 0 -(CH 2 ) NH 2 H NHS0 2 Ph -2-ylaminomethyl 6192 tetrahydropyrimidin 0 COPh H NHS0 2 Ph -2-ylaminomethyl 6193 tetrahydropyrimidin 0 cyclopropyl- H NHS0 2 Ph -2-ylaminomethyl methyl 6194 tetrahydropyrimidin 0 S0 2 -n-Bu H NHS0 2 Ph -2-ylaminomethyl 6195 tetrahydropyrimidin 0 Cbz H NHS0 2 - (2,4,6- -2-ylaminomethyl tri ethylphenyl) 6196 tetrahydropyrimidin 0 S0 2 Ph H NHSO2- (2,4,6- -2-ylaminomethyl trimethylphenyl) 6197 tetrahydropyrimidin 0 C0(CH 2 ) 2 Ph H NHS0 - (2,4,6- -2-ylaminomethyl trimethylphenyl) 6198 tetrahydropyrimidin 0 Bn NHS0 -(2,4,6- -2-ylaminomethyl trimethylphenyl) 6199 tetrahydropyrimidin 0 n-Bu NHS0 2 - (2,4,6- -2-ylaminomethyl trimethylphenyl) 6200 tetrahydropyrimidin 0 C0 2 -n-Bu H NHS0 2 - (2,4,6- -2-ylaminomethyl trimethylphenyl) 6201 tetrahydropyrimidin 0 C0 -i-Bu H NHS0 2 - (2,4,6- -2-ylaminomethyl trimethylphenyl) 6202 tetrahydropyrimidin 0 C0 2 -t-Bu H NHS0 2 - (2,4,6- -2-ylaminomethyl trimethylphenyl) 6203 tetrahydropyrimidin 0 -(CH 2 ) 4 NH 2 H NHS0 2 -(2,4,6- -2-ylaminomethyl trimethylphenyl) 6204 tetrahydropyrimidin 0 COPh H NHS0 2 - (2,4,6- -2-ylaminomethyl trimethylphenyl) 6205 tetrahydropyrimidin 0 S0 2 -n-Bu H NHS0 2 -(2,4,6- -2-ylaminomethyl trimethylphenyl) 6206 tetrahydropyrimidin 0 Cbz H NHCbz -2-ylaminomethyl 6207 tetrahydropyrimidin 0 S0 2 Ph H NHCbz -2-ylaminomethyl 6208 tetrahydropyrimidin 0 CO(CH 2 ) 2 Ph H NHCbz -2-ylaminomethyl 6209 tetrahydropyrimidin 0 Bn H NHCbz -2-ylaminomethyl 6210 tetrahydropyrimidin 0 n-Bu H NHCbz -2-ylaminomethyl 6211 tetrahydropyrimidin 0 C0 2 -n-Bu H NHCbz -2-ylaminomethyl 6212 tetrahydropyrimidin 0 C0 2 -i-Bu H NHCbz -2-ylaminomethyl 6213 tetrahydropyrimidin 0 C0 2 -t-Bu H NHCbz -2-ylaminomethyl 6214 tetrahydropyrimidin 0 -(CH 2 ) NH 2 H NHCbz -2-ylaminomethyl 6215 tetrahydropyrimidin 0 COPh H NHCbz -2-ylaminomethyl 6216 tetrahydropyrimidin 0 S0 2 -n-Bu H NHCbz -2-ylaminomethyl 6217 2-pyridinylamino¬ 1 Cbz H NHS0 2 Ph methyl 6218 2-pyridinylamino¬ 1 S0 2 Ph H NHS0 2 Ph methyl 6219 2-pyridinylamino¬ 1 C0(CH 2 ) 2 Ph H NHS0 2 Ph methyl 6220 2-pyridinylamino¬ 1 Bn H NHS0 2 Ph methyl 6221 2-pyridinylamino¬ 1 n-Bu H NHS0 Ph methyl 6222 2-pyridinylamino¬ 1 C0CH 2 (3- H NHS0 Ph methyl indolyl) 6223 2-pyridinylamino- 1 S02- H NHS0 2 Ph methyl (biphenyl) 6224 2-pyridinylamino¬ 1 C0 2 -n-Bu H NHS0 2 Ph methyl 6225 2-pyridinylamino¬ 1 C0 2 -i-Bu H NHS0 2 Ph methyl 6226 2-pyridinylamino¬ 1 C0 2 -t-Bu H NHS0 2 Ph methyl 6227 2-pyridinylamino¬ 1 -<CH 2 ) 4 NH 2 H NHS0 2 Ph methyl 6228 2-pyridinylamino- 1 COPh H NHS0 2 Ph methyl 6229 2-pyridinylamino¬ 1 cyclopropyl- H NHS0 2 Ph methyl methyl 6230 2-pyridinylamino¬ 1 S0 2 -n-Bu H NHS0 Ph methyl 6231 2-pyridinylamino¬ 1 Cbz H NHS0 - (2,4,6- methyl trimethylphenyl) 6232 2-pyridinylamino¬ 1 S0 2 Ph H NHS0 2 -(2,4,6- methyl trimethylphenyl) 6233 2-pyridinylamino¬ 1 C0(CH 2 ) 2 Ph H NHS0 2 -(2,4,6- methyl trimethylphenyl) 6234 2-pyridinylamino¬ Bn NHS0 -(2,4,6- methyl trimethylphenyl) 6235 2-pyridinylamino¬ n-Bu NHS0 2 -(2,4,6- methyl trimethylphenyl) 6236 2-pyridinylamino¬ 1 C0 2 -n-Bu H NHS0 2 -(2,4,6- methyl trimethylphenyl) 6237 2-pyridinylamino¬ 1 C0 2 -i-Bu H NHS0 2 -(2,4,6- methyl trimethylphenyl) 6238 2-pyridinylamino¬ 1 C02-t-Bu H NHS0 2 - (2,4,6- methyl trimethylphenyl) 6239 2-pyridinylamino¬ 1 -(CH 2 ) 4 NH 2 H NHS0 2 - (2,4,6- methyl trimethylphenyl) 6240 2-pyridinylamino¬ 1 COPh H NHS0 2 -(2,4,6- methyl trimethylphenyl) 6241 2-pyridinylamino¬ 1 S0 2 -n-Bu H NHS0 2 - (2,4,6- methyl trimethylphenyl) 6242 2-pyridinylamino¬ 1 Cbz H NHCbz methyl 6243 2-pyridinylamino¬ 1 S0 2 Ph H NHCbz methyl 6244 2-pyridinylamino¬ 1 C0(CH 2 ) 2 Ph H NHCbz methyl 6245 2-pyridinylamino¬ 1 Bn H NHCbz methyl 6246 2-pyridinylamino¬ 1 n-Bu H NHCbz methyl 6247 2-pyridinylamino¬ 1 C0 2 -n-Bu H NHCbz methyl 6248 2-pyridinylamino¬ 1 C0 -i-Bu H NHCbz methyl 6249 2-pyridinylamino¬ 1 C0 2 -t-Bu H NHCbz methyl 6250 2-pyridinylamino¬ 1 -(CH 2 ) 4 NH 2 H NHCbz methyl 6251 2 -pyridinylamino¬ 1- COPh H NHCbz methyl 6252 2 -pyridinylamino¬ 1 S0 2 -n-Bu H NHCbz methyl 6253 2 -imidazolylammo 1 Cbz H NHS0 2 Ph methyl 6254 2 -imidazolylammo 1 S0 2 Ph H NHS0 2 Ph methyl 6255 2-imidazolylamino 1 CO(CH 2 ) 2 Ph H NHS0 2 Ph methyl 6256 2-imidazolylamino 1 Bn H NHS0 2 Ph methyl 6257 2-imidazolylamino 1 n-Bu H NHS0 2 Ph methyl 6258 -imidazolylamino¬ 1 C0CH 2 (3- H NHS0 Ph methyl indolyl) 6259 2 -imidazolylamino¬ 1 S02- H NHS0 2 Ph methyl (biphenyl) 6260 2 -imidazolylamino¬ 1 C02-n-Bu H NHS0 2 Ph methyl 6261 2 -imidazolylamino¬ 1 C0 2 -i-Bu H NHS0 Ph methyl 6262 2-imidazolylamino- 1 C0 2 -t-Bu H NHS0 2 Ph methyl 6263 2 -imidazolylammo 1 -(CH 2 ) 4 NH 2 H NHS0 2 Ph methyl 6264 2-imidazolylamino 1 COPh H NHS0 2 Ph methyl 6265 2-imidazolylamino 1 cyclopropyl- H NHS02Ph methyl methyl 6266 2 -imidazolylamino 1 S02-n-Bu H NHS0 2 Ph methyl 6267 2 -imidazolylammo 1 Cbz H NHS0 2 - (2,4,6- methyl trimethylphenyl) 6268 2-imidazolylamino¬ 1 S0 2 Ph H NHS0 2 - (2,4,6- methyl tπmethylphenyl) 6269 2-imidazolylamino¬ 1 CO(CH 2 ) 2 Ph H NHS0 2 -(2,4,6- methyl trimethylphenyl) 6270 2-imidazolylamino¬ 1 Bn H NHS0 2 -(2,4,6- methyl tnmethylphenyl) 6271 2-ιmιdazolylamιno- 1 n-Bu H NHS0 2 -(2,4,6- methyl tπmethylphenyl) 6272 2-ιmιdazolylamιno- 1 C0 -n-Bu H NHS0 2 -(2,4,6- ethyl trimethylphenyl) 6273 2-imidazolylamino¬ 1 C0 2 -ι-Bu H NHS0 -(2,4,6- methyl tπmethylphenyl) 6274 2-ιmιdazolylamιno- 1 C0 2 -t-Bu H NHS0 2 -(2,4,6- methyl trimethylphenyl) 6275 2-ιπu.dazolylamιno- 1 -(CH 2 ) 4 NH 2 H NHS0 2 -(2,4,6- methyl tπmethylphenyl) 6276 2-imidazolylam o- 1 COPh H NHS0 2 -(2,4,6- methyl trimethylphenyl) 6277 2-imidazolylamino¬ 1 S0 2 -n-Bu H NHS0 2 -(2,4,6- methyl trimethylphenyl) 6278 2-imidazolylamino¬ 1 Cbz H NHCbz methyl 6279 2-imidazolylamino¬ 1 S0 2 Ph H NHCbz methyl 6280 2-ιmιdazolylamιno- 1 CO(CH 2 ) 2 Ph H NHCbz methyl 6281 2-imidazolylamino¬ 1 Bn H NHCbz methyl 6282 2-imidazolylamino¬ 1 n-Bu H NHCbz methyl 6283 2-imidazolylamino¬ 1 C0 2 -n-Bu H NHCbz methyl 6284 2-ιmιdazolylamιno- 1 C0 2 -ι-Bu H NHCbz methyl 6285 2-imidazolylammo 1 C0 2 -t-Bu H NHCbz methyl 6286 2-imidazolylamino 1 -(CH 2 ) 4 NH 2 H NHCbz methyl 6287 2-imidazolylammo - 1 COPh H NHCbz methyl 6288 2-imidazolylamino 1 Sθ 2 -n-Bu H NHCbz methyl 6289 2-imidazolinyl- 1 Cbz H NHS0 2 Ph aminomethyl 6290 2-imidazolinyl- 1 S0 2 Ph H NHS0 Ph aminomethyl 6291 2-imidazolinyl- 1 C0 ( CH 2 ) P H NHS0 2 Ph aminomethyl 6292 2-imidazolinyl- 1 Bn H NHS0 2 Ph aminomethyl 6293 2-imidazolinyl- 1 n-Bu H NHS0 2 Ph aminomethyl 6294 2-imidazolinyl- 1 C0CH 2 (3- H NHS0 2 Ph aminomethyl indolyl) 6295 2-imidazolinyl- 1 S02- H NHS0 2 Ph aminomethyl (biphenyl) 6296 2-imidazolinyl- 1 C0 2 ~n-Bu H NHS0 2 Ph aminomethyl 6297 2-imidazolinyl- 1 C0 2 -i-Bu H NHS0 2 Ph aminomethyl 6298 2-imidazolinyl- 1 C0 2 -t-Bu H NHS0 2 Ph aminomethyl 6299 2-imidazolinyl- 1 -(CH 2 ) 4 NH 2 H NHS0 Ph aminomethyl 6300 2-imidazolinyl- 1 COPh H NHS0 2 Ph aminomethyl 6301 2-imidazolinyl- 1 cyclopropyl- H NHS0 Ph aminomethyl methyl 6302 2-imidazolinyl- S0 2 -n-Bu NHS0 2 Ph aminomethyl 6303 2-imidazolinyl- Cbz NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 6304 2-imidazolinyl- S0 2 Ph NHS0 2 - (2,4,6- a inomethyl trimethylphenyl) 6305 2-imidazolinyl- 1 C0(CH 2 ) 2 Ph NHS0 2 - (2,4,6- a inomethyl trimethylphenyl) 6306 2-imidazolinyl- Bn NHS0 2 - (2,4,6- aminomethyl trimethylphenyl) 6307 2-imidazolinyl- n-Bu NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 6308 2-imidazolinyl- C0 2 -n-Bu NHS0 -(2,4,6- aminomethyl trimethylphenyl) 6309 2-imidazolinyl- C0 -i-Bu NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 6310 2-imidazolinyl- C0 -t-Bu NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 6311 2-imidazolinyl- -(CH 2 ) 4 NH 2 NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 6312 2-imidazolinyl- COPh NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 6313 2-imidazolinyl- S0 2 -n-Bu NHS0 - (2,4,6- aminomethyl trimethylphenyl) 6314 2-imidazolinyl- Cbz NHCbz aminomethyl 6315 2-imidazolinyl- S0 2 Ph NHCbz aminomethyl 6316 2-imidazolinyl- 1 CO(CH 2 ) 2 Ph NHCbz aminomethyl 6317 2-imidazolinyl- Bn NHCbz aminomethyl 6318 2-imidazolinyl- n-Bu NHCbz aminomethyl 6319 2-imidazolinyl- 1 C0 2 -n-Bu H NHCbz aminomethyl 6320 2-imidazolinyl- 1 C0 2 -i-Bu H NHCbz aminomethyl 6321 2-imidazolinyl- 1 C0 2 -t-Bu H NHCbz aminomethyl 6322 2-imidazolinyl- 1 -(CH 2 ) 4 NH 2 H NHCbz aminomethyl 6323 2-imidazolinyl- 1 COPh H NHCbz aminomethyl 6324 2-imidazolinyl- 1 S0 2 -n-Bu H NHCbz aminomethyl 6325 2-benzimidazolyl- 1 Cbz H NHS0 Ph aminomethyl 6326 2-benzimidazolyl- 1 S0 2 Ph H NHS0 2 Ph aminomethyl 6327 2-benzimidazolyl- 1 C0(CH 2 ) 2 Ph H NHS0 2 Ph aminomethyl 6328 2-benzimidazolyl- 1 Bn H NHS0 2 Ph aminome hyl 6329 2-benzimidazolyl- 1 n-Bu H NHS0 2 Ph aminomethyl 6330 2-benzimidazolyl- 1 C0CH 2 (3- H NHS0 2 Ph aminomethyl indolyl) 6331 2-benzimidazolyl- 1 S02- H NHS0 2 Ph aminomethyl (biphenyl) 6332 2-benzimidazolyl- 1 C0 2 -n-Bu H NHS0 2 Ph aminomethyl 6333 2-benzimidazolyl- 1 C0 -i-Bu H NHS0 2 Ph aminomethyl 6334 2-benzimidazolyl- 1 C0 2 -t-Bu H NHS0 Ph aminomethyl 6335 2-benzimidazolyl¬ 1 -(CH 2 ) 4 NH 2 H NHS0 2 Ph aminomethyl 6336 2-benzimidazolyl- 1 COPh H NHS0 2 Ph aminomethyl 6337 2-benzimidazolyl- 1 cyclopropyl- H NHS0 2 Ph aminomethyl methyl 6338 2-benzimidazolyl- 1 S0 2 -n-Bu H NHS0 2 Ph aminomethyl 6339 2-benzimidazolyl- Cbz H NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 6340 2-benzimidazolyl¬ 1 S0 2 Ph H NHSO2- (2,4,6- aminomethyl trimethylphenyl) 6341 2-benzimidazolyl- 1 C0(CH 2 ) 2 Ph H NHSO2-(2,4,6- aminomethyl trimethylphenyl) 6342 2-benzimidazolyl- Bn H NHS0 -(2,4,6- aminomethyl trimethylphenyl) 6343 2-benzimidazolyl¬ n-Bu NHS0 2 - (2,4,6- aminomethyl trimethylphenyl) 6344 2-benzimidazolyl- 1 C0 2 -n-Bu H NHS0 - (2,4,6- aminomethyl trimethylphenyl) 6345 2-benzimidazolyl- 1 C0 -i-Bu H NHS0 2 -(2,4,6- aminomethyl trimethylphenyl) 6346 2-benzimidazolyl¬ 1 C0 2 -t-Bu H NHS0 2 - (2,4,6- aminomethyl trimethylphenyl) 6347 2-benzimidazolyl¬ 1 -(CH 2 ) 4 NH 2 H NHS0 - (2,4,6- aminomethyl trimethylphenyl) 6348 2-benzimidazolyl- 1 COPh H NHS0 -(2,4,6- aminomethyl trimethylphenyl) 6349 2-benzimidazolyl¬ 1 S0 2 -n-Bu H NHS0 - (2,4,6- aminomethyl trimethylphenyl) 6350 2-benzimidazolyl- 1 Cbz H NHCbz aminomethyl 6351 2-benzimidazolyl- S0 2 Ph NHCbz a inomethyl 6352 2-benzimidazolyl¬ 1 C0(CH 2 ) 2 Ph H NHCbz aminomethyl 6353 2 -benzimidazolyl - Bn NHCbz aminomethyl 6354 2 -benzimidazolyl - n-Bu NHCbz aminomethyl 6355 2-benzimidazolyl- C0 2 -n-Bu NHCbz aminomethyl 6356 2-benzimidazolyl- C0 -i-Bu NHCbz aminomethyl 6357 2-benzimidazolyl- C0 -t-Bu NHCbz aminomethyl 6358 2-benzimidazolyl- (CH 2 ) 4 NH 2 NHCbz aminomethyl 6359 2-benzimidazolyl- 1 COPh H NHCbz aminomethyl 6360 2-benzimidazolyl- 1 S0 2 -n-Bu H NHCbz aminomethyl 6361 7-aza-2- 1 Cbz H NHS0 2 Ph benzimidazolyl 6362 7-aza-2- 1 S0 2 Ph H NHS0 Ph benzimidazolyl 6363 7-aza-2- 1 C0(CH 2 )2Ph H NHS0 2 Ph benzimidazolyl 6364 7-aza-2- 1 Bn H NHS0 2 Ph benzimidazolyl 6365 7-aza-2- 1 n-Bu H NHS0 2 Ph benzimidazolyl 6366 7-aza-2- 1 C0CH 2 (3- H NHS0 2 Ph benzimidazolyl indolyl) 6367 7-aza-2- 1 S02- H NHS0 2 Ph benzimidazolyl (biphenyl) 6368 7-aza-2- 1 C0 2 -n-Bu H NHS0 2 Ph benzimidazolyl 6369 7-aza-2- 1 C0 2 -i-Bu H NHS0 2 Ph benzimidazo1y1 6370 7-aza-2- 1 C0 -t-Bu H NHS0 2 Ph benzimidazolyl 6371 7-aza-2- 1 -(CH 2 ) 4 NH 2 H NHS0 2 Ph benzimidazolyl 6372 7-aza-2- 1 COPh H NHS0 2 Ph benzimidazolyl 6373 7-aza-2- 1 cyclopropyl- H NHS0 2 Ph benzimidazolyl methyl 6374 7-aza-2- 1 S0 2 -n-Bu H NHS0 2 Ph benzimidazolyl 6375 7-aza-2- 1 Cbz H NHS0 2 - (2,4,6- benzimidazolyl trimethylphenyl) 6376 7-aza-2- 1 S0 2 Ph H NHS0 2 -(2,4,6- benzimidazolyl trimethylphenyl) 6377 7-aza-2- 1 C0(CH 2 ) 2 Ph H NHS0 2 -(2,4,6- benzimidazolyl trimethylphenyl) 6378 7-aza-2- Bn H NHS0 -(2,4,6- benzimidazolyl trimethylphenyl) 6379 7-aza-2- 1 n-Bu NHS0 2 -(2,4,6- benzimidazolyl trimethylphenyl) 6380 7-aza-2- 1 C02~n-Bu H NHS0 2 -(2,4,6- benzimidazolyl trimethylphenyl) 6381 7-aza-2- 1 Cθ2-i-Bu H NHS0 2 -(2,4,6- benzimidazolyl trimethylphenyl) 6382 7-aza-2- 1 Cθ2~t-Bu H NHS0 -(2,4,6- benzimidazolyl trimethylphenyl) 6383 7-aza-2- 1 -(CH ) 4 NH 2 H NHS0 -(2,4,6- benzimidazolyl trimethylphenyl) 6384 7-aza-2- 1 COPh NHS0 2 - (2,4,6- benzimidazolyl trimethylphenyl) 6385 7-aza-2- 1 S0 2 -n-Bu H NHS0 2 - (2,4,6- benzimidazolyl trimethylphenyl) 6386 7-aza-2- 1 Cbz NHCbz benzimidazolyl 6387 7-aza-2- 1 S0 2 Ph H NHCbz benzimidazolyl 6388 7-aza-2- 1 C0(CH 2 ) 2 Ph H NHCbz benzimidazolyl 6389 7-aza-2- 1 Bn H NHCbz benzimidazolyl 6390 7-aza-2- 1 n-Bu H NHCbz benzimidazolyl 6391 7-aza-2- 1 C0 2 -n-Bu H NHCbz benzimidazolyl 6392 7-aza-2- 1 C0 2 -i-Bu H NHCbz benzimidazolyl 6393 7-aza-2- 1 C0 2 -t-Bu H NHCbz benzimidazolyl 6394 7-aza-2- 1 -(CH 2 ) NH 2 H NHCbz benzimidazolyl 6395 7-aza-2- 1 COPh H NHCbz benzimidazolyl 6396 7-aza-2- 1 S0 2 -n-Bu H NHCbz benzimidazolyl 6397 tetrahydropyrimidin Cbz H NHS0 2 Ph -2-ylaminomethyl 6398 tetrahydropyrimidin S0 Ph H NHS0 2 Ph -2-ylaminomethyl 6399 tetrahydropyrimidin C0(CH 2 ) 2 Ph H NHS0 2 Ph -2-ylaminomethyl 6400 tetrahydropyrimidin Bn H NHS0 2 Ph -2-ylaminomethyl 6401 tetrahydropyrimidin n-Bu H NHS0 Ph -2-ylaminomethyl 6402 tetrahydropyrimidin C0CH 2 (3- H NHS0 2 Ph -2-ylaminomethyl indolyl) 6403 tetrahydropyrimidin S02- H NHS0 2 Ph -2-ylaminomethyl (biphenyl) 6404 tetrahydropyrimidin 1 C0 -n-Bu NHS0 2 Ph -2-ylaminomethyl 6405 tetrahydropyrimidin 1 C0 2 -i-Bu NHS0 Ph -2-ylaminomethyl 6406 tetrahydropyrimidin 1 C0 2 -t-Bu NHS0 2 Ph -2-ylaminomethyl 6407 tetrahydropyrimidin 1 -(CH 2 ) 4 NH 2 NHS0 2 Ph -2-ylaminomethyl 6408 tetrahydropyrimidin 1 COPh NHS0 2 Ph -2-ylaminomethyl 6409 tetrahydropyrimidin 1 cyclopropyl- NHS0 2 Ph -2-ylaminomethyl methyl 6410 tetrahydropyrimidin 1 S0 2 -n-Bu NHS0 2 Ph -2-ylaminomethyl 6411 tetrahydropyrimidin 1 Cbz NHS0 2 -(2,4,6- -2-ylaminomethyl trimethylphenyl) 6412 tetrahydropyrimidin 1 S0 2 Ph NHS0 -(2,4,6- -2-ylaminomethyl tri ethylphenyl) 6413 tetrahydropyrimidin 1 C0(CH 2 ) Ph NHS0 2 -(2,4,6- -2-ylaminomethyl trimethylphenyl) 6414 tetrahydropyrimidin 1 Bn NHS0 -(2,4,6- -2-ylaminomethyl trimethylphenyl) 6415 tetrahydropyrimidin 1 n-Bu NHS0 2 -(2,4,6- -2-ylaminomethyl trimethylphenyl) 6416 tetrahydropyrimidin 1 C0 2 -n-Bu NHS0 2 -(2,4,6- -2-ylaminomethyl trimethylphenyl) 6417 tetrahydropyrimidin 1 C0 -i-Bu NHS0 2 -(2,4,6- -2-ylaminomethyl trimethylphenyl) 6418 tetrahydropyrimidin 1 C0 2 -t-Bu NHS0 2 -(2,4,6- -2-ylaminomethyl trimethylphenyl) 6419 tetrahydropyrimidin 1 -(CH 2 ) 4 NH 2 NHS0 2 -(2,4,6- -2-ylaminomethyl trimethylphenyl) 6420 tetrahydropyrimidin 1 COPh NHS0 2 -(2,4,6- -2-ylaminomethyl trimethylphenyl) 6421 tetrahydropyrimidin 1 S0 -n-Bu NHS0 2 -(2,4,6- -2-ylaminomethyl trimethylphenyl) 6422 tetrahydropyrimidin 1 Cbz NHCbz -2-ylaminomethyl 6423 tetrahydropyrimidin 1 S0 2 Ph NHCbz -2-ylaminomethyl 6424 tetrahydropyrimidin 1 CO(CH 2 ) 2 Ph NHCbz -2-ylaminomethyl 6425 tetrahydropyrimidin 1 Bn NHCbz -2-ylaminomethyl 6426 tetrahydropyrimidin 1 n-Bu NHCbz -2-ylaminomethyl 6427 tetrahydropyrimidin 1 C0 2 -n-Bu NHCbz -2-ylaminomethyl 6428 tetrahydropyrimidin 1 C0 2 -i-Bu NHCbz -2-ylaminomethyl 6429 tetrahydropyrimidin 1 C0 2 -t-Bu NHCbz -2-ylaminomethyl 6430 tetrahydropyrimidin 1 -(CH 2 ) NH 2 NHCbz -2-ylaminomethyl 6431 tetrahydropyrimidin 1 COPh NHCbz -2-ylaminomethyl 6432 tetrahydropyrimidin 1 S0 2 -n-Bu NHCbz -2-ylaminomethyl

Claims: CLAIMS WHAT IS CLAIMED IS: 1. A compound of Formula I: R l -Q-W-X-Y (I) and pharmaceutically acceptable salt forms thereof, wherein: Q is selected from A is selected from -N(R 10 )-, -C(R 11 )- or -0-; A 1 is selected from -0- or -N(R 10 )-; Z is a spiro-fused 4-7 membered ring system (including the sprio atom) containing 0-2 heteroatoms selected from 0, S, or N, said ring system optionally being substituted on carbon with keto, or being substituted on carbon or nitrogen independently with 0-2 R 9 or R 10 or R 10a ; R 1 is selected from: NR 7 NR 7 NR 7 R 7 R 6 N"V- R β — C . NR 6_ V _ f R 8 R 7 N _»_ V _ 5 R 8 R 7 N _{1. NR 6. V . B is independently selected from -CH 2 -, -0-, -N(R 2 )-, or -C(=0)-; B 1 is independently selected from -CH 2 - or -N(R 3 )-; D is -N(R 2 )-, -0-, -S-, -C(=0)- or -SO 2 -; E-F is -C(R )=C(R 5 )-, -N=C(R 4 )-, -C(R 4 )=N-, or -C ( R 4) 2 C ( R 5) 2 -; J, K, L and M are independently selected from -C(R 4 )-, -C(R 5 )- or -N-, provided that at least one of J, K, L and M is not -N-; R 2 is selected from: H, Ci-Cδ alkyl, (Ci-Cβ alkyl) carbonyl, (Ci-Cβ alkoxy) carbonyl; (Ci-Ce alkyl)a inocarbonyl, C3-C6 alkenyl, C 3 -C 7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, heteroaryl (Ci-Ce alkyl) carbonyl, heteroarylcarbonyl, aryl Ci-Cβ alkyl, (Ci-Cβ alkyl) carbonyl, arylcarbonyl, Ci-Cβ alkylsulfonyl, arylsulfonyl, aryl(Cι-C 6 alkyl)sulfonyl, heteroarylsulfonyl, heteroaryl (Cχ-C 6 alkyl) sulfonyl, aryloxycarbonyl, aryKCι-C 6 alkoxy) carbonyl, wherein said aryl groups are substituted with 0-2 substituents independently selected from the group consisting of C 1 -C 4 alkyl, C 1 -C 4 alkoxy, halo, CF 3 , and nitro; R 3 isselected from: H, Ci-Cβ alkyl, C 3 -C 7 cycloalkyl, C 4 - C 11 cycloalkylalkyl, aryl, aryl (Ci-Cβ alkyl)-, or heteroaryl (Ci-Cδ alkyl) - ; R 4 and R 5 are independently selected from: H, C 1 -C 4 alkoxy, R 2 R 3 , halogen, NO 2 , CN, CF3, Ci-Cβ alkyl, C 3 -C 6 alkenyl, C 3 -C7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, aryl(Cι-C 6 alkyl)-, (Cι~C 6 alkyl)carbonyl, (Ci-Cβ alkoxy)carbonyl, arylcarbonyl; alternatively, when substituents on adjacent atoms, R 4 and R 5 can be taken together with the carbon atoms to which they are attached to form a 5-7 membered carbocyclic or 5-7 membered heterocyclic aromatic or non-aromatic ring system, said carbocyclic or heterocyclic ring being optionally substituted with 0-2 groups independently selected from: C 1 -C 4 alkyl, C 1 -C 4 alkoxy, halo, cyano, amino, CF 3 , or N0 2 ; R 6 is selected from: H, C 1 -C 4 alkyl, or benzyl; R 7 and R 8 are independently selected from: H, Cχ-C 6 alkyl, C3-C7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, aryl (Cι-C 6 alkyl)-, or heteroaryl (C 0 -C 6 alkyl)-; U is selected from: -N(R 6 ) (CH 2 ) n -, -N(R 6 ) (CH 2 )mO-, -N(R 6 ) (CH 2 ) m N(R 7 )- -N(R 6 ) (CH 2 ) n Ξ(0) p - -N(R 6 )C(=0) (CH 2 ) n -; -N(R 6 ) (CH 2 )mC(=0)-? V is selected from: -(CH 2 ) n -, - ( CH 2 ) nS ( 0 ) p ( CH 2 ) n-, -(CH 2 ) m N(R 7 )C(=0) (CH 2 ) n -» - ( CH 2 ) n C ( =0 ) N ( R 7) (CH 2 ) n -, -(CH 2 ) n C(=0) (CH 2 ) n -; R 9 is selected from H, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, aryl, aryl(Cι-C 6 alkyl)-, (C 1 -C 4 alkoxy) carbonyl, (C 1 -C4 alkyl)carbonyl, C 1 -C 4 alkylsulfonyl, or C 1 -C 4 alkylaminosulfonyl; R 10 is selected from: H, C0 2 R 17 , C(=0)R 17 , C(=0)NR 17 R 20 , -SO2R 17 , -S0 2 NR 17 R 20 , C 1 -C6 alkyl substituted with 0- 1 R 15 , C3-C 6 alkenyl substituted with 0-1 R 15 , C3-C7 cycloalkyl substituted with 0-1 R 15 , C 4 -C 11 cycloalkylalkyl substituted with 0-1 R 15 , aryl substituted with 0-1 R 15 or 0-2 R 11 , or aryl (C1-C6 alkyl)- substituted with 0-1 R 15 or 0-2 R 11 ; R iOa is selected from: C0 2 R 17 , C(=0)R 17 , C (=0)NR 17 R 20 , -S0 2 R 17 , -S0 NR 17 R 2 °, Cι-C 6 alkyl substituted with 0- 1 R 15 , C 3 -C 6 alkenyl substituted with 0-1 R 15 , C 3 -C 7 cycloalkyl substituted with 0-1 R 15 , C 4 -C 11 cycloalkylalkyl substituted with 0-1 R 15 , aryl substituted with 0-1 R 15 or 0-2 R 11 , or aryl (Ci-Cβ alkyl)- substituted with 0-1 R 15 or 0-2 R 11 ; R ii is selected from H, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, aryl, aryl(Cι-C 6 alkyl)-, (C1-C 4 alkoxy) carbonyl, (C 1 -C 4 alkyl)carbonyl, C 1 -C 4 alkylsulfonyl, or C 1 -C 4 alkylaminosulfonyl; W is selected from: C 1 -C 4 alkylene, -(C(R 12) 2 ) qO(C ( R i2) 2 ) q -, -(C(R 12 ) 2 )qC(=0) (C(R 1 ) 2 )q-, -(C(R 12 ) 2 ) q C(=0)N(R l3 )-, -C ( =0 ) -N ( R l3) - ( C ( R 1 ) 2 ) q-; X is -(C(R 1 ) 2 ) q C(R 12 ) (R 1 )-C(Rl 2 ) (Rl5)- ; alternatively, W and X can be taken together to be R 12 is selected from H, Ci-Cβ alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C3-C7 cycloalkyl, C 4 -C 10 cycloalkylalkyl, (C 1 -C 4 alkyl)carbonyl, aryl, or aryl(Cι-C 6 alkyl)-; R 13 is selected from H, Ci-Cβ alkyl, C3-C 7 cycloalkylmethyl, or aryl (Ci-Cβ alkyl)- R 14 is selected from: H, Cι-C 6 alkylthio(Cι-C 6 alkyl)-, aryl(Cι-Cιo alkylthioalkyl)-, aryl (Ci-C . o alkoxyalkyl) -, C_-Cιo alkyl, Ci-Cio alkoxyalkyl, Cι-C 6 hydroxyalkyl, C2-C10 alkenyl, C 2 -Cι 0 alkynyl, C 3 -C 10 cycloalkyl, C3-C10 cycloalkylalkyl, aryl (Cι-C 6 alkyl) -, heteroaryl(Ci-Cβ alkyl) -, aryl, heteroaryl, CO 2 R 17 , C(=0)R 17 , or CONR 17 R 20 , provided that any of the above alkyl, cycloalkyl, aryl or heteroaryl groups may optionally be substituted independently with 0- 1 R 16 or 0-2 R 11 ; R 15 is selected from: H, R 16 , C1-C10 alkyl, C1-C 10 alkoxyalkyl, C 1 -C 1 0 alkylaminoalkyl, C 1 -C 10 dialkylaminoalkyl, (C1-C10 alkyl) carbonyl, aryl (Co-Cβ alkyl)carbonyl, C1-C10 alkenyl, C1-C10 alkynyl ,C 3 -Cιo cycloalkyl, C 3 -C 10 cycloalkylalkyl, aryl(Cι-C 6 alkyl)-, heteroaryl (Ci-Ce alkyl)-, aryl, heteroaryl, CO 2 R 17 , C(=0)R 17 , CONR 17 R 20 , SO2R 17 , or S0 2 NR 17 R 20 , .provided that any of the above alkyl, cycloalkyl, aryl or heteroaryl groups may optionally be substituted independently with 0-2 R 11 ,- Y is selected from: -COR 19 , -SO 3 H, -PO 3 H, tetrazolyl, -CONHNHS0 2 CF 3 , -CONHS0 2 R 17 -CONHSO 2 NHR 17 , -NHCOCF3, -NHCONHS0 2 R 17 , -NHSO2R 17 , -OPO3H2, -OSO3H, -PO3H 2 , -SO3H, -S0 2 NHCOR 17 , -S0 2 NHC0 2 R 17 , R 16 is selected from: -N(R 20 )-C(=O)-O-R 17 , -N(R 20 )-C(=O)-R 17 , -N(R 20 )-C(=O)-NH-R 17 , -N(R 20 )SO 2 -R 17 , or -N(R 20 )SO 2 -NR 20 R 17 ; R 17 is selected from: Ci-Cio alkyl, C3-C11 cycloalkyl, aryl (Ci-Cβ alkyl)-, (Ci-Ce alkyl)aryl, heteroaryl (Cι-C 6 alkyl) -, (Ci-Cβ alkyl) heteroaryl, arylaryl (Ci-Cβ alkyl)-, heteroarylaryl (Ci-Cβ alkyl) -, arylheteroaryl (Ci-Cβ alkyl)-, heteroarylheteroaryl (Ci-Ce alkyl)-, heteroaryl, or aryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents independently selected from the group consisting of: C1-C 4 alkyl, C 1 -C 4 alkoxy, aryl, halo, cyano, amino, CF 3 , and NO 2 ; R 18 is selected from: H, -C(=0)-0-R 17 , -C(=0)-R l7 , -C(=0)-NH-R 17 , -S0 2 -R 17 , or -SO 2 -NR 20 R 17 ; R 19 is selected from: hydroxy, C1-C10 alkyloxy, C 3 -C 11 cycloalkyloxy, aryloxy, aryKCi-Cβ alkoxy)-, C3-C10 alkylcarbonyloxyalkyloxy, C3-C10 alkoxycarbonyloxyalkyloxy, C -Cιo alkoxycarbonylalkyloxy, C5-C10 cycloalkylcarbonyloxyalkyloxy, C 5 -C10 cycloalkoxycarbonyloxyalkyloxy, C5-C10 cycloalkoxycarbonylalkyloxy, C7-C 11 aryloxycarbonylalkyloxy, C8-C12 aryloxycarbonyloxyalkyloxy, CΘ-CI 2 arylcarbonyloxyalkyloxy, C5-C10 alkoxyalkylcarbonyloxyalkyloxy, C5-C10 (5-alkyl-l, 3-dioxa-cyclopenten-2-one- yUmethyloxy, 10-C14 (5-aryl-l,3-dioxa-cyclopenten-2-one- yDmethyloxy, or (R 11 ) (R 12 )N-(Cι-Cιo alkoxy)-; R20 i s selected from: H, Cι-C 6 alkyl, C3-C 7 cycloalkyl, C4-C 11 cycloalkylalkyl, aryl, aryl (Ci-Cβ alkyl) -, or heteroaryl (Ci-Ce alkyl)-,. and provided that: n, q, and r are chosen such that the number of in-chain atoms between R 1 and Y is in the range of 8-18. 2. A compound of Claim 1 of the Formula I: R i -Q-W-X-Y (I) and pharmaceutically acceptable salt forms thereof wherein: Q is selected from: R 1 is selected from: NR 7 NR 7 NR 7 R β — C-NR 6 -V— , R 8 R 7 N— C— V- , R 8 R 7 N— C-NR 6 "V- ; D is -N(R 2 )-, -0-, -S-, -C(=0)- or -S0 2 -; E-F is -C(R 4 )=C(R 5 )-, -N=C(R 4 )-, -C(R 4 )=N-, or -C(R 4 ) 2 C(R 5 ) -; J, K, L and M are independently selected from -C(R 4 )-, -C(R 5 )- or -N-, provided that at least one of J, K, L and M is not -N-; R 2 is selected from: H, Ci-Cβ alkyl, (Ci-Cβ alkyl)carbonyl, (Ci-Cβ alkoxy)carbonyl; (Ci-Cβ alkyl)a inocarbonyl, C 3 -C 6 alkenyl, C 3 -C 7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, heteroaryl (Ci-Cβ alkyl)carbonyl, heteroarylcarbonyl, aryKCi-Cβ alkyl)-, (Ci-Cβ alkyl)carbonyl, arylcarbonyl, Ci-Cβ alkylsulfonyl, arylsulfonyl, aryKCi-Cβ alkyl)sulfonyl, heteroarylsulfonyl, heteroaryl (Ci-Cβ alkyl) sulfonyl, aryloxycarbonyl, or aryl (Ci-Cβ alkoxy)carbonyl, wherein said aryl groups are substituted with 0-2 substituents independently selected from the group consisting of C 1 -C 4 alkyl, C 1 -C 4 alkoxy, halo, CF3, and nitro; R 3 is selected from: H, Ci-Cβ alkyl, C 3 -C 7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, aryl (Cχ-C 6 alkyl)-, or heteroaryl (Ci-Ce alkyl)-,. R 4 and R 5 are independently selected from: H, C 1 -C 4 alkoxy, NR 2 R 3 , halogen, N0 2/ CN, CF 3 , Cι-C 6 alkyl, C 3 -C 6 alkenyl, C 3 -C7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, aryKCi-Cβ alkyl)-, (Ci-Ce alkyl)carbonyl, (Cχ-C 6 alkoxy)carbonyl, arylcarbonyl, or alternatively, when substituents on adjacent atoms, R 4 and R 5 can be taken together with the carbon atoms to which they are attached to form a 5-7 membered carbocyclic or 5-7 membered heterocyclic aromatic or non-aromatic ring system, said carbocyclic or heterocyclic ring being optionally substituted with 0-2 groups independently selected from: C 1 -C 4 alkyl, C 1 -C 4 alkoxy, halo, cyano, amino, CF 3 , or N0 2 ; R 6 is selected from: H, C 1 -C 4 alkyl, or benzyl; R 7 and R 8 are independently selected from: H, Ci-Cβ alkyl, C 3 -C 7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, aryl (Ci-Cβ alkyl)-, or heteroaryl (Co-Cδ alkyl) - ; U is selected from: -N(R6) (CH 2 ) n -, -N(R6) (CH 2 ) m O-, -N(R6) (CH 2 ) m N(R 7 )- -N(R6) (CH 2 ) n S(0)p- -N(R 6 )C(=0) (CH 2 ) n -; V is selected from: -(CH 2 )mp-(CH 2 )n-» -(CH 2 )mN(R 7 ) (CH 2 ) n -, -(CH 2 )nS(0)p(CH2)n-, -(CH 2 ) n C(=0)N(R 7 ) (CH 2 ) n -, -(CH 2 ) n C(=0) (CH 2 ) n -; R 9 is selected from H, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, aryl, aryKCi-Cβ alkyl)-, (C 1 -C 4 alkoxy) carbonyl, (C 1 -C 4 alkyl) carbonyl, C 1 -C 4 alkylsulfonyl, or C 1 -C 4 alkylaminosulfonyl; R 10 is selected from: H, C0 2 R 17 , C(=0)R 17 , C(=0)NR 17 R 20 , -S0 2 R 17 , -Sθ2NR 17 R 20 , Cι-C 6 alkyl substituted with 0- 1 R 15 , C 3 -C 6 alkenyl substituted with 0-1 R 15 , C 3 -C 7 cycloalkyl substituted with 0-1 R 15 , C 4 -C 11 cycloalkylalkyl substituted with 0-1 R 15 , aryl substituted with 0-1 R 15 or 0-2 R 11 , or aryl(Cι-C 6 alkyl)- substituted with 0-1 R 15 or 0-2 R 11 ; Rioa i s selected from: C0 2 R 17 , C(=0)R 17 , C(=0)NR 17 R 20 , -S0 2 R 17 , -S0 2 NR 17 R 2 °, Ci-Ce alkyl substituted with 0- 1 R 15 , C 3 -C 6 alkenyl substituted with 0-1 R 15 , C 3 -C 7 cycloalkyl substituted with 0-1 R 15 , C 4 -C 11 cycloalkylalkyl substituted with 0-1 R 15 , aryl substituted with 0-1 R 15 or 0-2 R 11 , or aryl(Cι-C 6 alkyl)- substituted with 0-1 R 15 or 0-2 R 11 ; R 11 is selected from H, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, aryl, aryl(Cι-C6 alkyl)-, (C1-C4 alkoxy) carbonyl, (C 1 -C 4 alkyl)carbonyl, C 1 -C 4 alkylsulfonyl, or Cχ-C 4 alkyla inosulfonyl; W is selected from: C 1 -C 4 alkylene, - ( C ( R i2) 2 ) q O ( C ( R 12) 2 ) q-, -(C(R 12 ) 2 ) q C(=0)N(R l3 )-, -C ( =0 ) -N ( R l ) - ( C ( R 12) 2 ) q-; X is -(C(Rl 2 ) 2 ) q C(R 12 ) (R 14 )-C(Rl 2 ) (Rl5)- ; alternatively, W and X can be taken together to be R 12 is selected from H, Ci-Cβ alkyl, C 2 -C 6 alkenyl, C2-C 6 alkynyl, C 3 -C 7 cycloalkyl, C 4 -C 10 cycloalkylalkyl, (C 1 -C 4 alkyl)carbonyl, aryl, or aryl(Cχ-C6 alkyl)-; R 13 is selected from H, Ci-Cβ alkyl, C 3 -C 7 cycloalkylmethyl, or aryl(Cχ-C 6 alkyl)-; R 14 is selected from: H, Ci-Cβ alkylthio(Cι-C 6 alkyl)-, aryl(Cι-Cι 0 alkylthioalkyl)-, aryl (C 1 -C 10 alkoxyalkyl) -, C 1 -C 10 alkyl, Cχ-Cιo alkoxyalkyl, Ci-Cβ hydroxyalkyl, C2-C10 alkenyl, C2-C1 0 alkynyl, C 3 -C1 0 cycloalkyl, C3-C 1 0 cycloalkylalkyl, aryl (Ci-Cβ alkyl) -, heteroaryl (Ci-C δ alkyl) -, aryl, heteroaryl, CO2R 17 , C(=0)R 17 , or CONR 17 R 20 , provided that any of the above alkyl, cycloalkyl, aryl or heteroaryl groups may optionally be substituted independently with 0- 1 R 16 or 0-2 R 11 ; R 15 is selected from: H, R 16 , Ci-Cio alkyl, Ci-Cio alkoxyalkyl, Cχ-Cιo alkylaminoalkyl, Ci-Cio dialkylaminoalkyl, (Ci-Cio alkyl) carbonyl, aryl (Co~ 6 alkyl)carbonyl, Ci-Cio alkenyl, Ci-Cio alkynyl ,C 3 -Cχo cycloalkyl, C3-C10 cycloalkylalkyl, aryKCi-Cβ alkyl)-, heteroaryl (Ci-Cβ alkyl) -, aryl, heteroaryl, C0 2 R 17 , C(=0)R 17 , CONR 17 R 20 , S0 2 R 17 , or S0 2 NR 17 R 20 , provided that any of the above alkyl, cycloalkyl, aryl or heteroaryl groups may optionally be substituted independently with 0-2 R 11 ; Y is selected from: -COR 19 , -SO3H, -PO 3 H, tetrazolyl, -CONHNHS0 2 CF 3 , -CONHSO 2 R 17 , -CONHS0 2 NHR 17 , -NHCOCF3, -NHCONHS0 2 R 17 , -NHSO2R 17 , -OP0 3 H 2 , -OSO 3 H, -PO3H2, -SO3H, -SO 2 NHCOR 17 , -SO 2 NHCO2R 17 , R 16 is selected from: -N(R 20 )-C(=O)-O-R 17 , -N(R 20 )-C(=O)-R 17 , -N(R 20 )-C(=O)-NH-R 17 , -N(R 20 )SO 2 -R 17 , or -N(R 20 )SO 2 -NR 20 R 17 ; R 17 is selected from: Ci-Cio alkyl, C3-C11 cycloalkyl, aryl(Cι-C 6 alkyl)-, (Ci-Cβ alkyl)aryl, heteroaryl (Ci-Cβ alkyl) -, (Cι-C 6 alkyl)heteroaryl, arylaryl (Ci-Cβ alkyl)-, heteroarylaryl (Ci-Cδ alkyl)-, arylheteroaryl (Ci-Cβ alkyl)-, heteroarylheteroaryl (Ci-Cβ alkyl) -, heteroaryl, or aryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents independently selected from the group consisting of: C 1 -C 4 alkyl, C 1 -C 4 alkoxy, aryl, halo, cyano, amino, CF 3 , and N0 2 ; R 18 is selected from: H, -C(=0)-0-R 17 , -C(=0)-R 17 , -C(=0)-NH-R 17 , -SO2-R 17 , or -SO 2 -NR 20 R 17 ; R 19 is selected from: hydroxy, C 1 -C10 alkyloxy, C 3 -C 11 cycloalkyloxy, aryloxy, aryl (Ci-C δ alkoxy)-, C 3 -C10 alkylcarbonyloxyalkyloxy, C 3 -C10 alkoxycarbonyloxyalkyloxy, C 2 -C 10 alkoxycarbonylalkyloxy, C 5 -C10 cycloalkylcarbonyloxyalkyloxy, C 5 -C10 cycloalkoxycarbonyloxyalkyloxy, C5-C10 cycloalkoxycarbonylalkyloxy, C 7 -C11 aryloxycarbonylalkyloxy, C 8 -C 12 aryloxycarbonyloxyalkyloxy, C 8 -C12 arylcarbonyloxyalkyloxy, C5-C 1 0 alkoxyalkylcarbonyloxyalkyloxy, C5-C10 ( 5-alkyl-l , 3 -dioxa-cyclopenten-2 -one- yl ) methy loxy , C10-C14 ( 5-aryl-l , 3-dioxa-cyclopenten-2 -one- yD methyloxy, or (R 11 ) (R 12 )N-(Cι-Cι 0 alkoxy)-; R2 0 selected from: H, Cι-C 6 alkyl, C 3 -C 7 cycloalkyl, C 4 - C11 cycloalkylalkyl, aryl, aryl(Cι-C 6 alkyl)-, or heteroaryl(Ci-Cδ alkyl) - ; and provided that: n, q, and r are chosen such that the number of in- chain atoms between R! and Y is in the range of 8- 18. 3. A compound of Claim 1 of the Formula I and pharmaceutically acceptable salt forms thereof wherein: Q is selected from: R 1 is selected from: wherein the above heterocycles are optionally substituted with 0-2 substituents selected from the group consisting of: NH 2 , halogen, NO 2 , CN, CF 3 , C 1 -C 4 alkoxy, C 1 -C 6 alkyl, and C 3 -C7 cycloalkyl; R 2 is selected from: H, C1-C4 alkyl or benzyl; U is -NH ( CH 2 ) n -; V is - ( CH 2 ) n -; R 10 is selected from: H, C0 2 R 17 , C(=0)R 17 , CONR 17 R 20 , -S0 2 R 17 , -S0 NR 17 R 2 °, Cι-C 6 alkyl substituted with 0- 1 R 15 , C 3 -C6 alkenyl substituted with 0-1 R 15 , C 3 -C 7 cycloalkyl substituted with 0-1 R 15 , C 4 -C 11 cycloalkylalkyl substituted with 0-1 R 15 , aryl substituted with 0-1 R 15 or 0-2 R 11 , or aryl (Cι-C 6 alkyl)- substituted with 0-1 R 15 or 0-2 R 11 ; R i oa is selected from: C0 R 17 , C(=0)R 17 , CONR 17 R 20 , -SO 2 R 17 , -Sθ 2 NR 17 R 20 , Ci-Cβ alkyl substituted with 0- 1 R 15 , C3-C6 alkenyl substituted with 0-1 R 15 , C3-C7 cycloalkyl substituted with 0-1 R 15 , C 4 -C 11 cycloalkylalkyl substituted with 0-1 R 15 , aryl substituted with 0-1 R 15 or 0-2 R 11 , or aryl (Ci-Cβ alkyl)- substituted with 0-1 R 15 or 0-2 R 11 ; R 11 is selected from H, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, aryl, aryKCi-Cβ alkyl)-, (C 1 -C 4 alkoxy)carbonyl, (C 1 -C 4 alkyl)carbonyl, C 1 -C 4 alkylsulfonyl, or C 1 -C 4 alkylaminosulfonyl; W is -C(=0)-N(R 13 )-; X is -CH(R 14 )-CH(R 15 )-; R 13 is H or CH3 ; R 14 is selected from: H, C1-C10 alkyl, aryl, or heteroaryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents independently selected from the group consisting of: C 1 -C 4 alkyl, C1-C4 alkoxy, aryl, halo, cyano, amino, CF 3 , and N0 2 ; R 15 is H or R 16 ; Y is -C(=0)R 19 ; R 16 is selected from: -N(R 0 )-C(=O)-O-R 17 , -N(R 20 )-C(=O)-R 17 , -N(R 20 )-C(=O)-NH-R 17 , -N(R 20 )SO 2 -R 17 , or -N(R 20 )SO 2 -N(R 20 )R 17 ; R 17 is selected from: C 1 -C 10 alkyl, C 3 -C 11 cycloalkyl, aryl (Ci-Cβ alkyl)-, (C 1 -C 5 alkyl)aryl, heteroaryl (Ci-Cβ alkyl)-, (Ci-Cβ alkyl)heteroaryl, arylaryl (Ci-Cβ alkyl)-, heteroarylaryl (Ci-Cβ alkyl) -, arylheteroaryl (Ci-Cβ alkyl)-, heteroarylheteroaryl (Ci-Ce alkyl)-, heteroaryl, or aryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents independently selected from the group consisting of: C1-C 4 alkyl, C1-C 4 alkoxy, aryl, halo, cyano, amino, CF 3 , and N0 2 ; R 19 is selected from: hydroxy, Ci-Cio alkoxy, methylcarbonyloxymethoxy-, ethylcarbonyloxymethoxy-, t-butylcarbonyloxymethoxy-, cyclohexylcarbonyloxymethoxy-, 1- (methylcarbonyloxy)ethoxy-, 1- (ethylcarbonyloxy)ethoxy-, 1- (t-butylcarbonyloxy) ethoxy-, 1- (cyclohexylcarbonyloxy) ethoxy-, i-propyloxycarbonyloxymethoxy-, t-butyloxycarbonyloxymethoxy-, 1- (i-propyloxycarbonyloxy)ethoxy-, 1- (cyclohexyloxycarbonyloxy) ethoxy-, 1- (c-butyloxycarbonyloxy)ethoxy-, dimethylaminoethoxy-, diethylaminoethoxy-, (5-methyl-1,3-dioxacyclopenten-2-on-4-yl)methoxy-, (5- ( -butyl) -l,3-dioxacyclopenten-2-on-4- yl)methoxy-, (1,3-dioxa-5-phenyl-cyclopenten-2-on-4-yl)methoxy-, or 1- (2- (2-methoxypropyl)carbonyloxy)ethoxy-; R 20 is H or CH 3 ; and n is 0-1. 4. A compound of Claim 1 of the Formula I and pharmaceutically acceptable salt forms thereof wherein: Q is selected from: is selected from: R 2 is selected from: H, C 1 -C 4 alkyl, or benzyl; U is -NH(CH 2 ) n -; V is - ( CH 2 ) n -; R 10 is selected from: H, C0 2 R 17 , C(=0)R 17 , C(=0)NR 17 R 20 , -S0 2 R 17 , -S0 2 NR 17 R 20 , Cι-C 6 alkyl substituted with 0- 1 R 15 , C 3 -C 6 alkenyl substituted with 0-1 R 15 , C 3 -C 7 cycloalkyl substituted with 0-1 R 15 , C 4 -C 11 cycloalkylalkyl substituted with 0-1 R 15 , aryl substituted with 0-1 R 15 or 0-2 R 11 , or aryl(Cι-C 6 alkyl)- substituted with 0-1 R 15 or 0-2 R 11 ; R i oa is selected from: C0 R 17 , C(=0)R 17 , CONR 17 R 20 , -S0 2 R 17 , -S0 2 NR 17 R 2 °, Cι~C 6 alkyl substituted with 0- 1 R 15 , C 3 -C 6 alkenyl substituted with 0-1 R 15 , C 3 -C 7 cycloalkyl substituted with 0-1 R 15 , C 4 -C 11 cycloalkylalkyl substituted with 0-1 R 15 , aryl substituted with 0-1 R 15 or 0-2 R 11 , or aryl (Ci-Cβ alkyl)- substituted with 0-1 R 15 or 0-2 R 11 ; R 11 is selected from H, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, aryl, aryl(Cι-C6 alkyl)-, (C1-C4 alkoxy) carbonyl, (C 1 -C 4 alkyl)carbonyl, C 1 -C 4 alkylsulfonyl, or C 1 -C 4 alkylaminosulfonyl; is -C(=0)-N(R 13 )-; X is -CH(R 1 )-CH(R 15 )-; R 13 is H or CH 3; R 14 is selected from: H, C 1 -C 10 alkyl, aryl, or heteroaryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents independently selected from the group consisting of: C 1 -C 4 alkyl, C 1 -C 4 alkoxy, aryl, halo, cyano, amino, CF 3 , and N0 2 ; R 15 is H or R 16 ; Y is -C(=0)R 19 ; R 16 is selected from: -N(R 0 )-C(=O)-O-R 17 , -N (R 20 ) -C ( =O) -R 17 , -N (R 20 ) SO 2 -R 17 , R 17 is selected from: Ci-Cio alkyl , C3-C11 cycloalkyl , aryl (Cι -C 6 alkyl ) - , (Ci-Cβ alkyl)aryl, heteroaryl (Ci-Cβ alkyl)-, (Cι-C 6 alkyl)heteroaryl, arylaryl (Ci-Cβ alkyl)-, heteroarylaryl (Ci-Cβ alkyl) -, arylheteroaryl (Ci-Cβ alkyl)-, heteroarylheteroaryl(Cι-C6 alkyl)-, heteroaryl, or aryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents independently selected from the group consisting of: C 1 -C 4 alkyl, C 1 -C 4 alkoxy, aryl, halo, cyano, amino, CF 3 , and NO 2 ; R 19 is selected from: hydroxy, C1-C10 alkoxy, methylcarbonyloxymethoxy-, ethylcarbonyloxymethoxy-, t-butylcarbonyloxymethoxy-, eyelohexylcarbonyloxymethoxy-, 1- (methylcarbonyloxy)ethoxy-, 1- (ethylcarbonyloxy)ethoxy-, 1- (t-butylcarbonyloxy)ethoxy-, 1- (cyclohexylcarbonyloxy)ethoxy-, i-propyloxycarbonyloxymethoxy-, c-butyloxycarbonyloxymethoxy-, 1- (i-propyloxycarbonyloxy)ethoxy-, 1- (cyclohexyloxycarbonyloxy) ethoxy-, 1- (t-butyloxycarbonyloxy)ethoxy-, dimethylaminoethoxy-, diethylaminoethoxy-, (5-methyl-1,3-dioxacyclopenten-2-on-4-yl)methoxy-, (5- (t-butyl) -1, 3-dioxacyclopenten-2-on-4- yl)methoxy-, (l , 3-dioxa-5-phenyl-cyclopenten-2-on-4-yl) methoxy- , or 1- (2- (2-methoxypropyl)carbonyloxy)ethoxy-; R 20 is H or CH 3 ; and n is 0-1. 5. A compound of Claim 1 and enantiomeric or diasteriomeric forms thereof, or mixtures of enantiomeric or diastereomeric forms thereof, and pharmaceutically acceptable salt forms thereof, selected from the group consisting of: (S)-2-phenylsulfonylamino-3- [ [ [8- (2- pyridinylaminomethyl)-]-l-oxa-2-azaspiro- [4,5]-dec-2-en-3-yl]carbonylamino]propionic acid, (S)-2-benzyloxycarbonylamino-3- [ [ [8-(2- pyridinylaminomethyl)-]-l-oxa-2-azaspiro- [4,5]-dec-2-en-3-yl]carbonylamino]propionic acid, (S)-2-[ (2,4,6-trimethylphenyl)sulfonyl]amino-3- [ [ [8-(2-pyridinylaminomethyl)-]-l-oxa-2- azaspiro- [4,5]-dec-2-en-3- yl]carbonylamino]propionic acid, (S)-2-[ (3,5-dimethylisoxazol4-yl)sulfonyl]amino-3- [ [ [8-(2-pyridinylaminomethyl)-]-l-oxa-2- azaspiro- [4,5]-dec-2-en-3- yl]carbonylamino]propionic acid, (S)-2-phenylsulfonylamino-3- [ [ [8- [ (6-aminopyridin- 2-yl)methyl]-]-l-oxa-2,8-diazaspiro-[4,5]-dec- 2-en-3-yl]carbonylamino]propionic acid, (S)-2-phenylsulfonylamino-3- [ [ [8- [ (6-aminopyridin- 2-yl)methyl] ]-l-oxa-2,8-diazaspiro- [4,4]-non- 2-en-3-yl]carbonylamino]propionic acid, (S)-2-phenylsulfonylamino-3-[ [ [8-(2- pyridinylaminomethyl) -]-l-oxa-2-azaspiro- [4,4]-non-2-en-3-yl]carbonylamino]propionic acid, (S)-2-phenylsulfonylamino-3- [ [ [8-[2- (4,5- dihydroimidazol-2-yl)aminomethyl]-]-l-oxa-2- azaspiro-[4,5]-dec-2-en-3-yl]carbonylamino]- propionic acid, (S)-2-[ (2-methylphenyl)sulfonyl]amino-3- [ [ [8- (2- pyridinylaminomethyl)-]-l-oxa-2-azaspiro- [4,5]-dec-2-en-3-yl]carbonylamino]propionic acid, (S)-2-[ (2-chloro-4-methylphenyl)sulfonyl]amino-3- [ [ [8- (2-pyridinylaminomethyl)-]-l-oxa-2- azaspiro- [4,5]-dec-2-en-3- yl]carbonylamino]propionic acid, (S)-2-[ (4-biphenyl)sulfonyl]amino-3-[[ [8- (2- pyridinylaminomethyl) -]-l-oxa-2-azaspiro- [4,5]-dec-2-en-3-yl]carbonylamino]propionic acid, (S)-2-[(2-bromophenyl)sulfonyl]amino-3-[ [ [8-(2- pyridinylaminomethyl)-]-l-oxa-2-azaspiro- [4,5]-dec-2-en-3-yl]carbonylamino]propionic acid, (S)-2-[ (2-naphthyl)sulfonyl]amino-3-[ [ [8-(2- pyridinylaminomethyl)-]-l-oxa-2-azaspiro- [4,5]-dec-2-en-3-yl]carbonylamino]propionic acid, (S)-2-[ (l-naphthyl)sulfonyl]amino-3-[ [ [8-(2- pyridinylaminomethyl)-]-l-oxa-2-azaspiro- [4,5]-dec-2-en-3-yl]carbonylamino]propionic acid. (S ) -2-phenylsul fonylamino-3 - [ [ [ 8- (2 - imidazolylaminomethyl)-]-l-oxa-2-azaspiro- [4,5] -dec-2-en-3-yl]carbonylamino]propionic acid, (S)-2-benzyloxycarbonylamino-3- [ [ [8- (2- imidazolylaminomethyl)-]-l-oxa-2-azaspiro- [4,5]-dec-2-en-3-yl]carbonylamino]propionic acid, (S)-2-[ (2,4,6-trimethylphenyl)sulfonyl]amino-3- [ [ [8- (2-imidazolylaminomethyl)-]-l-oxa-2- azaspiro- [4,5]-dec-2-en-3- yl]carbonylamino]propionic acid, (S)-2-[ (2,6-dimethylphenyl)sulfonyl]amino-3-[ [ [8- (2-imidazolylaminomethyl)-]-l-oxa-2-azaspiro- [4,5]-dec-2-en-3-yl]carbonylamino]propionic acid, (S)-2- [ (2,6-dichlorophenyl)sulfonyl]amino-3- [ [ [8- (2-imidazolylaminomethyl)-]-l-oxa-2-azaspiro- [4,5]-dec-2-en-3-yl]carbonylamino]propionic acid, (S)-2- [ (2,6-dimethyl-4-phenyl)phenylsulfonyl]amino- 3- [ [ [8-(2-imidazolylaminomethyl)-]-l-oxa-2- azaspiro- [4,5]-dec-2-en-3- yl]carbonylamino]propionic acid, (S)-2-[ (2-naphthyl)sulfonyl]amino-3- [ [ [8- (2- imidazolylaminomethyl)-]-l-oxa-2-azaspiro- [4,5]-dec-2-en-3-yl]carbonylamino]propionic acid, (S)-2-[biphenylsulfonyl]amino-3-[ [ [8-(2- imidazolylaminomethyl)-]-l-oxa-2-azaspiro- [4,5]-dec-2-en-3-yl]carbonylamino]propionic acid, (S)-2-phenylsulfonylamino-3- [ [7-benzyloxycarbonyl- 8- (2-imidazolylaminomethyl)-l-oxa-2,7- diazaspiro- [4,4]-non-2-en-3- yl]carbonylamino]propionic acid, (S) -2-benzyloxycarbonylamino-3- [ [7- benzyloxycarbonyl-8- (2-imidazolylaminomethyl) - l-oxa-2, 7-diazaspiro- [4,4] -non-2-en-3- yl]carbonylamino]propionic acid, (S)-2-[ (2,4, 6-trimethylphenyl)sulfonyl]amino-3- [ [7- benzyloxycarbonyl-8- (2-imidazolylaminomethyl) - l-oxa-2,7-diazaspiro- [4,4] -non-2-en-3- yl]carbonylamino]propionic acid, (S) -2- [ (2, 6-dimethylphenyl) sulfonyl]amino-3- [ [7- benzyloxycarbonyl-8- (2-imidazolylaminomethyl) - l-oxa-2, 7-diazaspiro- [4,4] -non-2-en-3- yl]carbonylamino]propionic acid, (S) -2- [ (2, 6-dichlorophenyl) sulfonyl]amino-3- [ [7- benzyloxycarbonyl-8- (2-imidazolylaminomethyl) - l-oxa-2, 7-diazaspiro- [4,4] -non-2-en-3- yl]carbonylamino]propionic acid, (S)-2- [ (2,6-dimethyl-4-phenyl)phenylsulfonyl]amino- 3- [ [7-benzyloxycarbonyl-8- (2- imidazolylaminomethyl) -l-oxa-2,7-diazaspiro- [4,4]-non-2-en-3-yl]carbonylamino]propionic acid, (S) -2- [ (2-naphthyl) sulfonyl]amino-3- [ [7- benzyloxycarbonyl-8- (2-imidazolylaminomethyl) • l-oxa-2, 7-diazaspiro- [4,4] -non-2-en-3- yl]carbonylamino]propionic acid, (S) -2- [biphenylsulfonyl]amino-3- [ [7- benzyloxycarbonyl-8- (2-imidazolylaminomethyl) • l-oxa-2, 7-diazaspiro- [4, 4] -non-2-en-3- yl]carbonylamino]propionic acid, (S) -2-phenylsulfonylamino-3- [ [8- (2- imidazolylaminomethyl) -l-oxa-2,7-diazaspiro- [4,4] -non-2-en-3-yl]carbonylamino]propionic acid, (S) -2-benzyloxycarbonylamino-3- [ [8- (2- imidazolylaminomethyl) -l-oxa-2,7-diazaspiro- [4,4] -non-2-en-3-yl] carbonylamino]propionic acid, (S ) -2-[ (2,4, 6-trimethylphenyl)sulfonyl]amino-3- [ [8- (2-imidazolylaminomethyl) -1-oxa-2,7- diazaspiro- [4,4] -non-2-en-3- yl]carbonylamino]propionic acid, (S)-2-[ (2,6-dimethylphenyl)sulfonyl]amino-3-[ [8- (2- imidazolylamino ethyl) -l-oxa-2,7-diazaspiro- [4,4] -non-2-en-3-yl]carbonylamino]propionic acid, (S)-2- [ (2,6-dichlorophenyl)sulfonyl]amino-3- [ [8- (2- imidazolylaminomethyl) -l-oxa-2,7-diazaspiro- [4,4] -non-2-en-3-yl]carbonylamino]propionic acid, (S)-2-[ (2, 6-dimethyl-4-phenyl)phenylsulfonyl]amino- 3- [ [8- (2-imidazolylaminomethyl) -l-oxa-2, 7- diazaspiro- [4,4] -non-2-en-3- yl]carbonylamino]propionic acid, (S)-2-[ (2-naphthyl)sulfonyl]amino-3-[ [8- (2- imidazolylaminomethyl) -l-oxa-2,7-diazaspiro- [4,4] -non-2-en-3-yl]carbonylamino]propionic acid, (S) -2- [biphenylsulfonyl]amino-3- [ [8- (2- imidazolylaminomethyl) -l-oxa-2,7-diazaspiro- [4,4] -non-2-en-3-yl]carbonylamino]propionic acid, (S) -2-phenylsulfonylamino-3- [ [7-benzyloxycarbonyl- 8- (2-pyridinylaminomethyl) -l-oxa-2, 7- diazaspiro- [4,4] -non-2-en-3- yl]carbonylamino]propionic acid, (S) -2-benzyloxycarbonylamino-3- [ [7- benzyloxycarbonyl-8- (2-pyridinylaminomethyl) - l-oxa-2, 7-diazaspiro- [4,4] -non-2-en-3- yl]carbonylamino]propionic acid, (S)-2- [ (2,4, 6-trimethylphenyl)sulfonyl] amino-3- [ [7- benzyloxycarbonyl-8- (2-pyridinylaminomethyl) - l-oxa-2,7-diazaspiro- [4,4]-non-2-en-3- yl]carbonylamino]propionic acid, (S)-2-[(2,6-dimethylphenyl)sulfonyl]amino-3-[ [7- benzyloxycarbonyl-8- (2-pyridinylaminomethyl) - l-oxa-2, 7-diazaspiro- [4,4] -non-2-en-3- yl]carbonylamino] ropionic acid, (S) -2- [ (2, 6-dichlorophenyl) sulfonyl]amino-3- [ [7- benzyloxycarbonyl-8- (2-pyridinylaminomethyl) - l-oxa-2, 7-diazaspiro- [4,4]-non-2-en-3- yl]carbonylamino]propionic acid, (S) -2- [ (2, 6-dimethyl-4-phenyl)phenylsulfonyl]amino- 3- [ [7-benzyloxycarbonyl-8- (2- pyridinylaminomethyl) -l-oxa-2,7-diazaspiro- [4,4] -non-2-en-3-yl]carbonylamino]propionic acid, (S)-2-[ (2-naphthyl)sulfonyl]amino-3-[ [7- benzyloxycarbonyl-8- (2-pyridinylaminomethyl) - l-oxa-2,7-diazaspiro- [4,4] -non-2-en-3- yl]carbonylamino]propionic acid, (S)-2-[biphenylsulfonyl]amino-3-[ [7- benzyloxycarbonyl-8-(2-pyridinylaminomethyl) - l-oxa-2,7-diazaspiro- [4,4] -non-2-en-3- yl]carbonylamino] ropionic acid, (S) -2-phenylsulfonylamino-3- [ [7-benzyloxycarbonyl- 8- (4, 5-dihydroimidazol-2-yl)aminomethyl-1-oxa- 2,7-diazaspiro- [4,4] -non-2-en-3- yl]carbonylamino]propionic acid, (S) -2-benzyloxycarbonylamino-3- [ [7- benzyloxycarbonyl-8- (4, 5-dihydroimidazol-2- yl)aminomethyl-l-oxa-2,7-diazaspiro- [4,4] -non- 2-en-3-yl]carbonylamino]propionic acid, (Sϊ -2- [ (2,4, 6-trimethylphenyl)sulfonyl]amino-3-[ [7- benzyloxycarbonyl-8- (4,5-dihydroimidazol-2- yl)aminomethyl-1-oxa-2,7-diazaspiro- [4,4] -non- 2-en-3-yl]carbonylamino]propionic acid, (S)-2-[ (2, 6-dimethylphenyl) sulfonyl]amino-3-[ [7- benzyloxycarbonyl-8- (4, 5-dihydroimidazol-2- yl)aminomethyl-1-oxa-2,7-diazaspiro- [4,4] -non- 2-en-3-yl] carbonylamino]propionic acid, (S) -2- [ (2, 6-dichlorophenyl) sulfonyl]amino-3- [ [7- benzyloxycarbonyl-8- (4, 5-dihydroimidazol-2- yl)aminomethyl-1-oxa-2,7-diazaspiro- [4,4] -non- 2-en-3-yl]carbonylamino]propionic acid, (S)-2- [ (2,6-dimethyl-4-phenyl)phenylsulfonyl]amino- 3- [ [7-benzyloxycarbonyl-8- (4, 5- dihydroimidazol-2-yl)aminomethyl-l-oxa-2,7- diazaspiro- [4,4] -non-2-en-3- yl]carbonylamino]propionic acid, (S) -2- [ (2-naphthyl) sulfonyl]amino-3- [ [7- benzyloxycarbonyl-8- (4, 5-dihydroimidazol-2- yl)aminomethyl-l-oxa-2,7-diazaspiro- [4,4] -non- 2-en-3-yl]carbonylamino]propionic acid, (S) -2- [biphenylsulfonyl]amino-3- [ [7- benzyloxycarbonyl-8-8- (4, 5-dihydroimidazol-2- yl)aminomethyl-1-oxa-2,7-diazaspiro- [4,4] -non- 2-en-3-yl]carbonylamino]propionic acid, (S) -2-phenylsulfonylamino-3- [ [8- (4, 5- dihydroimidazol-2-yl)aminomethyl-1-oxa-2,7- diazaspiro- [4,4] -non-2-en-3- yl]carbonylamino]propionic acid, (S) -2-benzyloxycarbonyla ino-3- [ [8- (4, 5- dihydroimidazol-2-yl)aminomethyl-1-oxa-2 ,7- diazaspiro- [4,4] -non-2-en-3- yl]carbonylamino]propionic acid, (S) -2- [ (2,4, 6-trimethylphenyl) sulfonyl]amino-3- [ [8- (4, 5-dihydroimidazol-2-yl)aminomethyl-l-oxa- 2, 7-diazaspiro- [4,4] -non-2-en-3- yl] carbonylamino]propionic acid, (S) -2- [ (2, 6-dimethylphenyl) sulfonyl]amino-3- [ [8- (4, 5-dihydroimidazol-2-yl)aminomethyl-l-oxa- 2,7-diazaspiro- [4,4]-non-2-en-3- yl]carbonylamino]propionic acid, (S)-2-[ (2,6-dichlorophenyl)sulfonyl]amino-3- [ [8- (4,5-dihydroimidazol-2-yl)aminomethyl-1-oxa- 2,7-diazaspiro- [4,4]-non-2-en-3- yl]carbonylamino] ropionic acid, (S)-2-[ (2,6-dimethyl-4-phenyl)phenylsulfonyl]amino- 3- [ [8-(4,5-dihydroimidazol-2-yl)aminomethyl-l- oxa-2,7-diazaspiro- [4,4]-non-2-en-3- yl]carbonylamino]propionic acid, (S)-2-[ (2-naphthyl)sulfonyl]amino-3- [ [8-(4,5- dihydroimidazol-2-yl)aminomethyl-l-oxa-2,7- diazaspiro- [4,4] -non-2-en-3- yl]carbonylamino]propionic acid, (S)-2-[biphenylsulfonyl]amino-3-[ [8-(4,5- dihydroimidazol-2-yl)aminomethyl-l-oxa-2,7- diazaspiro- [4,4] -non-2-en-3- yl]carbonylamino]propionic acid, and (S)-2- [ (2,4,6-trimethylphenyl)sulfonyl]amino-3-[ [8- (2-benzimidazolyl)aminomethyl-l-oxa-2,7- diazaspiro-[4,4] -non-2-en-3- yl]carbonylamino]propionic acid. 6. A method for the treatment of cancer metastasis, diabetic retinopathy, neovascular glaucoma, thrombosis, restenosis, osteoporosis, or macular degeneration which comprises administering to a host in need of such treatment a therapeutically effective amount of a compound of Claim 1-5. 7. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of Claim 1-5.

Inventors: JADHAV PRABHAKAR KONDAJI, SMALLHEER JOANNE MARIE, JADHAV, PRABHAKAR, KONDAJI, SMALLHEER, JOANNE, MARIE
Applicants: DU PONT MERCK PHARMA, THE DU PONT MERCK PHARMACEUTICAL COMPANY
Application year: 1997
Main classification: C07D413
IPC codes: A61K31, A61P3, A61P7, A61P9, A61P19, A61P27, A61P29, A61P35, A61P43, C07D231, C07D261, C07D271, C07D401, C07D403, C07D413, C07D417, C07D471, C07D498, C07D519